0001628280-23-026596.txt : 20230802 0001628280-23-026596.hdr.sgml : 20230802 20230802084756 ACCESSION NUMBER: 0001628280-23-026596 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230802 DATE AS OF CHANGE: 20230802 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vericel Corp CENTRAL INDEX KEY: 0000887359 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943096597 STATE OF INCORPORATION: MI FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35280 FILM NUMBER: 231133867 BUSINESS ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 7349305555 MAIL ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC DATE OF NAME CHANGE: 19960428 10-Q 1 vcel-20230630.htm 10-Q vcel-20230630
000088735912/312023Q2FALSEhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent00008873592023-01-012023-06-3000008873592023-07-27xbrli:shares00008873592023-06-30iso4217:USD00008873592022-12-3100008873592023-04-012023-06-3000008873592022-01-012022-06-3000008873592022-04-012022-06-30iso4217:USDxbrli:shares0000887359us-gaap:CommonStockMember2022-12-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000887359us-gaap:RetainedEarningsMember2022-12-310000887359us-gaap:RetainedEarningsMember2023-01-012023-03-3100008873592023-01-012023-03-310000887359us-gaap:CommonStockMember2023-01-012023-03-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000887359us-gaap:CommonStockMember2023-03-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000887359us-gaap:RetainedEarningsMember2023-03-3100008873592023-03-310000887359us-gaap:RetainedEarningsMember2023-04-012023-06-300000887359us-gaap:CommonStockMember2023-04-012023-06-300000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000887359us-gaap:CommonStockMember2023-06-300000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000887359us-gaap:RetainedEarningsMember2023-06-300000887359us-gaap:CommonStockMember2021-12-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000887359us-gaap:RetainedEarningsMember2021-12-3100008873592021-12-310000887359us-gaap:RetainedEarningsMember2022-01-012022-03-3100008873592022-01-012022-03-310000887359us-gaap:CommonStockMember2022-01-012022-03-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310000887359us-gaap:CommonStockMember2022-03-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310000887359us-gaap:RetainedEarningsMember2022-03-3100008873592022-03-310000887359us-gaap:RetainedEarningsMember2022-04-012022-06-300000887359us-gaap:CommonStockMember2022-04-012022-06-300000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300000887359us-gaap:CommonStockMember2022-06-300000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000887359us-gaap:RetainedEarningsMember2022-06-3000008873592022-06-30vcel:productvcel:segmentvcel:pharmacyxbrli:pure0000887359vcel:MediWoundLtdMember2023-05-092023-05-090000887359us-gaap:SalesChannelThroughIntermediaryMembervcel:ImplantsMemberus-gaap:FixedPriceContractMember2023-04-012023-06-300000887359us-gaap:SalesChannelThroughIntermediaryMembervcel:ImplantsMemberus-gaap:FixedPriceContractMember2022-04-012022-06-300000887359us-gaap:SalesChannelThroughIntermediaryMembervcel:ImplantsMemberus-gaap:FixedPriceContractMember2023-01-012023-06-300000887359us-gaap:SalesChannelThroughIntermediaryMembervcel:ImplantsMemberus-gaap:FixedPriceContractMember2022-01-012022-06-300000887359us-gaap:SalesChannelThroughIntermediaryMemberus-gaap:TimeAndMaterialsContractMembervcel:ImplantsMember2023-04-012023-06-300000887359us-gaap:SalesChannelThroughIntermediaryMemberus-gaap:TimeAndMaterialsContractMembervcel:ImplantsMember2022-04-012022-06-300000887359us-gaap:SalesChannelThroughIntermediaryMemberus-gaap:TimeAndMaterialsContractMembervcel:ImplantsMember2023-01-012023-06-300000887359us-gaap:SalesChannelThroughIntermediaryMemberus-gaap:TimeAndMaterialsContractMembervcel:ImplantsMember2022-01-012022-06-300000887359vcel:ProviderorFacilityMembervcel:ImplantsMemberus-gaap:FixedPriceContractMember2023-04-012023-06-300000887359vcel:ProviderorFacilityMembervcel:ImplantsMemberus-gaap:FixedPriceContractMember2022-04-012022-06-300000887359vcel:ProviderorFacilityMembervcel:ImplantsMemberus-gaap:FixedPriceContractMember2023-01-012023-06-300000887359vcel:ProviderorFacilityMembervcel:ImplantsMemberus-gaap:FixedPriceContractMember2022-01-012022-06-300000887359us-gaap:TimeAndMaterialsContractMemberus-gaap:TimeAndMaterialsContractMembervcel:ImplantsMember2023-04-012023-06-300000887359us-gaap:TimeAndMaterialsContractMemberus-gaap:TimeAndMaterialsContractMembervcel:ImplantsMember2022-04-012022-06-300000887359us-gaap:TimeAndMaterialsContractMemberus-gaap:TimeAndMaterialsContractMembervcel:ImplantsMember2023-01-012023-06-300000887359us-gaap:TimeAndMaterialsContractMemberus-gaap:TimeAndMaterialsContractMembervcel:ImplantsMember2022-01-012022-06-300000887359us-gaap:SalesChannelDirectlyToConsumerMembervcel:BiopsyKitsMember2023-04-012023-06-300000887359us-gaap:SalesChannelDirectlyToConsumerMembervcel:BiopsyKitsMember2022-04-012022-06-300000887359us-gaap:SalesChannelDirectlyToConsumerMembervcel:BiopsyKitsMember2023-01-012023-06-300000887359us-gaap:SalesChannelDirectlyToConsumerMembervcel:BiopsyKitsMember2022-01-012022-06-300000887359us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMemberus-gaap:AccountingStandardsUpdate201409Member2023-04-012023-06-300000887359us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMemberus-gaap:AccountingStandardsUpdate201409Member2022-04-012022-06-300000887359us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMemberus-gaap:AccountingStandardsUpdate201409Member2023-01-012023-06-300000887359us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMemberus-gaap:AccountingStandardsUpdate201409Member2022-01-012022-06-300000887359vcel:MACIImplantsAndKitsMember2023-04-012023-06-300000887359vcel:MACIImplantsAndKitsMember2022-04-012022-06-300000887359vcel:MACIImplantsAndKitsMember2023-01-012023-06-300000887359vcel:MACIImplantsAndKitsMember2022-01-012022-06-300000887359us-gaap:SalesChannelDirectlyToConsumerMembervcel:EpicelMember2023-04-012023-06-300000887359us-gaap:SalesChannelDirectlyToConsumerMembervcel:EpicelMember2022-04-012022-06-300000887359us-gaap:SalesChannelDirectlyToConsumerMembervcel:EpicelMember2023-01-012023-06-300000887359us-gaap:SalesChannelDirectlyToConsumerMembervcel:EpicelMember2022-01-012022-06-300000887359vcel:NexoBridMembervcel:ProviderorFacilityMember2023-04-012023-06-300000887359vcel:NexoBridMembervcel:ProviderorFacilityMember2022-04-012022-06-300000887359vcel:NexoBridMembervcel:ProviderorFacilityMember2023-01-012023-06-300000887359vcel:NexoBridMembervcel:ProviderorFacilityMember2022-01-012022-06-300000887359us-gaap:MachineryAndEquipmentMember2023-06-300000887359us-gaap:MachineryAndEquipmentMember2022-12-310000887359us-gaap:FurnitureAndFixturesMember2023-06-300000887359us-gaap:FurnitureAndFixturesMember2022-12-310000887359vcel:ComputerEquipmentAndComputerSoftwareIntangibleAssetMember2023-06-300000887359vcel:ComputerEquipmentAndComputerSoftwareIntangibleAssetMember2022-12-310000887359us-gaap:LeaseholdImprovementsMember2023-06-300000887359us-gaap:LeaseholdImprovementsMember2022-12-310000887359us-gaap:ConstructionInProgressMember2023-06-300000887359us-gaap:ConstructionInProgressMember2022-12-310000887359us-gaap:LicensingAgreementsMember2022-12-310000887359us-gaap:LicensingAgreementsMember2023-06-300000887359us-gaap:LicensingAgreementsMember2023-04-012023-06-300000887359us-gaap:LicensingAgreementsMember2023-01-012023-06-300000887359srt:MinimumMembervcel:AnnArborMichiganMember2023-03-012023-03-310000887359vcel:AnnArborMichiganMembersrt:MaximumMember2023-03-012023-03-310000887359vcel:A25NetworkDriveBurlingtonMassachusettsMember2022-01-28utr:sqft0000887359vcel:A25NetworkDriveBurlingtonMassachusettsMember2023-04-300000887359vcel:A25NetworkDriveBurlingtonMassachusettsMember2023-06-012023-06-010000887359vcel:A25NetworkDriveBurlingtonMassachusettsMember2023-06-01vcel:renewal_optioniso4217:USDutr:sqft0000887359srt:MinimumMembervcel:A25NetworkDriveBurlingtonMassachusettsMember2023-06-012023-06-010000887359srt:MaximumMembervcel:A25NetworkDriveBurlingtonMassachusettsMember2023-06-012023-06-010000887359vcel:A25NetworkDriveBurlingtonMassachusettsMember2022-01-012022-01-310000887359vcel:A25NetworkDriveBurlingtonMassachusettsMember2022-07-292022-07-290000887359us-gaap:CommercialPaperMember2023-06-300000887359us-gaap:CorporateDebtSecuritiesMember2023-06-300000887359us-gaap:USGovernmentDebtSecuritiesMember2023-06-300000887359us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-06-300000887359us-gaap:ShortTermInvestmentsMember2023-06-300000887359vcel:LongtermInvestmentsMember2023-06-300000887359us-gaap:CommercialPaperMember2022-12-310000887359us-gaap:CorporateDebtSecuritiesMember2022-12-310000887359us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310000887359us-gaap:ShortTermInvestmentsMember2022-12-310000887359vcel:LongtermInvestmentsMember2022-12-3100008873592022-01-012022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Member2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Member2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateNoteSecuritiesMember2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateNoteSecuritiesMember2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMember2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMember2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:CashAndCashEquivalentsMember2023-06-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310000887359us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-07-290000887359us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-07-292022-07-290000887359us-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2022-07-290000887359us-gaap:LineOfCreditMember2022-07-290000887359vcel:SecuredOvernightFinancingRateSOFRMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-07-292022-07-290000887359vcel:SecuredOvernightFinancingRateSOFRMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-07-292022-07-290000887359vcel:SecuredOvernightFinancingRateSOFRMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberus-gaap:LineOfCreditMember2022-07-292022-07-290000887359srt:MinimumMemberus-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-07-292022-07-290000887359us-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberus-gaap:LineOfCreditMember2022-07-292022-07-290000887359srt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-07-292022-07-290000887359us-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberus-gaap:LineOfCreditMember2022-07-292022-07-290000887359us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-06-300000887359us-gaap:CostOfSalesMembervcel:EmployeeStockAndEmployeeStockOptionMember2023-04-012023-06-300000887359us-gaap:CostOfSalesMembervcel:EmployeeStockAndEmployeeStockOptionMember2022-04-012022-06-300000887359us-gaap:CostOfSalesMembervcel:EmployeeStockAndEmployeeStockOptionMember2023-01-012023-06-300000887359us-gaap:CostOfSalesMembervcel:EmployeeStockAndEmployeeStockOptionMember2022-01-012022-06-300000887359us-gaap:ResearchAndDevelopmentExpenseMembervcel:EmployeeStockAndEmployeeStockOptionMember2023-04-012023-06-300000887359us-gaap:ResearchAndDevelopmentExpenseMembervcel:EmployeeStockAndEmployeeStockOptionMember2022-04-012022-06-300000887359us-gaap:ResearchAndDevelopmentExpenseMembervcel:EmployeeStockAndEmployeeStockOptionMember2023-01-012023-06-300000887359us-gaap:ResearchAndDevelopmentExpenseMembervcel:EmployeeStockAndEmployeeStockOptionMember2022-01-012022-06-300000887359us-gaap:SellingGeneralAndAdministrativeExpensesMembervcel:EmployeeStockAndEmployeeStockOptionMember2023-04-012023-06-300000887359us-gaap:SellingGeneralAndAdministrativeExpensesMembervcel:EmployeeStockAndEmployeeStockOptionMember2022-04-012022-06-300000887359us-gaap:SellingGeneralAndAdministrativeExpensesMembervcel:EmployeeStockAndEmployeeStockOptionMember2023-01-012023-06-300000887359us-gaap:SellingGeneralAndAdministrativeExpensesMembervcel:EmployeeStockAndEmployeeStockOptionMember2022-01-012022-06-300000887359vcel:EmployeeStockAndEmployeeStockOptionMember2023-04-012023-06-300000887359vcel:EmployeeStockAndEmployeeStockOptionMember2022-04-012022-06-300000887359vcel:EmployeeStockAndEmployeeStockOptionMember2023-01-012023-06-300000887359vcel:EmployeeStockAndEmployeeStockOptionMember2022-01-012022-06-300000887359us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-06-300000887359us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300000887359us-gaap:RestrictedStockUnitsRSUMember2022-04-012022-06-300000887359us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300000887359us-gaap:EmployeeStockOptionMember2023-04-012023-06-300000887359us-gaap:EmployeeStockOptionMember2022-04-012022-06-300000887359us-gaap:EmployeeStockOptionMember2023-01-012023-06-300000887359us-gaap:EmployeeStockOptionMember2022-01-012022-06-300000887359us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-06-300000887359us-gaap:RestrictedStockUnitsRSUMember2022-04-012022-06-300000887359us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300000887359us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300000887359vcel:MediWoundLtdMember2019-05-310000887359vcel:MediWoundLtdMember2023-02-280000887359vcel:MediWoundLtdMember2019-05-012019-05-31



UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 Form 10-Q
 
☒      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
FOR THE QUARTERLY PERIOD ENDED: June 30, 2023 
or
☐         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 Commission File Number 001-35280
 
VERICEL CORPORATION
(Exact name of registrant as specified in its charter)
Michigan 94-3096597
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
 
64 Sidney Street
Cambridge, MA 02139
(Address of principal executive offices, including zip code) 

Registrant’s telephone number, including area code: (617) 588-5555 

 Securities registered pursuant to Section 12(b) of the Act: 
Title of ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common Stock (No par value)VCELNASDAQ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x No o
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes x No o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
 Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐ No x


As of July 27, 2023, 47,642,194 shares of Common Stock, no par value per share, were outstanding. 

1
VERICEL CORPORATION
 QUARTERLY REPORT ON FORM 10-Q
 TABLE OF CONTENTS
 
  Page
 PART I - FINANCIAL INFORMATION 
Item 1.
Financial Statements (Unaudited):
 
 
 
 
Item 2.
Item 3.
Item 4.
PART II — OTHER INFORMATION
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
2

PART I - FINANCIAL INFORMATION
 

Item 1. Financial Statements (Unaudited)

VERICEL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, amounts in thousands)

 June 30,December 31,
 20232022
ASSETS  
Current assets:  
Cash and cash equivalents$43,023 $51,067 
Restricted cash27,794 — 
Short-term investments54,808 68,471 
Accounts receivable (net of allowance for doubtful accounts of $44 and $47, respectively)
38,319 46,539 
Inventory13,883 15,986 
Other current assets5,044 4,803 
Total current assets182,871 186,866 
Property and equipment, net23,408 15,837 
Intangible assets, net7,188 7,500 
Right-of-use assets75,063 41,535 
Long-term investments20,985 19,962 
Other long-term assets1,196 1,303 
Total assets$310,711 $273,003 
LIABILITIES AND SHAREHOLDERS’ EQUITY  
Current liabilities:  
Accounts payable$14,401 $16,930 
Accrued expenses13,971 16,190 
Current portion of operating lease liabilities7,218 4,302 
Other current liabilities21 41 
Total current liabilities35,611 37,463 
Operating lease liabilities76,144 43,268 
Other long-term liabilities28 — 
Total liabilities111,783 80,731 
COMMITMENTS AND CONTINGENCIES (Note 12)
Shareholders’ equity:  
Common stock, no par value; shares authorized — 75,000; shares issued and outstanding 47,616 and 47,253, respectively
612,059 593,245 
Accumulated other comprehensive loss(621)(978)
Accumulated deficit(412,510)(399,995)
Total shareholders’ equity198,928 192,272 
Total liabilities and shareholders’ equity$310,711 $273,003 

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

3
VERICEL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, amounts in thousands, except per share amounts)
 
 Three Months Ended June 30,Six Months Ended June 30,
 2023202220232022
Product sales, net$45,922 $36,826 $86,939 $72,678 
Other revenue— 220 — 442 
Total revenue45,922 37,046 86,939 73,120 
Cost of product sales15,981 14,192 30,478 26,814 
Gross profit29,941 22,854 56,461 46,306 
Research and development5,253 4,792 10,465 9,652 
Selling, general and administrative30,649 27,144 60,134 53,009 
Total operating expenses35,902 31,936 70,599 62,661 
Loss from operations(5,961)(9,082)(14,138)(16,355)
Other income (expense):   
Interest income1,095 148 1,934 236 
Interest expense(149)(20)(294)(38)
Other (expense) income(5)(9)(17)103 
Total other income941 119 1,623 301 
Net loss$(5,020)$(8,963)$(12,515)$(16,054)
Net loss per common share:
Basic and diluted$(0.11)$(0.19)$(0.26)$(0.34)
Weighted-average common shares outstanding:
Basic and diluted47,572 47,117 47,480 47,052 

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

4
VERICEL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited, amounts in thousands)

 Three Months Ended June 30,Six Months Ended June 30,
 2023202220232022
Net loss$(5,020)$(8,963)$(12,515)$(16,054)
Other comprehensive loss:
Unrealized gain (loss) on investments15 (242)357 (701)
Comprehensive loss$(5,005)$(9,205)$(12,158)$(16,755)

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

5
VERICEL CORPORATION 
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(Unaudited, amounts in thousands)

Common StockAccumulated Other Comprehensive Gain (Loss)Accumulated DeficitTotal Shareholders’ Equity
SharesAmount
BALANCE, DECEMBER 31, 202247,253 $593,245 $(978)$(399,995)$192,272 
Net loss— — — (7,495)(7,495)
Stock-based compensation expense— 8,731 — — 8,731 
Stock option exercises132 2,009 — — 2,009 
Shares issued under the Employee Stock Purchase Plan11 216 — — 216 
Issuance of stock for restricted stock unit vesting183 — — — — 
Restricted stock withheld for employee tax remittance(72)(2,097)— — (2,097)
Unrealized gain on investments— — 342 — 342 
BALANCE, MARCH 31, 202347,507 $602,104 $(636)$(407,490)$193,978 
Net loss— — — (5,020)(5,020)
Stock-based compensation expense— 8,761 — — 8,761 
Stock option exercises68 889 — — 889 
Shares issued under the Employee Stock Purchase Plan18 384 — — 384 
Issuance of stock for restricted stock unit vesting26 — — — — 
Restricted stock withheld for employee tax remittance(3)(79)— — (79)
Unrealized gain on investments— — 15 — 15 
BALANCE, JUNE 30, 202347,616 $612,059 $(621)$(412,510)$198,928 


Common StockAccumulated Other Comprehensive LossAccumulated DeficitTotal Shareholders’ Equity
SharesAmount
BALANCE, DECEMBER 31, 202146,880 $553,902 $(154)$(383,286)$170,462 
Net loss— — — (7,091)(7,091)
Stock-based compensation expense— 9,531 — — 9,531 
Stock option exercises125 1,155 — — 1,155 
Shares issued under the Employee Stock Purchase Plan9 310 — — 310 
Issuance of stock for restricted stock unit vesting108 — — — — 
Restricted stock withheld for employee tax remittance(41)(1,423)— — (1,423)
Unrealized loss on investments— — (459)— (459)
BALANCE, MARCH 31, 202247,081 $563,475 $(613)$(390,377)$172,485 
Net loss— — — (8,963)(8,963)
Stock-based compensation expense— 10,808 — — 10,808 
Stock option exercises32 428 — — 428 
Shares issued under the Employee Stock Purchase Plan10 318 — — 318 
Issuance of stock for restricted stock unit vesting19 — — — — 
Restricted stock withheld for employee tax remittance(1)(18)— — (18)
Unrealized loss on investments— — (242)— (242)
BALANCE, JUNE 30, 202247,141 $575,011 $(855)$(399,340)$174,816 

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.


6

VERICEL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, amounts in thousands)

 Six Months Ended June 30,
 20232022
Operating activities:  
Net loss$(12,515)$(16,054)
Adjustments to reconcile net loss to net cash flows from operating activities:  
Depreciation and amortization expense2,329 1,928 
Stock-based compensation expense17,492 20,339 
Amortization of premiums and discounts on marketable securities(504)302 
Amortization of debt issuance costs108 — 
Non-cash lease costs2,466 2,155 
Other17 16 
Changes in operating assets and liabilities:  
Inventory2,103 (2,548)
Accounts receivable8,220 3,773 
Other current assets(241)(563)
Accounts payable956 1,152 
Accrued expenses(2,219)(1,912)
Operating lease liabilities(184)(1,977)
Other non-current assets and liabilities, net28 — 
Net cash provided by operating activities18,056 6,611 
Investing activities:  
Purchases of investments(28,537)(34,948)
Sales and maturities of investments42,038 26,344 
Expenditures for property and equipment(5,609)(5,062)
Purchases of intangible assets(7,500)— 
Net cash provided by (used in) investing activities392 (13,666)
Financing activities:  
Net proceeds from common stock issuance 3,498 2,211 
Payments on employee’s behalf for taxes related to vesting of restricted stock unit awards(2,176)(1,441)
Other(20)(18)
Net cash provided by financing activities1,302 752 
Net increase (decrease) in cash, cash equivalents, and restricted cash19,750 (6,303)
Cash, cash equivalents, and restricted cash at beginning of period51,067 68,541 
Cash, cash equivalents, and restricted cash at end of period$70,817 $62,238 

7
VERICEL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
(Unaudited, amounts in thousands)


Six Months Ended June 30,
20232022
Supplemental disclosure of cash flow information:
Non-cash information:
Right-of-use asset and lease liability recognized$35,976 $— 
Additions to property and equipment included in accounts payable4,321 869 

Six Months Ended June 30,
20232022
Reconciliation of amounts within the condensed consolidated balance sheets:
Cash and cash equivalents$43,023 $56,054 
Restricted cash27,794 6,184 
Total cash, cash equivalents, and restricted cash at end of period$70,817 $62,238 


The accompanying notes to condensed consolidated financial statements are an integral part of these statements.
8
VERICEL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Organization

Vericel Corporation, a Michigan corporation (together with its consolidated subsidiaries referred to herein as the Company, or Vericel), was incorporated in March 1989 and began employee-based operations in 1991. The Company is a fully-integrated, commercial-stage biopharmaceutical company and is a leader in advanced therapies for the sports medicine and severe burn care markets. Vericel currently markets three commercial-stage products in the U.S., MACI®, Epicel® and NexoBrid®.

MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (“TBSA”). The Company also holds an exclusive license from MediWound Ltd. (“MediWound”) to commercialize NexoBrid (anacaulase-bcdb) in North America. On December 28, 2022, the U.S. Food and Drug Administration (“FDA”) approved a Biologics License Application (“BLA”) for NexoBrid, granting a license for commercial use in the U.S. NexoBrid is a topically-administered biological product containing proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns. The Company operates its business primarily in the U.S. in one reportable segment - the research, product development, manufacture and distribution of cellular therapies and specialty biologics for use in the treatment of specific diseases.

The Company is subject to risks common to companies in the life sciences industry including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with FDA regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.

COVID-19

On May 11, 2023, the U.S. Department of Health and Human Services announced the expiration of the federal Public Health Emergency for COVID-19. At this juncture, the pandemic’s effects on the Company’s business and results of operations have largely moderated and we have begun to see a return to more normal operations. Should a resurgence of COVID-19 occur, or new virus variants emerge, it could result in additional disruptions that could impact the Company’s business and operations in the future, including U.S. hospital or surgical center staffing shortages, periodic cancellation or delay of elective MACI surgical procedures, intermittent restrictions on the ability of Company personnel to travel and access customers for selling, marketing, training, case support and product development feedback, delays in approvals by regulatory bodies, delays in product development efforts, and additional government requirements or other incremental mitigation efforts that may further impact the Company’s capacity to manufacture, sell and support the use of its products.

The War in Ukraine

The ongoing war between Russia and Ukraine and the related sanctions and other penalties imposed by countries across the globe against Russia are continuing to create substantial uncertainty in the global economy and have contributed to heightened inflation and supply chain disruptions. While the Company does not have operations in Russia or Ukraine and does not have exposure to distributors, or third-party service providers in Russia or Ukraine, it is unable to predict the ultimate impact that these actions will have on the global economy or on its financial condition, results of operations, and cash flows as of the date of these condensed consolidated financial statements.

9
Liquidity

The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of June 30, 2023, the Company had an accumulated deficit of $412.5 million and had a net loss of $12.5 million during the six months ended June 30, 2023. The Company had cash and cash equivalents of $43.0 million and investments of $75.8 million as of June 30, 2023. The Company expects that cash from the sales of its products and existing cash, cash equivalents, investments, and available borrowing capacity will be sufficient to support the Company’s current operations through at least 12 months from the issuance of these condensed consolidated financial statements. If revenues decline for a sustained period, the Company may need to access additional capital; however, the Company may not be able to obtain additional financing on acceptable terms or at all. The terms of any additional financing may adversely affect the holdings or the rights of the Company’s shareholders.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and investments in marketable debt securities. The Company may maintain deposits in financial institutions in excess of the insurance coverage offered by the Federal Deposit Insurance Corporation, the loss of which could have a negative effect on our operations and liquidity. The Company believes that it is not exposed to significant credit risk as its deposits, including cash and cash equivalents, are held at multiple high credit quality financial institutions. The Company has not experienced any losses on these deposits; however no assurances can be provided that there will not be losses experienced in the future. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.

2. Basis of Presentation

The accompanying condensed consolidated financial statements of Vericel are unaudited and have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations.

The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expenses.

The condensed consolidated balance sheet as of December 31, 2022 has been derived from the audited consolidated financial statements at that date, but does not include all the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on February 23, 2023 (“Annual Report”).

Recent Accounting Pronouncements

No new accounting standards were adopted during the six months ended June 30, 2023. The Company considers the applicability and impact of any recent Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). Based on the assessment, the ASUs were determined to be either not applicable or are expected to have minimal impact on the Company’s condensed consolidated financial statements.


10
3. Revenue

Revenue Recognition and Product Sales, Net

The Company recognizes product revenue from sales of MACI biopsy kits, MACI implants, Epicel grafts and NexoBrid following the five-step model in Accounting Standards Codification 606, Revenue Recognition.

MACI Biopsy Kits

MACI biopsy kits are sold directly to hospitals and ambulatory surgical centers based on contracted rates in an approved contract or sales order. The Company recognizes MACI kit revenue upon delivery of the biopsy kit, at which time the customer (the facility) is in control of the kit. The kit is used by the doctor to provide a sample of cartilage tissue to the Company, which can later be used to manufacture a MACI implant. The ordering of the kit does not obligate the Company to manufacture an implant nor does the receipt of the cartilage tissue by the Company from the customer following biopsy. The customer’s order of an implant is separate from the process of ordering the biopsy kit. Therefore, the sale of the biopsy kit and any subsequent sale of an implant are distinct contracts and are accounted for separately.

MACI Implants

The Company contracts with two specialty pharmacies, Orsini Pharmaceutical Services, Inc. (“Orsini”) and AllCare Plus Pharmacy, Inc. (“AllCare”) to distribute MACI in a manner in which the Company retains the credit and collection risk from the end customer. The Company pays both specialty pharmacies a fee for each patient to whom MACI is dispensed. Both Orsini and AllCare perform collection activities to collect payment from customers. The Company engages a third party to provide services in connection with a patient support program to manage patient cases and to ensure complete and correct billing information is provided to the insurers and hospitals. In addition, the Company also sells MACI directly to DMS Pharmaceutical Group, Inc. (“DMS”) for patients treated at military treatment facilities. The sales directly to DMS are made at a contracted rate.

Prior authorization and confirmation of coverage level by the patient’s private insurance plan, hospital or government payer is a prerequisite to the shipment of product to a patient. The Company recognizes product revenue from sales of all MACI implants upon delivery at which time the customer obtains control of the implant and the claim is billable. The total consideration that the Company expects to collect in exchange for MACI implants (the “Transaction Price”) may be fixed or variable. Direct sales to hospitals or distributors are recorded at a contracted price, and there are typically no forms of variable consideration.

When the Company sells MACI the patient is responsible for payment; however, the Company is typically reimbursed by a third-party insurer or government payer, subject to a patient co-pay amount. Reimbursements from third-party insurers and government payers vary by patient and payer and are based on either contracted rates, publicly available rates, fee schedules or past payer precedents. Net product revenue is recognized net of estimated contractual allowances, which considers historical collection experience from both the payer and patient, denial rates and the terms of the Company’s contractual arrangements. The Company estimates expected collections for these transactions using the portfolio approach. The Company records a reduction to revenue at the time of sale for its estimate of the amount of consideration that will not be collected. In addition, potential credit risk exposure has been evaluated for the Company’s accounts receivable in accordance with ASC 326, Financial Instruments - Credit Losses. The Company assesses risk and determines a loss percentage by pooling accounts receivable based on similar risk characteristics. The loss percentage is calculated through the use of forecasts that are based on current and historical economic and financial information. This loss percentage was applied to the accounts receivables as of June 30, 2023. The total allowance for uncollectible consideration as of June 30, 2023 and December 31, 2022 was $5.3 million and $6.1 million, respectively. Changes to the estimate of the amount of consideration that will not be collected could have a material impact on the revenue recognized. A 50 basis points change to the estimated uncollectible percentage could result in an approximately $0.3 million decrease or increase in the revenue recognized for the six months ended June 30, 2023.

Changes in estimates of the Transaction Price are recorded through revenue in the period in which such change occurs. Changes in estimates related to prior periods are shown in the Revenue by Product and Customer table below and relate primarily to changes in the initial expected reimbursement or collection expectation upon completion of the billing claims process for MACI implants that occurred in a prior year.

11
Epicel

The Company sells Epicel directly to hospitals and burn centers based on contracted rates stated in an approved contract or purchase order. Similar to MACI, there is no obligation to manufacture Epicel grafts upon receipt of a skin biopsy, and Vericel has no contractual right to receive payment until the product is delivered to the hospital. The Company recognizes product revenue from sales of Epicel upon delivery to the hospital, at which time the customer is in control of the Epicel grafts and the claim is billable to the hospital.

NexoBrid

The Company entered into exclusive license and supply agreements with MediWound in May 2019, pursuant to which MediWound will manufacture and supply NexoBrid on a unit price basis, which may be increased pursuant to the terms of the agreements. Additionally, beginning in 2020 the U.S. Biomedical Advanced Research and Development Authority (“BARDA”) procured quantities of NexoBrid from MediWound, for use as a medical countermeasure in the event of a mass casualty emergency in the U.S. involving thermal burns. The initial, quarterly, procurement of NexoBrid by BARDA under its agreement with MediWound completed during the third quarter of 2022. The Company recognized revenue based on a percentage of gross profits for sales of NexoBrid to BARDA upon delivery, at which time BARDA was in control of the product. As of June 30, 2023, the Company did not hold a direct contract or distribution agreement with BARDA, or take title to the product procured by BARDA.

On May 9, 2023, MediWound announced BARDA’s award of additional funding under the parties’ existing agreement, $3 million of which will support the replacement of NexoBrid, previously procured for emergency response preparedness, which has since expired. Pursuant to the terms of the Company’s license agreement with MediWound, the Company would recognize revenue based on a percentage of gross profits, minus a percentage of net sales, on any sales of NexoBrid directly to BARDA upon delivery, pursuant to this additional award.

Additionally, on December 28, 2022, the FDA approved a BLA for NexoBrid, granting a license for commercial use in the U.S. NexoBrid is a topically-administered biological product containing proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns.

12
Revenue by Product and Customer

The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated:
 Three Months Ended June 30,Six Months Ended June 30,
Revenue by product (in thousands) 2023202220232022
MACI implants and kits
Implants based on contracted rate sold through a specialty pharmacy (a)
$22,377 $15,714 $45,331 $31,009 
Implants subject to third party reimbursement sold through a specialty pharmacy (b)
4,015 4,295 8,004 7,803 
Implants sold direct based on contracted rates (c)
7,252 5,756 14,222 11,390 
Implants sold direct subject to third-party reimbursement (d)
1,045 570 1,538 1,441 
Biopsy kits - direct bill528 545 1,062 1,066 
Change in estimates related to prior periods (e)
1,119 1,733 369 1,898 
Total MACI implants and kits36,336 28,613 70,526 54,607 
Epicel
Direct bill (hospital)9,586 8,213 16,413 18,071 
NexoBrid revenue (f)
— 220 — 442 
Total revenue$45,922 $37,046 $86,939 $73,120 
(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts.
(b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer, and are subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.
(f) Represents revenue based on a percentage of gross profits for sales of NexoBrid to BARDA, pursuant to the license agreement between the Company and MediWound (see Note 11).

4. Selected Balance Sheet Components

Inventory

Inventory consisted of the following:
(In thousands)June 30, 2023December 31, 2022
Raw materials$12,847 $15,101 
Work-in-process863 832 
Finished goods173 53 
Total inventory$13,883 $15,986 

13
Property and Equipment

Property and Equipment, net consisted of the following:

(In thousands)June 30, 2023December 31, 2022
Machinery and equipment$5,544 $5,041 
Furniture, fixtures and office equipment1,710 1,710 
Computer equipment and software8,308 8,224 
Leasehold improvements14,896 13,689 
Construction in process13,148 5,438 
Financing right-of-use lease18 37 
Total property and equipment, gross43,624 34,139 
Less accumulated depreciation(20,216)(18,302)
Total property and equipment, net$23,408 $15,837 

Depreciation expense for the three and six months ended June 30, 2023 was $1.0 million and $2.0 million, respectively, and $1.1 million and $1.9 million, respectively, for the same periods in 2022.

Intangible Assets

Intangible assets, net consisted of the following:

June 30, 2023December 31, 2022
(In thousands)Useful Life (in years)Amortization MethodCostAccumulated AmortizationNetCostAccumulated AmortizationNet
NexoBrid license12Straight-line$7,500 $(312)$7,188 $7,500 $— $7,500 

Amortization expense for the three and six months ended June 30, 2023 was $0.2 million and $0.3 million, respectively.

Future amortization expense of intangible assets as of June 30, 2023 is estimated to be as follows:

(In thousands)Amount
Remainder of 2023$313 
2024625 
2025625 
2026625 
2027625 
Thereafter4,375 
Total$7,188 

Accrued Expenses

Accrued Expenses consisted of the following:
(In thousands)June 30, 2023December 31, 2022
Bonus-related compensation$5,090 $7,132 
Employee-related accruals3,436 3,101 
Insurance reimbursement-related liabilities5,160 5,030 
Other accrued expenses285 927 
Total accrued expenses$13,971 $16,190 


14
5. Leases

The Company leases facilities in Ann Arbor, Michigan and Cambridge, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facilities include clean rooms, laboratories for MACI and Epicel manufacturing, and office space. The Company also leases offsite warehouse space, and other computer-related equipment.

With respect to the Ann Arbor facility, in March 2023, the Company entered into an amendment to that lease extending its term until April 30, 2025. Monthly contractual payments are expected to range from $17,000 to $18,000.

On January 28, 2022, the Company entered into a lease agreement (the “Burlington Lease”) to lease approximately 126,000 square feet of to-be-constructed manufacturing, laboratory and office space in Burlington, Massachusetts (the “Premises”). Once constructed, the Premises will serve as the Company’s new corporate headquarters and primary manufacturing facility.

In April 2023, in connection with the Burlington Lease, the Company entered into a construction escrow agreement (the “Construction Escrow Agreement”) with the facility’s landlord and an escrow agent. Pursuant to the terms of the Construction Escrow Agreement, in April 2023, the Company began funding, into an escrow account maintained by the escrow agent, a portion of its share of tenant improvement construction costs at the facility, which are designated as restricted cash. At the same time, the facility’s landlord began funding a portion of its tenant improvement allowance through a separate escrow account. To date, the Company has transferred into its escrow account 50% of its required cost amount, or approximately $28.3 million. The Company anticipates funding the remaining 50% of its required cost amount in late 2023 or early 2024.

The term of the Burlington Lease began on June 1, 2023, (the “Commencement Date”), when the Company gained control of and commenced tenant improvement work at the Premises. The Company’s obligation to pay rent for the Premises will begin on the earlier of: 13 months from the Commencement Date; or the date on which the Company first occupies the Premises to conduct operations (the “Rent Commencement Date”). The initial term of the Lease is 144 months following the Rent Commencement Date. The Company has a one-time option to extend the term of the Lease for an additional 10 years, exercisable under certain conditions and at a market rate determined in accordance with the Burlington Lease.

The annual base rent of the Burlington Lease is initially $57 per square foot per year, subject to annual increases of 2.5%. Monthly contractual payments are expected to range from $0.6 million to $0.8 million. Additionally, the Company is responsible for reimbursing the landlord for the Company’s share of the Premises’ property taxes and certain other operating expenses. The Burlington Lease also provides for a tenant improvement allowance from the landlord in an amount equal to $200 per square foot of the Premises, or approximately $24.4 million. The tenant improvement allowance will be used towards the design and construction of the tenant improvements made to the Premises, subject to the terms set forth in the Burlington Lease.

The Company was not involved in the initial construction of the core and shell of the building. On June 1, 2023, the Company gained control of the Premises to begin construction of its tenant improvements. As such, the corresponding right-of-use asset and lease liability of $35.5 million was recorded on the Company’s condensed consolidated balance sheet. As there was not an implicit rate within the lease available, the Company estimated the incremental borrowing rate of 7.7%, based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. The lease term of 13.1 years does not include the lease extension option, as the Company is not reasonably certain to exercise that option.

In January 2022, in connection with the execution of the Burlington Lease, the Company issued a letter of credit collateralized by cash deposits of approximately $6.0 million. Subsequent to the execution of the Revolving Credit Agreement on July 29, 2022 (see Note 8, “Revolving Credit Agreement” for further details), the letter of credit is issued under the sub-facility limit of the Revolving Credit Agreement. Such letter of credit shall be reduced to approximately $4.2 million and $1.8 million at the conclusion of the third and sixth lease years, respectively, provided certain conditions set forth in the Burlington Lease are satisfied.

For the three and six months ended June 30, 2023 and 2022, lease expense of less than $0.1 million was recorded related to short-term leases. For the three and six months ended June 30, 2023, the Company recognized $2.3 million and $4.0 million, respectively, of operating lease expense and $1.7 million and $3.5 million, respectively, for the same period in 2022. For the three and six months ended June 30, 2023 and 2022, the Company recognized less than $0.1 million of financing lease expense.


15
Operating and finance lease assets and liabilities are as follows:

(In thousands)ClassificationJune 30, 2023December 31, 2022
Assets
OperatingRight-of-use assets$75,063 $41,535 
FinanceProperty and equipment, net18 37 
Total leased assets$75,081 $41,572 
Liabilities
Current
OperatingCurrent portion of operating lease liabilities$7,218 $4,302 
FinanceOther current liabilities21 41 
Non-current
OperatingOperating lease liabilities$76,144 $43,268 
Total leased liabilities$83,383 $47,611 

Future minimum lease payments under non-cancellable leases as of June 30, 2023 are as follows:
(In thousands)Operating LeasesFinance LeasesTotal
Remainder of 2023$3,576 $21 $3,597 
202410,743 — 10,743 
202513,677 — 13,677 
202613,969 — 13,969 
202714,351 — 14,351 
Thereafter103,229 — 103,229 
Total lease payments$159,545 $21 $159,566 
Less: tenant improvement allowances(25,167)— (25,167)
Less: interest(51,016)— (51,016)
Total leased liabilities$83,362 $21 $83,383 

6. Investments

Marketable debt securities held by the Company are classified as available-for-sale pursuant to ASC 320, Investments – Debt and Equity Securities, and carried at fair value in the accompanying condensed consolidated balance sheets on a settlement date basis. The following tables summarize the gross unrealized gains and losses of the Company’s marketable securities:

June 30, 2023
Gross UnrealizedEstimated Fair Value
(In thousands)Amortized CostGainsLossesCredit Losses
Commercial paper$12,494 $— $(15)$— $12,479 
Corporate notes43,864 — (492)— 43,372 
U.S. government securities2,476 — (1)— 2,475 
U.S. government agency bonds17,583 — (116)— 17,467 
$76,417 $— $(624)$— $75,793 
Classified as:
Short-term investments$54,808 
Long-term investments20,985 
$75,793 

16
December 31, 2022
Gross UnrealizedEstimated Fair Value
(In thousands)Amortized CostGainsLossesCredit Losses
Commercial paper$15,707 $— $(101)$— $15,606 
Corporate notes52,159 — (831)— 51,328 
U.S. government agency bonds21,545 — (46)— 21,499 
$89,411 $— $(978)$— $88,433 
Classified as:
Short-term investments$68,471 
Long-term investments19,962 
$88,433 

As of June 30, 2023 and December 31, 2022, all marketable securities held by the Company had remaining contractual maturities of three years or less. There have been no impairments of the Company’s assets measured and carried at fair value during the three and six months ended June 30, 2023 and 2022.

7. Fair Value Measurements

The Company’s fair value measurements are classified and disclosed in one of the following three categories:

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
•Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;
•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The commercial paper, corporate notes, U.S. government securities, and U.S. government agency bonds are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. There were no transfers into or out of Level 3 from December 31, 2022 to June 30, 2023.

The following table summarizes the valuation of the Company’s financial instruments that are measured at fair value on a recurring basis:

 June 30, 2023December 31, 2022
  Fair value measurement category Fair value measurement category
(In thousands)TotalLevel 1Level 2Level 3TotalLevel 1Level 2Level 3
Assets:
Money market funds$7,620 $7,620 $— $— $1,262 $1,262 $— $— 
Commercial paper12,479 — 12,479 — 15,606 — 15,606 — 
Corporate notes43,372 — 43,372 — 51,328 — 51,328 — 
U.S. government securities (a)
22,382 — 22,382 — — — — — 
U.S. government agency bonds (b)
17,467 — 17,467 — 27,976 — 27,976 — 
$103,320 $7,620 $95,700 $— $96,172 $1,262 $94,910 $— 

(a) Approximately $19.9 million of U.S. government securities had an original maturity of 90 days or less and were recorded as a cash equivalent as of June 30, 2023.

(b) Approximately $6.5 million of U.S. government agency bonds had an original maturity of 90 days or less and were recorded as a cash equivalent as of December 31, 2022.

The fair values of the cash equivalents and marketable securities are based on observable market prices. The Company’s accounts receivables, accounts payable and accrued expenses are valued at cost, which approximates fair value.
17

8. Revolving Credit Agreement

On July 29, 2022, the Company, as borrower, entered into a $150.0 million five-year senior secured revolving credit agreement by and among the Company, the other loan parties thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as the administrative agent (the “Revolving Credit Agreement”). The Revolving Credit Agreement includes a $15.0 million sub-facility for the issuance of letters of credit, of which the Company is utilizing approximately $6.2 million. Amounts available under the Revolving Credit Agreement are for the working capital needs and other general corporate purposes of the Company. The Company incurred and capitalized approximately $1.1 million of debt issuance costs related to the Revolving Credit Agreement.

Outstanding borrowings under the Revolving Credit Agreement bear interest, with pricing based from time to time at the Company’s election at (i) the Secured Overnight Financing Rate (“SOFR”) plus 0.10% plus a spread ranging from 1.25% to 2.50% as determined by the Company’s Total Net Leverage Ratio (as defined in the Revolving Credit Agreement) or (ii) the alternative base rate (as defined in the Revolving Credit Agreement) plus a spread ranging from 0.25% to 1.50% as determined by the Company’s Total Net Leverage Ratio. The Revolving Credit Agreement also includes a commitment fee, which ranges from 0.20% to 0.25% as determined by the Company’s Total Net Leverage Ratio.

The Company is permitted to voluntarily prepay borrowings under the Revolving Credit Agreement, in whole or in part, without premium or penalty. On any business day on which the total amount of outstanding Revolving Loans (as defined in the Revolving Credit Agreement) and letters of credit exceeds the total Revolving Commitments (as defined in the Revolving Credit Agreement), the Company must prepay the Revolving Loans in an amount equal to such excess. As of June 30, 2023, there are no outstanding borrowings under the Revolving Credit Agreement.

The Revolving Credit Agreement contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. The Revolving Credit Agreement requires the Company to be in quarterly compliance, measured on a trailing four quarter basis, with a financial covenant. The maximum Total Net Leverage Ratio (as defined in the Revolving Credit Agreement is 3.50 to 1.00. The Company may elect to increase the maximum Total Net Leverage Ratio to 4.00 to 1.00 for a period of four consecutive quarters in connection with a Permitted Acquisition (as defined in the Revolving Credit Agreement).

The Revolving Credit Agreement contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all, or substantially all, of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.

Obligations under the Revolving Credit Agreement are secured by first priority liens over substantially all of the assets of Vericel Corporation, excluding certain subsidiaries (subject to customary exclusions set forth in the Revolving Credit Agreement and the other transaction documents).

9. Stock-Based Compensation

The Vericel Corporation 2022 Omnibus Incentive Plan (“2022 Plan”) was approved on April 27, 2022, and provides incentives through the grant of stock options, stock appreciation rights, restricted stock awards and restricted stock units. The exercise price of stock options granted under the 2022 Plan shall not be less than the fair market value of the Company’s common stock on the date of grant. The 2022 Plan replaced the 1992 Stock Option Plan, the 2001 Stock Option Plan, the Amended and Restated 2004 Equity Incentive Plan, the 2009 Second Amended and Restated Omnibus Incentive Plan, the 2017 Omnibus Incentive Plan, and the Amended and Restated 2019 Omnibus Incentive Plan (collectively the “Prior Plans”), and no new grants have been granted under the Prior Plans after approval of the 2022 Plan. However, the expiration or forfeiture of options previously granted under the Prior Plans will increase the number of shares available for issuance under the 2022 Plan.

Stock Compensation Expense

Non-cash stock-based compensation expense (service-based stock options, restricted stock units and employee stock purchase plan) is summarized in the following table:
18
 Three Months Ended June 30,Six Months Ended June 30,
(in thousands)2023202220232022
Cost of product sales$796 $1,035 $1,681 $2,153 
Research and development993 1,520 1,970 2,870 
Selling, general and administrative6,972 8,253 13,841 15,316 
Total non-cash stock-based compensation expense$8,761 $10,808 $17,492 $20,339 

Service-Based Stock Options

During the three and six months ended June 30, 2023, the Company granted service-based options to purchase common stock of 67,760 and 535,717, respectively, and 170,060 and 1,163,649, respectively, for the same periods in 2022. The weighted-average grant-date fair value of service-based options granted during the three and six months ended June 30, 2023 was $19.30 and $18.41 per option, respectively, and $19.25 and $20.74, respectively, for the same periods in 2022.

Restricted Stock Units

During the three and six months ended June 30, 2023, the Company granted 32,816 and 529,321 restricted stock units, respectively, and 39,746 and 382,768, respectively, for the same periods in 2022. The weighted-average grant-date fair value of restricted stock units granted during the three and six months ended June 30, 2023 was $32.16 and $29.97 per unit, respectively, and $31.94 and $34.65, respectively, for the same periods in 2022.

10. Net Loss Per Common Share

A summary of net loss per common share is presented below:
 Three Months Ended June 30,Six Months Ended June 30,
(Amounts in thousands, except per share amounts)2023202220232022
Net loss$(5,020)$(8,963)$(12,515)$(16,054)
   
Basic weighted-average common shares outstanding47,572 47,117 47,480 47,052 
Effect of dilutive stock options and restricted stock units— — — — 
Diluted weighted-average common shares outstanding47,572 47,117 47,480 47,052 
Basic loss per common share$(0.11)$(0.19)$(0.26)$(0.34)
Diluted loss per common share$(0.11)$(0.19)$(0.26)$(0.34)
Anti-dilutive shares excluded from diluted net loss per common share:
Stock options6,876 6,586 6,876 6,586 
Restricted stock units939 636 939 636 

11. NexoBrid License and Supply Agreements

On May 6, 2019, the Company entered into exclusive license and supply agreements with MediWound to commercialize NexoBrid in North America. The FDA subsequently approved a Biologics License Application (“BLA”) for the product on December 28, 2022. NexoBrid is a topically-administered biological product, which contains proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns.

Pursuant to the terms of the license agreement, following the FDA approval of NexoBrid, MediWound transferred the BLA to Vericel effective February 20, 2023. Both MediWound and Vericel, under the supervision of a Central Steering Committee comprised of members of both companies will continue to guide the development of NexoBrid in North America (the “Central Steering Committee”). NexoBrid is approved in the European Union (“EU”) and other international markets and has been designated as an orphan biologic in the U.S., EU and other international markets.

19
In May 2019, the Company paid MediWound $17.5 million in consideration for the license, which was recorded as research and development expense during 2019. Pursuant to the terms of the license agreement, in February 2023, the Company tendered to MediWound a $7.5 million regulatory milestone payment following the FDA’s BLA approval of NexoBrid on December 28, 2022. The Company recorded the $7.5 million milestone payment for the licensing rights to commercially sell NexoBrid in the U.S., as an intangible asset (see Note 4, “Selected Balance Sheet Components” for further details).

The Company is additionally obligated to pay MediWound up to $125.0 million, which is contingent upon meeting certain sales milestones. The first sales milestone payment of $7.5 million would be triggered when annual net sales of NexoBrid or improvements to it in North America exceed $75.0 million. As of June 30, 2023, the sales milestone payments are not yet probable and therefore, not recorded as a liability. The Company also will pay MediWound tiered royalties on net sales ranging from mid-high single-digit to mid-teen percentages, subject to customary reductions. Pursuant to the terms of the Company’s supply agreement with MediWound, MediWound will manufacture NexoBrid for the Company on a unit price basis, which may be increased pursuant to the terms of the supply agreement. MediWound is obligated to supply the Company with NexoBrid for sale in North America on an exclusive basis for the first five years of the term of the supply agreement. Under the supply agreement, the Company possesses the option to extend the initial term of the agreement by an additional 24 months, which it did in May 2022. Under the supply agreement, the Company is permitted to establish an alternate source of supply in certain circumstances, including the event of a supply failure.

Additionally, beginning in 2020 BARDA procured quantities of NexoBrid from MediWound for use as a medical countermeasure in the event of a mass casualty emergency in the U.S. involving thermal burns. The initial, quarterly, procurement of NexoBrid by BARDA under its agreement with MediWound completed during the third quarter of 2022. As a part of BARDA’s commitment to procure NexoBrid, the Company has received a percentage of gross profit for sales directly to BARDA. As of June 30, 2023, the Company did not hold a direct contract or distribution agreement with BARDA, or take title to the product procured by BARDA.

On May 9, 2023, MediWound announced BARDA’s award of additional funding under the parties’ existing agreement, $3 million of which will support the replacement of NexoBrid, previously procured for emergency response preparedness, which has since expired. Pursuant to the terms of the Company’s license agreement with MediWound, the Company will recognize revenue based on a percentage of gross profits, minus a percentage of net sales, on any sales of NexoBrid directly to BARDA, upon delivery, pursuant to this additional award.

12. Commitments and Contingencies

From time to time, the Company could be a party to various legal proceedings arising in the ordinary course of business. The costs and outcome of litigation, regulatory, investigatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in a material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its condensed consolidated financial statements.

As of June 30, 2023, the Company has no material ongoing litigation in which the Company was a party or any material ongoing regulatory or other proceedings and had no knowledge of any investigations by government or regulatory authorities in which the Company is a target that could have a material adverse effect on its current business.

20
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company and a leader in advanced therapies for the sports medicine and severe burn care markets. We currently market two U.S. Food and Drug Administration (“FDA”) approved autologous cell therapy products and one FDA-approved specialty biologic product in the U.S. MACI® is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® is a permanent skin replacement Humanitarian Use Device (“HUD”) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (“TBSA”). We also hold an exclusive license from MediWound Ltd. (“MediWound”) for North American rights to NexoBrid® (anacaulase-bcdb). On December 28, 2022, the FDA approved a Biologics License Application (“BLA”) for NexoBrid, granting a license for commercial use in the U.S. NexoBrid is a topically-administered biological product containing proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns. Following NexoBrid’s approval, we are conducting cross-functional commercial launch activities for the product, including education, training and engagement activities and the deployment of additional NexoBrid account managers. We have received the first lot of NexoBrid finished product from MediWound for the U.S. commercial market, which currently is warehoused at our third-party logistics distributor. Although this NexoBrid finished product has met all required release criteria for distribution in the U.S., we are unable to release this product into the commercial channel at this time due to a deviation associated with a third-party testing lab used during MediWound’s manufacturing process. A detailed risk assessment has concluded that the deviation presents no incremental risk to the finished product’s quality and safety and we are actively engaged with MediWound and the FDA to address this matter. Although future manufacturing of NexoBrid for the U.S. market will not be impacted because the at-issue test will be conducted directly by MediWound, absent the FDA allowing the commercial release of the finished product affected by the deviation, we expect to begin commercial sales of future NexoBrid lots during the first quarter of 2024. The FDA’s evaluation of the deviation will not affect the $3 million committed by BARDA for the replacement of NexoBrid previously procured for emergency response preparedness, which has since expired.

COVID-19

On May 11, 2023, the U.S. Department of Health and Human Services announced the expiration of the federal Public Health Emergency for COVID-19. At this juncture, the pandemic’s effects on our business and results of operations have largely moderated and we have begun to see a return to more normal operations. Should a resurgence of COVID-19 occur, or new virus variants emerge, it could result in additional disruptions that could impact our business and operations in the future, including U.S. hospital or surgical center staffing shortages, periodic cancellation or delay of elective MACI surgical procedures, intermittent restrictions on the ability of our personnel to travel and access customers for selling, marketing, training, case support and product development feedback, delays in approvals by regulatory bodies, delays in product development efforts, and additional government requirements or other incremental mitigation efforts that may further impact our capacity to manufacture, sell and support the use of our products.

The War in Ukraine

The ongoing war between Russia and Ukraine and the related sanctions and other penalties imposed by countries across the globe against Russia are continuing to create substantial uncertainty in the global economy and have contributed to heightened inflation and supply chain disruptions. While we do not have operations in Russia or Ukraine and do not have exposure to distributors, or third-party service providers in Russia or Ukraine, we are unable to predict the ultimate impact that these actions will have on the global economy or on our financial condition, results of operations, and cash flows as of the date of these condensed consolidated financial statements.

Manufacturing

We have a cell manufacturing facility in Cambridge, Massachusetts, which is used for U.S. manufacturing and distribution of MACI and Epicel. The manufacturing process for NexoBrid is conducted by MediWound, primarily at manufacturing locations in Israel. Certain raw materials utilized in NexoBrid’s manufacture, including the supply of the active ingredient bromelain, are obtained from Taiwan.


21
On July 1, 2023, we renewed our long-term supply agreement with Matricel GmbH (“Matricel”) for the supply of ACI-Maix collagen membranes used in the manufacture of MACI (the “Matricel Supply Agreement”). In the event Matricel is unable to supply the membranes, we may license the technology and procure the membranes from another source. The Matricel Supply Agreement provides that Matricel shall supply the ACI-Maix membranes exclusively to us during the term of the agreement. The Matricel Supply Agreement is effective until December 31, 2030, with an option to extend its term for three additional years to December 31, 2033. Thereafter, the Matricel Supply Agreement may be renewed for additional three-year periods.

Product Portfolio

Our marketed products include two FDA-approved autologous cell therapies: MACI, a third-generation autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults; and Epicel, a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent TBSA. Both autologous cell therapy products are currently manufactured and marketed in the U.S. Our product portfolio also includes a FDA-approved specialty biologic, NexoBrid, which is a topically-administered biological orphan product containing proteolytic enzymes that is indicated for eschar removal in adults with deep partial-thickness and/or full-thickness burns. We have entered into exclusive license and supply agreements with MediWound to commercialize NexoBrid in North America.

MACI

MACI is a third-generation autologous chondrocyte implantation (“ACI”) product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults.

Our target audiences are orthopedic surgeons who self-identify and/or have formal specialty training in sports medicine, and a subpopulation of general orthopedic surgeons who perform a high volume of cartilage repair procedures involving the knee. As of the date of this report, we employ approximately 75 MACI sales representatives to enable the sales force to reach our target audience. The team is divided into geographic regions, each managed by a Regional Manager and led by a Vice President of National MACI Sales. Most private payers have a medical policy that covers treatment with MACI with the top 30 largest commercial payers having a formal medical policy for MACI or ACI in general. With respect to private commercial payers that have not yet approved a medical policy for MACI, we often obtain approval on a case-by-case basis.

MACI is currently implanted into the patient’s cartilage defect through an open surgical procedure. We are currently evaluating the potential for the arthroscopic delivery of MACI to the cartilage defect – a procedure in which a surgeon can evaluate, prepare and treat the cartilage defect under direct arthroscopic visualization using specialized instruments delivered through a number of smaller incisions or portals. The arthroscopic delivery of MACI could increase the ease of MACI’s use for physicians and reduce both the length of the procedure as well as procedure-induced trauma, ultimately resulting in a reduction of a patient’s post-operative pain and accelerating a patient’s recovery. We have designed and are currently developing novel and specialized instruments to be used in and help facilitate such a procedure. We have recently discussed with the FDA a non-clinical regulatory strategy to support the potential inclusion of arthroscopic delivery in MACI’s approved labeling. Specifically, following a Type C meeting with the FDA, we submitted a protocol for a MACI arthroscopic delivery human factors validation study and are on track to initiate the study during the third quarter of 2023.

We also are evaluating the feasibility and potential market opportunity involved in delivering MACI treatment to patients suffering from cartilage damage in the ankle. We believe that this potential lifecycle enhancement and indication expansion for MACI will require conducting an additional randomized clinical trial concerning the product’s use in the ankle. Earlier this year, we conducted pre-IND interactions with the FDA concerning our clinical development program for MACI to treat cartilage injuries in the ankle, and based on feedback from the FDA, our team is actively working to finalize our non-clinical testing and propose a clinical development plan/protocol to FDA for review.

22
Epicel

Epicel is a permanent skin replacement for deep-dermal or full-thickness burns comprising greater than or equal to 30 percent TBSA. Epicel is regulated by the Center for Biologics Evaluation and Research (“CBER”) of the FDA under medical device authorities, and is the only FDA-approved cultured epidermal autograft product available for large total surface area burns in both adult and pediatric patients. Epicel was designated as a HUD in 1998 and a Humanitarian Device Exemption (“HDE”) application for the product was submitted in 1999. HUDs are devices that are intended for diseases or conditions that affect fewer than 8,000 individuals annually in the U.S. Under an HDE approval, a HUD cannot be sold for an amount that exceeds the cost of research and development, fabrication and distribution unless certain conditions are met. A HUD is eligible to be sold for profit after receiving HDE approval if the device meets certain eligibility criteria, including where the device is intended for the treatment of a disease or condition that occurs in pediatric patients and such device is labeled for use in pediatric patients. If the FDA determines that a HUD meets the eligibility criteria, the HUD is permitted to be sold for profit so long as the number of devices distributed in any calendar year does not exceed the Annual Distribution Number (“ADN”). The ADN is defined as the number of devices reasonably needed to treat a population of 8,000 individuals per year in the U.S.

On February 18, 2016, the FDA approved our HDE supplement to revise the labeled indications of use for Epicel to specifically include pediatric patients. The revised product label also now specifies that the probable benefit of Epicel, mainly related to survival, was demonstrated in two Epicel clinical experience databases and a physician-sponsored study comparing outcomes in patients with large burns treated with Epicel relative to standard care. Because of the change in the label to specifically include use in pediatric patients, Epicel is no longer subject to the HDE profit restrictions. In conjunction with adding the pediatric labeling and meeting the pediatric eligibility criteria, the FDA has determined the ADN number for Epicel to be 360,400 which is approximately 40 times larger than the volume of grafts sold in 2022. As of the date of this report, our burn care field force consists of individual sales and clinical representatives that regularly engage with our target audience. The team is divided into geographic regions, each managed by a Regional Manager and led by a Vice President of National Burn Care Sales.

NexoBrid

Our portfolio of commercial-stage products now includes NexoBrid (anacaulase-bcdb), a topically-administered biological product containing proteolytic enzymes. The FDA approved NexoBrid on December 28, 2022, and the product is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns. We have entered into exclusive license and supply agreements with MediWound to commercialize NexoBrid in North America.

NexoBrid is approved in the European Union (“EU”) and other international markets and has been designated as an orphan biologic in the U.S., EU and other international markets. NexoBrid has the potential to change the standard of care for eschar removal with respect to hospitalized burn patients and treat a significant addressable market in the U.S. With respect to NexoBrid, of the approximately 40,000 burn patients that are hospitalized in the U.S. each year, the majority, over 30,000, have thermal burns and will likely require some level of eschar removal. NexoBrid’s FDA approval expands our burn care franchise’s total addressable market, which will permit us to treat a significantly larger segment of hospitalized burn patients than with Epicel alone. The expansion of our target addressable market supports a broader commercial footprint, and we believe that this may help drive both increased NexoBrid use as well as increased Epicel awareness throughout the burn care space. With NexoBrid’s approval, our cross-functional commercial launch activities for the product are underway, including education, training, and engagement activities.

The manufacturing process for NexoBrid is conducted by MediWound, primarily at manufacturing locations in Israel. Certain raw materials utilized in NexoBrid’s manufacture, including the supply of the active ingredient bromelain are obtained from Taiwan. We have received the first lot of NexoBrid finished product from MediWound for the U.S. commercial market, which currently is warehoused at our third-party logistics distributor. Although this NexoBrid finished product has met all required release criteria for distribution in the U.S., we are unable to release this product into the commercial channel at this time due to a deviation associated with a third-party testing lab used during MediWound’s manufacturing process. A detailed risk assessment has concluded that the deviation presents no incremental risk to the finished product’s quality and safety and we are actively engaged with MediWound and the FDA to address this matter. Although future manufacturing of NexoBrid for the U.S. market will not be impacted because the at-issue test will be conducted directly by MediWound, absent the FDA allowing the commercial release of the finished product affected by the deviation, we expect to begin commercial sales of future NexoBrid lots during the first quarter of 2024. The FDA’s evaluation of the deviation will not affect the $3 million committed by BARDA for the replacement of NexoBrid previously procured for emergency response preparedness, which has since expired.


23
Results of Operations

The following is a summary of our condensed consolidated results of operations:
 Three Months Ended June 30,Six Months Ended June 30,
(In thousands)20232022Change $Change %20232022Change $Change %
Total revenue$45,922 $37,046 $8,876 24.0 %$86,939 $73,120 $13,819 18.9 %
Cost of product sales15,981 14,192 1,789 12.6 %30,478 26,814 3,664 13.7 %
Gross profit29,941 22,854 7,087 31.0 %56,461 46,306 10,155 21.9 %
Research and development5,253 4,792 461 9.6 %10,465 9,652 813 8.4 %
Selling, general and administrative30,649 27,144 3,505 12.9 %60,134 53,009 7,125 13.4 %
Total operating expenses35,902 31,936 3,966 12.4 %70,599 62,661 7,938 12.7 %
Loss from operations(5,961)(9,082)3,121 (34.4)%(14,138)(16,355)2,217 (13.6)%
Total other income941 119 822 690.8 %1,623 301 1,322 439.2 %
Net loss$(5,020)$(8,963)$3,943 (44.0)%$(12,515)$(16,054)$3,539 (22.0)%

Comparison of the Periods Ended June 30, 2023 and 2022

Total Revenue

Revenue by product is as follows:

 Three Months Ended June 30,Six Months Ended June 30,
(In thousands)20232022Change $Change %20232022Change $Change %
MACI$36,336 $28,613 $7,723 27.0 %$70,526 $54,607 $15,919 29.2 %
Epicel9,586 8,213 1,373 16.7 %16,413 18,071 (1,658)(9.2)%
NexoBrid— 220 (220)(100.0)%— 442 (442)(100.0)%
Total revenue$45,922 $37,046 $8,876 24.0 %$86,939 $73,120 $13,819 18.9 %

Total revenue increase for the three and six months ended June 30, 2023 compared to the same periods in 2022, was driven primarily by higher MACI volume and price growth.

Seasonality. As a result of the uncertainty and other impacts of the COVID-19 pandemic and the resulting shifts of timing in some revenue, our historically observable seasonality of revenues has been impacted or obscured in 2022 and 2023 and potentially beyond. At this juncture the pandemic’s effects on our business and results of operations have largely moderated, although there continues to be a level of uncertainty whether MACI seasonality will return to pre-pandemic patterns. In the last five years through 2022, MACI sales volumes from the first through the fourth quarter on average represented 20% (18%-21% range), 21% (16%-24% range), 24% (21%-26% range) and 35% (33%-38% range) respectively, of total annual volumes. Historically, MACI orders are normally stronger in the fourth quarter due to several factors including the satisfaction by patients of insurance deductible limits and the time of year patients prefer to start rehabilitation. Due to the low incidence and variable occurrence of severe burns, Epicel revenue has inherent variability from quarter-to-quarter and does not exhibit significant seasonality.

Gross Profit

Gross profit increase for the three and six months ended June 30, 2023, compared to the same periods in 2022, was driven by higher MACI volume and price growth, which more than offset higher employee costs, raw material price increases and higher external storage and manufacturing facility costs.

24
Research and Development Expenses

The following table summarizes research and development expenses, which include materials, professional fees and an allocation of employee-related salary and fringe benefit costs for our research and development projects:

 Three Months Ended June 30,Six Months Ended June 30,
(In thousands)20232022Change $Change %20232022Change $Change %
MACI$3,319 $2,972 $347 11.7 %$6,392 $5,961 $431 7.2 %
Epicel914 1,238 (324)(26.2)%2,085 2,458 (373)(15.2)%
NexoBrid1,020 582 438 75.3 %1,988 1,233 755 61.2 %
Total research and development expenses$5,253 $4,792 $461 9.6 %$10,465 $9,652 $813 8.4 %

Research and development expenses increased for the three and six months ended June 30, 2023 compared to the same periods in 2022, primarily due to lower reimbursement of expenses from MediWound related to NexoBrid BLA resubmission that occurred in 2022 and MACI arthroscopic program costs.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the three months ended June 30, 2023 were $30.6 million, compared to $27.1 million for the same period in 2022. The increase in selling, general and administrative expenses was primarily due to higher marketing expenses, external costs and lease expense associated with the Burlington Lease.

Selling, general and administrative expenses for the six months ended June 30, 2023 were $60.1 million, compared to $53.0 million for the same period in 2022. The increase in selling, general and administrative expenses was primarily due to higher headcount and employee expenses, additional travel and in-person events across the commercial organization, and an increase in marketing and external expenses, which were partially offset by lower stock-based compensation expenses.

Total Other Income 

The change in other income for the three and six months ended June 30, 2023, compared to the same periods in 2022 was due primarily to fluctuations in the rates of return on our investments in various marketable debt securities slightly offset by interest expense related to our Revolving Credit Agreement.

Stock-based Compensation Expense

Non-cash stock-based compensation expense is summarized in the following table: 

 Three Months Ended June 30,Six Months Ended June 30,
(In thousands)20232022Change $Change %20232022Change $Change %
Cost of product sales$796 $1,035 $(239)(23.1)%$1,681 $2,153 $(472)(21.9)%
Research and development993 1,520 (527)(34.7)%1,970 2,870 (900)(31.4)%
Selling, general and administrative6,972 8,253 (1,281)(15.5)%13,841 15,316 (1,475)(9.6)%
Total non-cash stock-based compensation expense$8,761 $10,808 $(2,047)(18.9)%$17,492 $20,339 $(2,847)(14.0)%

The decrease in stock-based compensation expense for the three and six months ended June 30, 2023, compared to the same periods in 2022, was due primarily to fluctuations in stock prices and the mix of service-based options and restricted stock units, which impacts the fair value of the options and restricted stock units awarded and the expense recognized in the period.


25
Liquidity and Capital Resources

Cash Flows

The following table summarizes our sources and uses of cash for each of the periods presented:

Six Months Ended June 30,
(In thousands)20232022
Net cash provided by operating activities$18,056 $6,611 
Net cash provided by (used in) investing activities392 (13,666)
Net cash provided by financing activities1,302 752 
Net increase (decrease) in cash, cash equivalents, and restricted cash$19,750 $(6,303)

Net Cash Provided by Operating Activities

Our cash, cash equivalents and restricted cash totaled $70.8 million, short-term investments totaled $54.8 million and long-term investments totaled $21.0 million as of June 30, 2023. The $18.1 million of cash provided by operations during the six months ended June 30, 2023 was primarily the result of non-cash charges of $17.5 million related to stock-based compensation expense, $2.5 million of operating lease amortization and $2.3 million in depreciation and amortization expense, offset by a net loss of $12.5 million and a net increase of $8.7 million related to movements in our working capital accounts. The overall increase in cash from our working capital accounts was primarily driven by a decrease in accounts receivable due to cash collections and receipts of tenant improvement allowances, offset by a decrease in accrued expenses due to timing of payments.

Our cash, cash equivalents and restricted cash totaled $62.2 million, short-term investments totaled $44.6 million and long-term investments totaled $23.7 million as of June 30, 2022. The $6.6 million of cash provided by operations during the six months ended June 30, 2022 was primarily the result of non-cash charges of $20.3 million related to stock-based compensation expense, $2.2 million of operating lease amortization, $1.9 million in depreciation and amortization expense, offset by a net loss of $16.1 million and a net decrease of $2.1 million related to movements in our working capital accounts. The overall decrease in cash from our working capital accounts was primarily driven by a decrease in accrued expenses due to timing of payments, a decrease in operating lease liabilities, and an increase in inventory due to increased production needs, offset by a decrease in accounts receivable due to cash collections.

Net Cash Provided By (Used In) Investing Activities

Net cash provided by investing activities during the six months ended June 30, 2023 was the result of $42.0 million of investment sales and maturities, offset by $28.5 million in investment purchases, a $7.5 million regulatory milestone payment to MediWound resulting from the FDA’s approval of the NexoBrid BLA, and $5.6 million of property and equipment purchases primarily for manufacturing upgrades and construction in process related to the Burlington Lease.

Net cash used in investing activities during the six months ended June 30, 2022 was the result of $34.9 million in investments purchases and $5.1 million of property and equipment purchases primarily for manufacturing upgrades and leasehold improvements, offset by $26.3 million of investment sales and maturities.

Net Cash Provided by Financing Activities

Net cash provided by financing activities during the six months ended June 30, 2023 was the result of net proceeds from the exercise of stock options and purchases under the employee stock purchase plan of $3.5 million, partially offset by the payment of employee withholding taxes related to the vesting of restricted stock units of $2.2 million.

Net cash provided by financing activities during the six months ended June 30, 2022 was primarily the result of net proceeds from the exercise of stock options and purchases under the employee stock purchase plan of $2.2 million partially offset by payments of employee withholding taxes related to the vesting of restricted stock units of $1.4 million.

26
Liquidity

Since our acquisition of MACI and Epicel in 2014, our primary focus has been to invest in our existing commercial business with the goal of growing revenue. We have raised significant funds in order to advance and complete our product development and product life-cycle management programs and to market and commercialize our products, including NexoBrid. To date, we have financed our operations primarily through cash received through MACI and Epicel sales, debt, and public and private sales of our equity securities. We may finance our operations through the sales of equity securities, revolver borrowings or other debt financings, in addition to cash generated from operations.

We believe that our current cash on hand, cash equivalents, investments, and available borrowing capacity will be sufficient to support our current operations through at least 12 months from the issuance of the condensed consolidated financial statements included in this report. Although the effects of the COVID-19 pandemic have largely moderated in recent months, our business and operations may be adversely affected in the future if conditions were to worsen. Our actual cash requirements may differ from projections and will depend on many factors, including the level and pace of future research and development efforts, the scope and results of ongoing and potential clinical trials, the costs involved in filing, prosecuting and enforcing patents, the need for additional manufacturing capacity, competing technological and market developments, global macroeconomic conditions, costs associated with possible acquisitions or development of complementary business activities, and the cost to market our products.

As of June 30, 2023, we were not party to any off-balance sheet arrangements.

Sources of Capital

On August 27, 2021, we entered into a Sales Agreement with Leerink Partners (f/k/a SVB Leerink LLC), as sales agent, pursuant to which we may offer and sell up to $200.0 million of shares of our common stock, no par value per share (“ATM Shares”). The ATM Shares to be offered and sold under the Sales Agreement will be issued and sold pursuant to an automatically effective shelf registration statement on Form S-3ASR (File No. 333-259119) filed by us on August 27, 2021, which expires three years from the filing date. We also filed a prospectus supplement relating to the offering and sale of the ATM Shares on August 27, 2021. We are not obligated to make any sales of ATM Shares, and Leerink Partners is not required to sell any specific number or dollar amount of the ATM Shares under the Sales Agreement. As of June 30, 2023, we have sold no shares pursuant to the Sales Agreement.

On July 29, 2022, we entered into a $150.0 million five-year senior secured revolving credit agreement by and among the Company, the other loan parties thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as the administrative agent (the “Revolving Credit Agreement”). We have no immediate plans to borrow under the Revolving Credit Agreement, but we may use the facility for working capital needs and other general corporate purposes. As of June 30, 2023, there are no outstanding borrowings under the Revolving Credit Agreement, and we are in compliance with all applicable covenant requirements. See Note 8, “Revolving Credit Agreement” in the accompanying condensed consolidated financial statements for further details.

Contractual Obligations and Commitments

The disclosure of our contractual obligations and commitments is set forth in the heading “Management’s Discussion and Analysis of Financial Conditions and Results of Operations - Contractual Obligations” in our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no material changes, outside of the ordinary course of business, to our contractual obligations and commitments since December 31, 2022, except as noted below.

In April 2023, in connection with the Burlington Lease, we entered into a construction escrow agreement (the “Construction Escrow Agreement”) with the facility’s landlord and an escrow agent. Pursuant to the terms of the Construction Escrow Agreement, in April 2023 we began funding into an escrow account maintained by the escrow agent a portion of our share of tenant improvement construction costs at the facility, which will be designated as restricted cash. At the same time, the facility’s landlord began funding a portion of its tenant improvement allowance through a separate escrow account. To date, we have transferred into our escrow account 50% of our required cost amount, or approximately $28.3 million. We anticipate funding the remaining 50% of our required cost amount in late 2023 or early 2024. Additionally, and in order to support the expansion of our autologous cell manufacturing operations at the new facility in Burlington, we plan to invest in the acquisition and installation of certain specialized manufacturing and laboratory equipment.

27
On July 1, 2023, we renewed our long-term supply agreement with Matricel for the supply of ACI-Maix collagen membranes used in the manufacture of MACI. Under the terms of the Matricel Supply Agreement, we have committed to annual minimum purchase values totaling approximately €12.5 million over the eight-year term.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect our reported assets, liabilities, revenues, expenses, and related disclosures. Actual results may differ materially from these estimates under different assumptions and conditions.

There have been no material changes to our critical accounting policies and estimates in the six months ended June 30, 2023. For further information, refer to our summary of significant accounting policies and estimates in our Annual Report on Form 10-K filed for the year ended December 31, 2022.

Cautionary Note Regarding Forward-Looking Statements

This report, including the documents incorporated by reference herein, contains certain statements that describe our management’s beliefs concerning future business conditions, plans and prospects, growth opportunities and the outlook for our business based upon information currently available. Such statements are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). Wherever possible, we have identified these forward-looking statements by words such as “will,” “may,” “anticipates,” “believes,” “intends,” “estimates,” “expects,” “plans,” “projects,” “trends,” “opportunity,” “current,” “intention,” “position,” “assume,” “potential,” “outlook,” “remain,” “continue,” “maintain,” “sustain,” “seek,” “target,” “achieve,” “continuing,” “ongoing,” and similar words or phrases, or future or conditional verbs such as “would,” “should,” “could,” “may,” or similar expressions. Among the factors that could cause actual results to differ materially from those set forth in the forward-looking statements include, but are not limited to, uncertainties associated with our expectations regarding future revenue, growth in revenue, market penetration for MACI®, Epicel®, and NexoBrid®, growth in profit, gross margins and operating margins, the ability to continue to scale our manufacturing operations to meet the demand for our cell therapy products, including the timely completion of a new headquarters and manufacturing facility in Burlington, Massachusetts, the ability to achieve or sustain profitability, the expected target surgeon audience, potential fluctuations in sales and volumes and our results of operations over the course of the year, timing and conduct of clinical trial and product development activities, timing and likelihood of the FDA’s potential approval of the arthroscopic delivery of MACI to the knee or the use of MACI to treat cartilage defects in the ankle, the estimate of the commercial growth potential of our products and product candidates, competitive developments, changes in third-party coverage and reimbursement, the ultimate timing of the commercial launch of NexoBrid in the United States, physician and burn center adoption of NexoBrid, supply chain disruptions, regulatory decisions or other events affecting MediWound Ltd.’s ability to manufacture and supply NexoBrid to meet customer demand, negative impacts on the global economy and capital markets resulting from the conflict in Ukraine, adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, global geopolitical tensions or record inflation and potential future impacts on our business or the economy generally stemming from a resurgence of COVID-19 or another similar public health emergency. These forward-looking statements are based upon assumptions our management believes are reasonable. Such forward-looking statements are subject to risks and uncertainties, which could cause our actual results, performance and achievements to differ materially from those expressed in, or implied by, these statements, including, among others, the risks and uncertainties listed in our Annual Report under “Part I, Item 1A Risk Factors” and the risk listed in this Quarterly Report under “Part I, Item 1A Risk Factors.”

Because our forward-looking statements are based on estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different and any or all of our forward-looking statements may turn out to be wrong. Forward-looking statements speak only as of the date made and can be affected by assumptions we might make or by known or unknown risks and uncertainties. Many factors mentioned in our discussion in our Annual Report on Form 10-K will be important in determining future results. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. Consequently, we cannot assure you that our expectations or forecasts expressed in such forward-looking statements will be achieved. Except as required by law, we undertake no obligation to publicly update any of our forward-looking or other statements, whether as a result of new information, future events, or otherwise.


28
Item 3. Quantitative and Qualitative Disclosures About Market Risk

For quantitative and qualitative disclosures about market risk, see Part II, Item 7A. “Quantitative and Qualitative Disclosures About Market Risk,” of our Annual Report on Form 10-K for the year ended December 31, 2022. Our exposures to market risk have not changed materially since December 31, 2022.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer (its Certifying Officers), evaluated the effectiveness of the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on the evaluation as of June 30, 2023, the Company’s Certifying Officers concluded that the Company’s disclosure controls and procedures were effective.

The Company has established disclosure controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to management of the Company, with the participation of its Certifying Officers, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

During the three months ended June 30, 2023, there were no material changes made in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act).


PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We are currently not party to any material legal proceedings, although from time to time we may become involved in disputes in connection with the operation of our business.

Item 1A. Risk Factors

Factors that could cause the Company’s actual results to differ materially from those in this Quarterly Report are any of the risks described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on February 23, 2023. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, except as follows.

Adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, such as actual events or concerns involving liquidity, defaults or non-performance, could adversely affect our operations and liquidity.

Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds, have in the past and may in the future lead to market-wide liquidity problems.

29
We maintain cash and investments that are held in a number of investment and deposit accounts at leading financial institutions. The amounts held in the deposit accounts are in excess of the insurance coverage offered by the U.S. Department of Treasury, Federal Deposit Insurance Corporation (“FDIC”), and we may in the future, continue to have assets held at financial institutions that exceed the insurance coverage offered by the FDIC, the loss of which would have a severe negative effect on our operations and liquidity. Uncertainty and liquidity concerns in the broader financial services industry remain. Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates.

Our access to our cash and cash equivalents in amounts adequate to finance our operations could be significantly impaired if the financial institutions with which we have arrangements directly face liquidity constraints or failures. In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any material decline in available funding or our ability to access our cash and cash equivalents could adversely impact our ability to meet our operating expenses, result in breaches of our contractual obligations or result in violations of federal or state wage and hour laws, any of which could have material adverse impacts on our operations and liquidity. Furthermore, should our customers have relationships with financial institutions that fail, this may result in a delay of collecting outstanding receivables, which could have a material adverse effect on our business.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Rule 10b5-1 Trading Plans

During the fiscal quarter ended June 30, 2023, none of the Company’s directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”

30
Item 6. Exhibits

The Exhibits listed in the Exhibit Index are filed as a part of this Quarterly Report on Form 10-Q.

EXHIBIT INDEX

Incorporated by Reference
Exhibit NumberDescription of ExhibitsFormFile NumberExhibitFiling Date
3.18-K000-220254.1December 17, 2009
3.2S-1333-1600443.2March 31, 2010
3.38-K000-220253.1March 25, 2011
3.48-K001-352803.1November 24, 2014
3.58-K000-220253.1November 12, 2010
4.110-K001-352804.5February 25, 2020
10.1#*
10.2*
31.1*
31.2*
32.1*
101.INS*Inline XBRL Instance Document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document
104*

# Management contract or compensatory plan or arrangement covering executive officers or directors of Vericel.
* Filed herewith.

31

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
Date: August 2, 2023
 
 VERICEL CORPORATION
  
  
 /s/ DOMINICK C. COLANGELO
 Dominick C. Colangelo
 President and Chief Executive Officer
 (Principal Executive Officer)
  
  
 /s/ JOSEPH A. MARA
 Joseph A. Mara
 Chief Financial Officer
 (Principal Financial Officer)


32
 EX-10.1 2 ex101vericelcorporationdef.htm EX-10.1 Document











VERICEL CORPORATION
DEFERRED COMPENSATION PLAN





Effective May 3, 2023
























TABLE OF CONTENTS

Page

ARTICLE 1Definitions1
1.1Account1
1.2Annual Account1
1.3Annual Deferral Amount1
1.4Annual Installment Method1
1.5Base Salary2
1.6Beneficiary2
1.7Beneficiary Designation Form2
1.8Benefit Distribution Date2
1.9Board2
1.1Bonus2
1.11Cash Account3
1.12Cash Director Fees3
1.13Change in Control3
1.14Code3
1.15Committee3
1.16Company Contribution Amount3
1.17Company Group3
1.18Director3
1.19Disability or Disabled3
1.2Election Form3
1.21Employee3
1.22Equity Plan3
1.23ERISA4
1.24Participant4
1.25Performance-Based Compensation4
1.26Plan Agreement4
1.27Plan Year4
1.28Restricted Stock Unit or RSU4
1.29RSU Amount4
1.3Section 409A4
1.31Separation from Service4
1.32Stock4
1.33Stock Account4
1.34Trust5
1.35Unforeseeable Emergency5
ARTICLE 2Selection, Enrollment, Eligibility5
2.1Selection by Committee5
i

2.2Enrollment and Eligibility Requirements5
ARTICLE 3Deferrals, Vesting, Crediting & Taxes5
3.1Maximum Deferral5
(a) Cash Annual Deferral Amount5
(b) RSU Amount6
(c) Short Plan Year6
3.2Timing of Deferral Elections; Effect of Election Form6
(a) General Timing Rule for Deferral Elections6
(b) Timing of Deferral Elections for Newly Eligible Plan Participants6
(c) RSU Deferral7
(d) Timing of Deferral Elections for Performance-Based Compensation7
(e) Timing Rule for Deferral of Compensation Subject to Risk of Forfeiture8
3.3Withholding and Crediting of Annual Deferral Amounts8
3.4Company Contribution Account8
3.5RSUs9
3.6Vesting9
3.7Crediting/Debiting of Accounts9
(a) Cash Account9
(b) Stock Account11
3.8FICA and Other Taxes13
(a) Annual Deferral Amounts13
(b) Company Contribution Amounts13
(c) RSU Amount13
(d) Distributions13
ARTICLE 4In-Service Distributions of Account, Unforeseeable Emergency13
4.1Scheduled Distribution13
4.2Postponing Scheduled Distributions14
4.3Other Benefits Take Precedence Over Scheduled Distributions14
4.4Unforeseeable Emergencies14
ARTICLE 5Other Distributions of Account15
5.1Termination Benefit15
ii

(a) Termination Benefit15
(b) Timing of Termination Benefits15
(c) Election of Payment Form15
(d) Modification of Payment Form15
(e) Timing of Payments16
5.2Change in Control Benefits16
5.3Disability Benefit16
5.4Death Benefit16
ARTICLE 6Beneficiary Designation17
6.1Beneficiary17
6.2Beneficiary Designation; Change17
6.3Acknowledgment17
6.4No Beneficiary Designation17
6.5Discharge of Obligations17
ARTICLE 7Leave of Absence17
7.1Paid Leave of Absence17
7.2Unpaid Leave of Absence17
ARTICLE 8Termination of Plan, Amendment or Modification18
8.1Termination of Plan18
8.2Amendment18
8.3Effect of Payment18
ARTICLE 9Administration18
9.1Committee Duties18
9.2Agents18
9.3Binding Effect of Decisions19
9.4Indemnity of Committee19
9.5Section 16 Compliance19
ARTICLE 10Claims Procedures19
10.1Presentation of Claim19
10.2Notification of Decision19
10.3Review of a Denied Claim20
10.4Decision on Review20
10.5Legal Action21
ARTICLE 11Trust21
iii

11.1Establishment of the Trust21
11.2Interrelationship of the Plan and the Trust21
11.3Distributions From the Trust21
ARTICLE 12Miscellaneous22
12.1Status of Plan22
12.2Section 409A22
12.3Unsecured General Creditor22
12.4Company’s Liability22
12.5Nonassignability22
12.6Not a Contract of Employment23
12.7Furnishing Information23
12.8Terms23
12.9Captions23
12.1Governing Law23
12.11Notice23
12.12Successors24
12.13Spouse’s Interest24
12.14Validity24
12.15Incompetent24

iv

VERICEL CORPORATION
DEFERRED COMPENSATION PLAN

Establishment and Purpose

Vericel Corporation, a Michigan corporation (the “Company”), hereby establishes this deferred compensation plan to be known as the Vericel Corporation Deferred Compensation Plan as amended and restated from time to time (the “Plan”), effective May 3, 2023. With respect to Directors, the Plan is intended to amend, restate and supersede the Vericel Corporation Non-Employee Directors’ Deferred Compensation Program. The terms of such program will remain in place for all deferrals made by Directors under such program prior to the effective date of the Plan.

The purpose of the Plan is to provide specified benefits to Directors and a select group of management or highly compensated Employees who contribute materially to the continued growth, development and future business success of the Company. The Plan does not authorize or contemplate the issuance of any Stock beyond the Stock authorized and issued under the Equity Plan. The Plan shall be unfunded for tax purposes and for purposes of Title I of ERISA.

ARTICLE 1
Definitions

For the purposes of the Plan, unless otherwise clearly apparent from the context, the following phrases or terms shall have the following indicated meanings:

1.1Account shall mean, with respect to a Participant, an entry on the records of the Company equal to the sum of the Participant’s Annual Accounts, which are allocated to a Participant’s Cash Account and/or Stock Account, as applicable. An Account shall be a bookkeeping entry only and shall be utilized solely as a device for the measurement and determination of the amounts to be paid to a Participant, or his or her designated Beneficiary, pursuant to the Plan.

1.2Annual Account shall mean, with respect to a Participant, an entry on the records of the Company equal to (a) the sum of the Participant’s Annual Deferral Amount, Company Contribution Amount and RSU Amount for any one Plan Year, plus (b) amounts credited or debited to such amounts pursuant to the Plan, less (c) all distributions made to the Participant or his or her Beneficiary pursuant to the Plan that relate to the Annual Account for such Plan Year. The Annual Account shall be a bookkeeping entry only and shall be utilized solely as a device for the measurement and determination of the amounts to be paid to a Participant, or his or her designated Beneficiary, pursuant to the Plan.

1.3Annual Deferral Amount shall mean that portion of a Participant’s Base Salary, Bonus, or Cash Director Fees that a Participant defers in accordance with Article 3 for any one Plan Year, without regard to whether such amounts are withheld and credited during such Plan Year.

1.4Annual Installment Method shall mean the method used to determine the amount of each payment due to a Participant who has elected to receive a benefit over a period of years in
1

accordance with the applicable provisions of the Plan. The amount of each annual payment due to the Participant shall be calculated by multiplying the balance of the Participant’s benefit by a fraction, the numerator of which is one and the denominator of which is the remaining number of annual payments due to the Participant. Shares of Stock distributable from a Participant’s Stock Account shall be distributable in shares of actual Stock in the same manner previously described, with any fractional shares distributed in cash. The amount of the first annual payment shall be calculated as of the close of business on or around the Participant’s Benefit Distribution Date, and the amount of each subsequent annual payment shall be calculated on or around each anniversary of such Benefit Distribution Date.

1.5Base Salary shall mean the Participant’s base salary relating to services performed during any calendar year, subject to the provisions of Section 3.3 related to the final payroll period of the year. Base Salary shall be calculated before reduction for compensation voluntarily deferred or contributed by the Participant pursuant to all qualified or nonqualified plans of the Company Group and shall be calculated to include amounts not otherwise included in the Participant’s gross income under Code Sections 125, 402(e)(3), 402(h), or 403(b) pursuant to plans established by the Company Group; provided, however, that all such amounts will be included in compensation only to the extent that had there been no such plan, the amount would have been payable in cash to the Employee. For the avoidance of doubt, “Base Salary” shall exclude, without limitation, all bonuses, all incentive payments, commissions, overtime, fringe benefits (cash and noncash), stock options, restricted stock units, performance share unit awards, other equity-based awards, relocation expenses, nonqualified deferred compensation, non-monetary awards, moving expense and other reimbursements, welfare benefits, severance and automobile and other allowances.

1.6Beneficiary shall mean one or more persons, trusts, estates or other entities, designated in accordance with Article 6, that are entitled to receive benefits under the Plan upon the death of a Participant.

1.7Beneficiary Designation Form shall mean the written or electronic form established from time to time by the Committee that a Participant returns to the Committee to designate one or more Beneficiaries.

1.8Benefit Distribution Date shall mean the date upon which all or an objectively determinable portion of a Participant’s benefits will become eligible for distribution in accordance with Article 4 or 5.

1.9Board shall mean the Board of Directors of the Company.

1.10Bonus shall mean any periodic cash bonus earned by the Participant pursuant to applicable Company guidelines. Bonus shall be calculated before reduction for compensation voluntarily deferred or contributed by the Participant pursuant to all qualified or nonqualified plans of the Company Group and shall be calculated to include amounts not otherwise included in the Participant’s gross income under Code Sections 125, 402(e)(3), 402(h), or 403(b) pursuant to plans established by the Company Group; provided, however, that all such amounts will be included in compensation only to the extent that had there been no such plan, the amount would have been payable in cash to the Employee.

2

1.11Cash Account shall mean the aggregate value, measured on any given date, of (i) the cash deferred by a Participant as a result of deferrals of Base Salary, Bonus and Cash Director Fees, plus (ii) amounts credited or debited to such amounts pursuant to the Plan, less (iii) the any amount previously distributed from the Cash Account to the Participant or his or her Beneficiary pursuant to the Plan. The Cash Account shall be a bookkeeping entry only and shall be utilized solely as a device for the measurement and determination of the amounts to be paid to a Participant, or his or her designated Beneficiary, pursuant to the Plan.

1.12Cash Director Fees shall mean the annual fees payable in cash that are earned by a Director from the Company, including retainer fees and meetings fees, as compensation for serving on the Board.

1.13Change in Control shall have the meaning set forth in the Equity Plan; provided, however, a transaction will not be deemed a Change in Control unless the transaction qualifies as a change in control event within the meaning of Section 409A.

1.14Code shall mean the Internal Revenue Code of 1986, as it may be amended from time to time.

1.15Committee shall mean the Compensation Committee of the Board or a subcommittee formed by the Compensation Committee to act as the Committee hereunder.

1.16Company Contribution Amount shall mean, for any one Plan Year, the amount determined in accordance with Section 3.4.

1.17Company Group shall mean the Company and any “parent corporation” (as defined in Section 424(e) of the Code) and any “subsidiary corporation” (defined in Section 424(f) of the Code), whether now or hereafter existing.

1.18Director shall mean any non-employee member of the Board.

1.19Disability or Disabled shall mean either (i) the Social Security Administration determines that a Participant is totally disabled; or (ii) a Participant incurs a mental or physical impairment that would qualify the Participant for long-term disability benefits under a Company-sponsored long-term disability program as in effect from time to time, provided that the definition of “disability” applied under such long-term disability program complies with Section 409A.

1.20Election Form shall mean the form, which may be in electronic format, established from time to time by the Committee that a Participant returns to the Committee to make an election under the Plan. An Election Form will apply only to the Plan Year for which it is submitted.

1.21Employee shall mean a person classified as a full-time U.S. employee by the Company Group for payroll purposes.

1.22Equity Plan shall mean the Vericel Corporation 2022 Omnibus Incentive Plan, as it may be amended from time to time.

3

1.23ERISA shall mean the Employee Retirement Income Security Act of 1974, as it may be amended from time to time.

1.24Participant shall mean any Employee or Director (a) who is selected and becomes a participant in the Plan as provided in Article 2, and (b) whose Account has not been completely distributed.

1.25Performance-Based Compensation shall mean compensation, the entitlement to or amount of which is contingent on the satisfaction of pre-established organizational and/or individual performance criteria relating to a performance period of at least 12 consecutive months, as determined by the Committee in accordance with Treas. Reg. §1.409A-1(e).

1.26Plan Agreement shall mean an agreement, if any, in the form prescribed by or acceptable to the Committee that evidences a Participant’s agreement to the terms of the Plan and which may establish additional terms or conditions of Plan participation for a Participant. Unless otherwise determined by the Committee, the most recent Plan Agreement accepted with respect to a Participant shall supersede any prior Plan Agreements for such Participant. Plan Agreements may vary among Participants and may provide additional benefits not set forth in the Plan or limit the benefits otherwise provided under the Plan.

1.27Plan Year shall mean a period beginning on January 1 of each calendar year and continuing through December 31 of such calendar year.

1.28Restricted Stock Unit or RSU shall mean the right to receive a share of Company common stock in the future, as awarded to the Participant under the Equity Plan.

1.29RSU Amount shall mean, with respect to a Participant for any one Plan Year, the number of RSUs deferred in accordance with Section 3.1(b).

1.30Section 409A shall mean Section 409A of the Code and any regulations or other formal guidance promulgated thereunder.

1.31Separation from Service shall mean a Participant’s “separation from service” with the Company Group within the meaning of Section 409A.

1.32Stock shall mean the common stock of the Company.

1.33Stock Account shall mean the aggregate value, measured on any given date, of (i) the number of RSUs deferred by a Participant as a result of all RSUs Amounts, plus (ii) the number of additional shares of Stock credited to a Participant’s Stock Account as a result of Stock dividends in accordance with Section 3.7(b)(ii) the Plan, less (iii) the number of RSUs previously distributed to the Participant or his or her Beneficiary pursuant to the Plan. The Stock Account shall be a bookkeeping entry only and shall be utilized solely as a device for the measurement and determination of the amounts to be paid to a Participant, or his or her designated Beneficiary, pursuant to the Plan.

4

1.34Trust shall mean one or more trusts established by the Company in accordance with Article 11.

1.35Unforeseeable Emergency shall mean a severe financial hardship of the Participant resulting from (a) an illness or accident of the Participant, the Participant’s spouse, the Participant’s Beneficiary or the Participant’s dependent (as defined in Section 152 of the Code without regard to paragraphs (b)(1), (b)(2) and (d)(1)(B) thereof), (b) a loss of the Participant’s property due to casualty, or (c) such other similar extraordinary and unforeseeable circumstances arising as a result of events beyond the control of the Participant, all as determined by the Committee based on the relevant facts and circumstances and in accordance with Section 409A.

ARTICLE 2
Selection, Enrollment, Eligibility

2.1Selection by Committee. Participation in the Plan shall be limited to Directors and, as determined by the Committee in its sole discretion, a select group of management or highly compensated Employees. From that group, the Committee shall select, in its sole discretion, those individuals who may actually participate in the Plan.

2.2Enrollment and Eligibility Requirements.

(a)As a condition to participation, each Director or selected Employee shall complete, execute and return to the Committee such written or electronic forms and information as the Committee may require, which may include a Plan Agreement, an Election Form and a Beneficiary Designation Form, by the deadline(s) established by the Committee in accordance with the applicable provisions of the Plan. In addition, the Committee shall establish from time to time such other enrollment requirements as it determines, in its sole discretion, are necessary.

(b)If a Director or an Employee fails to meet all requirements established by the Committee within the period required for a specified Plan Year, that Director or Employee shall not be eligible to participate in the Plan during such Plan Year.

ARTICLE 3
Deferrals, Vesting, Crediting & Taxes

3.1Maximum Deferral.

(a)Cash Annual Deferral Amount. Except as otherwise determined by the Committee and provided in a Plan Agreement or an Election Form, for each Plan Year, a Participant may elect to defer, as his or her Annual Deferral Amount, Base Salary, Bonus and/or Cash Director Fees, as applicable, up to the following maximum percentages for each deferral elected:

5

Deferral
Maximum Percentage
Base Salary
100%
Bonus
100%
Cash Director Fees
100%

(b)RSU Amount. Except as otherwise determined by the Committee and provided in a Plan Agreement or an Election Form, for each grant of RSUs, a Participant may elect to defer, as his or her RSU Amount, the following maximum percentages for each deferral elected:

Deferral
Maximum Percentage
RSUs
100%

For the avoidance of doubt, any RSUs deferred under this Plan shall be granted pursuant to the Equity Plan and shall be subject to individual award agreements.

(c)Short Plan Year. Notwithstanding the foregoing, in the case of an individual first becoming a Participant after the first day of a Plan Year, then to the extent required by Section 3.2 and Section 409A, the maximum amount of the Participant’s Base Salary, Bonus and Cash Director Fees that may be deferred by the Participant for the Plan Year shall be determined by applying the percentages set forth in Sections 3.1(a) and (b) to the portion of such compensation attributable to services performed after the date that the Participant’s deferral election is made.

3.2Timing of Deferral Elections; Effect of Election Form.

(a)General Timing Rule for Deferral Elections. Except as otherwise provided in this Section 3.2, in order for a Participant to make a valid election to defer Base Salary, Bonus, and Cash Director Fees, the Participant must submit an Election Form on or before the deadline established by the Committee, which in no event shall be later than December 31st preceding the Plan Year in which such compensation will be earned.

Any deferral election made in accordance with this Section 3.2(a) shall be irrevocable; provided, however, that if the Committee permits or requires Participants to make a deferral election by the deadline described above for an amount that qualifies as Performance-Based Compensation, the Committee may permit a Participant to subsequently change his or her deferral election for such compensation by submitting a new Election Form in accordance with Section 3.2(d) below.

(b)Timing of Deferral Elections for Newly Eligible Plan Participants. A Director or selected Employee who first becomes eligible to participate in the Plan on or after the beginning of a Plan Year, as determined in
6

accordance with Treas. Reg. §1.409A-2(a)(7)(ii) and the “plan aggregation” rules provided in Treas. Reg. §1.409A-1(c)(2), may be permitted by the Committee to make an election to defer (i) RSUs that may be initially granted to the Participant under the terms of the Equity Plan and which are attributable to services to be performed after such election and/or (ii) the portion of Base Salary, Bonus, and/or Cash Director Fees attributable to services to be performed after such election, provided that the Participant submits an Election Form on or before the deadline established by the Committee, which in no event shall be later than 30 days after the Participant first becomes eligible to participate in the Plan.

If a deferral election made in accordance with this Section 3.2(b) relates to compensation earned based upon a specified performance period, the amount eligible for deferral shall be equal to (i) the total amount of compensation for the performance period, multiplied by (ii) a fraction, the numerator of which is the number of days remaining in the service period after the Participant’s deferral election is made, and the denominator of which is the total number of days in the performance period.

Any deferral election made in accordance with this Section 3.2(b) shall become irrevocable as of the date the election is made, but in no event later than the 30th day after the date the Director or selected Employee becomes eligible to participate in the Plan.

(c)RSU Deferral. For an election to defer RSUs to be valid, (i) an Election Form must be submitted by the Participant with respect to such RSUs, and (ii) such Election Form must be timely delivered to the Committee and accepted by the Committee no later than (A) the end of the calendar year preceding the Plan Year during which such RSUs are initially granted to the Participant under the terms of Equity Plan, or (B) such other deadline established by the Committee in accordance with the requirements of Section 409A, including, without limitation, such deadline as may be applicable under Section 3.2(d) or 3.2(e) below.

(d)Timing of Deferral Elections for Performance-Based Compensation. Subject to the limitations described below, the Committee may determine that an irrevocable deferral election for an amount that qualifies as Performance-Based Compensation may be made by submitting an Election Form on or before the deadline established by the Committee, which in no event shall be later than 6 months before the end of the performance period.

In order for a Participant to be eligible to make a deferral election for Performance-Based Compensation in accordance with the deadline established pursuant to this Section 3.2(d), the Participant must have performed services continuously from the later of (i) the beginning of the performance period for such compensation, or (ii) the date upon which the performance criteria for such compensation are established, through the date
7

upon which the Participant makes the deferral election for such compensation. In no event shall a deferral election submitted under this Section 3.2(d) be permitted to apply to any amount of Performance-Based Compensation that has become readily ascertainable.

(e)Timing Rule for Deferral of Compensation Subject to Risk of Forfeiture. With respect to compensation (i) to which a Participant has a legally binding right to payment in a subsequent year, and (ii) that is subject to a forfeiture condition requiring the Participant’s continued services for a period of at least 12 months from the date the Participant obtains the legally binding right, the Committee may determine that an irrevocable deferral election for such compensation may be made by timely delivering an Election Form to the Committee in accordance with its rules and procedures, no later than the 30th day after the Participant obtains the legally binding right to the compensation, provided that the election is made at least 12 months in advance of the earliest date at which the forfeiture condition could lapse, as determined in accordance with Treas. Reg. §1.409A-2(a)(5).

Any deferral election(s) made in accordance with this Section 3.2(e) shall become irrevocable no later than the 30th day after the Participant obtains the legally binding right to the compensation subject to such deferral election(s).

3.3Withholding and Crediting of Annual Deferral Amounts. The Base Salary portion and the Cash Director Fees portion of the Annual Deferral Amount shall be withheld from the Participant’s pay earned during the Plan Year. The Bonus portion of the Annual Deferral Amount shall be withheld at the time the Bonus is or otherwise would be paid to the Participant, whether or not this occurs during the Plan Year itself. Such Annual Deferral Amounts shall be credited to the Participant’s Cash Account for such Plan Year at the time such amounts would otherwise have been paid to the Participant. Base Salary that is both (i) attributable solely to services performed during the final payroll period containing the last day of the Plan Year, and (ii) payable in the subsequent Plan Year, will be treated as earned in that subsequent Plan Year; accordingly, Base Salary related to such final payroll period shall be withheld in accordance with the Participant’s Base Salary deferral election applicable to such subsequent Plan Year.

3.4Company Contribution Account

(a)For each Plan Year, the Company may be required to credit amounts to a Participant’s Annual Account in accordance with employment or other agreements entered into between the Participant and any member of the Company Group, which amounts shall be part of the Participant’s Company Contribution Amount for that Plan Year. Such amounts shall be credited to the Participant’s Annual Account for the applicable Plan Year on the date or dates prescribed by such agreements.

(b)For each Plan Year, the Company, in its sole discretion, may, but is not required to, credit any amount it desires to any Participant’s Annual Account
8

under the Plan, which amount shall be part of the Participant’s Company Contribution Amount for that Plan Year. The amount so credited to a Participant may be smaller or larger than the amount credited to any other Participant, and the amount credited to any Participant for a Plan Year may be zero, even though one or more other Participants receive a Company Contribution Amount for that Plan Year. The Company Contribution Amount described in this Section 3.4(b), if any, shall be credited to the Participant’s Annual Account for the applicable Plan Year on a date or dates to be determined by the Committee.

(c)If not otherwise specified in the Participant’s employment or other agreement entered into between the Participant and any member of the Company Group, the amount (or the method or formula for determining the amount) of a Participant’s Company Contribution Amount shall be set forth in writing in one or more documents, which shall be deemed to be incorporated into the Plan in accordance with Section 1.26.

3.5RSUs. A Participant may elect to defer RSUs under the Plan, which amount shall be for that Participant the RSU Amount for that Plan Year. Any RSUs deferred shall, at the time the RSUs would otherwise vest and become transferable to the Participant under the terms of the Equity Plan, but for the election to defer, be reflected on the books of the Company as an unfunded, unsecured promise to deliver to the Participant a specific number of actual shares of Stock in the future.

3.6Vesting. A Participant shall at all times be 100% vested in his or her Account. Notwithstanding the foregoing, a Participant shall be vested in the portion of his or her Account attributable to any Company Contribution Amounts, as adjusted pursuant to Section 3.7, in accordance with the vesting schedule(s) set forth in his or her Plan Agreement, employment agreement or any other agreement entered into between the Participant and any member of the Company Group. If not addressed in such agreements, a Participant shall be 100% vested in such Company Contribution Amounts. All unvested Company Contribution Amounts shall become 100% vested in the event of a Change in Control or upon a Participant’s death or Disability.

3.7Crediting/Debiting of Accounts. In accordance with, and subject to, the rules and procedures that are established from time to time by the Committee, in its sole discretion, amounts shall be credited or debited to a Participant’s Account in accordance with the following rules:

(a)Cash Account

(i)Measurement Funds. A Participant may elect one or more of the measurement funds selected by the Committee, in its sole discretion (the “Measurement Funds”), for the purpose of crediting or debiting investment experience to his or her Cash Account. The Committee shall determine the number and type of Measurement Funds, which may include a specified interest rate, one or more investment options, an index or similar measure, or a series of hypothetical
9

investment options. As necessary, the Committee may, in its sole discretion, discontinue, substitute or add a Measurement Fund.

(ii)Election of Measurement Funds. A Participant, in connection with his or her initial deferral election in accordance with Section 3.2 above, shall elect, on the Election Form, one or more Measurement Fund(s) to be used to determine the amounts to be credited or debited to his or her Cash Account. If a Participant does not elect any of the Measurement Funds as described in the previous sentence, the Participant’s Cash Account shall automatically be allocated into the designated default Measurement Fund, as determined by the Committee, in its sole discretion. The Participant may (but is not required to) elect, by submitting an Election Form to the Committee that is accepted by the Committee, to add or delete one or more Measurement Fund(s) to be used to determine the amounts to be credited or debited to his or her Cash Account, or to change the portion of his or her Cash Account allocated to each previously or newly elected Measurement Fund. If an election is made in accordance with the previous sentence, it shall apply as of the first business day deemed reasonably practicable by the Committee, in its sole discretion, and shall continue thereafter for each subsequent day in which the Participant participates in the Plan, unless changed in accordance with the previous sentence. Notwithstanding the foregoing, the Committee, in its sole discretion, may impose limitations on the frequency with which one or more of the Measurement Funds elected in accordance with this Section 3.7(a) may be added or deleted by such Participant; furthermore, the Committee, in its sole discretion, may impose limitations on the frequency with which the Participant may change the portion of his or her Cash Account allocated to each previously or newly elected Measurement Fund.

(iii)Proportionate Allocation. In making any election described in this Section 3.7(a), the Participant shall specify on the Election Form, in increments of one percent (1%), the percentage of his or her Cash Account or Measurement Fund, as applicable, to be allocated/reallocated.

(iv)Crediting or Debiting Method. The performance of each Measurement Fund (either positive or negative) will be determined on a daily basis based on the manner in which such Participant’s Account Balance has been hypothetically allocated among the Measurement Funds by the Participant.

(v)No Actual Investment. Notwithstanding any other provision of the Plan that may be interpreted to the contrary, the Measurement Funds are to be used for measurement purposes only, and a Participant’s
10

election of any such Measurement Fund, the allocation of his or her Cash Account thereto, the calculation of additional amounts and the crediting or debiting of such amounts to a Participant’s Cash Account shall not be considered or construed in any manner as an actual investment of his or her Cash Account in any such Measurement Fund. In the event that the Company or the Trustee (as that term is defined in the Trust), in its own discretion, decides to invest funds in any or all of the investments on which the Measurement Funds are based, no Participant shall have any rights in or to such investments themselves. Without limiting the foregoing, a Participant’s Account shall at all times be a bookkeeping entry only and shall not represent any investment made on his or her behalf by the Company or the Trust; the Participant shall at all times remain an unsecured creditor of the Company.

(b)Stock Account.

(i)The portion of a Participant’s Account attributable to the deferral of RSUs pursuant to the terms of the Plan will be automatically and irrevocably allocated to the Stock Account. No portion of the Participant’s Cash Account can be either initially allocated or re-allocated to the Stock Account. Amounts allocated to the Stock Account shall only be distributable in actual shares of Stock, provided that fractional shares may be distributed in cash. Amounts credited to a Stock Account shall not accrue interest or earnings.

(ii)Any stock dividends that are paid pursuant to the Equity Plan and related award agreements during any period that a Participant holds Stock in a Stock Account, shall be credited to the Participant’s Stock Account in the form of additional shares of Stock and shall automatically and irrevocably be deemed to be re-invested in the Stock Account until such amounts are distributed to the Participant. The number of shares credited to the Participant for a particular stock dividend shall be equal to (A) the number of shares of Stock credited to the Participant’s Stock Account as of the payment date for such dividend in respect of each share of Stock, multiplied by (B) the number of additional whole or fractional shares of Stock actually paid as a dividend in respect of each share of Stock. Any cash dividends that are paid pursuant to the Equity Plan and related award agreements during any period that a Participant holds Stock in a Stock Account shall be credited to the Participant’s Cash Account on the date on which the applicable dividend is paid to stockholders generally or such other date as is determined by the Committee and held in the Cash Account until such amounts are distributed to the Participant. The cash credited to a Participant’s Cash Account for a particular cash dividend shall be equal to (A) the number of shares of Stock credited to the Participant’s Stock Account as of the payment
11

date for such dividend in respect of each share of Stock, multiplied by (B) the fair market value of the dividend, divided by (C) the fair market value of the Stock on the payment date for such dividend.

(iii)For purposes of this Section 3.7(b), the fair market value of a share of Stock as of a particular date shall mean the fair market value of a share of Stock as determined in accordance with the Equity Plan. The RSUs that may be paid pursuant to the Plan shall be issued under the Equity Plan subject to all of the terms and conditions of the Equity Plan, and only to the extent that Stock remains available for issuance under the Equity Plan. The terms and conditions of the Equity Plan are incorporated into and made a part of this Plan with respect to any RSUs paid pursuant to this Plan, and any awards of RSUs shall be governed by and construed in accordance with the provisions of the Equity Plan. In the event of any inconsistency between the Equity Plan and this Plan with respect to RSUs, the terms of the Equity Plan shall control. The Plan does not constitute a separate source of Stock for the RSU grants described herein.

(iv)Notwithstanding anything to the contrary, all Stock or other securities delivered under the Plan shall be subject to such stop transfer orders and other restrictions as the Committee may deem advisable under the Plan or the rules, regulations and other requirements of the Securities and Exchange Commission, any stock exchange on which such Stock or other securities are then listed, and any applicable federal, state or local securities laws. The Committee may at any time alter the effective date of any investment or allocation involving the Stock Account pursuant to Section 9.1 (relating to safeguards against insider trading). The Committee may also, to the extent necessary to ensure compliance with Rule 16b-3(f) of the Act, arrange for tracking of any such transaction defined in Rule 16b-3(b)(1) of the Act and bar any such transaction to the extent it would not be exempt under Rule 16b-3(f). The Company may also impose blackout periods pursuant to the requirements of the Sarbanes-Oxley Act of 2002 whenever the Company determines that circumstances warrant. Further, the Company may impose blackout periods on insider trading with respect to Stock Accounts, as needed (as determined by the Company) in accordance with the Company’s insider trading policy, as it may be amended from time to time.

3.8FICA and Other Taxes.

(a)Annual Deferral Amounts. For each Plan Year in which an Annual Deferral Amount is being withheld from a Participant, the Company Group shall withhold from that portion of the Participant’s Base Salary and/or Bonus that is not being deferred, in a manner determined by Company Group, the
12

Participant’s share of FICA and other employment taxes on such Annual Deferral Amount. If necessary, the Committee may reduce the Annual Deferral Amount in order to comply with this Section 3.8.

(b)Company Contribution Amounts. When a Participant becomes vested in a portion of his or her Account attributable to any Company Contribution Amounts, the Company Group shall withhold from that portion of the Participant’s Base Salary and/or Bonus that is not deferred, in a manner determined by the Company Group, the Participant’s share of FICA and other employment taxes on such amounts. If necessary, the Committee may reduce the vested portion of the Company Contribution Amount in order to comply with this Section 3.8.

(c)RSU Amounts. For each Plan Year in which an RSU Amount is being first withheld from an Employee Participant, the Company Group shall withhold from that portion of the Participant’s compensation not being deferred, in a manner determined by the Company Group, the Participant’s share of FICA and other employment taxes on such RSU Amount. If necessary, the Committee may reduce the RSU Amount in order to comply with this Section 3.8.

(d)Distributions. The Company Group, or the trustee of the Trust, shall withhold from any payments made to a Participant under the Plan all federal, state and local income, employment and other taxes required to be withheld by the Company Group, or the trustee of the Trust, in connection with such payments, in amounts and in a manner to be determined in the sole discretion of Company Group and the trustee of the Trust.

ARTICLE 4
In-Service Distribution of Account; Unforeseeable Emergency

4.1Scheduled Distribution. In connection with each election to defer an Annual Deferral Amount and RSU Amount, a Participant may elect to receive such Annual Deferral Amount and/or RSU Amount, as adjusted pursuant to Section 3.7, on a Benefit Distribution Date designated by the Participant in accordance with this Section (a “Scheduled Distribution”). The Benefit Distribution Date for the amount subject to a Scheduled Distribution election shall be, or commence on, the date designated by the Participant as permitted on an Election Form approved by the Committee. The Participant may elect to receive the Scheduled Distribution in the form of a lump sum payment or pursuant to the Annual Installment Method, calculated as of the close of business on or around the Benefit Distribution Date, as permitted on an Election Form approved by the Committee. If a Participant does not make any election with respect to a Scheduled Distribution, then the Participant will be deemed to have elected to receive such Annual Deferral Account as a lump sum.

4.2Postponing Scheduled Distributions. To the extent permitted by the Committee, a Participant may elect to postpone a Scheduled Distribution described in Section 4.1 above, and have such amount paid out upon an allowable alternative Benefit Distribution Date designated in
13

accordance with this Section 4.2. In order to make such an election, the Participant must submit an Election Form to the Committee in accordance with the following criteria:

(a)The election of the new Benefit Distribution Date shall have no effect until at least 12 months after the date on which the election is made;

(b)The new Benefit Distribution Date selected by the Participant for such Scheduled Distribution must be the first day of a Plan Year that is no sooner than 5 years after the previously designated Benefit Distribution Date; and

(c)The election must be made at least 12 months prior to the Participant’s previously designated Benefit Distribution Date for such Scheduled Distribution.

For purposes of applying the provisions of this Section 4.2, a Participant’s election to postpone a Scheduled Distribution shall not be considered to be made until the date on which the election becomes irrevocable. Such an election shall become irrevocable no later than the date that is 12 months prior to the Participant’s previously designated Benefit Distribution Date for such Scheduled Distribution.

4.3Other Benefits Take Precedence Over Scheduled Distributions. Should an event occur prior to any Benefit Distribution Date designated for a Scheduled Distribution that would trigger a benefit under Article 5, all amounts subject to a Scheduled Distribution election shall be paid in accordance with Article 5 and not in accordance with this Article 4.

4.4Unforeseeable Emergencies.

(a)If a Participant experiences an Unforeseeable Emergency prior to the occurrence of a distribution event described in this Article 4 and Article 5, as applicable, the Participant may petition the Committee to receive a partial or full payout from the Plan. The payout, if any, from the Plan shall not exceed the lesser of (i) the Participant’s Cash Account, calculated as of the close of business on or around the Benefit Distribution Date for such payout, as determined by the Committee in accordance with provisions set forth below, or (ii) the amount necessary to satisfy the Unforeseeable Emergency, plus amounts necessary to pay Federal, state, or local income taxes or penalties reasonably anticipated as a result of the distribution. A Participant shall not be eligible to receive a payout from the Plan to the extent that the Unforeseeable Emergency is or may be relieved (A) through reimbursement or compensation by insurance or otherwise; (B) by liquidation of the Participant’s assets, to the extent the liquidation of such assets would not itself cause severe financial hardship; or (C) by cessation of deferrals under the Plan.

If the Committee, in its sole discretion, approves a Participant’s petition for payout from the Plan, the Participant’s Benefit Distribution Date for such payout shall be the date on which such Committee approval occurs. In
14

addition, in the event of such approval the Participant’s outstanding deferral elections under the Plan shall be cancelled.

(b)A Participant’s deferral elections under the Plan shall also be cancelled to the extent the Committee determines that such action is required for the Participant to obtain a hardship distribution from a 401(k) plan of the Company Group pursuant to Treas. Reg. §1.401(k)-1(d)(3).

ARTICLE 5
Other Distributions of Account

5.1Termination Benefit.

(a)Termination Benefit. If a Participant experiences a Separation from Service, the Participant will receive a distribution of his or her Account (a “Termination Benefit”).

(b)Timing of Termination Benefits. A Participant’s Termination Benefit will be calculated as of the close of business on or around the Benefit Distribution Date for such benefit.

(c)Election of Payment Form. In connection with a Participant’s election to defer an Annual Deferral Amount, the Participant may elect the form of Termination Benefit in which his or her Annual Account for such Plan Year will be paid. The Participant may elect to receive the Termination Benefit in the form of a lump sum payment or pursuant to the Annual Installment Method, as permitted by the Committee and provided in an Election Form approved by the Committee. If a Participant does not make any election with respect to the Termination Benefit, then the Participant will be deemed to have elected to receive such Annual Account as a lump sum.

(d)Modification of Payment Form. If permitted by the Committee, a Participant may change the form of Termination Benefit payment for an Annual Account, by submitting an Election Form to the Committee in accordance with the following criteria:

(i)The election will not take effect until 12 months after the date on which the election is made;

(ii)The new Benefit Distribution Date for such Annual Account will be 5 years after the Benefit Distribution Date that would otherwise have been applicable to such Annual Account; and

(iii)The election must be made at least 12 months prior to the Benefit Distribution Date that would otherwise have been applicable to such Annual Account.

15

For purposes of applying the provisions of this Section 5.1(d), a Participant’s election to change the form of Termination Benefit payment for an Annual Account will not be considered to be made until the date on which the election becomes irrevocable. Such an election will become irrevocable no later than the date that is 12 months prior to the Benefit Distribution Date that would otherwise have been applicable to such Annual Account. Subject to the requirements of this Section 5.1(d), the Election Form most recently accepted by the Committee that has become effective for an Annual Account will govern the form of payout of such Annual Account.

(e)Timing of Payments. The lump sum payment will be made, or installment payments will commence, upon the Participant’s Benefit Distribution Date. Remaining installments, if any, will be paid upon each anniversary of the Participant’s Benefit Distribution Date.

5.2Change in Control Benefit. In the event of a Change in Control prior to the occurrence of a distribution event described in Article 4 and this Article 5, the Participant will receive his or her Account in the form of a lump sum payment (the “Change in Control Benefit”). A Participant’s Change in Control Benefit will be calculated as of the close of business on or around the Benefit Distribution Date for such benefit.

5.3Disability Benefit. If a Participant becomes Disabled prior to the occurrence of a distribution event described in Article 4 and this Article 5, the Participant shall receive his or her Account in the form of a lump sum payment (the “Disability Benefit”). The Disability Benefit shall be calculated as of the close of business on or around the Participant’s Benefit Distribution Date for such benefit, which shall be the date on which the Participant becomes Disabled. The Disability Benefit shall be paid to the Participant upon the Participant’s Benefit Distribution Date.

5.4Death Benefit. In the event of a Participant’s death prior to the complete distribution of his or her Account, the Participant’s Beneficiary(ies) shall receive the Participant’s unpaid Account in a lump sum payment (the “Death Benefit”). The Death Benefit shall be calculated as of the close of business on or around the Benefit Distribution Date for such benefit, which shall be the date of the Participant’s death. The Death Benefit shall be paid to the Participant’s Beneficiary(ies) upon the Participant’s Benefit Distribution Date.

5.5Timing of Payments to Specified Employees.. Notwithstanding anything in the Plan to the contrary, if a Participant is a Specified Employee (as defined in Section 409A(a)(2)(B)(i) of the Code and Treas. Reg. §1.409A-1(i)) as of the date of their Separation from Service, then no distribution of such Participant's Account shall be made upon the Participant's Separation from Service until the first payroll date of the seventh month following the Participant's Separation from Service (or, if earlier, upon the date of the Participant's death or Disability) (the "Specified Employee Payment Date"). Any payments to which a Specified Employee otherwise would have been entitled under the Plan during the period between the Participant's Separation from Service and the Specified Employee Payment date shall be accumulated and paid in a lump sum payment on the Specified Employee Payment Date.

16

ARTICLE 6
Beneficiary Designation

6.1Beneficiary. Each Participant shall have the right, at any time, to designate his or her Beneficiary(ies) (both primary as well as contingent) to receive any benefits payable under the Plan to a beneficiary upon the death of a Participant. The Beneficiary designated under the Plan may be the same as or different from the Beneficiary designation under any other plan of a Company Group in which the Participant participates.

6.2Beneficiary Designation; Change. A Participant shall designate his or her Beneficiary by completing the Beneficiary Designation Form and returning it to the Committee or its designated agent. A Participant shall have the right to change a Beneficiary by completing and otherwise complying with the terms of the Beneficiary Designation Form and the Committee’s rules and procedures, as in effect from time to time. Upon the acceptance by the Committee of a new Beneficiary Designation Form, all Beneficiary designations previously filed shall be canceled. The Committee shall be entitled to rely on the last Beneficiary Designation Form filed by the Participant and accepted by the Committee prior to his or her death.

6.3Acknowledgment. No designation or change in designation of a Beneficiary shall be effective until received and acknowledged by the Committee or its designated agent.

6.4No Beneficiary Designation. If a Participant fails to designate a Beneficiary as provided in Sections 6.1, 6.2 and 6.3 above, or if all designated Beneficiaries predecease the Participant or die prior to complete distribution of the Participant’s benefits, then the Participant’s designated Beneficiary shall be deemed to be his or her surviving spouse. If the Participant has no surviving spouse, the benefits remaining under the Plan to be paid to a Beneficiary shall be payable to the executor or personal representative of the Participant’s estate.

6.5Discharge of Obligations. The payment of benefits under the Plan to a Beneficiary shall fully and completely discharge the Company Group and the Committee from all further obligations under the Plan with respect to the Participant, and that Participant’s Plan Agreement, if any, shall terminate upon such full payment of benefits.

ARTICLE 7
Leave of Absence

7.1Paid Leave of Absence. If a Participant is authorized by the Company Group to take a paid leave of absence, and such leave of absence does not constitute a Separation from Service, (a) the Participant shall continue to be considered eligible for the benefits provided under the Plan, and (b) the Annual Deferral Amount and any previously elected deferrals of RSUs shall continue to be withheld during such paid leave of absence in accordance with Section 3.2.

7.2Unpaid Leave of Absence. If a Participant is authorized by the Company Group to take an unpaid leave of absence for any reason, and such leave of absence does not constitute a Separation from Service, such Participant shall continue to be eligible for the benefits provided under the Plan. During the unpaid leave of absence, the Participant shall not be allowed to make any additional deferral elections. However, if the Participant returns to employment, the
17

Participant may elect to defer an Annual Deferral Amount, and/or RSU Amount for the Plan Year following his or her return to employment and for every Plan Year thereafter while a Participant in the Plan, provided such deferral elections are otherwise allowed and an Election Form is delivered to and accepted by the Committee for each such election in accordance with Section 3.2 above.

ARTICLE 8
Termination of Plan, Amendment or Modification

8.1Termination of Plan. The Company expects the Plan to be continued indefinitely but reserves the right to terminate the Plan at any time by action of its Board. If the Plan is terminated, the value of the Accounts shall be paid to Participants and Beneficiaries in a single lump-sum cash payment and in accordance with Section 409A.

8.2Amendment. The Company may, at any time, amend or modify the Plan in whole or in part. Notwithstanding the foregoing, (a) no amendment or modification shall be effective to decrease the value of a Participant’s Account in existence at the time the amendment or modification is made, and (b) no amendment or modification of this Section 8.2 shall be effective.

8.3Effect of Payment. The full payment of the Participant’s Account in accordance with the applicable provisions of the Plan shall completely discharge all obligations to a Participant and his or her designated Beneficiaries under the Plan, and the Participant’s Plan Agreement, if any, shall terminate.

ARTICLE 9
Administration

9.1Committee Duties. Except as otherwise provided in this Article 9, the Plan shall be administered by a Committee. Members of the Committee may be Participants under the Plan. The Committee shall also have the discretion and authority to (a) make, amend, interpret, and enforce all appropriate rules and regulations for the administration of the Plan, and (b) decide or resolve any and all questions, including benefit entitlement determinations and interpretations of the Plan, as may arise in connection with the Plan. Any individual serving on the Committee who is a Participant shall not vote or act on any matter relating solely to himself or herself. When making a determination or calculation, the Committee shall be entitled to rely on information furnished by a Participant or the Company. Notwithstanding any other provision of the Plan, except provisions relating to compliance with Section 409A, the Committee may take any action it deems is necessary to assure compliance with any policy of the Company respecting insider trading as may be in effect from time to time. Such actions may include altering the effective date of intra-fund transfers or the distribution date of Annual Accounts, to the extent permitted under Section 409A. Any such actions shall alter the normal operation of the Plan to the minimum extent necessary.

9.2Agents. In the administration of the Plan, the Committee may, from time to time, employ agents and delegate to them such administrative duties as it sees fit (including acting through a duly appointed representative) and may from time to time consult with counsel.

18

9.3Binding Effect of Decisions. The decision or action of the Committee with respect to any question arising out of or in connection with the administration, interpretation and application of the Plan and the rules and regulations promulgated hereunder shall be final and conclusive and binding upon all persons having any interest in the Plan.

9.4Indemnity of Committee. The Company shall indemnify and hold harmless the members of the Committee and any Employee to whom the duties of the Committee may be delegated against any and all claims, losses, damages, expenses or liabilities arising from any action or failure to act with respect to the Plan, except in the case of willful misconduct by the Committee, any of its members, or any such Employee.

9.5Section 16 Compliance. The Plan is intended to be a formula plan for purposes of Section 16 of the Securities Exchange Act of 1934, as it may be amended from time to time (the “Act”). Accordingly, in the case of a deferral or other action under the Plan that constitutes a transaction that could be covered by Rule 16b-3(d) or (e), if it were approved by the Company’s Board or Compensation Committee of the Board (“Board Approval”), it is intended that the Plan shall be administered by delegates of the Compensation Committee of the Board, in the case of a Participant who is subject to Section 16 of the Act, in a manner that will permit the Board Approval of the Plan to avoid any additional Board Approval of specific transactions to the maximum possible extent. The liquidation of the Participant’s Stock Account in connection with a distribution to the Participant may, as determined by the Committee and if permitted by Section 409A, be delayed until the date such distribution will not violate Section 16 of the Act.

ARTICLE 10
Claims Procedures

10.1Presentation of Claim. Any Participant or Beneficiary of a deceased Participant (such Participant or Beneficiary being referred to below as a “Claimant”) may deliver to the Committee a written claim for a determination with respect to the amounts distributable to such Claimant from the Plan, eligibility for Plan participation, or any other question or issue regarding such Claimant’s rights under the Plan (referred to herein as a “claim”). If such a claim relates to the contents of a notice received by the Claimant, the claim must be made within 60 days after such notice was received by the Claimant. All other claims must be made within 180 days of the date on which the event that caused the claim to arise first occurred. The claim must state with particularity the determination desired by the Claimant. Additionally, upon denial of an appeal pursuant to this Article, a Claimant shall have 180 days within which to bring suit against the Plan or the Company for any claim related to such denied appeal; any such suit initiated after such 180-day period shall be precluded.

10.2Notification of Decision. The Committee shall consider a Claimant’s claim within a reasonable time, but no later than 90 days after receiving the claim. If the Committee determines that special circumstances require an extension of time for processing the claim, written notice of the extension shall be furnished to the Claimant prior to the termination of the initial 90 day period. In no event shall such extension exceed a period of 90 days from the end of the initial period. The extension notice shall indicate the special circumstances requiring an extension of time and the date by which the Committee expects to render the benefit determination. The Committee shall notify the Claimant in writing:
19


(a)that the Claimant’s requested determination has been made, and that the claim has been allowed in full; or

(b)that the Committee has reached a conclusion contrary, in whole or in part, to the Claimant’s requested determination, and such notice must set forth in a manner calculated to be understood by the Claimant;

(c)the specific reason(s) for the denial of the claim, or any part of it;

(d)specific reference(s) to pertinent provisions of the Plan upon which such denial was based;

(e)a description of any additional material or information necessary for the Claimant to perfect the claim, and an explanation of why such material or information is necessary;

(f)an explanation of the claim review procedure set forth in Section 10.3 below; and

(g)a statement of the Claimant’s right to bring a civil action under ERISA Section 502(a) following an adverse benefit determination on review.

10.3Review of a Denied Claim. On or before 60 days after receiving a notice from the Committee that a claim has been denied, in whole or in part, a Claimant (or the Claimant’s duly authorized representative) may file with the Committee a written request for a review of the denial of the claim. The Claimant (or the Claimant’s duly authorized representative):

(a)may, upon request and free of charge, have reasonable access to, and copies of all documents, records and other information relevant (as defined in applicable ERISA regulations) to the claim for benefits;

(b)may submit written comments or other documents; and/or

(c)may request a hearing, which the Committee, in its sole discretion, may grant.

10.4Decision on Review. The Committee shall render its decision on review promptly, and no later than 60 days after the Committee receives the Claimant’s written request for a review of the denial of the claim. If the Committee determines that special circumstances require an extension of time for processing the claim, written notice of the extension shall be furnished to the Claimant prior to the termination of the initial 60 day period. In no event shall such extension exceed a period of 60 days from the end of the initial period. The extension notice shall indicate the special circumstances requiring an extension of time and the date by which the Committee expects to render its determination. In rendering its decision, the Committee shall take into account all comments, documents, records and other information submitted by the Claimant relating to the claim, without regard to whether such information was submitted or considered in
20

the initial determination. The decision must be written in a manner calculated to be understood by the Claimant, and it must contain:

(a)specific reasons for the decision;

(b)specific reference(s) to the pertinent Plan provisions upon which the decision was based;

(c)a statement that the Claimant is entitled to receive, upon request and free of charge, reasonable access to and copies of all documents, records and other information relevant (as defined in applicable ERISA regulations) to the Claimant’s claim for benefits; and

(d)a statement of the Claimant’s right to bring a civil action under ERISA Section 502(a).

10.5Legal Action. A Claimant’s compliance with the foregoing provisions of this Article 10 is a mandatory prerequisite to a Claimant’s right to commence any legal action with respect to any claim for benefits under the Plan.

ARTICLE 11
Trust

11.1Establishment of the Trust. In order to provide assets from which to fulfill its obligations to the Participants and their Beneficiaries under the Plan, the Company may, in its discretion, establish a grantor trust by a trust agreement with a third party, the trustee, to which the Company may, in its discretion, contribute cash or other property, including securities issued by the Company, to provide for the benefit payments under the Plan (the “Trust”). Any creation or maintenance of a trust or other informal funding vehicle shall not create or constitute a trust or a fiduciary relationship between the Committee or the Company and a Participant, or otherwise confer on any Participant or Beneficiary or his or her creditors a vested or beneficial interest in any assets of the Company whatsoever. Participants and Beneficiaries shall have no claim against the Company for any changes in the value of any assets which may be invested or reinvested by the Company with respect to this Plan.

11.2Interrelationship of the Plan and the Trust. The provisions of the Plan and any Plan Agreement shall govern the rights of a Participant to receive distributions pursuant to the Plan. The provisions of the Trust shall govern the rights of the Company, Participants and the creditors of the Company to the assets transferred to the Trust. The Company shall at all times remain liable to carry out its obligations under the Plan.

11.3Distributions From the Trust. The Company’s obligations under the Plan may be satisfied with Trust assets distributed pursuant to the terms of the Trust, and any such distribution shall reduce the Company’s obligations under the Plan.

ARTICLE 12
Miscellaneous
21


12.1Status of Plan. The Plan is intended to be a plan that is not qualified within the meaning of Section 401(a) of the Code and that “is unfunded and is maintained by an employer primarily for the purpose of providing deferred compensation for a select group of management or highly compensated employees” within the meaning of ERISA Sections 201(2), 301(a)(3) and 401(a)(1). The Plan shall be administered and interpreted to the extent possible in a manner consistent with the intent described in the preceding sentence.

12.2Section 409A. The Plan is intended to comply with, or be exempt from, the requirements of Section 409A, and the provisions of the Plan (including any Election Form, Plan Agreement or related agreement) shall be interpreted in a manner that satisfies the requirements of Section 409A. If any provision of the Plan (including any Election Form, Plan Agreement or related agreement) would otherwise frustrate or conflict with this intent, such provision will be interpreted and deemed amended so as to avoid such conflict. Notwithstanding anything to the contrary, to the extent that any payment under the Plan is determined by the Committee to constitute “nonqualified deferred compensation” subject to Section 409A and is payable to a Participant by reason of a Participant’s Separation from Service, then (i) such payment shall be made or provided only upon a Separation from Service and (ii) if the Participant is a “specified employee” (within the meaning of Section 409A and as determined by the Committee), such payment shall not be made or provided to the Participant until first day of the seventh month following the date of the Participant’s Separation from Service (or, if earlier, on the date of the Participant’s death). Neither the Company Group, the Committee nor any person acting on behalf of the Company Group, will be liable to any Participant, a Beneficiary, or to any other person by reason of any acceleration of income, any additional tax, or any penalty, interest or other liability asserted by reason of the Plan failing to satisfy the requirements of Section 409A. For purposes of the Plan, the right to receive a benefit payment in annual installments shall be treated as the entitlement to a single payment.

12.3Unsecured General Creditor. Participants and their Beneficiaries, heirs, successors and assigns shall have no legal or equitable rights, interests or claims in any property or assets of the Company Group. For purposes of the payment of benefits under the Plan, any and all of the Company’s assets shall be, and remain, the general, unpledged unrestricted assets of the Company. The Company’s obligation under the Plan shall be merely that of an unfunded and unsecured promise to pay money in the future.

12.4Company’s Liability. The Company’s liability for the payment of benefits shall be defined only by the Plan and any Plan Agreement, as entered into between the Company and a Participant. The Company shall have no obligation to a Participant under the Plan except as expressly provided in the Plan and his or her Plan Agreement.

12.5Nonassignability. Neither a Participant nor any other person shall have any right to commute, sell, assign, transfer, pledge, anticipate, mortgage or otherwise encumber, transfer, hypothecate, alienate or convey in advance of actual receipt, the amounts, if any, payable hereunder, or any part thereof, which are, and all rights to which are expressly declared to be, unassignable and non-transferable. No part of the amounts payable shall, prior to actual payment, be subject to seizure, attachment, garnishment or sequestration for the payment of any debts, judgments, alimony or separate maintenance owed by a Participant or any other person, be
22

transferable by operation of law in the event of a Participant’s or any other person’s bankruptcy or insolvency or be transferable to a spouse as a result of a property settlement or otherwise, including but not limited to a domestic relations order.

12.6Not a Contract of Employment. The terms and conditions of the Plan shall not be deemed to constitute a contract of employment between any member of the Company Group and the Participant. Such employment is hereby acknowledged to be an “at will” employment relationship that can be terminated at any time for any reason, or no reason, with or without cause, and with or without notice, unless expressly provided in a written employment agreement. Nothing in the Plan shall be deemed to give a Participant the right to be retained in the service of the Company Group, either as an Employee or a Director, or to interfere with the right of the Company Group to discipline or discharge the Participant at any time.

12.7Furnishing Information. A Participant or his or her Beneficiary will cooperate with the Committee by furnishing any and all information requested by the Committee and take such other actions as may be requested in order to facilitate the administration of the Plan and the payments of benefits hereunder, including but not limited to taking such physical examinations as the Committee may deem necessary.

12.8Terms. Whenever any words are used herein in the masculine, they shall be construed as though they were in the feminine in all cases where they would so apply; and whenever any words are used herein in the singular or in the plural, they shall be construed as though they were used in the plural or the singular, as the case may be, in all cases where they would so apply.

12.9Captions. The captions of the articles, sections and paragraphs of the Plan are for convenience only and shall not control or affect the meaning or construction of any of its provisions.

12.10Governing Law. Subject to ERISA, the provisions of the Plan shall be construed and interpreted according to the internal laws of the State of Michigan without regard to its conflicts of laws principles.

12.11Notice. Any notice or filing required or permitted to be given to the Committee under the Plan shall be sufficient if in writing and hand-delivered, or sent by registered or certified mail, to the address below:

Vericel Corporation
Attn: Office of the General Counsel
64 Sidney Street
Cambridge, MA 02139

Such notice shall be deemed given as of the date of delivery or, if delivery is made by mail, as of the date shown on the postmark on the receipt for registration or certification.

23

Any notice or filing required or permitted to be given to a Participant under the Plan shall be sufficient if in writing and hand-delivered, or sent by mail, to the last known address of the Participant.

12.12Successors. The provisions of the Plan shall bind and inure to the benefit of the Company and its successors and assigns and the Participant and the Participant’s designated Beneficiaries.

12.13Spouse’s Interest. The interest in the benefits hereunder of a spouse of a Participant who has predeceased the Participant shall automatically pass to the Participant and shall not be transferable by such spouse in any manner, including but not limited to such spouse’s will, nor shall such interest pass under the laws of intestate succession.

12.14Validity. In case any provision of the Plan shall be illegal or invalid for any reason, said illegality or invalidity shall not affect the remaining parts hereof, but the Plan shall be construed and enforced as if such illegal or invalid provision had never been inserted herein.

12.15Incompetent. If the Committee determines in its discretion that a benefit under the Plan is to be paid to a minor, a person declared incompetent or to a person incapable of handling the disposition of that person’s property, the Committee may direct payment of such benefit to the guardian, legal representative or person having the care and custody of such minor, incompetent or incapable person. The Committee may require proof of minority, incompetence, incapacity or guardianship, as it may deem appropriate prior to distribution of the benefit. Any payment of a benefit shall be a payment for the account of the Participant and the Participant’s Beneficiary, as the case may be, and shall be a complete discharge of any liability under the Plan for such payment amount.


24


IN WITNESS WHEREOF, the Plan is executed as of May 3, 2023, the date the Board approved the Plan, to be effective as of May 3, 2023.


VERICEL CORPORATION
By: /s/ Sean C. Flynn
Name: Sean C. Flynn
Title: Senior Vice President, General Counsel and Secretary


25



VERICEL CORPORATION
DEFERRED COMPENSATION PLAN
ELECTION FORM
EMPLOYEE PARTICIPANT FORM

An Employee of Vericel Corporation (“Vericel”) who is eligible to participate in the Vericel Corporation Deferred Compensation Plan (the “Plan”) may use this Election Form to elect to defer Base Salary, Bonus and/or restricted stock units (“RSUs”) granted pursuant to the Vericel Corporation 2022 Omnibus Incentive Plan (the “Equity Plan”). Any election you make on this Election Form will apply only if the Base Salary or Bonus would otherwise be payable to you, and only if RSUs are actually granted to you and have terms such that the election can be given effect. Vericel has no obligation to grant RSUs to you at any time, or to provide any particular terms of RSUs to you if they are actually granted. Deferrals are subject to all terms of the Plan, Equity Plan and applicable RSU award agreements, which terms may be amended and restated from time to time and are incorporated herein by reference. This includes any additional restrictions as may be necessary to comply with the requirements of Section 409A of the Internal Revenue Code.


First Name
Middle Name
Last Name
Street Address
City
State
Zip Code
Telephone Number
Email

ELECTION TO DEFER
I.Cash Deferral. I hereby elect to defer the following (my “Annual Deferral Amount”): (please specify a whole percentage)

___% of my Base Salary, up to a maximum of 100%

___% of my Bonus, up to a maximum of 100%

I understand and acknowledge that by making this election, I am irrevocably electing to defer my Base Salary and/or Bonus that may be otherwise payable to me in the 202 calendar year.

II.RSU Deferral. I hereby elect to defer the following (the “RSU Amount”): (please specify a whole percentage)

___% of the RSUs that Vericel grants to me pursuant to the Equity Plan, up to a maximum of 100%




Please Note: For deferral of 2023 calendar year RSUs, you may only defer the installments vesting in February 2025, 2026 and 2027. Please specify the installment(s) you would like to defer and the applicable deferral percentage (please specify a whole percentage for each RSU installment):

☐ RSU Installment vesting February 2025. Percentage Deferred ______%
☐ RSU Installment vesting February 2026. Percentage Deferred ______%
☐ RSU Installment vesting February 2027. Percentage Deferred ______%

I understand and acknowledge that by making this election, I am irrevocably electing to defer the stock settled after vesting of my RSUs, which RSUs may otherwise be awarded to me in the 202 calendar year pursuant to the Equity Plan.

III.Time of Distribution.

Optional Election: I hereby elect that my Annual Deferral Amount and/or RSU Amount deferred pursuant to this Election Form be distributed to me, or commence to be distributed to me, on ___________ (If you would like to elect a specific distribution date, please specify a date of distribution (the “Scheduled Distribution Date”), which must be no earlier than 2 years from the date of this election form. If deferring RSUs, the Scheduled Distribution Date must be no earlier than the last date the deferred RSU Amount is originally scheduled to vest in accordance with the vesting schedule as provided in the RSU award agreements).

However, I understand that my Annual Deferral Amount and/or RSU Amount (to the extent vested) deferred pursuant to this Election Form may be paid before my Scheduled Distribution Date. My Account will be distributed to me, or commence to be distributed to me, on the earliest to occur in accordance with the terms of the Plan:

•My Scheduled Distribution Date;

•Within 60 days after my “separation from service” (as defined in the Plan)*;

•Within 60 days after a “change in control” (as defined in the Plan);

•Within 60 days after my “disability” (as defined in the Plan); or

•Within 60 days after my death.

*I understand that if I qualify as a “specified employee,” within the meaning of Section 409A of the Internal Revenue Code, a distribution of my Account triggered by a “separation from service” may be delayed by six months following my termination of service in accordance with the Plan.

IV.Form of Distribution. I hereby elect that my Annual Deferral Amount and/or RSU Amount deferred pursuant to this Election Form will be distributed to me, or commence to be distributed to me, in the following form: (please select and if applicable, specify a number of years)
2

Form of Distribution for Separation from Service

☐ One lump sum payment

☐ A series of substantially equal annual installments, payable over ☐ 5 years or ☐ 10 years (please select on option) on each anniversary of the Scheduled Distribution Date

Form of Distribution for Scheduled Distribution Date (if applicable)
☐ One lump sum payment

☐ A series of substantially equal annual installments, payable over ☐ 5 years or ☐ 10 years (please select on option) on each anniversary of the Scheduled Distribution Date


I understand that my RSU Amount deferred pursuant to this Election Form will only be distributed to me to the extent vested under the terms of the applicable award agreements.

I understand that this election for the form of distribution only applies to the form of distribution for a Scheduled Distribution Date and a benefit payable on a “separation from service” (referred to as a “Termination Benefit” under the Plan). My account will be distributed to me in a lump sum upon a “change in control” (as defined in the Plan) or upon my death or “disability” (as defined in the Plan).

V.Allocation of Investment Options for Cash Deferrals. I hereby elect that my Annual Deferral Amount deferred pursuant to this Election Form will be allocated amongst the following investment options (referred to as “Measurement Funds” under the Plan), which will determine my rate of return in accordance with Section 3.7 of the Plan: (please specify whole percentage(s), which must total 100% ).

___% Fidelity 500 Index

___% Fidelity Extended Market Index

___% Fidelity International Index

___% Fidelity Inflation-Protected Bond Index

___% Fidelity U.S. Bond Index

___% Fidelity Government Money Market

I understand that the amounts deferred hereunder will be deemed invested in the above Measurement Funds solely for purposes of determining the value of my Account on the Benefit Distribution Date and that the Committee may change the Investment Options available under the Plan at any time. The Company has no obligation to invest any assets in the Investment Options I select. I also understand that the value of my Account on the payment date may be less than the amount originally deferred.

3

VI.Beneficiary Designation. I hereby designate the following individual(s), trust or other entity as my Beneficiary (or Beneficiaries) to receive any amounts payable under the Plan in the event of my death before I have received the entire amount credited to my Account: (please complete this section for an initial election under the Plan or if the Beneficiary designation is being changed)

I hereby designate (full name) as my primary Beneficiary under the Plan. His or her Social Security Number, relationship to me and current address are as follows:

Social Security Number:

Relationship:

Current Address:

If my primary Beneficiary fails to survive me, I hereby designate (full name) as my contingent Beneficiary. His or her Social Security Number, relationship to me and current address are as follows:

Social Security Number:

Relationship:

Current Address:


If I previously made a Beneficiary designation, I understand that the designations which I have made on this Election Form will revoke any and all of my prior Beneficiary designations when the Committee receives this Election Form.




4



AGREEMENT AND AUTHORIZATION
I understand that my election to defer my Base Salary, Bonus and/or RSUs is subject to review and final approval by the Committee, and that my election is governed by the terms and conditions of the Plan. I also acknowledge and agree that:

•This election only applies for Base Salary, Bonus and/or RSUs paid or awarded in the 20__ calendar year (if any). If I wish to defer any of my compensation with respect to future years, I will need to make a new election.

•The Plan has been made available to me, and I have had the opportunity to ask questions and receive answers regarding the terms and conditions of the Plan. I have read and understand the terms of the Plan and this Election Form and agree to all of the terms and conditions.

•I may make, with the consent of the Committee, a subsequent election to further defer payment subject to this Election Form, and that such an election must be made at least 12 months prior to my original Scheduled Distribution Date and I further understand that my newly selected Scheduled Distribution Date must be at least five years after the date of the original Scheduled Distribution Date. I further understand that the ability to make such a subsequent deferral election may not be available to me if the Committee changes the administration policies.

•Vericel may take whatever steps it, in its sole discretion, deems appropriate or necessary to satisfy the applicable local, state, federal or foreign income tax, Social Security, Medicare and other tax withholding obligations.

I hereby certify that the above information about me is true, accurate, and complete.

I acknowledge that I have been advised to consult with my own financial, tax, estate planning and legal advisors before making any election to defer compensation in order to determine the tax effects and other implications of my participation in the Plan.

5


I understand that for this election to be effective it must be completed, signed and returned to Vericel on or before _________, and its receipt is acknowledged by Vericel. This election will become irrevocable as of the date it is executed.

Date:, 202__.
Signature
Print Name:
Return signed form by email to sflynn@vcel.com
Return original by mail to:
Vericel Corporation
Attn: Office of the General Counsel
64 Sidney Street
Cambridge, MA 02139



Receipt of Election Form acknowledged on behalf of Vericel Corporation


Date:, 202__.
Signature
Print Name:
Title:




6

VERICEL CORPORATION
DEFERRED COMPENSATION PLAN
ELECTION FORM
DIRECTOR PARTICIPANT FORM
A non-employee Director of Vericel Corporation (“Vericel”) who is eligible to participate in the Vericel Corporation Deferred Compensation Plan (the “Plan”) may use this Election Form to elect to defer Cash Director Fees and/or restricted stock units (“RSUs”) granted pursuant to the Vericel Corporation 2022 Omnibus Incentive Plan (the “Equity Plan”). Any election you make on this Election Form will apply only if the Cash Director Fees would otherwise be payable to you, and only if RSUs are actually granted to you and have terms such that the election can be given effect. Vericel has no obligation to grant RSUs to you at any time, or to provide any particular terms of RSUs to you if they are actually granted. Deferrals are subject to all terms of the Plan, Equity Plan and applicable RSU award agreements and Vericel’s Non-Employee Director Compensation Guidelines, which terms may be amended and restated from time to time and are incorporated herein by reference. This includes any additional restrictions as may be necessary to comply with the requirements of Section 409A of the Internal Revenue Code.



First Name
Middle Name
Last Name
Street Address
City
State
Zip Code
Telephone Number
Email

ELECTION TO DEFER
I.Cash Deferral. I hereby elect to defer the following (my “Annual Deferral Amount”): (please specify a whole percentage)

___% of my Cash Director Fees, up to a maximum of 100%

I understand and acknowledge that by making this election, I am irrevocably electing to defer my Cash Director Fees that may be otherwise payable to me in the 202 calendar year.

II.RSU Deferral. I hereby elect to defer the following (the “RSU Amount”): (please specify a whole percentage)

___% of the RSUs that Vericel grants to me pursuant to the Equity Plan, up to a maximum of 100%

I understand and acknowledge that by making this election, I am irrevocably electing to defer the stock settled after vesting of my RSUs, which RSUs may otherwise be awarded to me in the 202 calendar year pursuant to the Equity Plan and Vericel’s Non-Employee Director Compensation Guidelines.

1

III.Time of Distribution. I hereby elect that my Annual Deferral Amount and/or RSU Amount deferred pursuant to this Election Form be distributed to me, or commence to be distributed to me, on [___________](If you would like to elect a specific distribution date, please specify a date of distribution (the “Scheduled Distribution Date”), which must be no earlier than 2 years from the date of this election form. If deferring RSUs, the Scheduled Distribution Date must be no earlier than the last date the deferred RSU Amount is originally scheduled to vest in accordance with the vesting schedule as provided in the RSU award agreements).

However, I understand that my Annual Deferral Amount and/or RSU Amount (to the extent vested) deferred pursuant to this Election Form may be paid before my Scheduled Distribution Date. My Account will be distributed to me, or commence to be distributed to me, on the earliest to occur in accordance with the terms of the Plan:

•My Scheduled Distribution Date;

•Within 60 days after my “separation from service” (as defined in the Plan);

•Within 60 days after a “change in control” (as defined in the Plan);

•Within 60 days after my “disability” (as defined in the Plan); or

•Within 60 days after my death.

IV.Form of Distribution. I hereby elect that my Annual Deferral Amount and/or RSU Amount deferred pursuant to this Election Form will be distributed to me, or commence to be distributed to me, in the following form: (please select and if applicable, specify a number of years)

Form of Distribution for Separation from Service

☐ One lump sum payment

☐ A series of substantially equal annual installments, payable over ☐ 5 years or ☐ 10 years (please select on option) on each anniversary of the Scheduled Distribution Date

Form of Distribution for Scheduled Distribution Date (if applicable)

☐ One lump sum payment

☐ A series of substantially equal annual installments, payable over ☐ 5 years or ☐ 10 years (please select on option) on each anniversary of the Scheduled Distribution Date

I understand that my RSU Amount deferred pursuant to this Election Form will only be distributed to me to the extent vested under the terms of the applicable award agreements.

I understand that this election for the form of distribution only applies to the form of distribution for a Scheduled Distribution Date and a benefit payable on a “separation from service” (referred to as a “Termination Benefit” under the Plan). My account will be distributed to me in a lump sum upon a “change in control” (as defined in the Plan) or upon my death or “disability” (as defined in the Plan).
2

V.Allocation of Investment Options for Cash Deferrals. I hereby elect that my Annual Deferral Amount deferred pursuant to this Election Form will be allocated amongst the following investment options (referred to as “Measurement Funds” under the Plan), which will determine my rate of return in accordance with Section 3.7 of the Plan: (please specify whole percentage(s), which must total 100% ).

___% Fidelity 500 Index

___% Fidelity Extended Market Index

___% Fidelity International Index

___% Fidelity Inflation-Protected Bond Index

___% Fidelity U.S. Bond Index

___% Fidelity Government Money Market

I understand that the amounts deferred hereunder will be deemed invested in the above Measurement Funds solely for purposes of determining the value of my Account on the Benefit Distribution Date and that the Committee may change the Investment Options available under the Plan at any time. The Company has no obligation to invest any assets in the Investment Options I select. I also understand that the value of my Account on the payment date may be less than the amount originally deferred.

VI.Beneficiary Designation. I hereby designate the following individual(s), trust or other entity as my Beneficiary (or Beneficiaries) to receive any amounts payable under the Plan in the event of my death before I have received the entire amount credited to my Account: (please complete this section for an initial election under the Plan or if the Beneficiary designation is being changed)

I hereby designate (full name) as my primary Beneficiary under the Plan. His or her Social Security Number, relationship to me and current address are as follows:

Social Security Number:

Relationship:

Current Address:


3

If my primary Beneficiary fails to survive me, I hereby designate (full name) as my contingent Beneficiary. His or her Social Security Number, relationship to me and current address are as follows:

Social Security Number:

Relationship:

Current Address:

If I previously made a Beneficiary designation, I understand that the designations which I have made on this Election Form will revoke any and all of my prior Beneficiary designations when the Committee receives this Election Form.

AGREEMENT AND AUTHORIZATION
I understand that my election to defer my Cash Director Fees and/or RSUs is subject to review and final approval by the Committee, and that my election is governed by the terms and conditions of the Plan. I also acknowledge and agree that:

•This election only applies Cash Deferral Fees and/or RSUs paid or awarded in the 20__ calendar year (if any). If I wish to defer any of my compensation with respect to future years, I will need to make a new election.

•The Plan has been made available to me, and I have had the opportunity to ask questions and receive answers regarding the terms and conditions of the Plan. I have read and understand the terms of the Plan and this Election Form and agree to all of the terms and conditions.

•I may make, with the consent of the Committee, a subsequent election to further defer payment subject to this Election Form, and that such an election must be made at least 12 months prior to my original Scheduled Distribution Date and I further understand that my newly selected Scheduled Distribution Date must be at least five years after the date of the original Scheduled Distribution Date. I further understand that the ability to make such a subsequent deferral election may not be available to me if the Committee changes the administration policies.

•Vericel may take whatever steps it, in its sole discretion, deems appropriate or necessary to satisfy the applicable local, state, federal or foreign income tax, Social Security, Medicare and other tax withholding obligations.

4

I hereby certify that the above information about me is true, accurate, and complete.

I acknowledge that I have been advised to consult with my own financial, tax, estate planning and legal advisors before making any election to defer compensation in order to determine the tax effects and other implications of my participation in the Plan.

I understand that for this election to be effective it must be completed, signed and returned to Vericel on or before _________, and its receipt is acknowledged by Vericel. This election will become irrevocable as of the date it is executed.


Date:, 202__.
Signature
Print Name:
Return signed form by email to sflynn@vcel.com
Return original by mail to:
Vericel Corporation
Attn: Office of the General Counsel
64 Sidney Street
Cambridge, MA 02139



Receipt of Election Form acknowledged on behalf of Vericel Corporation

Date:, 202__.
Signature
Print Name:
Title:
5
 EX-10.2 3 ex102vericelcorporation202.htm EX-10.2 Document

Vericel Corporation 2022 Omnibus Incentive Plan
Restricted Stock Unit Award (Deferred) Agreement for Non-Employee Directors


Name of Participant:
No. of Restricted Stock Units:
Grant Date:
Vesting Start Date:

Pursuant to the Vericel Corporation 2022 Omnibus Incentive Plan as amended through the date hereof (the “Plan”), Vericel Corporation (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Participant named above. Each Restricted Stock Unit shall relate to one share of common stock, no par value per share (each, a “Share”) of the Company. Reference is also made to the Vericel Corporation Deferred Compensation Plan (the “Program”).

1.Restrictions on Transfer of Award. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Participant, and any Shares issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii) Shares have been issued to the Participant in accordance with the terms of the Plan, this Agreement and the Program.

2.Vesting of Restricted Stock Units. The restrictions and conditions of Paragraph 1 of this Agreement shall lapse as to [100% of the number of Restricted Stock Units on the earlier of the first anniversary of the Vesting Start Date or the date of the first Annual Meeting of Stockholders following the Vesting Start Date (such date, the “Vesting Date”), provided that the Participant is providing services to the Company as a Director on the relevant Vesting Date] OR [33% of the number of the Restricted Stock Units on each anniversary of the Vesting Start Date over a three-year period (such date, the “Vesting Date”), provided that the Participant is providing services to the Company as a Director on the relevant Vesting Date]. Subject to the terms of the Plan and the Program, the Committee may at any time accelerate the vesting schedule specified in this Paragraph 2.

3.Termination of Service. Subject to the discretion of the Committee to permit continued vesting of the Restricted Stock Units, if the Participant’s services as a Director terminates for any reason other than due to the Participant’s death or Disability prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Participant nor any of his or her successors, heirs, assigns, or personal representatives will


thereafter have any further rights or interests in such unvested Restricted Stock Units. Upon termination of the Participant’s services as a Director due to the Participant’s death or Disability, the restrictions and conditions of Paragraph 1 of this Agreement shall lapse as to 100% of the number of Restricted Stock Units. For purposes of this Award, “Disability” shall have the meaning set forth in Treas. Reg. Section 1.409A‑3(i)(4).

4.Issuance of Shares. As soon as practicable following the Settlement Date (but in no event later than the later of the last day of the calendar year in which such event occurs or two and one-half months after the Settlement Date occurs), the Company shall issue to the Participant the number of Shares equal to the aggregate number of Restricted Stock Units that have vested pursuant to Paragraph 2 of this Agreement on such date and the Participant shall thereafter have all the rights of a stockholder of the Company with respect to such Shares. For purposes of this Agreement, “Settlement Date” means the earlier of (i) the date specified by the Participant in the Participant’s deferral election under the Company’s nonqualified deferred compensation plan, (ii) the date the Participant ceases to serve as a member of the Board of Directors of the Company and incurs a “separation from service” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder (“Section 409A”) and (iii) a Change in Control (as defined in the Plan), so long as such Change in Control also constitutes a “change in the ownership or effective control” of the Company or a “change in the ownership of a substantial portion of the assets” of the Company (as such terms are defined in Section 409A).

5.Change in Control. In the event of a Change in Control, the Award shall (i) become fully vested and nonforfeitable on the day prior to the date of the Change in Control if the Participant is then providing services to the Company as a Director and (ii) terminate on the date of the Change in Control.

6.Incorporation of Plan and the Program. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Committee set forth in Section 4.2 of the Plan, and the Program. Capitalized terms in this Agreement shall have the meaning specified in the Plan or in the Program, unless a different meaning is specified herein.

7.Section 409A of the Code. This Agreement is intended to be a compliant deferred compensation plan under Section 409A and shall be administered in accordance with the requirements of Section 409A. If the Participant is a “specified employee” (as defined in Section 409A) at the time of his or her separation from service and the Restricted Stock Units are settled on account of such separation from service, then the settlement shall be delayed for six months or until the Participant’s death, if earlier, to the extent required to avoid adverse taxation under Section 409A.

8.Severability. If any provision of this Agreement shall be held unlawful or otherwise invalid or unenforceable in whole or in part by a court of competent jurisdiction, such provision shall (i) be deemed limited to the extent that such court of competent jurisdiction deems it lawful, valid and/or enforceable and as so limited shall remain in full force and effect, and (ii) not affect
2

any other provision of this Agreement or part thereof, each of which shall remain in full force and effect.

9.Governing Law. This Agreement shall be governed by, and interpreted in accordance with, the laws of the State of Michigan, other than its conflict of laws principles.

10.Headings. The headings in this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement.

11.Notices. All notices required or permitted under this Agreement shall be in writing and shall be sufficiently made or given if hand delivered or mailed by registered or certified mail, postage prepaid. Notice by mail shall be deemed delivered on the date on which it is postmarked.

Notices to the Company should be addressed to:

Vericel Corporation
64 Sidney Street
Cambridge, MA 02139
Attention: Chief Financial Officer

Notice to the Participant should be addressed to the Participant at the Participant’s address as it appears on the Company’s records.

The Company or the Participant may by writing to the other party, designate a different address for notices. If the receiving party consents in advance, notice may be transmitted and received via telecopy or via such other electronic transmission mechanism as may be available to the parties. Such notices shall be deemed delivered when received.

12.No Obligation to Continue as a Director. Neither the Plan, the Program or this Award confers upon the Participant any rights with respect to continuance as a Director.

13.Entire Agreement; Modification. The Agreement contains the entire agreement between the parties with respect to the subject matter contained herein and may not be modified, except as provided in the Plan or the Program or in a written document signed by each of the parties hereto, and may be rescinded only by a written agreement signed by both parties.





3

14.Data Privacy Consent. In order to administer the Plan, the Program and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the “Relevant Companies”) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the “Relevant Information”). By entering into this Agreement, the Participant (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Participant may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Participant shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.IN WITNESS WHEREOF, the parties have executed the Agreement as of the date first above written.


VERICEL CORPORATION

By:

__________________________________________


Title: President and CEO

PARTICIPANT

__________________________________________

[_____________]

4
 EX-31.1 4 ex311ceocertificationq22023.htm EX-31.1 Document

EXHIBIT 31.1
 
CERTIFICATION
 
I, Dominick C. Colangelo, certify that:
 
1.                        I have reviewed this Quarterly Report on Form 10-Q of Vericel Corporation;
 
2.                        Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.                        Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.                        The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.                        The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 2, 2023
 
 /s/ DOMINICK C. COLANGELO
 Dominick C. Colangelo
 President and Chief Executive Officer
 (Principal Executive Officer)
 


 EX-31.2 5 ex312cfocertificationq22023.htm EX-31.2 Document

EXHIBIT 31.2
 
CERTIFICATION
 
I, Joseph A. Mara, certify that:
 
1. I have reviewed this Quarterly Report on Form 10-Q of Vericel Corporation;
 
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 2, 2023
 
 /s/ JOSEPH A. MARA
 Joseph A. Mara
 Chief Financial Officer
 (Principal Financial Officer)
 


 EX-32.1 6 ex321ceoandcfosoxcertifica.htm EX-32.1 Document

EXHIBIT 32.1
 
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Vericel Corporation (the “Company”) on Form 10-Q for the quarter ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (“Section 906”), the following:
 
(1)         The Report fully complies with the requirements of section 13(a) and 15(d) of the Securities Exchange Act of 1934; and
 
(2)         The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:  August 2, 2023
 
 /s/ DOMINICK C. COLANGELO
 Dominick C. Colangelo
 President and Chief Executive Officer
 (Principal Executive Officer)
 /s/ JOSEPH MARA
 Joseph Mara
 Chief Financial Officer
 (Principal Financial Officer)

 
A signed original of this written statement required by Section 906 has been provided to Vericel Corporation and will be retained by Vericel Corporation and furnished to the Securities and Exchange Commission or its staff upon request.


 EX-101.SCH 7 vcel-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Selected Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Revolving Credit Agreement link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Net Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - NexoBrid License and Supply Agreements link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9954701 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 9954702 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 9954703 - Disclosure - Selected Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 9954704 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954705 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954706 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954707 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954708 - Disclosure - Net Loss Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954709 - Disclosure - Organization (Details) link:presentationLink link:calculationLink link:definitionLink 9954710 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954711 - Disclosure - Revenue - Summary of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954712 - Disclosure - Selected Balance Sheet Components - Summary of inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954713 - Disclosure - Selected Balance Sheet Components - Schedule of property and equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 9954714 - Disclosure - Selected Balance Sheet Components - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954715 - Disclosure - Selected Balance Sheet Components -Schedule of finite-lived intangible assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954716 - Disclosure - Selected Balance Sheet Components -Schedule of finite-lived intangible assets, future amortization expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954717 - Disclosure - Selected Balance Sheet Components - Schedule of accrued expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9954718 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954719 - Disclosure - Leases - Summary of assets and liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954720 - Disclosure - Leases - Maturities of lease liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954720 - Disclosure - Leases - Maturities of lease liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954720 - Disclosure - Leases - Maturities of lease liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954721 - Disclosure - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954722 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954723 - Disclosure - Revolving Credit Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 9954724 - Disclosure - Stock-Based Compensation - Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954725 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954726 - Disclosure - Net Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954727 - Disclosure - NexoBrid License and Supply Agreements (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 vcel-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 vcel-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 vcel-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable Rate [Domain] Variable Rate [Domain] Pay vs Performance Disclosure [Line Items] Accrued expenses Total accrued expenses Accrued Liabilities, Current Statistical Measurement [Domain] Statistical Measurement [Domain] Less: interest Lease, Liability, Undiscounted Excess Amount Lease, Liability, Undiscounted Excess Amount Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Related Party Transaction [Line Items] Related Party Transaction [Line Items] Corporate notes Corporate Note Securities [Member] Sales threshold for first milestone License Agreement, Initial Milestone, Sales License Agreement, Initial Milestone, Sales Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Percent contributed to escrow account Escrow Deposit, Percent Contributed Escrow Deposit, Percent Contributed Revolving Credit Agreement Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Remainder of 2023 Lease Liability, Payments Due, Remainder Of Fiscal Year Lease Liability, Payments Due, Remainder Of Fiscal Year Investments, Debt and Equity Securities [Abstract] Revolving credit facility Revolving Credit Facility [Member] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Restatement Determination Date: Restatement Determination Date [Axis] Corporate notes Corporate Debt Securities [Member] Total other income Nonoperating Income (Expense) COMMITMENTS AND CONTINGENCIES (Note 12) Commitments and Contingencies Operating Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Net proceeds from common stock issuance Proceeds from Issuance of Common Stock Number of specialty pharmacies Number of Contracted Specialty Pharmacies Number of Contracted Specialty Pharmacies Accrued expenses Accrued Liabilities, Current [Abstract] Term of supply agreement License Agreement, Supply Agreement Term License Agreement, Supply Agreement Term Issuance of stock for restricted stock unit vesting (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Total property and equipment, gross Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Current liabilities: Current Liabilities, Current [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Inventory: Inventory, Net [Abstract] Diluted (in USD per share) Diluted loss per common share (in USD per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Letter of credit cash deposit lease year three Letter Of Credit Cash Deposit Lease Year Three Letter Of Credit Cash Deposit Lease Year Three Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Accounts receivable (net of allowance for doubtful accounts of $44 and $47, respectively) Accounts Receivable, after Allowance for Credit Loss, Current Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Line of credit Line of Credit [Member] Leverage ratio Debt Instrument, Covenant, Leverage Ratio, Maximum Debt Instrument, Covenant, Leverage Ratio, Maximum Other income (expense): Other Nonoperating Income (Expense) [Abstract] Stock option exercises Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Issuance of letters of credit Letters of Credit Outstanding, Amount U.S. government agency bonds US Government Agencies Debt Securities [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Weighted average grant-date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Net loss Net loss Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] 2025 Finance Lease, Liability, to be Paid, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Machinery and equipment Machinery and Equipment [Member] Leases Lessee, Operating Leases [Text Block] Property and equipment, net Total property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization LIABILITIES AND SHAREHOLDERS’ EQUITY Liabilities and Equity [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Shareholders’ equity: Equity, Attributable to Parent [Abstract] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Stock option exercises (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Accounts receivable Increase (Decrease) in Receivables Thereafter Lessee, Operating Lease, Liability, to be Paid, After Year Four Lessee, Operating Lease, Liability, to be Paid, After Year Four Schedule of net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two class method Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of product sales Cost of Goods and Services Sold Executive Category: Executive Category [Axis] Epicel Epicel [Member] Epicel [Member] Contract with Customer, Sales Channel [Axis] Contract with Customer, Sales Channel [Axis] Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Purchases of investments Payments to Acquire Short-Term Investments Schedule of property and equipment, net Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Total lease payments Lease Liability Payments Due Lease Liability Payments Due Accrued expenses Increase (Decrease) in Accrued Liabilities Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Letter of credit Letter of Credit [Member] Number of renewal options Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Selling, general and administrative Selling, General and Administrative Expenses [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Operating lease liabilities Operating Operating Lease, Liability, Noncurrent Sales and maturities of investments Proceeds from Sale, Maturity and Collection of Short-Term Investments Restricted stock units Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Debt instrument, term Debt Instrument, Term Depreciation Depreciation Income Statement Location [Axis] Income Statement Location [Axis] Change in revenue recognized due to 0.5% change in uncollectible percentage Revenue, Revenue Recognized, Effect Of 0.5% Change In The Estimated Uncollectible Percentage, Amount Revenue, Revenue Recognized, Effect Of 0.5% Change In The Estimated Uncollectible Percentage, Amount Restricted stock withheld for employee tax remittance Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Maturity of lease liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Rent start date, term Lessee, Lease Commencement, Rent Payment Start Date, Term Lessee, Lease Commencement, Rent Payment Start Date, Term Total revenue Revenues Computer equipment and software Computer Equipment And Computer Software Intangible Asset [Member] Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and the collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks. Allowance for doubtful accounts Allowance for Credit Loss, Receivable, Other, Current Product and Service [Domain] Product and Service [Domain] Schedule of accrued expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Inventory Increase (Decrease) in Inventories Unrealized gain (loss) on investments Unrealized gain (loss) on investment Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Research and development Research and Development Expense [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Four Finite-Lived Intangible Asset, Expected Amortization, after Year Four Anti-dilutive shares excluded from the calculation of diluted earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Restricted stock units granted (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Interest expense Interest Expense Additions to property and equipment included in accounts payable Capital Expenditures Incurred but Not yet Paid Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Total property and equipment, gross Property, Plant and Equipment, Gross Remainder of 2023 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Trading Arrangement: Trading Arrangement [Axis] Less: interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Leases Lessee, Finance Leases [Text Block] 2026 Lease Liability Payments Due Year Three Lease Liability Payments Due Year Three Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Current portion of operating lease liabilities Operating Operating Lease, Liability, Current Finance lease expense (less than) Finance Lease, Interest Expense Credit Losses Debt Securities, Available-for-Sale, Allowance for Credit Loss Shares issued under the Employee Stock Purchase Plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Amortization of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Accounting Standards Update 2014-09 Accounting Standards Update 2014-09 [Member] Property and equipment, net: Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Intangible assets, net Total Finite-Lived Intangible Assets, Net Restatement Determination Date Restatement Determination Date Counterparty Name [Domain] Counterparty Name [Domain] Other non-current assets and liabilities, net Increase (Decrease) in Other Operating Liabilities Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Total cash, cash equivalents, and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Common stock, shares issued (in shares) Common Stock, Shares, Issued Renewal term of supply agreement License Agreement, Supply Agreement Renewal Term License Agreement, Supply Agreement Renewal Term Number of commercial-stage products Number Of Products Number Of Products Gross profit Gross Profit Line of credit facility, commitment fee (in percent) Line of Credit Facility, Commitment Fee Percentage Security Exchange Name Security Exchange Name Assets, fair value Assets, Fair Value Disclosure Selling, general and administrative Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Stock options Employee Stock Option [Member] Other Proceeds from (Payments for) Other Financing Activities Maximum Maximum [Member] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Annual lease per square foot Lessee, Operating Lease, Annual Lease Per Square Foot Lessee, Operating Lease, Annual Lease Per Square Foot Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Short-term lease costs (less than) Short-Term Lease, Cost Type of Adoption [Domain] Accounting Standards Update [Domain] Operating lease liabilities Increase (Decrease) In Lease Liabilities Increase (Decrease) In Lease Liabilities Entity Address, Address Line One Entity Address, Address Line One 2026 Finance Lease, Liability, to be Paid, Year Three Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Other Other Noncash Income (Expense) 2024 Finance Lease, Liability, to be Paid, Year One Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Schedule of finite-lived intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Other current liabilities Other Liabilities, Current Variable Rate [Axis] Variable Rate [Axis] Income Statement [Abstract] Income Statement [Abstract] Contract with Customer, Basis of Pricing [Axis] Contract with Customer, Basis of Pricing [Axis] Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Money market funds Cash and Cash Equivalents, Fair Value Disclosure Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate by Type [Axis] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Net Income (Loss) Attributable to Parent [Abstract] Net Income (Loss) Attributable to Parent [Abstract] 25 Network Drive, Burlington, Massachusetts 25 Network Drive, Burlington, Massachusetts [Member] 25 Network Drive, Burlington, Massachusetts Member Other current assets Other Assets, Current Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Less: tenant improvement allowances Finance Lease, Liability, Tenant Improvement Allowance Finance Lease, Liability, Tenant Improvement Allowance Entity Tax Identification Number Entity Tax Identification Number MACI implants and kits Implants [Member] Implants [Member] Inventory Total inventory Inventory, Net Statistical Measurement [Axis] Statistical Measurement [Axis] Other current assets Increase (Decrease) in Other Current Assets Balance Sheet Location [Domain] Balance Sheet Location [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Total Shareholder Return Amount Total Shareholder Return Amount Reconciliation of amounts within the condensed consolidated balance sheets: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Stock-Based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Remaining percent to be contributed to escrow account Escrow Deposit, Remaining Percent To Be Contributed Escrow Deposit, Remaining Percent To Be Contributed Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Letter of credit cash deposit lease year six Letter Of Credit Cash Deposit Lease Year Four Letter Of Credit Cash Deposit Lease Year Four Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Total lease payments Finance Lease, Liability, to be Paid Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Thereafter Finance Lease, Liability, to be Paid, After Year Four Finance Lease, Liability, to be Paid, After Year Four 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Monthly contractual lease payments Lessee, Operating Lease, Monthly Contractual Payments Lessee, Operating Lease, Monthly Contractual Payments Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding PEO PEO [Member] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] NexoBrid NexoBrid [Member] NexoBrid Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Tenant improvement allowance per square foot Lessee, Operating Lease, Tenant Improvement Allowance, Per Square Foot Lessee, Operating Lease, Tenant Improvement Allowance, Per Square Foot Schedule of inventory Schedule of Inventory, Current [Table Text Block] Remaining contractual maturity period Debt Securities, Available-for-sale, Contractual Maturity Period Debt Securities, Available-for-sale, Contractual Maturity Period Name of Property [Domain] Name of Property [Domain] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Total leased liabilities Operating Lease, Liability Remainder of 2023 Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Credit Facility [Axis] Credit Facility [Axis] Total liabilities Liabilities Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] 2024 Lease Liability, Liability, to be Paid, Year One Lease Liability, Liability, to be Paid, Year One Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Accumulated Other Comprehensive Gain (Loss) AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Non-current Liabilities, Noncurrent [Abstract] Bonus-related compensation Accrued Bonuses, Current Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Other accrued expenses Accrued Expenses, Other, Current Represents other accrued expenses, current. Number of reportable segments Number of Reportable Segments Net loss per common share: Earnings Per Share [Abstract] Basis of Presentation Basis of Accounting [Text Block] Common stock, no par value; shares authorized — 75,000; shares issued and outstanding 47,616 and 47,253, respectively Common Stock, Value, Issued U.S. government securities US Government Debt Securities [Member] Letter of credit cash deposit Letter Of Credit Cash Deposit Letter Of Credit Cash Deposit Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Non-cash lease costs Operating Lease, Right-of-Use Asset, Periodic Reduction Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Annual lease base rent square subject to increase percentage Lessee, Operating Lease, Annual Lease Increase Limit, Percentage Lessee, Operating Lease, Annual Lease Increase Limit, Percentage Total current assets Assets, Current Maturity of lease liabilities Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Impairments of assets Asset Impairment Charges Schedule of valuation of the company's investments and financial instruments that are measured at fair value on a recurring basis Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Restricted cash Restricted Cash All Individuals All Individuals [Member] Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other (expense) income Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Term of contract Lessee, Operating Lease, Term of Contract Inclusive Of Free Rent Lessee, Operating Lease, Term of Contract Inclusive Of Free Rent PEO Name PEO Name Base rate Base Rate [Member] Short term investments Investments Weighted-average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Restricted cash Restricted Cash, Current Increase option for leverage ratio Debt Instrument, Covenant, Increase Option, Leverage Ratio, Maximum Debt Instrument, Covenant, Increase Option, Leverage Ratio, Maximum 2027 Finance Lease, Liability, to be Paid, Year Four Marketable Securities [Line Items] Marketable Securities [Line Items] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Schedule of finite-lived intangible assets, future amortization expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Organization Nature of Operations [Text Block] Depreciation and amortization expense Depreciation, Depletion and Amortization Furniture, fixtures and office equipment Furniture and Fixtures [Member] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total shareholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Commercial paper Commercial Paper [Member] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Finance Leases Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Purchases of intangible assets Payments to Acquire Intangible Assets Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Level 2 Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Estimated incremental borrowing rate Operating Lease Liability, Incremental Borrowing Rate Operating Lease Liability, Incremental Borrowing Rate Debt issuance costs, net Debt Issuance Costs, Net Finished goods Inventory, Finished Goods, Gross Increase (Decrease) in Shareholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Total leased liabilities Lease Liability Lease Liability Document Fiscal Period Focus Document Fiscal Period Focus 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Useful Life (in years) Finite-Lived Intangible Asset, Useful Life Schedule of assets and liabilities Assets And Liabilities, Leases [Table Text Block] Assets And Liabilities, Leases [Table Text Block] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Title Trading Arrangement, Individual Title Operating lease expense Operating Lease, Expense Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Long-term investments Debt Securities, Available-for-Sale, Noncurrent Individual: Individual [Axis] Financing right-of-use lease Finance Lease, Right-of-Use Asset, before Accumulated Amortization City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Net Loss Per Common Share Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Marketable Securities [Table] Marketable Securities [Table] Term of contract Lessee, Operating Lease, Term of Contract Minimum Minimum [Member] Weighted-average common shares outstanding: Anti-dilutive shares excluded from diluted net loss per common share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Directly to consumer Sales Channel, Directly to Consumer [Member] Exercise Price Award Exercise Price Area of real estate property Area of Real Estate Property Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Insurance reimbursement-related liabilities Accrued Insurance, Current Contract with Customer, Basis of Pricing [Domain] Contract with Customer, Basis of Pricing [Domain] Payments on employee’s behalf for taxes related to vesting of restricted stock unit awards Payment, Tax Withholding, Share-Based Payment Arrangement Liabilities Liabilities [Abstract] Financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Total leased assets Right Of Use Asset Right Of Use Asset Accumulated Deficit Retained Earnings [Member] Schedule of non-cash stock-based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Amortization of premiums and discounts on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Total liabilities and shareholders’ equity Liabilities and Equity Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Other long-term assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Basic (in USD per share) Basic loss per common share (in USD per share) Earnings Per Share, Basic Right-of-use assets Operating Operating Lease, Right-of-Use Asset Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Shares issued under the Employee Stock Purchase Plan Stock Issued During Period, Value, Employee Stock Purchase Plan Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Remainder of 2023 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Lease option to extend term Lease Option To Extend Term Lease Option To Extend Term Total leased liabilities Lease Liability Noncurrent Lease Liability Noncurrent Selected Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Change in Accounting Estimate, Type [Domain] Change in Accounting Estimate, Type [Domain] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Through Intermediary Sales Channel, Through Intermediary [Member] Termination Date Trading Arrangement Termination Date Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized Estimated Fair Value Debt securities, fair value Debt Securities, Available-for-Sale Raw materials Inventory, Raw Materials, Gross Liabilities that are measured at fair value on a recurring basis Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Short-term investments Short-Term Investments [Member] Change in estimate of uncollectible (percent) Revenue, Revenue Recognized, Change in Uncollectible Analysis, Percentage Revenue, Revenue Recognized, Change in Uncollectible Analysis, Percentage Adjustments to reconcile net loss to net cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] All Trading Arrangements All Trading Arrangements [Member] Less accumulated depreciation Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Less: tenant improvement allowances Lessee, Operating Lease, Liability, Tenant Improvement Allowance Lessee, Operating Lease, Liability, Tenant Improvement Allowance Compensation Amount Outstanding Recovery Compensation Amount Escrow deposit amount Escrow Deposit Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] 2025 Lease Liability Payments Due Year Two Lease Liability Payments Due Year Two Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Total leased liabilities Finance Lease, Liability 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three Work-in-process Inventory, Work in Process, Gross Insider Trading Arrangements [Line Items] Revenue, Product and Service [Extensible List] Revenue, Product and Service [Extensible Enumeration] Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Effect of dilutive stock options and restricted stock units (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two Adjustment to Compensation, Amount Adjustment to Compensation Amount Cost of product sales Cost of Sales [Member] Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Ann Arbor Michigan Ann Arbor, Michigan [Member] Ann Arbor, Michigan Other revenue NexoBrid revenue Revenue Not from Contract with Customer, Other Entity Central Index Key Entity Central Index Key Less: tenant improvement allowances Lease, Liability, Tenant Improvement Allowance Lease, Liability, Tenant Improvement Allowance Total non-cash stock-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Cost Finite-Lived Intangible Assets, Gross Biopsy kits Biopsy Kits [Member] Biopsy Kits [Member] Finance Finance Lease, Right-of-Use Asset, after Accumulated Amortization Employee-related accruals Employee-related Liabilities, Current Fair Value Measurements Fair Value Disclosures [Text Block] Name Trading Arrangement, Individual Name Schedule of disaggregation of revenue Disaggregation of Revenue [Table Text Block] Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Additional funding License Agreement, Additional Funding License Agreement, Additional Funding Product sales, net Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Maximum contingent consideration License Agreement, Contingent Consideration, Maximum License Agreement, Contingent Consideration, Maximum Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Money market funds Money Market Funds [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Tenant improvement allowance Lessee, Operating Lease, Tenant Improvement Allowance Lessee, Operating Lease, Tenant Improvement Allowance Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Restricted stock withheld for employee tax remittance (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Licensing Agreements Licensing Agreements [Member] MediWound Ltd MediWound Ltd [Member] MediWound Ltd [Member] Credit Facility [Domain] Credit Facility [Domain] Basis spread on variable rate (in percent) Debt Instrument, Basis Spread on Variable Rate Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Cost, Product and Service [Extensible List] Cost, Product and Service [Extensible Enumeration] Leasehold improvements Leasehold Improvements [Member] Employee stock purchase plan and service-based stock options Employee Stock And Employee Stock Option [Member] Employee Stock And Employee Stock Option [Member] Diluted (in shares) Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Long-term investments Long-term Investments [Member] Long-term Investments [Member] Thereafter Lease Liability Payments Due After Year Four Lease Liability Payments Due After Year Four Right-of-use asset and lease liability recognized Right-of-Use Asset Obtained in Exchange for Finance Lease Liability SOFR Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Less: interest Finance Lease, Liability, Undiscounted Excess Amount Change in estimates related to prior periods Change in Accounting Method Accounted for as Change in Estimate [Member] Revenue Revenue from Contract with Customer [Text Block] Expenditures for property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Cover [Abstract] Cover [Abstract] M A C I Implants and kits MACI Implants And Kits [Member] MACI Implants And Kits Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Amortization of debt issuance costs Amortization of Debt Issuance Costs Contingent consideration License Agreement, Contingent Consideration License Agreement, Contingent Consideration Recurring Fair Value, Recurring [Member] Other long-term liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Total lease payments Lessee, Operating Lease, Liability, to be Paid Short-term investments Short-Term Investments Construction in process Construction in Progress [Member] 2027 Lease Liability Payments Due Year Four Lease Liability Payments Due Year Four Total operating expenses Operating Expenses Consideration payment for license License Agreement, Consideration License Agreement, Consideration Net increase (decrease) in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Non-PEO NEO Non-PEO NEO [Member] Provider or Facility Provider or Facility [Member] Provider or Facility [Member] Time-and-materials contract Time-and-Materials Contract [Member] Equity Component [Domain] Equity Component [Domain] Finance Finance Lease, Liability, Current Adjustment to Compensation: Adjustment to Compensation [Axis] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Basic (in shares) Basic weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Contract rate Fixed-Price Contract [Member] Loss from operations Operating Income (Loss) NexoBrid License and Supply Agreements License Agreement [Text Block] License Agreement [Text Block] Cash and cash equivalents Cash and Cash Equivalents [Member] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Statement Statement [Line Items] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Outstanding borrowings Long-Term Line of Credit Schedule of fair value of securities, not including cash Debt Securities, Available-for-Sale [Table Text Block] Name of Property [Axis] Name of Property [Axis] Contract with Customer, Sales Channel [Domain] Contract with Customer, Sales Channel [Domain] Product [Member] EX-101.PRE 11 vcel-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover - shares
 6 Months Ended
Jun. 30, 2023
Jul. 27, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2023  
Document Transition Report false  
Entity File Number 001-35280  
Entity Registrant Name VERICEL CORPORATION  
Entity Incorporation, State or Country Code MI  
Entity Tax Identification Number 94-3096597  
Entity Address, Address Line One 64 Sidney Street  
Entity Address, City or Town Cambridge  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02139  
City Area Code 617  
Local Phone Number 588-5555  
Title of 12(b) Security Common Stock (No par value)  
Trading Symbol VCEL  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   47,642,194
Entity Central Index Key 0000887359  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Amendment Flag false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 43,023 $ 51,067
Restricted cash 27,794 0
Short-term investments 54,808 68,471
Accounts receivable (net of allowance for doubtful accounts of $44 and $47, respectively) 38,319 46,539
Inventory 13,883 15,986
Other current assets 5,044 4,803
Total current assets 182,871 186,866
Property and equipment, net 23,408 15,837
Intangible assets, net 7,188 7,500
Right-of-use assets 75,063 41,535
Long-term investments 20,985 19,962
Other long-term assets 1,196 1,303
Total assets 310,711 273,003
Current liabilities:    
Accounts payable 14,401 16,930
Accrued expenses 13,971 16,190
Current portion of operating lease liabilities 7,218 4,302
Other current liabilities 21 41
Total current liabilities 35,611 37,463
Operating lease liabilities 76,144 43,268
Other long-term liabilities 28 0
Total liabilities 111,783 80,731
COMMITMENTS AND CONTINGENCIES (Note 12)
Shareholders’ equity:    
Common stock, no par value; shares authorized — 75,000; shares issued and outstanding 47,616 and 47,253, respectively 612,059 593,245
Accumulated other comprehensive loss (621) (978)
Accumulated deficit (412,510) (399,995)
Total shareholders’ equity 198,928 192,272
Total liabilities and shareholders’ equity $ 310,711 $ 273,003
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 44 $ 47
Common stock, shares authorized (in shares) 75,000,000 75,000,000
Common stock, shares issued (in shares) 47,616,000 47,253,000
Common stock, shares outstanding (in shares) 47,616,000 47,253,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]        
Product sales, net $ 45,922 $ 36,826 $ 86,939 $ 72,678
Other revenue 0 220 0 442
Total revenue 45,922 37,046 86,939 73,120
Cost of product sales 15,981 14,192 30,478 26,814
Gross profit 29,941 22,854 56,461 46,306
Research and development 5,253 4,792 10,465 9,652
Selling, general and administrative 30,649 27,144 60,134 53,009
Total operating expenses 35,902 31,936 70,599 62,661
Loss from operations (5,961) (9,082) (14,138) (16,355)
Other income (expense):        
Interest income 1,095 148 1,934 236
Interest expense (149) (20) (294) (38)
Other (expense) income (5) (9) (17) 103
Total other income 941 119 1,623 301
Net loss $ (5,020) $ (8,963) $ (12,515) $ (16,054)
Net loss per common share:        
Basic (in USD per share) $ (0.11) $ (0.19) $ (0.26) $ (0.34)
Diluted (in USD per share) $ (0.11) $ (0.19) $ (0.26) $ (0.34)
Weighted-average common shares outstanding:        
Basic (in shares) 47,572 47,117 47,480 47,052
Diluted (in shares) 47,572 47,117 47,480 47,052
Cost, Product and Service [Extensible List] Product [Member] Product [Member] Product [Member] Product [Member]
Revenue, Product and Service [Extensible List] Product [Member] Product [Member] Product [Member] Product [Member]
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Statement of Comprehensive Income [Abstract]        
Net loss $ (5,020) $ (8,963) $ (12,515) $ (16,054)
Other comprehensive loss:        
Unrealized gain (loss) on investments 15 (242) 357 (701)
Comprehensive loss $ (5,005) $ (9,205) $ (12,158) $ (16,755)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Accumulated Other Comprehensive Gain (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021   46,880    
Beginning balance at Dec. 31, 2021 $ 170,462 $ 553,902 $ (154) $ (383,286)
Increase (Decrease) in Shareholders' Equity        
Net loss (7,091)     (7,091)
Stock-based compensation expense 9,531 $ 9,531    
Stock option exercises (in shares)   125    
Stock option exercises 1,155 $ 1,155    
Shares issued under the Employee Stock Purchase Plan (in shares)   9    
Shares issued under the Employee Stock Purchase Plan 310 $ 310    
Issuance of stock for restricted stock unit vesting (in shares)   108    
Restricted stock withheld for employee tax remittance (in shares)   (41)    
Restricted stock withheld for employee tax remittance (1,423) $ (1,423)    
Unrealized gain (loss) on investment (459)   (459)  
Ending balance (in shares) at Mar. 31, 2022   47,081    
Ending balance at Mar. 31, 2022 172,485 $ 563,475 (613) (390,377)
Beginning balance (in shares) at Dec. 31, 2021   46,880    
Beginning balance at Dec. 31, 2021 170,462 $ 553,902 (154) (383,286)
Increase (Decrease) in Shareholders' Equity        
Net loss (16,054)      
Unrealized gain (loss) on investment (701)      
Ending balance (in shares) at Jun. 30, 2022   47,141    
Ending balance at Jun. 30, 2022 174,816 $ 575,011 (855) (399,340)
Beginning balance (in shares) at Mar. 31, 2022   47,081    
Beginning balance at Mar. 31, 2022 172,485 $ 563,475 (613) (390,377)
Increase (Decrease) in Shareholders' Equity        
Net loss (8,963)     (8,963)
Stock-based compensation expense 10,808 $ 10,808    
Stock option exercises (in shares)   32    
Stock option exercises 428 $ 428    
Shares issued under the Employee Stock Purchase Plan (in shares)   10    
Shares issued under the Employee Stock Purchase Plan 318 $ 318    
Issuance of stock for restricted stock unit vesting (in shares)   19    
Restricted stock withheld for employee tax remittance (in shares)   (1)    
Restricted stock withheld for employee tax remittance (18) $ (18)    
Unrealized gain (loss) on investment (242)   (242)  
Ending balance (in shares) at Jun. 30, 2022   47,141    
Ending balance at Jun. 30, 2022 $ 174,816 $ 575,011 (855) (399,340)
Beginning balance (in shares) at Dec. 31, 2022 47,253 47,253    
Beginning balance at Dec. 31, 2022 $ 192,272 $ 593,245 (978) (399,995)
Increase (Decrease) in Shareholders' Equity        
Net loss (7,495)     (7,495)
Stock-based compensation expense 8,731 $ 8,731    
Stock option exercises (in shares)   132    
Stock option exercises 2,009 $ 2,009    
Shares issued under the Employee Stock Purchase Plan (in shares)   11    
Shares issued under the Employee Stock Purchase Plan 216 $ 216    
Issuance of stock for restricted stock unit vesting (in shares)   183    
Restricted stock withheld for employee tax remittance (in shares)   (72)    
Restricted stock withheld for employee tax remittance (2,097) $ (2,097)    
Unrealized gain (loss) on investment 342   342  
Ending balance (in shares) at Mar. 31, 2023   47,507    
Ending balance at Mar. 31, 2023 $ 193,978 $ 602,104 (636) (407,490)
Beginning balance (in shares) at Dec. 31, 2022 47,253 47,253    
Beginning balance at Dec. 31, 2022 $ 192,272 $ 593,245 (978) (399,995)
Increase (Decrease) in Shareholders' Equity        
Net loss (12,515)      
Unrealized gain (loss) on investment $ 357      
Ending balance (in shares) at Jun. 30, 2023 47,616 47,616    
Ending balance at Jun. 30, 2023 $ 198,928 $ 612,059 (621) (412,510)
Beginning balance (in shares) at Mar. 31, 2023   47,507    
Beginning balance at Mar. 31, 2023 193,978 $ 602,104 (636) (407,490)
Increase (Decrease) in Shareholders' Equity        
Net loss (5,020)     (5,020)
Stock-based compensation expense 8,761 $ 8,761    
Stock option exercises (in shares)   68    
Stock option exercises 889 $ 889    
Shares issued under the Employee Stock Purchase Plan (in shares)   18    
Shares issued under the Employee Stock Purchase Plan 384 $ 384    
Issuance of stock for restricted stock unit vesting (in shares)   26    
Restricted stock withheld for employee tax remittance (in shares)   (3)    
Restricted stock withheld for employee tax remittance (79) $ (79)    
Unrealized gain (loss) on investment $ 15   15  
Ending balance (in shares) at Jun. 30, 2023 47,616 47,616    
Ending balance at Jun. 30, 2023 $ 198,928 $ 612,059 $ (621) $ (412,510)
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Operating activities:    
Net loss $ (12,515) $ (16,054)
Adjustments to reconcile net loss to net cash flows from operating activities:    
Depreciation and amortization expense 2,329 1,928
Stock-based compensation expense 17,492 20,339
Amortization of premiums and discounts on marketable securities (504) 302
Amortization of debt issuance costs 108 0
Non-cash lease costs 2,466 2,155
Other 17 16
Changes in operating assets and liabilities:    
Inventory 2,103 (2,548)
Accounts receivable 8,220 3,773
Other current assets (241) (563)
Accounts payable 956 1,152
Accrued expenses (2,219) (1,912)
Operating lease liabilities (184) (1,977)
Other non-current assets and liabilities, net 28 0
Net cash provided by operating activities 18,056 6,611
Investing activities:    
Purchases of investments (28,537) (34,948)
Sales and maturities of investments 42,038 26,344
Expenditures for property and equipment (5,609) (5,062)
Purchases of intangible assets (7,500) 0
Net cash provided by (used in) investing activities 392 (13,666)
Financing activities:    
Net proceeds from common stock issuance 3,498 2,211
Payments on employee’s behalf for taxes related to vesting of restricted stock unit awards (2,176) (1,441)
Other (20) (18)
Net cash provided by financing activities 1,302 752
Net increase (decrease) in cash, cash equivalents, and restricted cash 19,750 (6,303)
Cash, cash equivalents, and restricted cash at beginning of period 51,067 68,541
Cash, cash equivalents, and restricted cash at end of period 70,817 62,238
Supplemental disclosure of cash flow information:    
Right-of-use asset and lease liability recognized 35,976 0
Additions to property and equipment included in accounts payable 4,321 869
Reconciliation of amounts within the condensed consolidated balance sheets:    
Cash and cash equivalents 43,023 56,054
Restricted cash 27,794 6,184
Total cash, cash equivalents, and restricted cash at end of period $ 70,817 $ 62,238
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Organization
 6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization Organization
Vericel Corporation, a Michigan corporation (together with its consolidated subsidiaries referred to herein as the Company, or Vericel), was incorporated in March 1989 and began employee-based operations in 1991. The Company is a fully-integrated, commercial-stage biopharmaceutical company and is a leader in advanced therapies for the sports medicine and severe burn care markets. Vericel currently markets three commercial-stage products in the U.S., MACI®, Epicel® and NexoBrid®.

MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (“TBSA”). The Company also holds an exclusive license from MediWound Ltd. (“MediWound”) to commercialize NexoBrid (anacaulase-bcdb) in North America. On December 28, 2022, the U.S. Food and Drug Administration (“FDA”) approved a Biologics License Application (“BLA”) for NexoBrid, granting a license for commercial use in the U.S. NexoBrid is a topically-administered biological product containing proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns. The Company operates its business primarily in the U.S. in one reportable segment - the research, product development, manufacture and distribution of cellular therapies and specialty biologics for use in the treatment of specific diseases.

The Company is subject to risks common to companies in the life sciences industry including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with FDA regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.

COVID-19

On May 11, 2023, the U.S. Department of Health and Human Services announced the expiration of the federal Public Health Emergency for COVID-19. At this juncture, the pandemic’s effects on the Company’s business and results of operations have largely moderated and we have begun to see a return to more normal operations. Should a resurgence of COVID-19 occur, or new virus variants emerge, it could result in additional disruptions that could impact the Company’s business and operations in the future, including U.S. hospital or surgical center staffing shortages, periodic cancellation or delay of elective MACI surgical procedures, intermittent restrictions on the ability of Company personnel to travel and access customers for selling, marketing, training, case support and product development feedback, delays in approvals by regulatory bodies, delays in product development efforts, and additional government requirements or other incremental mitigation efforts that may further impact the Company’s capacity to manufacture, sell and support the use of its products.

The War in Ukraine

The ongoing war between Russia and Ukraine and the related sanctions and other penalties imposed by countries across the globe against Russia are continuing to create substantial uncertainty in the global economy and have contributed to heightened inflation and supply chain disruptions. While the Company does not have operations in Russia or Ukraine and does not have exposure to distributors, or third-party service providers in Russia or Ukraine, it is unable to predict the ultimate impact that these actions will have on the global economy or on its financial condition, results of operations, and cash flows as of the date of these condensed consolidated financial statements.
Liquidity

The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of June 30, 2023, the Company had an accumulated deficit of $412.5 million and had a net loss of $12.5 million during the six months ended June 30, 2023. The Company had cash and cash equivalents of $43.0 million and investments of $75.8 million as of June 30, 2023. The Company expects that cash from the sales of its products and existing cash, cash equivalents, investments, and available borrowing capacity will be sufficient to support the Company’s current operations through at least 12 months from the issuance of these condensed consolidated financial statements. If revenues decline for a sustained period, the Company may need to access additional capital; however, the Company may not be able to obtain additional financing on acceptable terms or at all. The terms of any additional financing may adversely affect the holdings or the rights of the Company’s shareholders.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and investments in marketable debt securities. The Company may maintain deposits in financial institutions in excess of the insurance coverage offered by the Federal Deposit Insurance Corporation, the loss of which could have a negative effect on our operations and liquidity. The Company believes that it is not exposed to significant credit risk as its deposits, including cash and cash equivalents, are held at multiple high credit quality financial institutions. The Company has not experienced any losses on these deposits; however no assurances can be provided that there will not be losses experienced in the future. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Basis of Presentation
 6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation Basis of Presentation
The accompanying condensed consolidated financial statements of Vericel are unaudited and have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations.

The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expenses.

The condensed consolidated balance sheet as of December 31, 2022 has been derived from the audited consolidated financial statements at that date, but does not include all the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on February 23, 2023 (“Annual Report”).

Recent Accounting Pronouncements

No new accounting standards were adopted during the six months ended June 30, 2023. The Company considers the applicability and impact of any recent Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). Based on the assessment, the ASUs were determined to be either not applicable or are expected to have minimal impact on the Company’s condensed consolidated financial statements.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue
 6 Months Ended
Jun. 30, 2023
Risks and Uncertainties [Abstract]  
Revenue Revenue
Revenue Recognition and Product Sales, Net

The Company recognizes product revenue from sales of MACI biopsy kits, MACI implants, Epicel grafts and NexoBrid following the five-step model in Accounting Standards Codification 606, Revenue Recognition.

MACI Biopsy Kits

MACI biopsy kits are sold directly to hospitals and ambulatory surgical centers based on contracted rates in an approved contract or sales order. The Company recognizes MACI kit revenue upon delivery of the biopsy kit, at which time the customer (the facility) is in control of the kit. The kit is used by the doctor to provide a sample of cartilage tissue to the Company, which can later be used to manufacture a MACI implant. The ordering of the kit does not obligate the Company to manufacture an implant nor does the receipt of the cartilage tissue by the Company from the customer following biopsy. The customer’s order of an implant is separate from the process of ordering the biopsy kit. Therefore, the sale of the biopsy kit and any subsequent sale of an implant are distinct contracts and are accounted for separately.

MACI Implants

The Company contracts with two specialty pharmacies, Orsini Pharmaceutical Services, Inc. (“Orsini”) and AllCare Plus Pharmacy, Inc. (“AllCare”) to distribute MACI in a manner in which the Company retains the credit and collection risk from the end customer. The Company pays both specialty pharmacies a fee for each patient to whom MACI is dispensed. Both Orsini and AllCare perform collection activities to collect payment from customers. The Company engages a third party to provide services in connection with a patient support program to manage patient cases and to ensure complete and correct billing information is provided to the insurers and hospitals. In addition, the Company also sells MACI directly to DMS Pharmaceutical Group, Inc. (“DMS”) for patients treated at military treatment facilities. The sales directly to DMS are made at a contracted rate.

Prior authorization and confirmation of coverage level by the patient’s private insurance plan, hospital or government payer is a prerequisite to the shipment of product to a patient. The Company recognizes product revenue from sales of all MACI implants upon delivery at which time the customer obtains control of the implant and the claim is billable. The total consideration that the Company expects to collect in exchange for MACI implants (the “Transaction Price”) may be fixed or variable. Direct sales to hospitals or distributors are recorded at a contracted price, and there are typically no forms of variable consideration.

When the Company sells MACI the patient is responsible for payment; however, the Company is typically reimbursed by a third-party insurer or government payer, subject to a patient co-pay amount. Reimbursements from third-party insurers and government payers vary by patient and payer and are based on either contracted rates, publicly available rates, fee schedules or past payer precedents. Net product revenue is recognized net of estimated contractual allowances, which considers historical collection experience from both the payer and patient, denial rates and the terms of the Company’s contractual arrangements. The Company estimates expected collections for these transactions using the portfolio approach. The Company records a reduction to revenue at the time of sale for its estimate of the amount of consideration that will not be collected. In addition, potential credit risk exposure has been evaluated for the Company’s accounts receivable in accordance with ASC 326, Financial Instruments - Credit Losses. The Company assesses risk and determines a loss percentage by pooling accounts receivable based on similar risk characteristics. The loss percentage is calculated through the use of forecasts that are based on current and historical economic and financial information. This loss percentage was applied to the accounts receivables as of June 30, 2023. The total allowance for uncollectible consideration as of June 30, 2023 and December 31, 2022 was $5.3 million and $6.1 million, respectively. Changes to the estimate of the amount of consideration that will not be collected could have a material impact on the revenue recognized. A 50 basis points change to the estimated uncollectible percentage could result in an approximately $0.3 million decrease or increase in the revenue recognized for the six months ended June 30, 2023.

Changes in estimates of the Transaction Price are recorded through revenue in the period in which such change occurs. Changes in estimates related to prior periods are shown in the Revenue by Product and Customer table below and relate primarily to changes in the initial expected reimbursement or collection expectation upon completion of the billing claims process for MACI implants that occurred in a prior year.
Epicel

The Company sells Epicel directly to hospitals and burn centers based on contracted rates stated in an approved contract or purchase order. Similar to MACI, there is no obligation to manufacture Epicel grafts upon receipt of a skin biopsy, and Vericel has no contractual right to receive payment until the product is delivered to the hospital. The Company recognizes product revenue from sales of Epicel upon delivery to the hospital, at which time the customer is in control of the Epicel grafts and the claim is billable to the hospital.

NexoBrid

The Company entered into exclusive license and supply agreements with MediWound in May 2019, pursuant to which MediWound will manufacture and supply NexoBrid on a unit price basis, which may be increased pursuant to the terms of the agreements. Additionally, beginning in 2020 the U.S. Biomedical Advanced Research and Development Authority (“BARDA”) procured quantities of NexoBrid from MediWound, for use as a medical countermeasure in the event of a mass casualty emergency in the U.S. involving thermal burns. The initial, quarterly, procurement of NexoBrid by BARDA under its agreement with MediWound completed during the third quarter of 2022. The Company recognized revenue based on a percentage of gross profits for sales of NexoBrid to BARDA upon delivery, at which time BARDA was in control of the product. As of June 30, 2023, the Company did not hold a direct contract or distribution agreement with BARDA, or take title to the product procured by BARDA.

On May 9, 2023, MediWound announced BARDA’s award of additional funding under the parties’ existing agreement, $3 million of which will support the replacement of NexoBrid, previously procured for emergency response preparedness, which has since expired. Pursuant to the terms of the Company’s license agreement with MediWound, the Company would recognize revenue based on a percentage of gross profits, minus a percentage of net sales, on any sales of NexoBrid directly to BARDA upon delivery, pursuant to this additional award.

Additionally, on December 28, 2022, the FDA approved a BLA for NexoBrid, granting a license for commercial use in the U.S. NexoBrid is a topically-administered biological product containing proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns.
Revenue by Product and Customer

The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated:
 Three Months Ended June 30,Six Months Ended June 30,
Revenue by product (in thousands) 2023202220232022
MACI implants and kits
Implants based on contracted rate sold through a specialty pharmacy (a)
$22,377 $15,714 $45,331 $31,009 
Implants subject to third party reimbursement sold through a specialty pharmacy (b)
4,015 4,295 8,004 7,803 
Implants sold direct based on contracted rates (c)
7,252 5,756 14,222 11,390 
Implants sold direct subject to third-party reimbursement (d)
1,045 570 1,538 1,441 
Biopsy kits - direct bill528 545 1,062 1,066 
Change in estimates related to prior periods (e)
1,119 1,733 369 1,898 
Total MACI implants and kits36,336 28,613 70,526 54,607 
Epicel
Direct bill (hospital)9,586 8,213 16,413 18,071 
NexoBrid revenue (f)
— 220 — 442 
Total revenue$45,922 $37,046 $86,939 $73,120 
(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts.
(b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer, and are subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.
(f) Represents revenue based on a percentage of gross profits for sales of NexoBrid to BARDA, pursuant to the license agreement between the Company and MediWound (see Note 11).
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Selected Balance Sheet Components
 6 Months Ended
Jun. 30, 2023
Balance Sheet Related Disclosures [Abstract]  
Selected Balance Sheet Components Selected Balance Sheet Components
Inventory

Inventory consisted of the following:
(In thousands)June 30, 2023December 31, 2022
Raw materials$12,847 $15,101 
Work-in-process863 832 
Finished goods173 53 
Total inventory$13,883 $15,986 
Property and Equipment

Property and Equipment, net consisted of the following:

(In thousands)June 30, 2023December 31, 2022
Machinery and equipment$5,544 $5,041 
Furniture, fixtures and office equipment1,710 1,710 
Computer equipment and software8,308 8,224 
Leasehold improvements14,896 13,689 
Construction in process13,148 5,438 
Financing right-of-use lease18 37 
Total property and equipment, gross43,624 34,139 
Less accumulated depreciation(20,216)(18,302)
Total property and equipment, net$23,408 $15,837 

Depreciation expense for the three and six months ended June 30, 2023 was $1.0 million and $2.0 million, respectively, and $1.1 million and $1.9 million, respectively, for the same periods in 2022.

Intangible Assets

Intangible assets, net consisted of the following:

June 30, 2023December 31, 2022
(In thousands)Useful Life (in years)Amortization MethodCostAccumulated AmortizationNetCostAccumulated AmortizationNet
NexoBrid license12Straight-line$7,500 $(312)$7,188 $7,500 $— $7,500 

Amortization expense for the three and six months ended June 30, 2023 was $0.2 million and $0.3 million, respectively.

Future amortization expense of intangible assets as of June 30, 2023 is estimated to be as follows:

(In thousands)Amount
Remainder of 2023$313 
2024625 
2025625 
2026625 
2027625 
Thereafter4,375 
Total$7,188 

Accrued Expenses

Accrued Expenses consisted of the following:
(In thousands)June 30, 2023December 31, 2022
Bonus-related compensation$5,090 $7,132 
Employee-related accruals3,436 3,101 
Insurance reimbursement-related liabilities5,160 5,030 
Other accrued expenses285 927 
Total accrued expenses$13,971 $16,190 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Leases
 6 Months Ended
Jun. 30, 2023
Leases [Abstract]  
Leases Leases
The Company leases facilities in Ann Arbor, Michigan and Cambridge, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facilities include clean rooms, laboratories for MACI and Epicel manufacturing, and office space. The Company also leases offsite warehouse space, and other computer-related equipment.

With respect to the Ann Arbor facility, in March 2023, the Company entered into an amendment to that lease extending its term until April 30, 2025. Monthly contractual payments are expected to range from $17,000 to $18,000.

On January 28, 2022, the Company entered into a lease agreement (the “Burlington Lease”) to lease approximately 126,000 square feet of to-be-constructed manufacturing, laboratory and office space in Burlington, Massachusetts (the “Premises”). Once constructed, the Premises will serve as the Company’s new corporate headquarters and primary manufacturing facility.

In April 2023, in connection with the Burlington Lease, the Company entered into a construction escrow agreement (the “Construction Escrow Agreement”) with the facility’s landlord and an escrow agent. Pursuant to the terms of the Construction Escrow Agreement, in April 2023, the Company began funding, into an escrow account maintained by the escrow agent, a portion of its share of tenant improvement construction costs at the facility, which are designated as restricted cash. At the same time, the facility’s landlord began funding a portion of its tenant improvement allowance through a separate escrow account. To date, the Company has transferred into its escrow account 50% of its required cost amount, or approximately $28.3 million. The Company anticipates funding the remaining 50% of its required cost amount in late 2023 or early 2024.

The term of the Burlington Lease began on June 1, 2023, (the “Commencement Date”), when the Company gained control of and commenced tenant improvement work at the Premises. The Company’s obligation to pay rent for the Premises will begin on the earlier of: 13 months from the Commencement Date; or the date on which the Company first occupies the Premises to conduct operations (the “Rent Commencement Date”). The initial term of the Lease is 144 months following the Rent Commencement Date. The Company has a one-time option to extend the term of the Lease for an additional 10 years, exercisable under certain conditions and at a market rate determined in accordance with the Burlington Lease.

The annual base rent of the Burlington Lease is initially $57 per square foot per year, subject to annual increases of 2.5%. Monthly contractual payments are expected to range from $0.6 million to $0.8 million. Additionally, the Company is responsible for reimbursing the landlord for the Company’s share of the Premises’ property taxes and certain other operating expenses. The Burlington Lease also provides for a tenant improvement allowance from the landlord in an amount equal to $200 per square foot of the Premises, or approximately $24.4 million. The tenant improvement allowance will be used towards the design and construction of the tenant improvements made to the Premises, subject to the terms set forth in the Burlington Lease.

The Company was not involved in the initial construction of the core and shell of the building. On June 1, 2023, the Company gained control of the Premises to begin construction of its tenant improvements. As such, the corresponding right-of-use asset and lease liability of $35.5 million was recorded on the Company’s condensed consolidated balance sheet. As there was not an implicit rate within the lease available, the Company estimated the incremental borrowing rate of 7.7%, based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. The lease term of 13.1 years does not include the lease extension option, as the Company is not reasonably certain to exercise that option.

In January 2022, in connection with the execution of the Burlington Lease, the Company issued a letter of credit collateralized by cash deposits of approximately $6.0 million. Subsequent to the execution of the Revolving Credit Agreement on July 29, 2022 (see Note 8, “Revolving Credit Agreement” for further details), the letter of credit is issued under the sub-facility limit of the Revolving Credit Agreement. Such letter of credit shall be reduced to approximately $4.2 million and $1.8 million at the conclusion of the third and sixth lease years, respectively, provided certain conditions set forth in the Burlington Lease are satisfied.

For the three and six months ended June 30, 2023 and 2022, lease expense of less than $0.1 million was recorded related to short-term leases. For the three and six months ended June 30, 2023, the Company recognized $2.3 million and $4.0 million, respectively, of operating lease expense and $1.7 million and $3.5 million, respectively, for the same period in 2022. For the three and six months ended June 30, 2023 and 2022, the Company recognized less than $0.1 million of financing lease expense.
Operating and finance lease assets and liabilities are as follows:

(In thousands)ClassificationJune 30, 2023December 31, 2022
Assets
OperatingRight-of-use assets$75,063 $41,535 
FinanceProperty and equipment, net18 37 
Total leased assets$75,081 $41,572 
Liabilities
Current
OperatingCurrent portion of operating lease liabilities$7,218 $4,302 
FinanceOther current liabilities21 41 
Non-current
OperatingOperating lease liabilities$76,144 $43,268 
Total leased liabilities$83,383 $47,611 

Future minimum lease payments under non-cancellable leases as of June 30, 2023 are as follows:
(In thousands)Operating LeasesFinance LeasesTotal
Remainder of 2023$3,576 $21 $3,597 
202410,743 — 10,743 
202513,677 — 13,677 
202613,969 — 13,969 
202714,351 — 14,351 
Thereafter103,229 — 103,229 
Total lease payments$159,545 $21 $159,566 
Less: tenant improvement allowances(25,167)— (25,167)
Less: interest(51,016)— (51,016)
Total leased liabilities$83,362 $21 $83,383 
Leases Leases
The Company leases facilities in Ann Arbor, Michigan and Cambridge, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facilities include clean rooms, laboratories for MACI and Epicel manufacturing, and office space. The Company also leases offsite warehouse space, and other computer-related equipment.

With respect to the Ann Arbor facility, in March 2023, the Company entered into an amendment to that lease extending its term until April 30, 2025. Monthly contractual payments are expected to range from $17,000 to $18,000.

On January 28, 2022, the Company entered into a lease agreement (the “Burlington Lease”) to lease approximately 126,000 square feet of to-be-constructed manufacturing, laboratory and office space in Burlington, Massachusetts (the “Premises”). Once constructed, the Premises will serve as the Company’s new corporate headquarters and primary manufacturing facility.

In April 2023, in connection with the Burlington Lease, the Company entered into a construction escrow agreement (the “Construction Escrow Agreement”) with the facility’s landlord and an escrow agent. Pursuant to the terms of the Construction Escrow Agreement, in April 2023, the Company began funding, into an escrow account maintained by the escrow agent, a portion of its share of tenant improvement construction costs at the facility, which are designated as restricted cash. At the same time, the facility’s landlord began funding a portion of its tenant improvement allowance through a separate escrow account. To date, the Company has transferred into its escrow account 50% of its required cost amount, or approximately $28.3 million. The Company anticipates funding the remaining 50% of its required cost amount in late 2023 or early 2024.

The term of the Burlington Lease began on June 1, 2023, (the “Commencement Date”), when the Company gained control of and commenced tenant improvement work at the Premises. The Company’s obligation to pay rent for the Premises will begin on the earlier of: 13 months from the Commencement Date; or the date on which the Company first occupies the Premises to conduct operations (the “Rent Commencement Date”). The initial term of the Lease is 144 months following the Rent Commencement Date. The Company has a one-time option to extend the term of the Lease for an additional 10 years, exercisable under certain conditions and at a market rate determined in accordance with the Burlington Lease.

The annual base rent of the Burlington Lease is initially $57 per square foot per year, subject to annual increases of 2.5%. Monthly contractual payments are expected to range from $0.6 million to $0.8 million. Additionally, the Company is responsible for reimbursing the landlord for the Company’s share of the Premises’ property taxes and certain other operating expenses. The Burlington Lease also provides for a tenant improvement allowance from the landlord in an amount equal to $200 per square foot of the Premises, or approximately $24.4 million. The tenant improvement allowance will be used towards the design and construction of the tenant improvements made to the Premises, subject to the terms set forth in the Burlington Lease.

The Company was not involved in the initial construction of the core and shell of the building. On June 1, 2023, the Company gained control of the Premises to begin construction of its tenant improvements. As such, the corresponding right-of-use asset and lease liability of $35.5 million was recorded on the Company’s condensed consolidated balance sheet. As there was not an implicit rate within the lease available, the Company estimated the incremental borrowing rate of 7.7%, based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. The lease term of 13.1 years does not include the lease extension option, as the Company is not reasonably certain to exercise that option.

In January 2022, in connection with the execution of the Burlington Lease, the Company issued a letter of credit collateralized by cash deposits of approximately $6.0 million. Subsequent to the execution of the Revolving Credit Agreement on July 29, 2022 (see Note 8, “Revolving Credit Agreement” for further details), the letter of credit is issued under the sub-facility limit of the Revolving Credit Agreement. Such letter of credit shall be reduced to approximately $4.2 million and $1.8 million at the conclusion of the third and sixth lease years, respectively, provided certain conditions set forth in the Burlington Lease are satisfied.

For the three and six months ended June 30, 2023 and 2022, lease expense of less than $0.1 million was recorded related to short-term leases. For the three and six months ended June 30, 2023, the Company recognized $2.3 million and $4.0 million, respectively, of operating lease expense and $1.7 million and $3.5 million, respectively, for the same period in 2022. For the three and six months ended June 30, 2023 and 2022, the Company recognized less than $0.1 million of financing lease expense.
Operating and finance lease assets and liabilities are as follows:

(In thousands)ClassificationJune 30, 2023December 31, 2022
Assets
OperatingRight-of-use assets$75,063 $41,535 
FinanceProperty and equipment, net18 37 
Total leased assets$75,081 $41,572 
Liabilities
Current
OperatingCurrent portion of operating lease liabilities$7,218 $4,302 
FinanceOther current liabilities21 41 
Non-current
OperatingOperating lease liabilities$76,144 $43,268 
Total leased liabilities$83,383 $47,611 

Future minimum lease payments under non-cancellable leases as of June 30, 2023 are as follows:
(In thousands)Operating LeasesFinance LeasesTotal
Remainder of 2023$3,576 $21 $3,597 
202410,743 — 10,743 
202513,677 — 13,677 
202613,969 — 13,969 
202714,351 — 14,351 
Thereafter103,229 — 103,229 
Total lease payments$159,545 $21 $159,566 
Less: tenant improvement allowances(25,167)— (25,167)
Less: interest(51,016)— (51,016)
Total leased liabilities$83,362 $21 $83,383 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Investments
 6 Months Ended
Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
Investments Investments
Marketable debt securities held by the Company are classified as available-for-sale pursuant to ASC 320, Investments – Debt and Equity Securities, and carried at fair value in the accompanying condensed consolidated balance sheets on a settlement date basis. The following tables summarize the gross unrealized gains and losses of the Company’s marketable securities:

June 30, 2023
Gross UnrealizedEstimated Fair Value
(In thousands)Amortized CostGainsLossesCredit Losses
Commercial paper$12,494 $— $(15)$— $12,479 
Corporate notes43,864 — (492)— 43,372 
U.S. government securities2,476 — (1)— 2,475 
U.S. government agency bonds17,583 — (116)— 17,467 
$76,417 $— $(624)$— $75,793 
Classified as:
Short-term investments$54,808 
Long-term investments20,985 
$75,793 
December 31, 2022
Gross UnrealizedEstimated Fair Value
(In thousands)Amortized CostGainsLossesCredit Losses
Commercial paper$15,707 $— $(101)$— $15,606 
Corporate notes52,159 — (831)— 51,328 
U.S. government agency bonds21,545 — (46)— 21,499 
$89,411 $— $(978)$— $88,433 
Classified as:
Short-term investments$68,471 
Long-term investments19,962 
$88,433 

As of June 30, 2023 and December 31, 2022, all marketable securities held by the Company had remaining contractual maturities of three years or less. There have been no impairments of the Company’s assets measured and carried at fair value during the three and six months ended June 30, 2023 and 2022.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements
 6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The Company’s fair value measurements are classified and disclosed in one of the following three categories:

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
•Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;
•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The commercial paper, corporate notes, U.S. government securities, and U.S. government agency bonds are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. There were no transfers into or out of Level 3 from December 31, 2022 to June 30, 2023.

The following table summarizes the valuation of the Company’s financial instruments that are measured at fair value on a recurring basis:

 June 30, 2023December 31, 2022
  Fair value measurement category Fair value measurement category
(In thousands)TotalLevel 1Level 2Level 3TotalLevel 1Level 2Level 3
Assets:
Money market funds$7,620 $7,620 $— $— $1,262 $1,262 $— $— 
Commercial paper12,479 — 12,479 — 15,606 — 15,606 — 
Corporate notes43,372 — 43,372 — 51,328 — 51,328 — 
U.S. government securities (a)
22,382 — 22,382 — — — — — 
U.S. government agency bonds (b)
17,467 — 17,467 — 27,976 — 27,976 — 
$103,320 $7,620 $95,700 $— $96,172 $1,262 $94,910 $— 

(a) Approximately $19.9 million of U.S. government securities had an original maturity of 90 days or less and were recorded as a cash equivalent as of June 30, 2023.

(b) Approximately $6.5 million of U.S. government agency bonds had an original maturity of 90 days or less and were recorded as a cash equivalent as of December 31, 2022.
The fair values of the cash equivalents and marketable securities are based on observable market prices. The Company’s accounts receivables, accounts payable and accrued expenses are valued at cost, which approximates fair value.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Revolving Credit Agreement
 6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
Revolving Credit Agreement Revolving Credit Agreement
On July 29, 2022, the Company, as borrower, entered into a $150.0 million five-year senior secured revolving credit agreement by and among the Company, the other loan parties thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as the administrative agent (the “Revolving Credit Agreement”). The Revolving Credit Agreement includes a $15.0 million sub-facility for the issuance of letters of credit, of which the Company is utilizing approximately $6.2 million. Amounts available under the Revolving Credit Agreement are for the working capital needs and other general corporate purposes of the Company. The Company incurred and capitalized approximately $1.1 million of debt issuance costs related to the Revolving Credit Agreement.

Outstanding borrowings under the Revolving Credit Agreement bear interest, with pricing based from time to time at the Company’s election at (i) the Secured Overnight Financing Rate (“SOFR”) plus 0.10% plus a spread ranging from 1.25% to 2.50% as determined by the Company’s Total Net Leverage Ratio (as defined in the Revolving Credit Agreement) or (ii) the alternative base rate (as defined in the Revolving Credit Agreement) plus a spread ranging from 0.25% to 1.50% as determined by the Company’s Total Net Leverage Ratio. The Revolving Credit Agreement also includes a commitment fee, which ranges from 0.20% to 0.25% as determined by the Company’s Total Net Leverage Ratio.

The Company is permitted to voluntarily prepay borrowings under the Revolving Credit Agreement, in whole or in part, without premium or penalty. On any business day on which the total amount of outstanding Revolving Loans (as defined in the Revolving Credit Agreement) and letters of credit exceeds the total Revolving Commitments (as defined in the Revolving Credit Agreement), the Company must prepay the Revolving Loans in an amount equal to such excess. As of June 30, 2023, there are no outstanding borrowings under the Revolving Credit Agreement.

The Revolving Credit Agreement contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. The Revolving Credit Agreement requires the Company to be in quarterly compliance, measured on a trailing four quarter basis, with a financial covenant. The maximum Total Net Leverage Ratio (as defined in the Revolving Credit Agreement is 3.50 to 1.00. The Company may elect to increase the maximum Total Net Leverage Ratio to 4.00 to 1.00 for a period of four consecutive quarters in connection with a Permitted Acquisition (as defined in the Revolving Credit Agreement).

The Revolving Credit Agreement contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all, or substantially all, of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.

Obligations under the Revolving Credit Agreement are secured by first priority liens over substantially all of the assets of Vericel Corporation, excluding certain subsidiaries (subject to customary exclusions set forth in the Revolving Credit Agreement and the other transaction documents).
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation
 6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
The Vericel Corporation 2022 Omnibus Incentive Plan (“2022 Plan”) was approved on April 27, 2022, and provides incentives through the grant of stock options, stock appreciation rights, restricted stock awards and restricted stock units. The exercise price of stock options granted under the 2022 Plan shall not be less than the fair market value of the Company’s common stock on the date of grant. The 2022 Plan replaced the 1992 Stock Option Plan, the 2001 Stock Option Plan, the Amended and Restated 2004 Equity Incentive Plan, the 2009 Second Amended and Restated Omnibus Incentive Plan, the 2017 Omnibus Incentive Plan, and the Amended and Restated 2019 Omnibus Incentive Plan (collectively the “Prior Plans”), and no new grants have been granted under the Prior Plans after approval of the 2022 Plan. However, the expiration or forfeiture of options previously granted under the Prior Plans will increase the number of shares available for issuance under the 2022 Plan.

Stock Compensation Expense

Non-cash stock-based compensation expense (service-based stock options, restricted stock units and employee stock purchase plan) is summarized in the following table:
 Three Months Ended June 30,Six Months Ended June 30,
(in thousands)2023202220232022
Cost of product sales$796 $1,035 $1,681 $2,153 
Research and development993 1,520 1,970 2,870 
Selling, general and administrative6,972 8,253 13,841 15,316 
Total non-cash stock-based compensation expense$8,761 $10,808 $17,492 $20,339 

Service-Based Stock Options

During the three and six months ended June 30, 2023, the Company granted service-based options to purchase common stock of 67,760 and 535,717, respectively, and 170,060 and 1,163,649, respectively, for the same periods in 2022. The weighted-average grant-date fair value of service-based options granted during the three and six months ended June 30, 2023 was $19.30 and $18.41 per option, respectively, and $19.25 and $20.74, respectively, for the same periods in 2022.

Restricted Stock Units
During the three and six months ended June 30, 2023, the Company granted 32,816 and 529,321 restricted stock units, respectively, and 39,746 and 382,768, respectively, for the same periods in 2022. The weighted-average grant-date fair value of restricted stock units granted during the three and six months ended June 30, 2023 was $32.16 and $29.97 per unit, respectively, and $31.94 and $34.65, respectively, for the same periods in 2022.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Net Loss Per Common Share
 6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Net Loss Per Common Share Net Loss Per Common Share
A summary of net loss per common share is presented below:
 Three Months Ended June 30,Six Months Ended June 30,
(Amounts in thousands, except per share amounts)2023202220232022
Net loss$(5,020)$(8,963)$(12,515)$(16,054)
   
Basic weighted-average common shares outstanding47,572 47,117 47,480 47,052 
Effect of dilutive stock options and restricted stock units— — — — 
Diluted weighted-average common shares outstanding47,572 47,117 47,480 47,052 
Basic loss per common share$(0.11)$(0.19)$(0.26)$(0.34)
Diluted loss per common share$(0.11)$(0.19)$(0.26)$(0.34)
Anti-dilutive shares excluded from diluted net loss per common share:
Stock options6,876 6,586 6,876 6,586 
Restricted stock units939 636 939 636 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.2
NexoBrid License and Supply Agreements
 6 Months Ended
Jun. 30, 2023
Related Party Transactions [Abstract]  
NexoBrid License and Supply Agreements NexoBrid License and Supply Agreements
On May 6, 2019, the Company entered into exclusive license and supply agreements with MediWound to commercialize NexoBrid in North America. The FDA subsequently approved a Biologics License Application (“BLA”) for the product on December 28, 2022. NexoBrid is a topically-administered biological product, which contains proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns.

Pursuant to the terms of the license agreement, following the FDA approval of NexoBrid, MediWound transferred the BLA to Vericel effective February 20, 2023. Both MediWound and Vericel, under the supervision of a Central Steering Committee comprised of members of both companies will continue to guide the development of NexoBrid in North America (the “Central Steering Committee”). NexoBrid is approved in the European Union (“EU”) and other international markets and has been designated as an orphan biologic in the U.S., EU and other international markets.
In May 2019, the Company paid MediWound $17.5 million in consideration for the license, which was recorded as research and development expense during 2019. Pursuant to the terms of the license agreement, in February 2023, the Company tendered to MediWound a $7.5 million regulatory milestone payment following the FDA’s BLA approval of NexoBrid on December 28, 2022. The Company recorded the $7.5 million milestone payment for the licensing rights to commercially sell NexoBrid in the U.S., as an intangible asset (see Note 4, “Selected Balance Sheet Components” for further details).

The Company is additionally obligated to pay MediWound up to $125.0 million, which is contingent upon meeting certain sales milestones. The first sales milestone payment of $7.5 million would be triggered when annual net sales of NexoBrid or improvements to it in North America exceed $75.0 million. As of June 30, 2023, the sales milestone payments are not yet probable and therefore, not recorded as a liability. The Company also will pay MediWound tiered royalties on net sales ranging from mid-high single-digit to mid-teen percentages, subject to customary reductions. Pursuant to the terms of the Company’s supply agreement with MediWound, MediWound will manufacture NexoBrid for the Company on a unit price basis, which may be increased pursuant to the terms of the supply agreement. MediWound is obligated to supply the Company with NexoBrid for sale in North America on an exclusive basis for the first five years of the term of the supply agreement. Under the supply agreement, the Company possesses the option to extend the initial term of the agreement by an additional 24 months, which it did in May 2022. Under the supply agreement, the Company is permitted to establish an alternate source of supply in certain circumstances, including the event of a supply failure.

Additionally, beginning in 2020 BARDA procured quantities of NexoBrid from MediWound for use as a medical countermeasure in the event of a mass casualty emergency in the U.S. involving thermal burns. The initial, quarterly, procurement of NexoBrid by BARDA under its agreement with MediWound completed during the third quarter of 2022. As a part of BARDA’s commitment to procure NexoBrid, the Company has received a percentage of gross profit for sales directly to BARDA. As of June 30, 2023, the Company did not hold a direct contract or distribution agreement with BARDA, or take title to the product procured by BARDA.

On May 9, 2023, MediWound announced BARDA’s award of additional funding under the parties’ existing agreement, $3 million of which will support the replacement of NexoBrid, previously procured for emergency response preparedness, which has since expired. Pursuant to the terms of the Company’s license agreement with MediWound, the Company will recognize revenue based on a percentage of gross profits, minus a percentage of net sales, on any sales of NexoBrid directly to BARDA, upon delivery, pursuant to this additional award.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
From time to time, the Company could be a party to various legal proceedings arising in the ordinary course of business. The costs and outcome of litigation, regulatory, investigatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in a material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its condensed consolidated financial statements.

As of June 30, 2023, the Company has no material ongoing litigation in which the Company was a party or any material ongoing regulatory or other proceedings and had no knowledge of any investigations by government or regulatory authorities in which the Company is a target that could have a material adverse effect on its current business.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Pay vs Performance Disclosure            
Net loss $ (5,020) $ (7,495) $ (8,963) $ (7,091) $ (12,515) $ (16,054)
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Insider Trading Arrangements
 3 Months Ended
Jun. 30, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Basis of Presentation (Policies)
 6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Concentration of Credit Risk
Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and investments in marketable debt securities. The Company may maintain deposits in financial institutions in excess of the insurance coverage offered by the Federal Deposit Insurance Corporation, the loss of which could have a negative effect on our operations and liquidity. The Company believes that it is not exposed to significant credit risk as its deposits, including cash and cash equivalents, are held at multiple high credit quality financial institutions. The Company has not experienced any losses on these deposits; however no assurances can be provided that there will not be losses experienced in the future. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.
Recent Accounting Pronouncements
Recent Accounting Pronouncements

No new accounting standards were adopted during the six months ended June 30, 2023. The Company considers the applicability and impact of any recent Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). Based on the assessment, the ASUs were determined to be either not applicable or are expected to have minimal impact on the Company’s condensed consolidated financial statements.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue (Tables)
 6 Months Ended
Jun. 30, 2023
Risks and Uncertainties [Abstract]  
Schedule of disaggregation of revenue
The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated:
 Three Months Ended June 30,Six Months Ended June 30,
Revenue by product (in thousands) 2023202220232022
MACI implants and kits
Implants based on contracted rate sold through a specialty pharmacy (a)
$22,377 $15,714 $45,331 $31,009 
Implants subject to third party reimbursement sold through a specialty pharmacy (b)
4,015 4,295 8,004 7,803 
Implants sold direct based on contracted rates (c)
7,252 5,756 14,222 11,390 
Implants sold direct subject to third-party reimbursement (d)
1,045 570 1,538 1,441 
Biopsy kits - direct bill528 545 1,062 1,066 
Change in estimates related to prior periods (e)
1,119 1,733 369 1,898 
Total MACI implants and kits36,336 28,613 70,526 54,607 
Epicel
Direct bill (hospital)9,586 8,213 16,413 18,071 
NexoBrid revenue (f)
— 220 — 442 
Total revenue$45,922 $37,046 $86,939 $73,120 
(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts.
(b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer, and are subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.
(f) Represents revenue based on a percentage of gross profits for sales of NexoBrid to BARDA, pursuant to the license agreement between the Company and MediWound (see Note 11).
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Selected Balance Sheet Components (Tables)
 6 Months Ended
Jun. 30, 2023
Balance Sheet Related Disclosures [Abstract]  
Schedule of inventory
Inventory consisted of the following:
(In thousands)June 30, 2023December 31, 2022
Raw materials$12,847 $15,101 
Work-in-process863 832 
Finished goods173 53 
Total inventory$13,883 $15,986 
Schedule of property and equipment, net
Property and Equipment, net consisted of the following:

(In thousands)June 30, 2023December 31, 2022
Machinery and equipment$5,544 $5,041 
Furniture, fixtures and office equipment1,710 1,710 
Computer equipment and software8,308 8,224 
Leasehold improvements14,896 13,689 
Construction in process13,148 5,438 
Financing right-of-use lease18 37 
Total property and equipment, gross43,624 34,139 
Less accumulated depreciation(20,216)(18,302)
Total property and equipment, net$23,408 $15,837 
Schedule of finite-lived intangible assets
Intangible assets, net consisted of the following:

June 30, 2023December 31, 2022
(In thousands)Useful Life (in years)Amortization MethodCostAccumulated AmortizationNetCostAccumulated AmortizationNet
NexoBrid license12Straight-line$7,500 $(312)$7,188 $7,500 $— $7,500 
Schedule of finite-lived intangible assets, future amortization expense
Future amortization expense of intangible assets as of June 30, 2023 is estimated to be as follows:

(In thousands)Amount
Remainder of 2023$313 
2024625 
2025625 
2026625 
2027625 
Thereafter4,375 
Total$7,188 
Schedule of accrued expenses
Accrued Expenses consisted of the following:
(In thousands)June 30, 2023December 31, 2022
Bonus-related compensation$5,090 $7,132 
Employee-related accruals3,436 3,101 
Insurance reimbursement-related liabilities5,160 5,030 
Other accrued expenses285 927 
Total accrued expenses$13,971 $16,190 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Leases (Tables)
 6 Months Ended
Jun. 30, 2023
Leases [Abstract]  
Schedule of assets and liabilities
Operating and finance lease assets and liabilities are as follows:

(In thousands)ClassificationJune 30, 2023December 31, 2022
Assets
OperatingRight-of-use assets$75,063 $41,535 
FinanceProperty and equipment, net18 37 
Total leased assets$75,081 $41,572 
Liabilities
Current
OperatingCurrent portion of operating lease liabilities$7,218 $4,302 
FinanceOther current liabilities21 41 
Non-current
OperatingOperating lease liabilities$76,144 $43,268 
Total leased liabilities$83,383 $47,611 
Maturity of lease liabilities
Future minimum lease payments under non-cancellable leases as of June 30, 2023 are as follows:
(In thousands)Operating LeasesFinance LeasesTotal
Remainder of 2023$3,576 $21 $3,597 
202410,743 — 10,743 
202513,677 — 13,677 
202613,969 — 13,969 
202714,351 — 14,351 
Thereafter103,229 — 103,229 
Total lease payments$159,545 $21 $159,566 
Less: tenant improvement allowances(25,167)— (25,167)
Less: interest(51,016)— (51,016)
Total leased liabilities$83,362 $21 $83,383 
Maturity of lease liabilities
Future minimum lease payments under non-cancellable leases as of June 30, 2023 are as follows:
(In thousands)Operating LeasesFinance LeasesTotal
Remainder of 2023$3,576 $21 $3,597 
202410,743 — 10,743 
202513,677 — 13,677 
202613,969 — 13,969 
202714,351 — 14,351 
Thereafter103,229 — 103,229 
Total lease payments$159,545 $21 $159,566 
Less: tenant improvement allowances(25,167)— (25,167)
Less: interest(51,016)— (51,016)
Total leased liabilities$83,362 $21 $83,383 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Investments (Tables)
 6 Months Ended
Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
Schedule of fair value of securities, not including cash The following tables summarize the gross unrealized gains and losses of the Company’s marketable securities:
June 30, 2023
Gross UnrealizedEstimated Fair Value
(In thousands)Amortized CostGainsLossesCredit Losses
Commercial paper$12,494 $— $(15)$— $12,479 
Corporate notes43,864 — (492)— 43,372 
U.S. government securities2,476 — (1)— 2,475 
U.S. government agency bonds17,583 — (116)— 17,467 
$76,417 $— $(624)$— $75,793 
Classified as:
Short-term investments$54,808 
Long-term investments20,985 
$75,793 
December 31, 2022
Gross UnrealizedEstimated Fair Value
(In thousands)Amortized CostGainsLossesCredit Losses
Commercial paper$15,707 $— $(101)$— $15,606 
Corporate notes52,159 — (831)— 51,328 
U.S. government agency bonds21,545 — (46)— 21,499 
$89,411 $— $(978)$— $88,433 
Classified as:
Short-term investments$68,471 
Long-term investments19,962 
$88,433 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements (Tables)
 6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of valuation of the company's investments and financial instruments that are measured at fair value on a recurring basis
The following table summarizes the valuation of the Company’s financial instruments that are measured at fair value on a recurring basis:

 June 30, 2023December 31, 2022
  Fair value measurement category Fair value measurement category
(In thousands)TotalLevel 1Level 2Level 3TotalLevel 1Level 2Level 3
Assets:
Money market funds$7,620 $7,620 $— $— $1,262 $1,262 $— $— 
Commercial paper12,479 — 12,479 — 15,606 — 15,606 — 
Corporate notes43,372 — 43,372 — 51,328 — 51,328 — 
U.S. government securities (a)
22,382 — 22,382 — — — — — 
U.S. government agency bonds (b)
17,467 — 17,467 — 27,976 — 27,976 — 
$103,320 $7,620 $95,700 $— $96,172 $1,262 $94,910 $— 

(a) Approximately $19.9 million of U.S. government securities had an original maturity of 90 days or less and were recorded as a cash equivalent as of June 30, 2023.

(b) Approximately $6.5 million of U.S. government agency bonds had an original maturity of 90 days or less and were recorded as a cash equivalent as of December 31, 2022.
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation (Tables)
 6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of non-cash stock-based compensation expense Non-cash stock-based compensation expense (service-based stock options, restricted stock units and employee stock purchase plan) is summarized in the following table:
 Three Months Ended June 30,Six Months Ended June 30,
(in thousands)2023202220232022
Cost of product sales$796 $1,035 $1,681 $2,153 
Research and development993 1,520 1,970 2,870 
Selling, general and administrative6,972 8,253 13,841 15,316 
Total non-cash stock-based compensation expense$8,761 $10,808 $17,492 $20,339 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Net Loss Per Common Share (Tables)
 6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Schedule of net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two class method
A summary of net loss per common share is presented below:
 Three Months Ended June 30,Six Months Ended June 30,
(Amounts in thousands, except per share amounts)2023202220232022
Net loss$(5,020)$(8,963)$(12,515)$(16,054)
   
Basic weighted-average common shares outstanding47,572 47,117 47,480 47,052 
Effect of dilutive stock options and restricted stock units— — — — 
Diluted weighted-average common shares outstanding47,572 47,117 47,480 47,052 
Basic loss per common share$(0.11)$(0.19)$(0.26)$(0.34)
Diluted loss per common share$(0.11)$(0.19)$(0.26)$(0.34)
Anti-dilutive shares excluded from diluted net loss per common share:
Stock options6,876 6,586 6,876 6,586 
Restricted stock units939 636 939 636 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Organization (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
USD ($)
product
Mar. 31, 2023
USD ($)
Jun. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Jun. 30, 2023
USD ($)
segment
product
Jun. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]              
Number of commercial-stage products | product 3       3    
Number of reportable segments | segment         1    
Accumulated deficit $ 412,510       $ 412,510   $ 399,995
Net loss 5,020 $ 7,495 $ 8,963 $ 7,091 12,515 $ 16,054  
Cash and cash equivalents 43,023   $ 56,054   43,023 $ 56,054 $ 51,067
Restricted cash 43,000       43,000    
Short term investments $ 75,800       $ 75,800    
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue - Narrative (Details)
$ in Millions
 6 Months Ended
May 09, 2023
USD ($)
Jun. 30, 2023
USD ($)
pharmacy
Dec. 31, 2022
USD ($)
Disaggregation of Revenue [Line Items]      
Number of specialty pharmacies | pharmacy   2  
Allowance for doubtful accounts   $ 5.3 $ 6.1
Change in estimate of uncollectible (percent)   0.50%  
Change in revenue recognized due to 0.5% change in uncollectible percentage   $ 0.3  
MediWound Ltd      
Disaggregation of Revenue [Line Items]      
Additional funding $ 3.0    
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue - Summary of Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Disaggregation of Revenue [Line Items]        
Product sales, net $ 45,922 $ 36,826 $ 86,939 $ 72,678
NexoBrid revenue 0 220 0 442
Total revenue 45,922 37,046 86,939 73,120
Accounting Standards Update 2014-09 | Change in estimates related to prior periods        
Disaggregation of Revenue [Line Items]        
Product sales, net 1,119 1,733 369 1,898
M A C I Implants and kits        
Disaggregation of Revenue [Line Items]        
Product sales, net 36,336 28,613 70,526 54,607
Through Intermediary | MACI implants and kits | Contract rate        
Disaggregation of Revenue [Line Items]        
Product sales, net 22,377 15,714 45,331 31,009
Through Intermediary | MACI implants and kits | Time-and-materials contract        
Disaggregation of Revenue [Line Items]        
Product sales, net 4,015 4,295 8,004 7,803
Time-and-materials contract | MACI implants and kits | Time-and-materials contract        
Disaggregation of Revenue [Line Items]        
Product sales, net 1,045 570 1,538 1,441
Provider or Facility | MACI implants and kits | Contract rate        
Disaggregation of Revenue [Line Items]        
Product sales, net 7,252 5,756 14,222 11,390
Provider or Facility | NexoBrid        
Disaggregation of Revenue [Line Items]        
NexoBrid revenue 0 220 0 442
Directly to consumer | Biopsy kits        
Disaggregation of Revenue [Line Items]        
Product sales, net 528 545 1,062 1,066
Directly to consumer | Epicel        
Disaggregation of Revenue [Line Items]        
Product sales, net $ 9,586 $ 8,213 $ 16,413 $ 18,071
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Selected Balance Sheet Components - Summary of inventory (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Inventory:    
Raw materials $ 12,847 $ 15,101
Work-in-process 863 832
Finished goods 173 53
Total inventory $ 13,883 $ 15,986
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Selected Balance Sheet Components - Schedule of property and equipment, net (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Property and equipment, net:    
Financing right-of-use lease $ 18 $ 37
Total property and equipment, gross 43,624 34,139
Less accumulated depreciation (20,216) (18,302)
Total property and equipment, net 23,408 15,837
Machinery and equipment    
Property and equipment, net:    
Total property and equipment, gross 5,544 5,041
Furniture, fixtures and office equipment    
Property and equipment, net:    
Total property and equipment, gross 1,710 1,710
Computer equipment and software    
Property and equipment, net:    
Total property and equipment, gross 8,308 8,224
Leasehold improvements    
Property and equipment, net:    
Total property and equipment, gross 14,896 13,689
Construction in process    
Property and equipment, net:    
Total property and equipment, gross $ 13,148 $ 5,438
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Selected Balance Sheet Components - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Property, Plant and Equipment [Line Items]        
Depreciation $ 1.0 $ 1.1 $ 2.0 $ 1.9
Licensing Agreements        
Property, Plant and Equipment [Line Items]        
Amortization of intangible assets $ 0.2   $ 0.3  
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Selected Balance Sheet Components -Schedule of finite-lived intangible assets (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Total $ 7,188 $ 7,500
Licensing Agreements    
Property, Plant and Equipment [Line Items]    
Useful Life (in years) 12 years 12 years
Cost $ 7,500 $ 7,500
Accumulated Amortization (312) 0
Total $ 7,188 $ 7,500
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.23.2
Selected Balance Sheet Components -Schedule of finite-lived intangible assets, future amortization expense (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Total $ 7,188 $ 7,500
Licensing Agreements    
Finite-Lived Intangible Assets [Line Items]    
Remainder of 2023 313  
2024 625  
2025 625  
2026 625  
2027 625  
Thereafter 4,375  
Total $ 7,188 $ 7,500
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.2
Selected Balance Sheet Components - Schedule of accrued expenses (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Accrued expenses    
Bonus-related compensation $ 5,090 $ 7,132
Employee-related accruals 3,436 3,101
Insurance reimbursement-related liabilities 5,160 5,030
Other accrued expenses 285 927
Total accrued expenses $ 13,971 $ 16,190
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.23.2
Leases - Narrative (Details)
ft² in Thousands, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Jun. 01, 2023
USD ($)
$ / ft²
renewal_option
Jul. 29, 2022
USD ($)
Mar. 31, 2023
USD ($)
Jan. 31, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Apr. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Jan. 28, 2022
ft²
Lessee, Lease, Description [Line Items]                      
Right-of-use assets         $ 75,063   $ 75,063     $ 41,535  
Total leased liabilities         83,362   83,362        
Short-term lease costs (less than)         100 $ 100 100 $ 100      
Operating lease expense         2,300 1,700 4,000 3,500      
Finance lease expense (less than)         $ 100 $ 100 $ 100 $ 100      
25 Network Drive, Burlington, Massachusetts                      
Lessee, Lease, Description [Line Items]                      
Area of real estate property | ft²                     126
Percent contributed to escrow account                 50.00%    
Escrow deposit amount                 $ 28,300    
Remaining percent to be contributed to escrow account                 50.00%    
Rent start date, term 13 months                    
Term of contract 144 months                    
Number of renewal options | renewal_option 1                    
Lease option to extend term 10 years                    
Annual lease per square foot | $ / ft² 57                    
Annual lease base rent square subject to increase percentage 2.50%                    
Tenant improvement allowance per square foot | $ / ft² 200                    
Tenant improvement allowance $ 24,400                    
Right-of-use assets 35,500                    
Total leased liabilities $ 35,500                    
Estimated incremental borrowing rate 0.077                    
Term of contract 13 years 1 month 6 days                    
Letter of credit cash deposit       $ 6,000              
Letter of credit cash deposit lease year three   $ 4,200                  
Letter of credit cash deposit lease year six   $ 1,800                  
Minimum | Ann Arbor Michigan                      
Lessee, Lease, Description [Line Items]                      
Monthly contractual lease payments     $ 17                
Minimum | 25 Network Drive, Burlington, Massachusetts                      
Lessee, Lease, Description [Line Items]                      
Monthly contractual lease payments $ 600                    
Maximum | Ann Arbor Michigan                      
Lessee, Lease, Description [Line Items]                      
Monthly contractual lease payments     $ 18                
Maximum | 25 Network Drive, Burlington, Massachusetts                      
Lessee, Lease, Description [Line Items]                      
Monthly contractual lease payments $ 800                    
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.23.2
Leases - Summary of assets and liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Assets    
Operating $ 75,063 $ 41,535
Finance 18 37
Total leased assets 75,081 41,572
Current    
Operating 7,218 4,302
Finance 21 41
Non-current    
Operating 76,144 43,268
Total leased liabilities $ 83,383 $ 47,611
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Property and equipment, net Property and equipment, net
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Other current liabilities Other current liabilities
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.23.2
Leases - Maturities of lease liabilities (Details)
$ in Thousands
Jun. 30, 2023
USD ($)
Operating Leases  
Remainder of 2023 $ 3,576
2024 10,743
2025 13,677
2026 13,969
2027 14,351
Thereafter 103,229
Total lease payments 159,545
Less: tenant improvement allowances (25,167)
Less: interest (51,016)
Total leased liabilities 83,362
Finance Leases  
Remainder of 2023 21
2024 0
2025 0
2026 0
2027 0
Thereafter 0
Total lease payments 21
Less: tenant improvement allowances 0
Less: interest 0
Total leased liabilities 21
Remainder of 2023 3,597
2024 10,743
2025 13,677
2026 13,969
2027 14,351
Thereafter 103,229
Total lease payments 159,566
Less: tenant improvement allowances (25,167)
Less: interest (51,016)
Total leased liabilities $ 83,383
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.23.2
Investments (Details) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Marketable Securities [Line Items]          
Amortized Cost $ 76,417,000   $ 76,417,000   $ 89,411,000
Gross Unrealized Gains 0   0   0
Gross Unrealized Losses (624,000)   (624,000)   (978,000)
Credit Losses 0   0   0
Estimated Fair Value 75,793,000   $ 75,793,000   $ 88,433,000
Remaining contractual maturity period     3 years   3 years
Impairments of assets 0 $ 0 $ 0 $ 0  
Short-term investments          
Marketable Securities [Line Items]          
Estimated Fair Value 54,808,000   54,808,000   $ 68,471,000
Long-term investments          
Marketable Securities [Line Items]          
Estimated Fair Value 20,985,000   20,985,000   19,962,000
Commercial paper          
Marketable Securities [Line Items]          
Amortized Cost 12,494,000   12,494,000   15,707,000
Gross Unrealized Gains 0   0   0
Gross Unrealized Losses (15,000)   (15,000)   (101,000)
Credit Losses 0   0   0
Estimated Fair Value 12,479,000   12,479,000   15,606,000
Corporate notes          
Marketable Securities [Line Items]          
Amortized Cost 43,864,000   43,864,000   52,159,000
Gross Unrealized Gains 0   0   0
Gross Unrealized Losses (492,000)   (492,000)   (831,000)
Credit Losses 0   0   0
Estimated Fair Value 43,372,000   43,372,000   51,328,000
U.S. government securities          
Marketable Securities [Line Items]          
Amortized Cost 2,476,000   2,476,000    
Gross Unrealized Gains 0   0    
Gross Unrealized Losses (1,000)   (1,000)    
Credit Losses 0   0    
Estimated Fair Value 2,475,000   2,475,000    
U.S. government agency bonds          
Marketable Securities [Line Items]          
Amortized Cost 17,583,000   17,583,000   21,545,000
Gross Unrealized Gains 0   0   0
Gross Unrealized Losses (116,000)   (116,000)   (46,000)
Credit Losses 0   0   0
Estimated Fair Value $ 17,467,000   $ 17,467,000   $ 21,499,000
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value $ 75,793 $ 88,433
U.S. government securities    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 2,475  
U.S. government agency bonds    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 17,467 21,499
Recurring    
Liabilities that are measured at fair value on a recurring basis    
Assets, fair value 103,320 96,172
Recurring | Level 1    
Liabilities that are measured at fair value on a recurring basis    
Assets, fair value 7,620 1,262
Recurring | Level 2    
Liabilities that are measured at fair value on a recurring basis    
Assets, fair value 95,700 94,910
Recurring | Level 3    
Liabilities that are measured at fair value on a recurring basis    
Assets, fair value 0 0
Recurring | Commercial paper    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 12,479 15,606
Recurring | Commercial paper | Level 1    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Recurring | Commercial paper | Level 2    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 12,479 15,606
Recurring | Commercial paper | Level 3    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Recurring | Corporate notes    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 43,372 51,328
Recurring | Corporate notes | Level 1    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Recurring | Corporate notes | Level 2    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 43,372 51,328
Recurring | Corporate notes | Level 3    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Recurring | U.S. government securities    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 22,382 0
Recurring | U.S. government securities | Cash and cash equivalents    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 19,900  
Recurring | U.S. government securities | Level 1    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Recurring | U.S. government securities | Level 2    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 22,382 0
Recurring | U.S. government securities | Level 3    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Recurring | U.S. government agency bonds    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 17,467 27,976
Recurring | U.S. government agency bonds | Cash and cash equivalents    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value   6,500
Recurring | U.S. government agency bonds | Level 1    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Recurring | U.S. government agency bonds | Level 2    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 17,467 27,976
Recurring | U.S. government agency bonds | Level 3    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Recurring | Money market funds    
Liabilities that are measured at fair value on a recurring basis    
Money market funds 7,620 1,262
Recurring | Money market funds | Level 1    
Liabilities that are measured at fair value on a recurring basis    
Money market funds 7,620 1,262
Recurring | Money market funds | Level 2    
Liabilities that are measured at fair value on a recurring basis    
Money market funds 0 0
Recurring | Money market funds | Level 3    
Liabilities that are measured at fair value on a recurring basis    
Money market funds $ 0 $ 0
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.23.2
Revolving Credit Agreement (Details) - Line of credit
Jul. 29, 2022
USD ($)
Jun. 30, 2023
USD ($)
Debt Instrument [Line Items]    
Issuance of letters of credit $ 6,200,000  
Revolving credit facility    
Debt Instrument [Line Items]    
Maximum borrowing capacity $ 150,000,000  
Debt instrument, term 5 years  
Debt issuance costs, net $ 1,100,000  
Outstanding borrowings   $ 0
Leverage ratio 3.50  
Increase option for leverage ratio 4.00  
Revolving credit facility | Minimum    
Debt Instrument [Line Items]    
Line of credit facility, commitment fee (in percent) 0.20%  
Revolving credit facility | Maximum    
Debt Instrument [Line Items]    
Line of credit facility, commitment fee (in percent) 0.25%  
Revolving credit facility | SOFR    
Debt Instrument [Line Items]    
Basis spread on variable rate (in percent) 0.10%  
Revolving credit facility | SOFR | Minimum    
Debt Instrument [Line Items]    
Basis spread on variable rate (in percent) 1.25%  
Revolving credit facility | SOFR | Maximum    
Debt Instrument [Line Items]    
Basis spread on variable rate (in percent) 2.50%  
Revolving credit facility | Base rate | Minimum    
Debt Instrument [Line Items]    
Basis spread on variable rate (in percent) 0.25%  
Revolving credit facility | Base rate | Maximum    
Debt Instrument [Line Items]    
Basis spread on variable rate (in percent) 1.50%  
Letter of credit    
Debt Instrument [Line Items]    
Maximum borrowing capacity $ 15,000,000  
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation - Expense (Details) - Employee stock purchase plan and service-based stock options - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total non-cash stock-based compensation expense $ 8,761 $ 10,808 $ 17,492 $ 20,339
Cost of product sales        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total non-cash stock-based compensation expense 796 1,035 1,681 2,153
Research and development        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total non-cash stock-based compensation expense 993 1,520 1,970 2,870
Selling, general and administrative        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total non-cash stock-based compensation expense $ 6,972 $ 8,253 $ 13,841 $ 15,316
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation - Narrative (Details) - $ / shares
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Stock-Based Compensation        
Granted (in shares) 67,760 170,060 535,717 1,163,649
Weighted average grant-date fair value (in dollars per share) $ 19.30 $ 19.25 $ 18.41 $ 20.74
Restricted stock units        
Stock-Based Compensation        
Restricted stock units granted (shares) 32,816 39,746 529,321 382,768
Weighted-average grant date fair value (in dollars per share) $ 32.16 $ 31.94 $ 29.97 $ 34.65
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.23.2
Net Loss Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Net Income (Loss) Attributable to Parent [Abstract]            
Net loss $ (5,020) $ (7,495) $ (8,963) $ (7,091) $ (12,515) $ (16,054)
Basic weighted-average common shares outstanding (in shares) 47,572   47,117   47,480 47,052
Effect of dilutive stock options and restricted stock units (in shares) 0   0   0 0
Diluted weighted-average common shares outstanding (in shares) 47,572   47,117   47,480 47,052
Basic loss per common share (in USD per share) $ (0.11)   $ (0.19)   $ (0.26) $ (0.34)
Diluted loss per common share (in USD per share) $ (0.11)   $ (0.19)   $ (0.26) $ (0.34)
Stock options            
Anti-dilutive shares excluded from diluted net loss per common share:            
Anti-dilutive shares excluded from the calculation of diluted earnings per share (in shares) 6,876   6,586   6,876 6,586
Restricted stock units            
Anti-dilutive shares excluded from diluted net loss per common share:            
Anti-dilutive shares excluded from the calculation of diluted earnings per share (in shares) 939   636   939 636
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.23.2
NexoBrid License and Supply Agreements (Details) - MediWound Ltd - USD ($)
$ in Millions
 1 Months Ended
May 09, 2023
May 31, 2019
Feb. 28, 2023
Related Party Transaction [Line Items]      
Consideration payment for license   $ 17.5  
Contingent consideration   7.5 $ 7.5
Maximum contingent consideration   125.0  
Sales threshold for first milestone   $ 75.0  
Term of supply agreement   5 years  
Renewal term of supply agreement   24 months  
Additional funding $ 3.0    
XML 60 vcel-20230630_htm.xml IDEA: XBRL DOCUMENT 0000887359 2023-01-01 2023-06-30 0000887359 2023-07-27 0000887359 2023-06-30 0000887359 2022-12-31 0000887359 2023-04-01 2023-06-30 0000887359 2022-01-01 2022-06-30 0000887359 2022-04-01 2022-06-30 0000887359 us-gaap:CommonStockMember 2022-12-31 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000887359 us-gaap:RetainedEarningsMember 2022-12-31 0000887359 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000887359 2023-01-01 2023-03-31 0000887359 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000887359 us-gaap:CommonStockMember 2023-03-31 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000887359 us-gaap:RetainedEarningsMember 2023-03-31 0000887359 2023-03-31 0000887359 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000887359 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000887359 us-gaap:CommonStockMember 2023-06-30 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000887359 us-gaap:RetainedEarningsMember 2023-06-30 0000887359 us-gaap:CommonStockMember 2021-12-31 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000887359 us-gaap:RetainedEarningsMember 2021-12-31 0000887359 2021-12-31 0000887359 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000887359 2022-01-01 2022-03-31 0000887359 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000887359 us-gaap:CommonStockMember 2022-03-31 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000887359 us-gaap:RetainedEarningsMember 2022-03-31 0000887359 2022-03-31 0000887359 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000887359 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0000887359 us-gaap:CommonStockMember 2022-06-30 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000887359 us-gaap:RetainedEarningsMember 2022-06-30 0000887359 2022-06-30 0000887359 vcel:MediWoundLtdMember 2023-05-09 2023-05-09 0000887359 vcel:ImplantsMember us-gaap:FixedPriceContractMember us-gaap:SalesChannelThroughIntermediaryMember 2023-04-01 2023-06-30 0000887359 vcel:ImplantsMember us-gaap:FixedPriceContractMember us-gaap:SalesChannelThroughIntermediaryMember 2022-04-01 2022-06-30 0000887359 vcel:ImplantsMember us-gaap:FixedPriceContractMember us-gaap:SalesChannelThroughIntermediaryMember 2023-01-01 2023-06-30 0000887359 vcel:ImplantsMember us-gaap:FixedPriceContractMember us-gaap:SalesChannelThroughIntermediaryMember 2022-01-01 2022-06-30 0000887359 vcel:ImplantsMember us-gaap:TimeAndMaterialsContractMember us-gaap:SalesChannelThroughIntermediaryMember 2023-04-01 2023-06-30 0000887359 vcel:ImplantsMember us-gaap:TimeAndMaterialsContractMember us-gaap:SalesChannelThroughIntermediaryMember 2022-04-01 2022-06-30 0000887359 vcel:ImplantsMember us-gaap:TimeAndMaterialsContractMember us-gaap:SalesChannelThroughIntermediaryMember 2023-01-01 2023-06-30 0000887359 vcel:ImplantsMember us-gaap:TimeAndMaterialsContractMember us-gaap:SalesChannelThroughIntermediaryMember 2022-01-01 2022-06-30 0000887359 vcel:ImplantsMember us-gaap:FixedPriceContractMember vcel:ProviderorFacilityMember 2023-04-01 2023-06-30 0000887359 vcel:ImplantsMember us-gaap:FixedPriceContractMember vcel:ProviderorFacilityMember 2022-04-01 2022-06-30 0000887359 vcel:ImplantsMember us-gaap:FixedPriceContractMember vcel:ProviderorFacilityMember 2023-01-01 2023-06-30 0000887359 vcel:ImplantsMember us-gaap:FixedPriceContractMember vcel:ProviderorFacilityMember 2022-01-01 2022-06-30 0000887359 vcel:ImplantsMember us-gaap:TimeAndMaterialsContractMember us-gaap:TimeAndMaterialsContractMember 2023-04-01 2023-06-30 0000887359 vcel:ImplantsMember us-gaap:TimeAndMaterialsContractMember us-gaap:TimeAndMaterialsContractMember 2022-04-01 2022-06-30 0000887359 vcel:ImplantsMember us-gaap:TimeAndMaterialsContractMember us-gaap:TimeAndMaterialsContractMember 2023-01-01 2023-06-30 0000887359 vcel:ImplantsMember us-gaap:TimeAndMaterialsContractMember us-gaap:TimeAndMaterialsContractMember 2022-01-01 2022-06-30 0000887359 vcel:BiopsyKitsMember us-gaap:SalesChannelDirectlyToConsumerMember 2023-04-01 2023-06-30 0000887359 vcel:BiopsyKitsMember us-gaap:SalesChannelDirectlyToConsumerMember 2022-04-01 2022-06-30 0000887359 vcel:BiopsyKitsMember us-gaap:SalesChannelDirectlyToConsumerMember 2023-01-01 2023-06-30 0000887359 vcel:BiopsyKitsMember us-gaap:SalesChannelDirectlyToConsumerMember 2022-01-01 2022-06-30 0000887359 us-gaap:AccountingStandardsUpdate201409Member us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember 2023-04-01 2023-06-30 0000887359 us-gaap:AccountingStandardsUpdate201409Member us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember 2022-04-01 2022-06-30 0000887359 us-gaap:AccountingStandardsUpdate201409Member us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember 2023-01-01 2023-06-30 0000887359 us-gaap:AccountingStandardsUpdate201409Member us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember 2022-01-01 2022-06-30 0000887359 vcel:MACIImplantsAndKitsMember 2023-04-01 2023-06-30 0000887359 vcel:MACIImplantsAndKitsMember 2022-04-01 2022-06-30 0000887359 vcel:MACIImplantsAndKitsMember 2023-01-01 2023-06-30 0000887359 vcel:MACIImplantsAndKitsMember 2022-01-01 2022-06-30 0000887359 vcel:EpicelMember us-gaap:SalesChannelDirectlyToConsumerMember 2023-04-01 2023-06-30 0000887359 vcel:EpicelMember us-gaap:SalesChannelDirectlyToConsumerMember 2022-04-01 2022-06-30 0000887359 vcel:EpicelMember us-gaap:SalesChannelDirectlyToConsumerMember 2023-01-01 2023-06-30 0000887359 vcel:EpicelMember us-gaap:SalesChannelDirectlyToConsumerMember 2022-01-01 2022-06-30 0000887359 vcel:NexoBridMember vcel:ProviderorFacilityMember 2023-04-01 2023-06-30 0000887359 vcel:NexoBridMember vcel:ProviderorFacilityMember 2022-04-01 2022-06-30 0000887359 vcel:NexoBridMember vcel:ProviderorFacilityMember 2023-01-01 2023-06-30 0000887359 vcel:NexoBridMember vcel:ProviderorFacilityMember 2022-01-01 2022-06-30 0000887359 us-gaap:MachineryAndEquipmentMember 2023-06-30 0000887359 us-gaap:MachineryAndEquipmentMember 2022-12-31 0000887359 us-gaap:FurnitureAndFixturesMember 2023-06-30 0000887359 us-gaap:FurnitureAndFixturesMember 2022-12-31 0000887359 vcel:ComputerEquipmentAndComputerSoftwareIntangibleAssetMember 2023-06-30 0000887359 vcel:ComputerEquipmentAndComputerSoftwareIntangibleAssetMember 2022-12-31 0000887359 us-gaap:LeaseholdImprovementsMember 2023-06-30 0000887359 us-gaap:LeaseholdImprovementsMember 2022-12-31 0000887359 us-gaap:ConstructionInProgressMember 2023-06-30 0000887359 us-gaap:ConstructionInProgressMember 2022-12-31 0000887359 us-gaap:LicensingAgreementsMember 2022-12-31 0000887359 us-gaap:LicensingAgreementsMember 2023-06-30 0000887359 us-gaap:LicensingAgreementsMember 2023-04-01 2023-06-30 0000887359 us-gaap:LicensingAgreementsMember 2023-01-01 2023-06-30 0000887359 srt:MinimumMember vcel:AnnArborMichiganMember 2023-03-01 2023-03-31 0000887359 srt:MaximumMember vcel:AnnArborMichiganMember 2023-03-01 2023-03-31 0000887359 vcel:A25NetworkDriveBurlingtonMassachusettsMember 2022-01-28 0000887359 vcel:A25NetworkDriveBurlingtonMassachusettsMember 2023-04-30 0000887359 vcel:A25NetworkDriveBurlingtonMassachusettsMember 2023-06-01 2023-06-01 0000887359 vcel:A25NetworkDriveBurlingtonMassachusettsMember 2023-06-01 0000887359 srt:MinimumMember vcel:A25NetworkDriveBurlingtonMassachusettsMember 2023-06-01 2023-06-01 0000887359 srt:MaximumMember vcel:A25NetworkDriveBurlingtonMassachusettsMember 2023-06-01 2023-06-01 0000887359 vcel:A25NetworkDriveBurlingtonMassachusettsMember 2022-01-01 2022-01-31 0000887359 vcel:A25NetworkDriveBurlingtonMassachusettsMember 2022-07-29 2022-07-29 0000887359 us-gaap:CommercialPaperMember 2023-06-30 0000887359 us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0000887359 us-gaap:USGovernmentDebtSecuritiesMember 2023-06-30 0000887359 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0000887359 us-gaap:ShortTermInvestmentsMember 2023-06-30 0000887359 vcel:LongtermInvestmentsMember 2023-06-30 0000887359 us-gaap:CommercialPaperMember 2022-12-31 0000887359 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:ShortTermInvestmentsMember 2022-12-31 0000887359 vcel:LongtermInvestmentsMember 2022-12-31 0000887359 2022-01-01 2022-12-31 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2023-06-30 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2023-06-30 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2023-06-30 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2023-06-30 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2023-06-30 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2023-06-30 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2023-06-30 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2023-06-30 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2023-06-30 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2023-06-30 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2023-06-30 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2023-06-30 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000887359 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000887359 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2023-06-30 0000887359 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-07-29 0000887359 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-07-29 2022-07-29 0000887359 us-gaap:LetterOfCreditMember us-gaap:LineOfCreditMember 2022-07-29 0000887359 us-gaap:LineOfCreditMember 2022-07-29 0000887359 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember vcel:SecuredOvernightFinancingRateSOFRMember 2022-07-29 2022-07-29 0000887359 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember vcel:SecuredOvernightFinancingRateSOFRMember 2022-07-29 2022-07-29 0000887359 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember vcel:SecuredOvernightFinancingRateSOFRMember 2022-07-29 2022-07-29 0000887359 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2022-07-29 2022-07-29 0000887359 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2022-07-29 2022-07-29 0000887359 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-07-29 2022-07-29 0000887359 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-07-29 2022-07-29 0000887359 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:CostOfSalesMember 2023-04-01 2023-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:CostOfSalesMember 2022-04-01 2022-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:CostOfSalesMember 2023-01-01 2023-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:CostOfSalesMember 2022-01-01 2022-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-04-01 2022-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember 2023-04-01 2023-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember 2022-04-01 2022-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember 2023-01-01 2023-06-30 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember 2022-01-01 2022-06-30 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0000887359 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0000887359 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0000887359 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0000887359 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0000887359 vcel:MediWoundLtdMember 2019-05-31 0000887359 vcel:MediWoundLtdMember 2023-02-28 0000887359 vcel:MediWoundLtdMember 2019-05-01 2019-05-31 shares iso4217:USD iso4217:USD shares vcel:product vcel:segment vcel:pharmacy pure utr:sqft vcel:renewal_option iso4217:USD utr:sqft 0000887359 --12-31 2023 Q2 false http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent 10-Q true 2023-06-30 false 001-35280 VERICEL CORPORATION MI 94-3096597 64 Sidney Street Cambridge MA 02139 617 588-5555 Common Stock (No par value) VCEL NASDAQ Yes Yes Large Accelerated Filer false false false 47642194 43023000 51067000 27794000 0 54808000 68471000 44000 47000 38319000 46539000 13883000 15986000 5044000 4803000 182871000 186866000 23408000 15837000 7188000 7500000 75063000 41535000 20985000 19962000 1196000 1303000 310711000 273003000 14401000 16930000 13971000 16190000 7218000 4302000 21000 41000 35611000 37463000 76144000 43268000 28000 0 111783000 80731000 75000000 75000000 47616000 47616000 47253000 47253000 612059000 593245000 -621000 -978000 -412510000 -399995000 198928000 192272000 310711000 273003000 45922000 36826000 86939000 72678000 0 220000 0 442000 45922000 37046000 86939000 73120000 15981000 14192000 30478000 26814000 29941000 22854000 56461000 46306000 5253000 4792000 10465000 9652000 30649000 27144000 60134000 53009000 35902000 31936000 70599000 62661000 -5961000 -9082000 -14138000 -16355000 1095000 148000 1934000 236000 149000 20000 294000 38000 -5000 -9000 -17000 103000 941000 119000 1623000 301000 -5020000 -8963000 -12515000 -16054000 -0.11 -0.11 -0.19 -0.19 -0.26 -0.26 -0.34 -0.34 47572000 47572000 47117000 47117000 47480000 47480000 47052000 47052000 -5020000 -8963000 -12515000 -16054000 15000 -242000 357000 -701000 -5005000 -9205000 -12158000 -16755000 47253000 593245000 -978000 -399995000 192272000 -7495000 -7495000 8731000 8731000 132000 2009000 2009000 11000 216000 216000 183000 72000 2097000 2097000 342000 342000 47507000 602104000 -636000 -407490000 193978000 -5020000 -5020000 8761000 8761000 68000 889000 889000 18000 384000 384000 26000 3000 79000 79000 15000 15000 47616000 612059000 -621000 -412510000 198928000 46880000 553902000 -154000 -383286000 170462000 -7091000 -7091000 9531000 9531000 125000 1155000 1155000 9000 310000 310000 108000 41000 1423000 1423000 -459000 -459000 47081000 563475000 -613000 -390377000 172485000 -8963000 -8963000 10808000 10808000 32000 428000 428000 10000 318000 318000 19000 1000 18000 18000 -242000 -242000 47141000 575011000 -855000 -399340000 174816000 -12515000 -16054000 2329000 1928000 17492000 20339000 504000 -302000 108000 0 2466000 2155000 -17000 -16000 -2103000 2548000 -8220000 -3773000 241000 563000 956000 1152000 -2219000 -1912000 -184000 -1977000 28000 0 18056000 6611000 28537000 34948000 42038000 26344000 5609000 5062000 7500000 0 392000 -13666000 3498000 2211000 2176000 1441000 -20000 -18000 1302000 752000 19750000 -6303000 51067000 68541000 70817000 62238000 35976000 0 4321000 869000 43023000 56054000 27794000 6184000 70817000 62238000 Organization<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vericel Corporation, a Michigan corporation (together with its consolidated subsidiaries referred to herein as the Company, or Vericel), was incorporated in March 1989 and began employee-based operations in 1991. The Company is a fully-integrated, commercial-stage biopharmaceutical company and is a leader in advanced therapies for the sports medicine and severe burn care markets. Vericel currently markets three commercial-stage products in the U.S., MACI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Epicel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and NexoBrid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (“TBSA”). The Company also holds an exclusive license from MediWound Ltd. (“MediWound”) to commercialize NexoBrid (anacaulase-bcdb) in North America. On December 28, 2022, the U.S. Food and Drug Administration (“FDA”) approved a Biologics License Application (“BLA”) for NexoBrid, granting a license for commercial use in the U.S. NexoBrid is a topically-administered biological product containing proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns. The Company operates its business primarily in the U.S. in one reportable segment - the research, product development, manufacture and distribution of cellular therapies and specialty biologics for use in the treatment of specific diseases.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the life sciences industry including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with FDA regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19</span></div><div style="padding-right:72pt;text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 11, 2023, the U.S. Department of Health and Human Services announced the expiration of the federal Public Health Emergency for COVID-19. At this juncture, the pandemic’s effects on the Company’s business and results of operations have largely moderated and we have begun to see a return to more normal operations. Should a resurgence of COVID-19 occur, or new virus variants emerge, it could result in additional disruptions that could impact the Company’s business and operations in the future, including U.S. hospital or surgical center staffing shortages, periodic cancellation or delay of elective MACI surgical procedures, intermittent restrictions on the ability of Company personnel to travel and access customers for selling, marketing, training, case support and product development feedback, delays in approvals by regulatory bodies, delays in product development efforts, and additional government requirements or other incremental mitigation efforts that may further impact the Company’s capacity to manufacture, sell and support the use of its products.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">The War in Ukraine</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing war between Russia and Ukraine and the related sanctions and other penalties imposed by countries across the globe against Russia are continuing to create substantial uncertainty in the global economy and have contributed to heightened inflation and supply chain disruptions. While the Company does not have operations in Russia or Ukraine and does not have exposure to distributors, or third-party service providers in Russia or Ukraine, it is unable to predict the ultimate impact that these actions will have on the global economy or on its financial condition, results of operations, and cash flows as of the date of these condensed consolidated financial statements.</span></div><div style="text-indent:13.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2023, the Company had an accumulated deficit of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$412.5 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and had a </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net loss of $12.5 million during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> June 30, 2023. The Company had cash and cash equivalents of $43.0 million and investments of $75.8 million as of June 30, 2023. The Company expects that cash from the sales of its products and existing cash, cash equivalents, investments, and available borrowing capacity will be sufficient to support the Company’s current operations through at least 12 months from the issuance of these condensed consolidated financial statements. If revenues decline for a sustained period, the Company may need to access additional capital; however, the Company may not be able to obtain additional financing on acceptable terms or at all. The terms of any additional financing may adversely affect the holdings or the rights of the Company’s shareholders.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and investments in marketable debt securities. The Company may maintain deposits in financial institutions in excess of the insurance coverage offered by the Federal Deposit Insurance Corporation, the loss of which could have a negative effect on our operations and liquidity. The Company believes that it is not exposed to significant credit risk as its deposits, including cash and cash equivalents, are held at multiple high credit quality financial institutions. The Company has not experienced any losses on these deposits; however no assurances can be provided that there will not be losses experienced in the future. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.</span></div> 3 1 -412500000 -12500000 43000000 75800000 <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and investments in marketable debt securities. The Company may maintain deposits in financial institutions in excess of the insurance coverage offered by the Federal Deposit Insurance Corporation, the loss of which could have a negative effect on our operations and liquidity. The Company believes that it is not exposed to significant credit risk as its deposits, including cash and cash equivalents, are held at multiple high credit quality financial institutions. The Company has not experienced any losses on these deposits; however no assurances can be provided that there will not be losses experienced in the future. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.</span></div> Basis of Presentation<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements of Vericel are unaudited and have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expenses. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of December 31, 2022 has been derived from the audited consolidated financial statements at that date, but does not include all the information and notes required by U.S. GAAP for complete financial statements. These c</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ondensed consolidated financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on February 23, 2023 (“Annual Report”).</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No new accounting standards were adopted during the six months ended June 30, 2023. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the applicability and impact of any recent Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). Based on the assessment, the ASUs were determined to be either not applicable or are expected to have minimal impact on the Company’s condensed consolidated financial statements.</span></div> <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No new accounting standards were adopted during the six months ended June 30, 2023. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the applicability and impact of any recent Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). Based on the assessment, the ASUs were determined to be either not applicable or are expected to have minimal impact on the Company’s condensed consolidated financial statements.</span></div> Revenue<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition and Product Sales, Net </span></div><div style="text-indent:-4.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes product revenue from sales of MACI biopsy kits, MACI implants, Epicel grafts and NexoBrid following the five-step model in Accounting Standards Codification 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition.</span></div><div style="text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MACI Biopsy Kits</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MACI biopsy kits are sold directly to hospitals and ambulatory surgical centers based on contracted rates in an approved contract or sales order. The Company recognizes MACI kit revenue upon delivery of the biopsy kit, at which time the customer (the facility) is in control of the kit. The kit is used by the doctor to provide a sample of cartilage tissue to the Company, which can later be used to manufacture a MACI implant. The ordering of the kit does not obligate the Company to manufacture an implant nor does the receipt of the cartilage tissue by the Company from the customer following biopsy. The customer’s order of an implant is separate from the process of ordering the biopsy kit. Therefore, the sale of the biopsy kit and any subsequent sale of an implant are distinct contracts and are accounted for separately.</span></div><div style="text-indent:13.5pt"><span><br/></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MACI Implants</span></div><div style="text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company contracts with two specialty pharmacies, Orsini Pharmaceutical Services, Inc. (“Orsini”) and AllCare Plus Pharmacy, Inc. (“AllCare”) to distribute MACI in a manner in which the Company retains the credit and collection risk from the end customer. The Company pays both specialty pharmacies a fee for each patient to whom MACI is dispensed. Both Orsini and AllCare perform collection activities to collect payment from customers. The Company engages a third party to provide services in connection with a patient support program to manage patient cases and to ensure complete and correct billing information is provided to the insurers and hospitals. In addition, the Company also sells MACI directly to DMS Pharmaceutical Group, Inc. (“DMS”) for patients treated at military treatment facilities. The sales directly to DMS are made at a contracted rate.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior authorization and confirmation of coverage level by the patient’s private insurance plan, hospital or government payer is a prerequisite to the shipment of product to a patient. The Company recognizes product revenue from sales of all MACI implants upon delivery at which time the customer obtains control of the implant and the claim is billable. The total consideration that the Company expects to collect in exchange for MACI implants (the “Transaction Price”) may be fixed or variable. Direct sales to hospitals or distributors are recorded at a contracted price, and there are typically no forms of variable consideration. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company sells MACI the patient is responsible for payment; however, the Company is typically reimbursed by a third-party insurer or government payer, subject to a patient co-pay amount. Reimbursements from third-party insurers and government payers vary by patient and payer and are based on either contracted rates, publicly available rates, fee schedules or past payer precedents. Net product revenue is recognized net of estimated contractual allowances, which considers historical collection experience from both the payer and patient, denial rates and the terms of the Company’s contractual arrangements. The Company estimates expected collections for these transactions using the portfolio approach. The Company records a reduction to revenue at the time of sale for its estimate of the amount of consideration that will not be collected. In addition, potential credit risk exposure has been evaluated for the Company’s accounts receivable in accordance with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 326, Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company assesses risk and determines a loss percentage by pooling accounts receivable based on similar risk characteristics. The loss percentage is calculated through the use of forecasts that are based on current and historical economic and financial information. This loss percentage was applied to the accounts receivables as of June 30, 2023. The total allowance for uncollectible consideration as of June 30, 2023 and December 31, 2022 was $5.3 million and $6.1 million, respectively. Changes to the estimate of the amount of consideration that will not be collected could have a material impact on the revenue recognized. A 50 basis points change to the estimated uncollectible percentage could result in an approximately $0.3 million decrease or increase in the revenue recognized for the six months ended June 30, 2023.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in estimates of the Transaction Price are recorded through revenue in the period in which such change occurs. Changes in estimates related to prior periods are shown in the Revenue by Product and Customer table below and relate primarily to changes in the initial expected reimbursement or collection expectation upon completion of the billing claims process for MACI implants that occurred in a prior year. </span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Epicel</span></div><div style="text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells Epicel directly to hospitals and burn centers based on contracted rates stated in an approved contract or purchase order. Similar to MACI, there is no obligation to manufacture Epicel grafts upon receipt of a skin biopsy, and Vericel has no contractual right to receive payment until the product is delivered to the hospital. The Company recognizes product revenue from sales of Epicel upon delivery to the hospital, at which time the customer is in control of the Epicel grafts and the claim is billable to the hospital. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NexoBrid</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into exclusive license and supply agreements with MediWound in May 2019, pursuant to which MediWound will manufacture and supply NexoBrid on a unit price basis, which may be increased pursuant to the terms of the agreements. Additionally, beginning in 2020 the U.S. Biomedical Advanced Research and Development Authority (“BARDA”) procured quantities of NexoBrid from MediWound, for use as a medical countermeasure in the event of a mass casualty emergency in the U.S. involving thermal burns. The initial, quarterly, procurement of NexoBrid by BARDA under its agreement with MediWound completed during the third quarter of 2022. The Company recognized revenue based on a percentage of gross profits for sales of NexoBrid to BARDA upon delivery, at which time BARDA was in control of the product. As of June 30, 2023, the Company did not hold a direct contract or distribution agreement with BARDA, or take title to the product procured by BARDA. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 9, 2023, MediWound announced BARDA’s award of additional funding under the parties’ existing agreement, $3 million of which will support the replacement of NexoBrid, previously procured for emergency response preparedness, which has since expired. Pursuant to the terms of the Company’s license agreement with MediWound, the Company would recognize revenue based on a percentage of gross profits, minus a percentage of net sales, on any sales of NexoBrid directly to BARDA upon delivery, pursuant to this additional award.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, on December 28, 2022, the FDA approved a BLA for NexoBrid, granting a license for commercial use in the U.S. NexoBrid is a topically-administered biological product containing proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by Product and Customer</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated:</span></div><div style="margin-bottom:9pt;margin-top:14pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.605%"><tr><td style="width:1.0%"></td><td style="width:52.068%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.873%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.873%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.873%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.879%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue by product (in thousands) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">MACI implants and kits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implants based on contracted rate sold through a specialty pharmacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,377 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,009 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implants subject to third party reimbursement sold through a specialty pharmacy </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,015 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,295 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,004 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implants sold direct based on contracted rates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (c)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,756 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implants sold direct subject to third-party reimbursement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biopsy kits - direct bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimates related to prior periods </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total MACI implants and kits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,336 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,613 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,526 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,607 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Epicel</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct bill (hospital)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NexoBrid revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (f)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,922 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,046 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,939 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="27" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts. </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer, and are subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(f) Represents revenue based on a percentage of gross profits for sales of NexoBrid to BARDA, pursuant to the license agreement between the Company and MediWound (see Note 11).</span></div></td></tr></table></div> 2 5300000 6100000 0.0050 300000 3000000 <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated:</span></div><div style="margin-bottom:9pt;margin-top:14pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.605%"><tr><td style="width:1.0%"></td><td style="width:52.068%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.873%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.873%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.873%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.879%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue by product (in thousands) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">MACI implants and kits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implants based on contracted rate sold through a specialty pharmacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,377 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,331 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,009 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implants subject to third party reimbursement sold through a specialty pharmacy </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,015 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,295 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,004 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implants sold direct based on contracted rates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (c)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,756 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implants sold direct subject to third-party reimbursement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biopsy kits - direct bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimates related to prior periods </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total MACI implants and kits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,336 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,613 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,526 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,607 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Epicel</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct bill (hospital)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NexoBrid revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (f)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,922 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,046 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,939 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="27" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts. </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer, and are subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(f) Represents revenue based on a percentage of gross profits for sales of NexoBrid to BARDA, pursuant to the license agreement between the Company and MediWound (see Note 11).</span></div></td></tr></table></div> 22377000 15714000 45331000 31009000 4015000 4295000 8004000 7803000 7252000 5756000 14222000 11390000 1045000 570000 1538000 1441000 528000 545000 1062000 1066000 1119000 1733000 369000 1898000 36336000 28613000 70526000 54607000 9586000 8213000 16413000 18071000 0 220000 0 442000 45922000 37046000 86939000 73120000 Selected Balance Sheet Components<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.813%"><tr><td style="width:1.0%"></td><td style="width:68.446%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,847 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,101 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,883 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,986 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and Equipment, net consisted of the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.813%"><tr><td style="width:1.0%"></td><td style="width:68.446%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,544 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,041 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,896 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,689 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing right-of-use lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,624 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,139 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,216)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,408 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,837 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three and six months ended June 30, 2023 was $1.0 million and $2.0 million, respectively, and $1.1 million and $1.9 million, respectively, for the same periods in 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.103%"><tr><td style="width:1.0%"></td><td style="width:14.228%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.805%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Method</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NexoBrid license</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the three and six months ended June 30, 2023 was $0.2 million and $0.3 million, respectively.</span></div><div><span><br/></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense of intangible assets as of June 30, 2023 is estimated to be as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:75.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,188 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Expenses</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Expenses consisted of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.247%"><tr><td style="width:1.0%"></td><td style="width:68.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonus-related compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related accruals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance reimbursement-related liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,030 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,971 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,190 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.813%"><tr><td style="width:1.0%"></td><td style="width:68.446%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,847 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,101 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,883 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,986 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 12847000 15101000 863000 832000 173000 53000 13883000 15986000 <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and Equipment, net consisted of the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.813%"><tr><td style="width:1.0%"></td><td style="width:68.446%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,544 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,041 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,896 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,689 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing right-of-use lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,624 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,139 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,216)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,408 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,837 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5544000 5041000 1710000 1710000 8308000 8224000 14896000 13689000 13148000 5438000 18000 37000 43624000 34139000 20216000 18302000 23408000 15837000 1000000 2000000 1100000 1900000 <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.103%"><tr><td style="width:1.0%"></td><td style="width:14.228%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.805%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Method</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NexoBrid license</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> P12Y P12Y 7500000 312000 7188000 7500000 0 7500000 200000 300000 <div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense of intangible assets as of June 30, 2023 is estimated to be as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:75.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,188 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 313000 625000 625000 625000 625000 4375000 7188000 <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Expenses consisted of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.247%"><tr><td style="width:1.0%"></td><td style="width:68.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonus-related compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related accruals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance reimbursement-related liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,030 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,971 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,190 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5090000 7132000 3436000 3101000 5160000 5030000 285000 927000 13971000 16190000 Leases<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases facilities in Ann Arbor, Michigan and Cambridge, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facilities include clean rooms, laboratories for MACI and Epicel manufacturing, and office space. The Company also leases offsite warehouse space, and other computer-related equipment. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the Ann Arbor facility, in March 2023, the Company entered into an amendment to that lease extending its term until April 30, 2025. Monthly contractual payments are expected to range from $17,000 to $18,000. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2022, the Company entered into a lease agreement (the “Burlington Lease”) to lease approximately 126,000 square feet of to-be-constructed manufacturing, laboratory and office space in Burlington, Massachusetts (the “Premises”). Once constructed, the Premises will serve as the Company’s new corporate headquarters and primary manufacturing facility.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, in connection with the Burlington Lease, the Company entered into a construction escrow agreement (the “Construction Escrow Agreement”) with the facility’s landlord and an escrow agent. Pursuant to the terms of the Construction Escrow Agreement, in April 2023, the Company began funding, into an escrow account maintained by the escrow agent, a portion of its share of tenant improvement construction costs at the facility, which are designated as restricted cash. At the same time, the facility’s landlord began funding a portion of its tenant improvement allowance through a separate escrow account. To date, the Company has transferred into its escrow account 50% of its required cost amount, or approximately $28.3 million. The Company anticipates funding the remaining 50% of its required cost amount in late 2023 or early 2024. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Burlington Lease began on June 1, 2023, (the “Commencement Date”), when the Company gained control of and commenced tenant improvement work at the Premises. The Company’s obligation to pay rent for the Premises will begin on the earlier of: 13 months from the Commencement Date; or the date on which the Company first occupies the Premises to conduct operations (the “Rent Commencement Date”). The initial term of the Lease is 144 months following the Rent Commencement Date. The Company has a one-time option to extend the term of the Lease for an additional 10 years, exercisable under certain conditions and at a market rate determined in accordance with the Burlington Lease.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual base rent of the Burlington Lease is initially $57 per square foot per year, subject to annual increases of 2.5%. Monthly contractual payments are expected to range from $0.6 million to $0.8 million. Additionally, the Company is responsible for reimbursing the landlord for the Company’s share of the Premises’ property taxes and certain other operating expenses. The Burlington Lease also provides for a tenant improvement allowance from the landlord in an amount equal to $200 per square foot of the Premises, or approximately $24.4 million. The tenant improvement allowance will be used towards the design and construction of the tenant improvements made to the Premises, subject to the terms set forth in the Burlington Lease.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was not involved in the initial construction of the core and shell of the building. On June 1, 2023, the Company gained control of the Premises to begin construction of its tenant improvements. As such, the corresponding right-of-use asset and lease liability of $35.5 million was recorded on the Company’s condensed consolidated balance sheet. As there was not an implicit rate within the lease available, the Company estimated the incremental borrowing rate of 7.7%, based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. The lease term of 13.1 years does not include the lease extension option, as the Company is not reasonably certain to exercise that option. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, in connection with the execution of the Burlington Lease, the Company issued a letter of credit collateralized by cash deposits of approximately $6.0 million. Subsequent to the execution of the Revolving Credit Agreement on July 29, 2022 (see Note 8, “Revolving Credit Agreement” for further details), the letter of credit is issued under the sub-facility limit of the Revolving Credit Agreement. Such letter of credit shall be reduced to approximately $4.2 million and $1.8 million at the conclusion of the third and sixth lease years, respectively, provided certain conditions set forth in the Burlington Lease are satisfied.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2023 and 2022, lease expense of less than $0.1 million was recorded related to short-term leases. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and six months ended</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2023</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized $2.3 million and $4.0 million, respectively, of operating lease expense and $1.7 million and $3.5 million, respectively, for the same period in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and six months ended</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2023 and 2022,</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company recognized less than </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.1 million</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of financing lease expense.</span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease assets and liabilities are as follows:</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.701%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.232%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,063 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-503"><span style="-sec-ix-hidden:f-504">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,081 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,572 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-511"><span style="-sec-ix-hidden:f-512">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,383 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,611 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of June 30, 2023 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.090%"><tr><td style="width:1.0%"></td><td style="width:43.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,576 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,597 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,743 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,743 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,677 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,677 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,969 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,969 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,545 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,566 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: tenant improvement allowances</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,362 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,383 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> Leases<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases facilities in Ann Arbor, Michigan and Cambridge, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facilities include clean rooms, laboratories for MACI and Epicel manufacturing, and office space. The Company also leases offsite warehouse space, and other computer-related equipment. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the Ann Arbor facility, in March 2023, the Company entered into an amendment to that lease extending its term until April 30, 2025. Monthly contractual payments are expected to range from $17,000 to $18,000. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2022, the Company entered into a lease agreement (the “Burlington Lease”) to lease approximately 126,000 square feet of to-be-constructed manufacturing, laboratory and office space in Burlington, Massachusetts (the “Premises”). Once constructed, the Premises will serve as the Company’s new corporate headquarters and primary manufacturing facility.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, in connection with the Burlington Lease, the Company entered into a construction escrow agreement (the “Construction Escrow Agreement”) with the facility’s landlord and an escrow agent. Pursuant to the terms of the Construction Escrow Agreement, in April 2023, the Company began funding, into an escrow account maintained by the escrow agent, a portion of its share of tenant improvement construction costs at the facility, which are designated as restricted cash. At the same time, the facility’s landlord began funding a portion of its tenant improvement allowance through a separate escrow account. To date, the Company has transferred into its escrow account 50% of its required cost amount, or approximately $28.3 million. The Company anticipates funding the remaining 50% of its required cost amount in late 2023 or early 2024. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Burlington Lease began on June 1, 2023, (the “Commencement Date”), when the Company gained control of and commenced tenant improvement work at the Premises. The Company’s obligation to pay rent for the Premises will begin on the earlier of: 13 months from the Commencement Date; or the date on which the Company first occupies the Premises to conduct operations (the “Rent Commencement Date”). The initial term of the Lease is 144 months following the Rent Commencement Date. The Company has a one-time option to extend the term of the Lease for an additional 10 years, exercisable under certain conditions and at a market rate determined in accordance with the Burlington Lease.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual base rent of the Burlington Lease is initially $57 per square foot per year, subject to annual increases of 2.5%. Monthly contractual payments are expected to range from $0.6 million to $0.8 million. Additionally, the Company is responsible for reimbursing the landlord for the Company’s share of the Premises’ property taxes and certain other operating expenses. The Burlington Lease also provides for a tenant improvement allowance from the landlord in an amount equal to $200 per square foot of the Premises, or approximately $24.4 million. The tenant improvement allowance will be used towards the design and construction of the tenant improvements made to the Premises, subject to the terms set forth in the Burlington Lease.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was not involved in the initial construction of the core and shell of the building. On June 1, 2023, the Company gained control of the Premises to begin construction of its tenant improvements. As such, the corresponding right-of-use asset and lease liability of $35.5 million was recorded on the Company’s condensed consolidated balance sheet. As there was not an implicit rate within the lease available, the Company estimated the incremental borrowing rate of 7.7%, based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. The lease term of 13.1 years does not include the lease extension option, as the Company is not reasonably certain to exercise that option. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, in connection with the execution of the Burlington Lease, the Company issued a letter of credit collateralized by cash deposits of approximately $6.0 million. Subsequent to the execution of the Revolving Credit Agreement on July 29, 2022 (see Note 8, “Revolving Credit Agreement” for further details), the letter of credit is issued under the sub-facility limit of the Revolving Credit Agreement. Such letter of credit shall be reduced to approximately $4.2 million and $1.8 million at the conclusion of the third and sixth lease years, respectively, provided certain conditions set forth in the Burlington Lease are satisfied.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2023 and 2022, lease expense of less than $0.1 million was recorded related to short-term leases. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and six months ended</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2023</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized $2.3 million and $4.0 million, respectively, of operating lease expense and $1.7 million and $3.5 million, respectively, for the same period in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and six months ended</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2023 and 2022,</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company recognized less than </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.1 million</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of financing lease expense.</span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease assets and liabilities are as follows:</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.701%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.232%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,063 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-503"><span style="-sec-ix-hidden:f-504">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,081 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,572 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-511"><span style="-sec-ix-hidden:f-512">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,383 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,611 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of June 30, 2023 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.090%"><tr><td style="width:1.0%"></td><td style="width:43.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,576 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,597 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,743 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,743 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,677 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,677 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,969 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,969 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,545 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,566 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: tenant improvement allowances</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,362 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,383 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 17000 18000 126000 0.50 28300000 0.50 P13M P144M 1 P10Y 57 0.025 600000 800000 200 24400000 35500000 35500000 0.077 P13Y1M6D 6000000 4200000 1800000 100000 100000 100000 100000 2300000 4000000 1700000 3500000 100000 100000 100000 100000 <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease assets and liabilities are as follows:</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.701%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.232%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,063 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-503"><span style="-sec-ix-hidden:f-504">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,081 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,572 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-511"><span style="-sec-ix-hidden:f-512">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,383 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,611 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 75063000 41535000 18000 37000 75081000 41572000 7218000 4302000 21000 41000 76144000 43268000 83383000 47611000 <div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of June 30, 2023 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.090%"><tr><td style="width:1.0%"></td><td style="width:43.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,576 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,597 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,743 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,743 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,677 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,677 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,969 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,969 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,545 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,566 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: tenant improvement allowances</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,362 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,383 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of June 30, 2023 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.090%"><tr><td style="width:1.0%"></td><td style="width:43.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,576 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,597 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,743 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,743 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,677 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,677 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,969 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,969 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,545 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,566 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: tenant improvement allowances</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,362 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,383 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3576000 21000 3597000 10743000 0 10743000 13677000 0 13677000 13969000 0 13969000 14351000 0 14351000 103229000 0 103229000 159545000 21000 159566000 25167000 0 25167000 51016000 0 51016000 83362000 21000 83383000 Investments<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable debt securities held by the Company are classified as available-for-sale pursuant to ASC 320, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments – Debt and Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and carried at fair value in the accompanying condensed consolidated balance sheets on a settlement date basis. The following tables summarize the gross unrealized gains and losses of the Company’s marketable securities:</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:right;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.090%"><tr><td style="width:1.0%"></td><td style="width:27.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Credit Losses</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,494 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,479 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,864 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(492)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,475 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,417 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(624)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,793 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,793 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:right;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.668%"><tr><td style="width:1.0%"></td><td style="width:27.199%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Credit Losses</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,707 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,606 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(831)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,411 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(978)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,433 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,962 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,433 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:right;text-indent:13.5pt"><span><br/></span></div><div style="margin-top:1pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023 and December 31, 2022, all marketable securities held by the Company had remaining contractual maturities of three years or less. There have been no impairments of the Company’s assets measured and carried at fair value during the three and six months ended June 30, 2023 and 2022.</span></div> The following tables summarize the gross unrealized gains and losses of the Company’s marketable securities:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.090%"><tr><td style="width:1.0%"></td><td style="width:27.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Credit Losses</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,494 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,479 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,864 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(492)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,475 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,417 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(624)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,793 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,793 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.668%"><tr><td style="width:1.0%"></td><td style="width:27.199%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Credit Losses</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,707 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,606 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(831)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,411 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(978)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,433 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,962 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,433 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 12494000 0 15000 0 12479000 43864000 0 492000 0 43372000 2476000 0 1000 0 2475000 17583000 0 116000 0 17467000 76417000 0 624000 0 75793000 54808000 20985000 75793000 15707000 0 101000 0 15606000 52159000 0 831000 0 51328000 21545000 0 46000 0 21499000 89411000 0 978000 0 88433000 68471000 19962000 88433000 P3Y P3Y 0 0 0 0 Fair Value Measurements<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s fair value measurements are classified and disclosed in one of the following three categories:</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The commercial paper, corporate notes, U.S. government securities, and U.S. government agency bonds are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. There were no transfers into or out of Level 3 from December 31, 2022 to June 30, 2023. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the valuation of the Company’s financial instruments that are measured at fair value on a recurring basis:</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.681%"><tr><td style="width:1.0%"></td><td style="width:27.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurement category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurement category</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency bonds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,320 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,620 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,700 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,172 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,910 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Approximately $19.9 million of U.S. government securities had an original maturity of 90 days or less and were recorded as a cash equivalent as of June 30, 2023.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Approximately $6.5 million of U.S. government agency bonds had an original maturity of 90 days or less and were recorded as a cash equivalent as of December 31, 2022.</span></div>The fair values of the cash equivalents and marketable securities are based on observable market prices. The Company’s accounts receivables, accounts payable and accrued expenses are valued at cost, which approximates fair value. <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the valuation of the Company’s financial instruments that are measured at fair value on a recurring basis:</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.681%"><tr><td style="width:1.0%"></td><td style="width:27.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurement category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurement category</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency bonds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,320 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,620 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,700 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,172 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,910 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Approximately $19.9 million of U.S. government securities had an original maturity of 90 days or less and were recorded as a cash equivalent as of June 30, 2023.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Approximately $6.5 million of U.S. government agency bonds had an original maturity of 90 days or less and were recorded as a cash equivalent as of December 31, 2022.</span></div> 7620000 7620000 0 0 1262000 1262000 0 0 12479000 0 12479000 0 15606000 0 15606000 0 43372000 0 43372000 0 51328000 0 51328000 0 22382000 0 22382000 0 0 0 0 0 17467000 0 17467000 0 27976000 0 27976000 0 103320000 7620000 95700000 0 96172000 1262000 94910000 0 19900000 6500000 Revolving Credit Agreement<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, the Company, as borrower, entered into a $150.0 million five-year senior secured revolving credit agreement by and among the Company, the other loan parties thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as the administrative agent (the “Revolving Credit Agreement”). The Revolving Credit Agreement includes a $15.0 million sub-facility for the issuance of letters of credit, of which the Company is utilizing approximately $6.2 million. Amounts available under the Revolving Credit Agreement are for the working capital needs and other general corporate purposes of the Company. The Company incurred and capitalized approximately $1.1 million of debt issuance costs related to the Revolving Credit Agreement.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding borrowings under the Revolving Credit Agreement bear interest, with pricing based from time to time at the Company’s election at (i) the Secured Overnight Financing Rate (“SOFR”) plus 0.10% plus a spread ranging from 1.25% to 2.50% as determined by the Company’s Total Net Leverage Ratio (as defined in the Revolving Credit Agreement) or (ii) the alternative base rate (as defined in the Revolving Credit Agreement) plus a spread ranging from 0.25% to 1.50% as determined by the Company’s Total Net Leverage Ratio. The Revolving Credit Agreement also includes a commitment fee, which ranges from 0.20% to 0.25% as determined by the Company’s Total Net Leverage Ratio.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is permitted to voluntarily prepay borrowings under the Revolving Credit Agreement, in whole or in part, without premium or penalty. On any business day on which the total amount of outstanding Revolving Loans (as defined in the Revolving Credit Agreement) and letters of credit exceeds the total Revolving Commitments (as defined in the Revolving Credit Agreement), the Company must prepay the Revolving Loans in an amount equal to such excess. As of June 30, 2023, there are no outstanding borrowings under the Revolving Credit Agreement.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Agreement contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. The Revolving Credit Agreement requires the Company to be in quarterly compliance, measured on a trailing four quarter basis, with a financial covenant. The maximum Total Net Leverage Ratio (as defined in the Revolving Credit Agreement is 3.50 to 1.00. The Company may elect to increase the maximum Total Net Leverage Ratio to 4.00 to 1.00 for a period of four consecutive quarters in connection with a Permitted Acquisition (as defined in the Revolving Credit Agreement).</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Agreement contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all, or substantially all, of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obligations under the Revolving Credit Agreement are secured by first priority liens over substantially all of the assets of Vericel Corporation, excluding certain subsidiaries (subject to customary exclusions set forth in the Revolving Credit Agreement and the other transaction documents).</span></div> 150000000 P5Y 15000000 6200000 1100000 0.0010 0.0125 0.0250 0.0025 0.0150 0.0020 0.0025 0 3.50 4.00 Stock-Based Compensation<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Vericel Corporation 2022 Omnibus Incentive Plan (“2022 Plan”) was approved on April 27, 2022, and provides incentives through the grant of stock options, stock appreciation rights, restricted stock awards and restricted stock units. The exercise price of stock options granted under the 2022 Plan shall not be less than the fair market value of the Company’s common stock on the date of grant. The 2022 Plan replaced the 1992 Stock Option Plan, the 2001 Stock Option Plan, the Amended and Restated 2004 Equity Incentive Plan, the 2009 Second Amended and Restated Omnibus Incentive Plan, the 2017 Omnibus Incentive Plan, and the Amended and Restated 2019 Omnibus Incentive Plan (collectively the “Prior Plans”), and no new grants have been granted under the Prior Plans after approval of the 2022 Plan. However, the expiration or forfeiture of options previously granted under the Prior Plans will increase the number of shares available for issuance under the 2022 Plan.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Compensation Expense</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash stock-based compensation expense (service-based stock options, restricted stock units and employee stock purchase plan) is summarized in the following table:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.247%"><tr><td style="width:1.0%"></td><td style="width:45.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,681 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,153 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,870 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,972 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-cash stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,761 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,808 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,492 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service-Based Stock Options</span></div><div style="text-align:justify;text-indent:6.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2023, the Company granted service-based options to purchase common stock of 67,760 and 535,717, respectively, and 170,060 and 1,163,649, respectively, for the same periods in 2022. The weighted-average grant-date fair value of service-based options granted during the three and six months ended June 30, 2023 was $19.30 and $18.41 per option, respectively, and $19.25 and $20.74, respectively, for the same periods in 2022. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units </span></div>During the three and six months ended June 30, 2023, the Company granted 32,816 and 529,321 restricted stock units, respectively, and 39,746 and 382,768, respectively, for the same periods in 2022. The weighted-average grant-date fair value of restricted stock units granted during the three and six months ended June 30, 2023 was $32.16 and $29.97 per unit, respectively, and $31.94 and $34.65, respectively, for the same periods in 2022. Non-cash stock-based compensation expense (service-based stock options, restricted stock units and employee stock purchase plan) is summarized in the following table:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.247%"><tr><td style="width:1.0%"></td><td style="width:45.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,681 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,153 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,870 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,972 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-cash stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,761 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,808 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,492 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 796000 1035000 1681000 2153000 993000 1520000 1970000 2870000 6972000 8253000 13841000 15316000 8761000 10808000 17492000 20339000 67760 535717 170060 1163649 19.30 18.41 19.25 20.74 32816 529321 39746 382768 32.16 29.97 31.94 34.65 Net Loss Per Common Share<div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of net loss per common share is presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.630%"><tr><td style="width:1.0%"></td><td style="width:46.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in thousands, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,963)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,515)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,054)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,572 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,480 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options and restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,117 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,480 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,052 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic loss per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted loss per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive shares excluded from diluted net loss per common share:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of net loss per common share is presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.630%"><tr><td style="width:1.0%"></td><td style="width:46.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in thousands, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,963)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,515)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,054)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,572 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,480 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options and restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,117 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,480 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,052 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic loss per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted loss per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive shares excluded from diluted net loss per common share:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -5020000 -8963000 -12515000 -16054000 47572000 47117000 47480000 47052000 0 0 0 0 47572000 47117000 47480000 47052000 -0.11 -0.19 -0.26 -0.34 -0.11 -0.19 -0.26 -0.34 6876000 6586000 6876000 6586000 939000 636000 939000 636000 NexoBrid License and Supply Agreements <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 6, 2019, the Company entered into exclusive license and supply agreements with MediWound to commercialize NexoBrid in North America. The FDA subsequently approved a Biologics License Application (“BLA”) for the product on December 28, 2022. NexoBrid is a topically-administered biological product, which contains proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the license agreement, following the FDA approval of NexoBrid, MediWound transferred the BLA to Vericel effective February 20, 2023. Both MediWound and Vericel, under the supervision of a Central Steering Committee comprised of members of both companies will continue to guide the development of NexoBrid in North America (the “Central Steering Committee”). NexoBrid is approved in the European Union (“EU”) and other international markets and has been designated as an orphan biologic in the U.S., EU and other international markets.</span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company paid MediWound $17.5 million in consideration for the license, which was recorded as research and development expense during 2019. Pursuant to the terms of the license agreement, in February 2023, the Company tendered to MediWound a $7.5 million regulatory milestone payment following the FDA’s BLA approval of NexoBrid on December 28, 2022. The Company recorded the $7.5 million milestone payment for the licensing rights to commercially sell NexoBrid in the U.S., as an intangible asset (see Note 4, “Selected Balance Sheet Components” for further details).</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is additionally obligated to pay MediWound up to $125.0 million, which is contingent upon meeting certain sales milestones. The first sales milestone payment of $7.5 million would be triggered when annual net sales of NexoBrid or improvements to it in North America exceed $75.0 million. As of June 30, 2023, the sales milestone payments are not yet probable and therefore, not recorded as a liability. The Company also will pay MediWound tiered royalties on net sales ranging from mid-high single-digit to mid-teen percentages, subject to customary reductions. Pursuant to the terms of the Company’s supply agreement with MediWound, MediWound will manufacture NexoBrid for the Company on a unit price basis, which may be increased pursuant to the terms of the supply agreement. MediWound is obligated to supply the Company with NexoBrid for sale in North America on an exclusive basis for the first five years of the term of the supply agreement. Under the supply agreement, the Company possesses the option to extend the initial term of the agreement by an additional 24 months, which it did in May 2022. Under the supply agreement, the Company is permitted to establish an alternate source of supply in certain circumstances, including the event of a supply failure.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, beginning in 2020 BARDA procured quantities of NexoBrid from MediWound for use as a medical countermeasure in the event of a mass casualty emergency in the U.S. involving thermal burns. The initial, quarterly, procurement of NexoBrid by BARDA under its agreement with MediWound completed during the third quarter of 2022. As a part of BARDA’s commitment to procure NexoBrid, the Company has received a percentage of gross profit for sales directly to BARDA. As of June 30, 2023, the Company did not hold a direct contract or distribution agreement with BARDA, or take title to the product procured by BARDA.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 9, 2023, MediWound announced BARDA’s award of additional funding under the parties’ existing agreement, $3 million of which will support the replacement of NexoBrid, previously procured for emergency response preparedness, which has since expired. Pursuant to the terms of the Company’s license agreement with MediWound, the Company will recognize revenue based on a percentage of gross profits, minus a percentage of net sales, on any sales of NexoBrid directly to BARDA, upon delivery, pursuant to this additional award.</span></div> 17500000 7500000 7500000 125000000 7500000 75000000 P5Y P24M 3000000 Commitments and Contingencies <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company could be a party to various legal proceedings arising in the ordinary course of business. The costs and outcome of litigation, regulatory, investigatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in a material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023, the Company has no material ongoing litigation in which the Company was a party or any material ongoing regulatory or other proceedings and had no knowledge of any investigations by government or regulatory authorities in which the Company is a target that could have a material adverse effect on its current business.</span></div> false false false false EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

P9 0!?L-OX;+00 /8? / " =4: M 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " #[10)7DBR@EK@! #G' M&@ @ $O'P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0 M2P$"% ,4 " #[10)7C$_JC[H! #N' $P @ $?(0$ I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 . X #\/ *(P$ ! end XML 62 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 209 269 1 false 53 0 false 10 false false R1.htm 0000001 - Document - Cover Sheet http://vcel.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Sheet http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Statements 6 false false R7.htm 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 0000008 - Disclosure - Organization Sheet http://vcel.com/role/Organization Organization Notes 8 false false R9.htm 0000009 - Disclosure - Basis of Presentation Sheet http://vcel.com/role/BasisofPresentation Basis of Presentation Notes 9 false false R10.htm 0000010 - Disclosure - Revenue Sheet http://vcel.com/role/Revenue Revenue Notes 10 false false R11.htm 0000011 - Disclosure - Selected Balance Sheet Components Sheet http://vcel.com/role/SelectedBalanceSheetComponents Selected Balance Sheet Components Notes 11 false false R12.htm 0000012 - Disclosure - Leases Sheet http://vcel.com/role/Leases Leases Notes 12 false false R13.htm 0000013 - Disclosure - Investments Sheet http://vcel.com/role/Investments Investments Notes 13 false false R14.htm 0000014 - Disclosure - Fair Value Measurements Sheet http://vcel.com/role/FairValueMeasurements Fair Value Measurements Notes 14 false false R15.htm 0000015 - Disclosure - Revolving Credit Agreement Sheet http://vcel.com/role/RevolvingCreditAgreement Revolving Credit Agreement Notes 15 false false R16.htm 0000016 - Disclosure - Stock-Based Compensation Sheet http://vcel.com/role/StockBasedCompensation Stock-Based Compensation Notes 16 false false R17.htm 0000017 - Disclosure - Net Loss Per Common Share Sheet http://vcel.com/role/NetLossPerCommonShare Net Loss Per Common Share Notes 17 false false R18.htm 0000018 - Disclosure - NexoBrid License and Supply Agreements Sheet http://vcel.com/role/NexoBridLicenseandSupplyAgreements NexoBrid License and Supply Agreements Notes 18 false false R19.htm 0000019 - Disclosure - Commitments and Contingencies Sheet http://vcel.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 19 false false R20.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 20 false false R21.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 21 false false R22.htm 9954701 - Disclosure - Basis of Presentation (Policies) Sheet http://vcel.com/role/BasisofPresentationPolicies Basis of Presentation (Policies) Policies 22 false false R23.htm 9954702 - Disclosure - Revenue (Tables) Sheet http://vcel.com/role/RevenueTables Revenue (Tables) Tables http://vcel.com/role/Revenue 23 false false R24.htm 9954703 - Disclosure - Selected Balance Sheet Components (Tables) Sheet http://vcel.com/role/SelectedBalanceSheetComponentsTables Selected Balance Sheet Components (Tables) Tables http://vcel.com/role/SelectedBalanceSheetComponents 24 false false R25.htm 9954704 - Disclosure - Leases (Tables) Sheet http://vcel.com/role/LeasesTables Leases (Tables) Tables http://vcel.com/role/Leases 25 false false R26.htm 9954705 - Disclosure - Investments (Tables) Sheet http://vcel.com/role/InvestmentsTables Investments (Tables) Tables http://vcel.com/role/Investments 26 false false R27.htm 9954706 - Disclosure - Fair Value Measurements (Tables) Sheet http://vcel.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://vcel.com/role/FairValueMeasurements 27 false false R28.htm 9954707 - Disclosure - Stock-Based Compensation (Tables) Sheet http://vcel.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://vcel.com/role/StockBasedCompensation 28 false false R29.htm 9954708 - Disclosure - Net Loss Per Common Share (Tables) Sheet http://vcel.com/role/NetLossPerCommonShareTables Net Loss Per Common Share (Tables) Tables http://vcel.com/role/NetLossPerCommonShare 29 false false R30.htm 9954709 - Disclosure - Organization (Details) Sheet http://vcel.com/role/OrganizationDetails Organization (Details) Details http://vcel.com/role/Organization 30 false false R31.htm 9954710 - Disclosure - Revenue - Narrative (Details) Sheet http://vcel.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 31 false false R32.htm 9954711 - Disclosure - Revenue - Summary of Disaggregation of Revenue (Details) Sheet http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails Revenue - Summary of Disaggregation of Revenue (Details) Details 32 false false R33.htm 9954712 - Disclosure - Selected Balance Sheet Components - Summary of inventory (Details) Sheet http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails Selected Balance Sheet Components - Summary of inventory (Details) Details 33 false false R34.htm 9954713 - Disclosure - Selected Balance Sheet Components - Schedule of property and equipment, net (Details) Sheet http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails Selected Balance Sheet Components - Schedule of property and equipment, net (Details) Details 34 false false R35.htm 9954714 - Disclosure - Selected Balance Sheet Components - Narrative (Details) Sheet http://vcel.com/role/SelectedBalanceSheetComponentsNarrativeDetails Selected Balance Sheet Components - Narrative (Details) Details 35 false false R36.htm 9954715 - Disclosure - Selected Balance Sheet Components -Schedule of finite-lived intangible assets (Details) Sheet http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails Selected Balance Sheet Components -Schedule of finite-lived intangible assets (Details) Details 36 false false R37.htm 9954716 - Disclosure - Selected Balance Sheet Components -Schedule of finite-lived intangible assets, future amortization expense (Details) Sheet http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails Selected Balance Sheet Components -Schedule of finite-lived intangible assets, future amortization expense (Details) Details 37 false false R38.htm 9954717 - Disclosure - Selected Balance Sheet Components - Schedule of accrued expenses (Details) Sheet http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails Selected Balance Sheet Components - Schedule of accrued expenses (Details) Details 38 false false R39.htm 9954718 - Disclosure - Leases - Narrative (Details) Sheet http://vcel.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 39 false false R40.htm 9954719 - Disclosure - Leases - Summary of assets and liabilities (Details) Sheet http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails Leases - Summary of assets and liabilities (Details) Details 40 false false R41.htm 9954720 - Disclosure - Leases - Maturities of lease liabilities (Details) Sheet http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails Leases - Maturities of lease liabilities (Details) Details 41 false false R42.htm 9954721 - Disclosure - Investments (Details) Sheet http://vcel.com/role/InvestmentsDetails Investments (Details) Details http://vcel.com/role/InvestmentsTables 42 false false R43.htm 9954722 - Disclosure - Fair Value Measurements (Details) Sheet http://vcel.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://vcel.com/role/FairValueMeasurementsTables 43 false false R44.htm 9954723 - Disclosure - Revolving Credit Agreement (Details) Sheet http://vcel.com/role/RevolvingCreditAgreementDetails Revolving Credit Agreement (Details) Details http://vcel.com/role/RevolvingCreditAgreement 44 false false R45.htm 9954724 - Disclosure - Stock-Based Compensation - Expense (Details) Sheet http://vcel.com/role/StockBasedCompensationExpenseDetails Stock-Based Compensation - Expense (Details) Details 45 false false R46.htm 9954725 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://vcel.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 46 false false R47.htm 9954726 - Disclosure - Net Loss Per Common Share (Details) Sheet http://vcel.com/role/NetLossPerCommonShareDetails Net Loss Per Common Share (Details) Details http://vcel.com/role/NetLossPerCommonShareTables 47 false false R48.htm 9954727 - Disclosure - NexoBrid License and Supply Agreements (Details) Sheet http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails NexoBrid License and Supply Agreements (Details) Details http://vcel.com/role/NexoBridLicenseandSupplyAgreements 48 false false All Reports Book All Reports vcel-20230630.htm ex101vericelcorporationdef.htm ex102vericelcorporation202.htm ex311ceocertificationq22023.htm ex312cfocertificationq22023.htm ex321ceoandcfosoxcertifica.htm vcel-20230630.xsd vcel-20230630_cal.xml vcel-20230630_def.xml vcel-20230630_lab.xml vcel-20230630_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 66 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vcel-20230630.htm": { "axisCustom": 0, "axisStandard": 22, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 666, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 4 }, "contextCount": 209, "dts": { "calculationLink": { "local": [ "vcel-20230630_cal.xml" ] }, "definitionLink": { "local": [ "vcel-20230630_def.xml" ] }, "inline": { "local": [ "vcel-20230630.htm" ] }, "labelLink": { "local": [ "vcel-20230630_lab.xml" ] }, "presentationLink": { "local": [ "vcel-20230630_pre.xml" ] }, "schema": { "local": [ "vcel-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] } }, "elementCount": 514, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 12, "http://xbrl.sec.gov/dei/2023": 5, "total": 17 }, "keyCustom": 50, "keyStandard": 219, "memberCustom": 13, "memberStandard": 38, "nsprefix": "vcel", "nsuri": "http://vcel.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://vcel.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Revenue", "menuCat": "Notes", "order": "10", "role": "http://vcel.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Selected Balance Sheet Components", "menuCat": "Notes", "order": "11", "role": "http://vcel.com/role/SelectedBalanceSheetComponents", "shortName": "Selected Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Leases", "menuCat": "Notes", "order": "12", "role": "http://vcel.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Investments", "menuCat": "Notes", "order": "13", "role": "http://vcel.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "14", "role": "http://vcel.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Revolving Credit Agreement", "menuCat": "Notes", "order": "15", "role": "http://vcel.com/role/RevolvingCreditAgreement", "shortName": "Revolving Credit Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Stock-Based Compensation", "menuCat": "Notes", "order": "16", "role": "http://vcel.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Net Loss Per Common Share", "menuCat": "Notes", "order": "17", "role": "http://vcel.com/role/NetLossPerCommonShare", "shortName": "Net Loss Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "vcel:LicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - NexoBrid License and Supply Agreements", "menuCat": "Notes", "order": "18", "role": "http://vcel.com/role/NexoBridLicenseandSupplyAgreements", "shortName": "NexoBrid License and Supply Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "vcel:LicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "19", "role": "http://vcel.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RestrictedCashCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "menuCat": "Notes", "order": "20", "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "shortName": "Pay vs Performance Disclosure", "subGroupType": "", "uniqueAnchor": null }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-5", "decimals": null, "first": true, "lang": "en-US", "name": "ecd:Rule10b51ArrAdoptedFlag", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "995445 - Disclosure - Insider Trading Arrangements", "menuCat": "Notes", "order": "21", "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "shortName": "Insider Trading Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-5", "decimals": null, "first": true, "lang": "en-US", "name": "ecd:Rule10b51ArrAdoptedFlag", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskCreditRisk", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954701 - Disclosure - Basis of Presentation (Policies)", "menuCat": "Policies", "order": "22", "role": "http://vcel.com/role/BasisofPresentationPolicies", "shortName": "Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskCreditRisk", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954702 - Disclosure - Revenue (Tables)", "menuCat": "Tables", "order": "23", "role": "http://vcel.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954703 - Disclosure - Selected Balance Sheet Components (Tables)", "menuCat": "Tables", "order": "24", "role": "http://vcel.com/role/SelectedBalanceSheetComponentsTables", "shortName": "Selected Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "vcel:AssetsAndLiabilitiesLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954704 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "25", "role": "http://vcel.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "vcel:AssetsAndLiabilitiesLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954705 - Disclosure - Investments (Tables)", "menuCat": "Tables", "order": "26", "role": "http://vcel.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954706 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "27", "role": "http://vcel.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954707 - Disclosure - Stock-Based Compensation (Tables)", "menuCat": "Tables", "order": "28", "role": "http://vcel.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954708 - Disclosure - Net Loss Per Common Share (Tables)", "menuCat": "Tables", "order": "29", "role": "http://vcel.com/role/NetLossPerCommonShareTables", "shortName": "Net Loss Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "INF", "first": true, "lang": "en-US", "name": "vcel:NumberOfProducts", "reportCount": 1, "unitRef": "product", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954709 - Disclosure - Organization (Details)", "menuCat": "Details", "order": "30", "role": "http://vcel.com/role/OrganizationDetails", "shortName": "Organization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": "INF", "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "INF", "first": true, "lang": "en-US", "name": "vcel:NumberOfContractedSpecialtyPharmacies", "reportCount": 1, "unique": true, "unitRef": "pharmacy", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954710 - Disclosure - Revenue - Narrative (Details)", "menuCat": "Details", "order": "31", "role": "http://vcel.com/role/RevenueNarrativeDetails", "shortName": "Revenue - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "INF", "first": true, "lang": "en-US", "name": "vcel:NumberOfContractedSpecialtyPharmacies", "reportCount": 1, "unique": true, "unitRef": "pharmacy", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954711 - Disclosure - Revenue - Summary of Disaggregation of Revenue (Details)", "menuCat": "Details", "order": "32", "role": "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails", "shortName": "Revenue - Summary of Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-65", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954712 - Disclosure - Selected Balance Sheet Components - Summary of inventory (Details)", "menuCat": "Details", "order": "33", "role": "http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails", "shortName": "Selected Balance Sheet Components - Summary of inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954713 - Disclosure - Selected Balance Sheet Components - Schedule of property and equipment, net (Details)", "menuCat": "Details", "order": "34", "role": "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails", "shortName": "Selected Balance Sheet Components - Schedule of property and equipment, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-5", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954714 - Disclosure - Selected Balance Sheet Components - Narrative (Details)", "menuCat": "Details", "order": "35", "role": "http://vcel.com/role/SelectedBalanceSheetComponentsNarrativeDetails", "shortName": "Selected Balance Sheet Components - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-5", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954715 - Disclosure - Selected Balance Sheet Components -Schedule of finite-lived intangible assets (Details)", "menuCat": "Details", "order": "36", "role": "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails", "shortName": "Selected Balance Sheet Components -Schedule of finite-lived intangible assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-92", "decimals": null, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954716 - Disclosure - Selected Balance Sheet Components -Schedule of finite-lived intangible assets, future amortization expense (Details)", "menuCat": "Details", "order": "37", "role": "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails", "shortName": "Selected Balance Sheet Components -Schedule of finite-lived intangible assets, future amortization expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-92", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedBonusesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954717 - Disclosure - Selected Balance Sheet Components - Schedule of accrued expenses (Details)", "menuCat": "Details", "order": "38", "role": "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails", "shortName": "Selected Balance Sheet Components - Schedule of accrued expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedBonusesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "vcel:AssetsAndLiabilitiesLeasesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954718 - Disclosure - Leases - Narrative (Details)", "menuCat": "Details", "order": "39", "role": "http://vcel.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ShortTermLeaseCost", "us-gaap:ShortTermLeaseCost", "us-gaap:ShortTermLeaseCost", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-5", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ShortTermLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-5", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "vcel:AssetsAndLiabilitiesLeasesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954719 - Disclosure - Leases - Summary of assets and liabilities (Details)", "menuCat": "Details", "order": "40", "role": "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails", "shortName": "Leases - Summary of assets and liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "vcel:AssetsAndLiabilitiesLeasesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954720 - Disclosure - Leases - Maturities of lease liabilities (Details)", "menuCat": "Details", "order": "41", "role": "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails", "shortName": "Leases - Maturities of lease liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954721 - Disclosure - Investments (Details)", "menuCat": "Details", "order": "42", "role": "http://vcel.com/role/InvestmentsDetails", "shortName": "Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-4", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954722 - Disclosure - Fair Value Measurements (Details)", "menuCat": "Details", "order": "43", "role": "http://vcel.com/role/FairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-157", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-170", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LettersOfCreditOutstandingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954723 - Disclosure - Revolving Credit Agreement (Details)", "menuCat": "Details", "order": "44", "role": "http://vcel.com/role/RevolvingCreditAgreementDetails", "shortName": "Revolving Credit Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-170", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LettersOfCreditOutstandingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-191", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954724 - Disclosure - Stock-Based Compensation - Expense (Details)", "menuCat": "Details", "order": "45", "role": "http://vcel.com/role/StockBasedCompensationExpenseDetails", "shortName": "Stock-Based Compensation - Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-191", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-5", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954725 - Disclosure - Stock-Based Compensation - Narrative (Details)", "menuCat": "Details", "order": "46", "role": "http://vcel.com/role/StockBasedCompensationNarrativeDetails", "shortName": "Stock-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-5", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954726 - Disclosure - Net Loss Per Common Share (Details)", "menuCat": "Details", "order": "47", "role": "http://vcel.com/role/NetLossPerCommonShareDetails", "shortName": "Net Loss Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-5", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-207", "decimals": "-5", "first": true, "lang": "en-US", "name": "vcel:LicenseAgreementConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954727 - Disclosure - NexoBrid License and Supply Agreements (Details)", "menuCat": "Details", "order": "48", "role": "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails", "shortName": "NexoBrid License and Supply Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-207", "decimals": "-5", "first": true, "lang": "en-US", "name": "vcel:LicenseAgreementConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "menuCat": "Statements", "order": "5", "role": "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-5", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-25", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "menuCat": "Statements", "order": "6", "role": "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-29", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "7", "role": "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Organization", "menuCat": "Notes", "order": "8", "role": "http://vcel.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Basis of Presentation", "menuCat": "Notes", "order": "9", "role": "http://vcel.com/role/BasisofPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 53, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r648" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r681" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r720" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r647" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "ecd_Additional402vDisclosureTextBlock": { "auth_ref": [ "r682" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "localname": "Additional402vDisclosureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AdjToCompAmt": { "auth_ref": [ "r688" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "localname": "AdjToCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AdjToCompAxis": { "auth_ref": [ "r688" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "localname": "AdjToCompAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "auth_ref": [ "r688" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "localname": "AdjToNonPeoNeoCompFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AdjToPeoCompFnTextBlock": { "auth_ref": [ "r688" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "localname": "AdjToPeoCompFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AggtErrCompAmt": { "auth_ref": [ "r653", "r664", "r674", "r699" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "localname": "AggtErrCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "auth_ref": [ "r656", "r667", "r677", "r702" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "localname": "AggtErrCompNotYetDeterminedTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AllAdjToCompMember": { "auth_ref": [ "r688" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "localname": "AllAdjToCompMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllExecutiveCategoriesMember": { "auth_ref": [ "r695" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "localname": "AllExecutiveCategoriesMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllIndividualsMember": { "auth_ref": [ "r660", "r668", "r678", "r695", "r703", "r707", "r715" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "localname": "AllIndividualsMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllTradingArrangementsMember": { "auth_ref": [ "r713" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "localname": "AllTradingArrangementsMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "domainItemType" }, "ecd_AwardExrcPrice": { "auth_ref": [ "r710" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "localname": "AwardExrcPrice", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "perShareItemType" }, "ecd_AwardGrantDateFairValue": { "auth_ref": [ "r711" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "localname": "AwardGrantDateFairValue", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AwardTmgDiscLineItems": { "auth_ref": [ "r706" ], "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "localname": "AwardTmgDiscLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "auth_ref": [ "r706" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgMethodTextBlock": { "auth_ref": [ "r706" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "localname": "AwardTmgMethodTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgMnpiCnsdrdFlag": { "auth_ref": [ "r706" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "localname": "AwardTmgMnpiCnsdrdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_AwardTmgMnpiDiscTextBlock": { "auth_ref": [ "r706" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "localname": "AwardTmgMnpiDiscTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgPredtrmndFlag": { "auth_ref": [ "r706" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "localname": "AwardTmgPredtrmndFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_AwardUndrlygSecuritiesAmt": { "auth_ref": [ "r709" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "localname": "AwardUndrlygSecuritiesAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_AwardsCloseToMnpiDiscIndName": { "auth_ref": [ "r708" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "localname": "AwardsCloseToMnpiDiscIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AwardsCloseToMnpiDiscTable": { "auth_ref": [ "r707" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "localname": "AwardsCloseToMnpiDiscTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "auth_ref": [ "r707" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "localname": "AwardsCloseToMnpiDiscTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ChangedPeerGroupFnTextBlock": { "auth_ref": [ "r686" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "localname": "ChangedPeerGroupFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CoSelectedMeasureAmt": { "auth_ref": [ "r687" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "localname": "CoSelectedMeasureAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_CoSelectedMeasureName": { "auth_ref": [ "r687" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "localname": "CoSelectedMeasureName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "auth_ref": [ "r692" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "auth_ref": [ "r691" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "localname": "CompActuallyPaidVsNetIncomeTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "auth_ref": [ "r693" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "auth_ref": [ "r690" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "auth_ref": [ "r689" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ErrCompAnalysisTextBlock": { "auth_ref": [ "r653", "r664", "r674", "r699" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "localname": "ErrCompAnalysisTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ErrCompRecoveryTable": { "auth_ref": [ "r650", "r661", "r671", "r696" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "localname": "ErrCompRecoveryTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_ExecutiveCategoryAxis": { "auth_ref": [ "r695" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "localname": "ExecutiveCategoryAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "auth_ref": [ "r657", "r668", "r678", "r703" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "auth_ref": [ "r657", "r668", "r678", "r703" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "auth_ref": [ "r657", "r668", "r678", "r703" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "auth_ref": [ "r657", "r668", "r678", "r703" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ForgoneRecoveryIndName": { "auth_ref": [ "r657", "r668", "r678", "r703" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "localname": "ForgoneRecoveryIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_IndividualAxis": { "auth_ref": [ "r660", "r668", "r678", "r695", "r703", "r707", "r715" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "localname": "IndividualAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_InsiderTradingArrLineItems": { "auth_ref": [ "r713" ], "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "localname": "InsiderTradingArrLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_InsiderTradingPoliciesProcLineItems": { "auth_ref": [ "r649", "r719" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "localname": "InsiderTradingPoliciesProcLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "auth_ref": [ "r649", "r719" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "localname": "InsiderTrdPoliciesProcAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "xbrltype": "booleanItemType" }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "auth_ref": [ "r649", "r719" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "xbrltype": "textBlockItemType" }, "ecd_MeasureAxis": { "auth_ref": [ "r687" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "localname": "MeasureAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_MeasureName": { "auth_ref": [ "r687" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "localname": "MeasureName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_MnpiDiscTimedForCompValFlag": { "auth_ref": [ "r706" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "localname": "MnpiDiscTimedForCompValFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_MtrlTermsOfTrdArrTextBlock": { "auth_ref": [ "r714" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "localname": "MtrlTermsOfTrdArrTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "textBlockItemType" }, "ecd_NamedExecutiveOfficersFnTextBlock": { "auth_ref": [ "r688" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "localname": "NamedExecutiveOfficersFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_NonGaapMeasureDescriptionTextBlock": { "auth_ref": [ "r687" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "localname": "NonGaapMeasureDescriptionTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_NonNeosMember": { "auth_ref": [ "r657", "r668", "r678", "r695", "r703" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "localname": "NonNeosMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "domainItemType" }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "auth_ref": [ "r685" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_NonPeoNeoAvgTotalCompAmt": { "auth_ref": [ "r684" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "localname": "NonPeoNeoAvgTotalCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_NonPeoNeoMember": { "auth_ref": [ "r695" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "localname": "NonPeoNeoMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_NonRule10b51ArrAdoptedFlag": { "auth_ref": [ "r714" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "localname": "NonRule10b51ArrAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_NonRule10b51ArrTrmntdFlag": { "auth_ref": [ "r714" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "localname": "NonRule10b51ArrTrmntdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_OtherPerfMeasureAmt": { "auth_ref": [ "r687" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "localname": "OtherPerfMeasureAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_OutstandingAggtErrCompAmt": { "auth_ref": [ "r655", "r666", "r676", "r701" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "localname": "OutstandingAggtErrCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_OutstandingRecoveryCompAmt": { "auth_ref": [ "r658", "r669", "r679", "r704" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "localname": "OutstandingRecoveryCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_OutstandingRecoveryIndName": { "auth_ref": [ "r658", "r669", "r679", "r704" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "localname": "OutstandingRecoveryIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_PayVsPerformanceDisclosureLineItems": { "auth_ref": [ "r683" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "localname": "PayVsPerformanceDisclosureLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_PeerGroupIssuersFnTextBlock": { "auth_ref": [ "r686" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "localname": "PeerGroupIssuersFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_PeerGroupTotalShareholderRtnAmt": { "auth_ref": [ "r686" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "localname": "PeerGroupTotalShareholderRtnAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PeoActuallyPaidCompAmt": { "auth_ref": [ "r685" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "localname": "PeoActuallyPaidCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PeoMember": { "auth_ref": [ "r695" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "localname": "PeoMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_PeoName": { "auth_ref": [ "r688" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "localname": "PeoName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_PeoTotalCompAmt": { "auth_ref": [ "r684" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "localname": "PeoTotalCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PvpTable": { "auth_ref": [ "r683" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "localname": "PvpTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_PvpTableTextBlock": { "auth_ref": [ "r683" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "localname": "PvpTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "auth_ref": [ "r650", "r661", "r671", "r696" ], "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "localname": "RecoveryOfErrCompDisclosureLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_RestatementDateAxis": { "auth_ref": [ "r651", "r662", "r672", "r697" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "localname": "RestatementDateAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_RestatementDeterminationDate": { "auth_ref": [ "r652", "r663", "r673", "r698" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "localname": "RestatementDeterminationDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "dateItemType" }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "auth_ref": [ "r659", "r670", "r680", "r705" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "localname": "RestatementDoesNotRequireRecoveryTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_Rule10b51ArrAdoptedFlag": { "auth_ref": [ "r714" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "localname": "Rule10b51ArrAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_Rule10b51ArrTrmntdFlag": { "auth_ref": [ "r714" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "localname": "Rule10b51ArrTrmntdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "auth_ref": [ "r654", "r665", "r675", "r700" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "localname": "StkPrcOrTsrEstimationMethodTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TabularListTableTextBlock": { "auth_ref": [ "r694" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "localname": "TabularListTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TotalShareholderRtnAmt": { "auth_ref": [ "r686" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "localname": "TotalShareholderRtnAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "auth_ref": [ "r693" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TradingArrAxis": { "auth_ref": [ "r713" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "localname": "TradingArrAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TradingArrByIndTable": { "auth_ref": [ "r715" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "localname": "TradingArrByIndTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrAdoptionDate": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "localname": "TrdArrAdoptionDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrDuration": { "auth_ref": [ "r717" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "localname": "TrdArrDuration", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "durationItemType" }, "ecd_TrdArrIndName": { "auth_ref": [ "r715" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "localname": "TrdArrIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrIndTitle": { "auth_ref": [ "r715" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "localname": "TrdArrIndTitle", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrSecuritiesAggAvailAmt": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "localname": "TrdArrSecuritiesAggAvailAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "sharesItemType" }, "ecd_TrdArrTerminationDate": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "localname": "TrdArrTerminationDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_UndrlygSecurityMktPriceChngPct": { "auth_ref": [ "r712" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "localname": "UndrlygSecurityMktPriceChngPct", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "pureItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r147", "r148", "r286", "r309", "r455", "r604", "r606" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails", "http://vcel.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r269", "r270", "r271", "r272", "r331", "r486", "r516", "r533", "r534", "r587", "r588", "r589", "r590", "r591", "r598", "r599", "r611", "r618", "r629", "r634", "r780", "r794", "r795", "r796", "r797", "r798", "r799" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails", "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r269", "r270", "r271", "r272", "r331", "r486", "r516", "r533", "r534", "r587", "r588", "r589", "r590", "r591", "r598", "r599", "r611", "r618", "r629", "r634", "r780", "r794", "r795", "r796", "r797", "r798", "r799" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails", "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r196", "r487", "r510", "r511", "r512", "r513", "r514", "r515", "r600", "r619", "r633", "r725", "r776", "r777", "r782", "r805" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r196", "r487", "r510", "r511", "r512", "r513", "r514", "r515", "r600", "r619", "r633", "r725", "r776", "r777", "r782", "r805" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r269", "r270", "r271", "r272", "r324", "r331", "r360", "r361", "r362", "r462", "r486", "r516", "r533", "r534", "r587", "r588", "r589", "r590", "r591", "r598", "r599", "r611", "r618", "r629", "r634", "r637", "r774", "r780", "r795", "r796", "r797", "r798", "r799" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails", "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r269", "r270", "r271", "r272", "r324", "r331", "r360", "r361", "r362", "r462", "r486", "r516", "r533", "r534", "r587", "r588", "r589", "r590", "r591", "r598", "r599", "r611", "r618", "r629", "r634", "r637", "r774", "r780", "r795", "r796", "r797", "r798", "r799" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails", "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r597", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818" ], "lang": { "en-us": { "role": { "label": "Name of Property [Axis]", "terseLabel": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [ "r597", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818" ], "lang": { "en-us": { "role": { "label": "Name of Property [Domain]", "terseLabel": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r147", "r148", "r286", "r309", "r455", "r605", "r606" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails", "http://vcel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "Accounting Standards Update 2014-09" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r12", "r632" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r199", "r200" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable (net of allowance for doubtful accounts of $44 and $47, respectively)" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r80" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedTerseLabel": "Amortization of premiums and discounts on marketable securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Bonuses, Current", "terseLabel": "Bonus-related compensation" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedInsuranceCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Insurance, Current", "terseLabel": "Insurance reimbursement-related liabilities" } } }, "localname": "AccruedInsuranceCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r22", "r67", "r126", "r502", "r524", "r528" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r1", "r8", "r22", "r390", "r393", "r454", "r519", "r520", "r740", "r741", "r742", "r749", "r750", "r751" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Gain (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r111", "r112", "r113", "r114", "r115", "r153", "r154", "r155", "r156", "r165", "r202", "r203", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r265", "r368", "r369", "r370", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r418", "r419", "r421", "r422", "r423", "r424", "r431", "r432", "r436", "r437", "r438", "r439", "r450", "r451", "r452", "r453", "r454", "r489", "r490", "r491", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Restricted stock withheld for employee tax remittance" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r41", "r42", "r334" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash flows from operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r364", "r371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total non-cash stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r127", "r201", "r248" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent": { "auth_ref": [ "r125" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on receivable, classified as other and current.", "label": "Allowance for Credit Loss, Receivable, Other, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulOtherReceivablesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r69", "r304", "r434", "r745" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r5", "r31", "r34" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive shares excluded from the calculation of diluted earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Area of real estate property" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "areaItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r5", "r35" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairments of assets" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r95", "r124", "r146", "r182", "r190", "r194", "r237", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r381", "r383", "r420", "r499", "r555", "r632", "r644", "r778", "r779", "r792" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS", "verboseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r117", "r130", "r146", "r237", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r381", "r383", "r420", "r632", "r778", "r779", "r792" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r46" ], "calculation": { "http://vcel.com/role/FairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Assets, fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r211" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r212" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r208", "r254", "r498" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "terseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r209", "r254", "r493", "r754" ], "calculation": { "http://vcel.com/role/FairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Estimated Fair Value", "verboseLabel": "Debt securities, fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails", "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r120", "r205", "r254" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-Sale, Noncurrent", "terseLabel": "Long-term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails", "http://vcel.com/role/StockBasedCompensationNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails", "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r44", "r45" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails", "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]", "terseLabel": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/BasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r26", "r27", "r28" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Additions to property and equipment included in accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r25", "r119", "r602" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://vcel.com/role/OrganizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://vcel.com/role/FairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Money market funds" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r25", "r78", "r144" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents, and restricted cash at end of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]", "terseLabel": "Reconciliation of amounts within the condensed consolidated balance sheets:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r0", "r78" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInAccountingEstimateByTypeAxis": { "auth_ref": [ "r30", "r160" ], "lang": { "en-us": { "role": { "documentation": "Information by type of change in accounting estimate.", "label": "Change in Accounting Estimate by Type [Axis]", "terseLabel": "Change in Accounting Estimate by Type [Axis]" } } }, "localname": "ChangeInAccountingEstimateByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInAccountingEstimateTypeDomain": { "auth_ref": [ "r30", "r160" ], "lang": { "en-us": { "role": { "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.", "label": "Change in Accounting Estimate, Type [Domain]", "terseLabel": "Change in Accounting Estimate, Type [Domain]" } } }, "localname": "ChangeInAccountingEstimateTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A change from one acceptable accounting method to another based upon a revision in estimated future benefits or obligations.", "label": "Change in Accounting Method Accounted for as Change in Estimate [Member]", "terseLabel": "Change in estimates related to prior periods" } } }, "localname": "ChangeInAccountingMethodAccountedForAsChangeInEstimateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r88", "r639", "r640", "r641", "r642" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "auth_ref": [ "r784", "r787" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r19", "r54", "r500", "r542" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "COMMITMENTS AND CONTINGENCIES (Note 12)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r86", "r267", "r268", "r595", "r775" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r635", "r636", "r637", "r639", "r640", "r641", "r642", "r749", "r750", "r786", "r807", "r809" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common\u00a0Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r59", "r543" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r9", "r59", "r543", "r561", "r809", "r810" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r59", "r501", "r632" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, no par value; shares authorized \u2014 75,000; shares issued and\u00a0outstanding 47,616 and 47,253, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r23", "r132", "r134", "r140", "r494", "r508" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r56", "r106" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in process" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerBasisOfPricingAxis": { "auth_ref": [ "r622", "r782" ], "lang": { "en-us": { "role": { "documentation": "Information by basis of pricing for contract representing right to consideration in exchange for good or service transferred to customer.", "label": "Contract with Customer, Basis of Pricing [Axis]", "terseLabel": "Contract with Customer, Basis of Pricing [Axis]" } } }, "localname": "ContractWithCustomerBasisOfPricingAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerBasisOfPricingDomain": { "auth_ref": [ "r622", "r782" ], "lang": { "en-us": { "role": { "documentation": "Basis of pricing for contract with customer. Includes, but is not limited to, fixed-price and time-and-materials contracts.", "label": "Contract with Customer, Basis of Pricing [Domain]", "terseLabel": "Contract with Customer, Basis of Pricing [Domain]" } } }, "localname": "ContractWithCustomerBasisOfPricingDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerSalesChannelAxis": { "auth_ref": [ "r625", "r782" ], "lang": { "en-us": { "role": { "documentation": "Information by sales channel for delivery of good or service in contract with customer.", "label": "Contract with Customer, Sales Channel [Axis]", "terseLabel": "Contract with Customer, Sales Channel [Axis]" } } }, "localname": "ContractWithCustomerSalesChannelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerSalesChannelDomain": { "auth_ref": [ "r625", "r782" ], "lang": { "en-us": { "role": { "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.", "label": "Contract with Customer, Sales Channel [Domain]", "terseLabel": "Contract with Customer, Sales Channel [Domain]" } } }, "localname": "ContractWithCustomerSalesChannelDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r626", "r628", "r806" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate notes" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNoteSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest).", "label": "Corporate Note Securities [Member]", "terseLabel": "Corporate notes" } } }, "localname": "CorporateNoteSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r71", "r487" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of product sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of product sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r87", "r145", "r282", "r288", "r289", "r290", "r291", "r292", "r293", "r298", "r305", "r306", "r308" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Revolving Credit Agreement" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreement" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate (in percent)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [ "r149", "r283", "r284", "r285", "r286", "r287", "r289", "r294", "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r307", "r435", "r613", "r614", "r615", "r616", "r617", "r747" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r17", "r38", "r39", "r47", "r48", "r50", "r55", "r89", "r90", "r149", "r283", "r284", "r285", "r286", "r287", "r289", "r294", "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r304", "r307", "r435", "r613", "r614", "r615", "r616", "r617", "r747" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r210", "r254", "r258", "r259" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "terseLabel": "Credit Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Schedule of fair value of securities, not including cash" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r49", "r781" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Debt issuance costs, net" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r5", "r36" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r5", "r187" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [ "r321", "r619", "r620", "r621", "r622", "r623", "r624", "r625" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevenueNarrativeDetails", "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r321", "r619", "r620", "r621", "r622", "r623", "r624", "r625" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevenueNarrativeDetails", "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r782" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of disaggregation of revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r332", "r337", "r365", "r366", "r367", "r630" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net loss per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r141", "r157", "r158", "r159", "r160", "r161", "r167", "r169", "r174", "r175", "r176", "r180", "r406", "r407", "r495", "r509", "r608" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "netLabel": "Basic loss per common share (in USD per share)", "terseLabel": "Basic (in USD per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r141", "r157", "r158", "r159", "r160", "r161", "r169", "r174", "r175", "r176", "r180", "r406", "r407", "r495", "r509", "r608" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "netLabel": "Diluted loss per common share (in USD per share)", "terseLabel": "Diluted (in USD per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r166", "r177", "r178", "r179" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/NetLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee-related accruals" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r9", "r113", "r135", "r136", "r137", "r150", "r151", "r152", "r154", "r162", "r164", "r181", "r241", "r247", "r311", "r368", "r369", "r370", "r376", "r377", "r388", "r390", "r391", "r392", "r393", "r395", "r405", "r425", "r426", "r427", "r428", "r429", "r430", "r454", "r519", "r520", "r521", "r531", "r584" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_EscrowDeposit": { "auth_ref": [ "r53", "r596" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.", "label": "Escrow Deposit", "terseLabel": "Escrow deposit amount" } } }, "localname": "EscrowDeposit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [ "r410", "r411", "r414" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Liabilities that are measured at fair value on a recurring basis" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r410", "r411", "r414" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r296", "r325", "r326", "r327", "r328", "r329", "r330", "r411", "r459", "r460", "r461", "r614", "r615", "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r410", "r411", "r412", "r413", "r415" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r296", "r325", "r330", "r411", "r459", "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r296", "r325", "r330", "r411", "r460", "r614", "r615", "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r296", "r325", "r326", "r327", "r328", "r329", "r330", "r411", "r461", "r614", "r615", "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r46", "r93" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of valuation of the company's investments and financial instruments that are measured at fair value on a recurring basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r296", "r325", "r326", "r327", "r328", "r329", "r330", "r459", "r460", "r461", "r614", "r615", "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r409", "r415" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r444", "r446", "r631" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Finance lease expense (less than)" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]", "terseLabel": "Finance Leases" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r442", "r449" ], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 2.0, "parentTag": "vcel_LeaseLiability", "weight": 1.0 }, "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Total leased liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r442" ], "calculation": { "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails": { "order": 2.0, "parentTag": "vcel_LeaseLiabilityNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r791" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Maturity of lease liabilities" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r449" ], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails_2": { "order": 2.0, "parentTag": "vcel_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r449" ], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r449" ], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2027" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r449" ], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r449" ], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r791" ], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r449" ], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 2.0, "parentTag": "vcel_LeaseLiabilityUndiscountedExcessAmount", "weight": 1.0 }, "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails_1": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r441" ], "calculation": { "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails": { "order": 2.0, "parentTag": "vcel_RightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Finance" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "auth_ref": [ "r721" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "terseLabel": "Financing right-of-use lease" } } }, "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r249", "r250", "r251", "r252", "r253", "r255", "r256", "r257", "r307", "r310", "r396", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r507", "r612", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r766", "r767", "r768", "r769" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails", "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Useful Life (in years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r122", "r262" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r84" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "Remainder of 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r84" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r84" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r84" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r260", "r261", "r262", "r263", "r488", "r492" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsNarrativeDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r83", "r492" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Cost" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r32", "r33" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsNarrativeDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r83", "r488" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FixedPriceContractMember": { "auth_ref": [ "r622" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which amount of consideration is fixed.", "label": "Fixed-Price Contract [Member]", "terseLabel": "Contract rate" } } }, "localname": "FixedPriceContractMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture, fixtures and office equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r70", "r146", "r182", "r189", "r193", "r195", "r237", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r420", "r610", "r778" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r264", "r266", "r568" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r266", "r568" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r4" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r4" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r4" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r744" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r4" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other non-current assets and liabilities, net" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r4" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Shareholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r170", "r171", "r172", "r176", "r336" ], "calculation": { "http://vcel.com/role/NetLossPerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Effect of dilutive stock options and restricted stock units (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r49", "r101", "r138", "r186", "r433", "r569", "r643", "r808" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r736" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r128", "r603", "r632" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Total inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventory:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r738" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r737" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r73", "r185" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Investments": { "auth_ref": [ "r497" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Short term investments" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/OrganizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r94", "r102", "r103", "r110", "r204", "r206", "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r791" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Maturity of lease liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r449" ], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails_2": { "order": 1.0, "parentTag": "vcel_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r449" ], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r449" ], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r449" ], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r449" ], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 1.0, "parentTag": "vcel_LeaseLiabilityPaymentsDueYearTwo", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r791" ], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r449" ], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 1.0, "parentTag": "vcel_LeaseLiabilityUndiscountedExcessAmount", "weight": 1.0 }, "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r790" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Term of contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Issuance of letters of credit" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r14", "r146", "r237", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r382", "r383", "r384", "r420", "r541", "r609", "r644", "r778", "r792", "r793" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r63", "r97", "r504", "r632", "r748", "r770", "r788" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r16", "r118", "r146", "r237", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r382", "r383", "r384", "r420", "r632", "r778", "r792", "r793" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:", "verboseLabel": "Current" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-current" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r43", "r373", "r785" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Agreements" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsNarrativeDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r10", "r96", "r803" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-Term Line of Credit", "terseLabel": "Outstanding borrowings" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Line of credit facility, commitment fee (in percent)" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r13" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r17", "r37" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-Term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Marketable Securities [Line Items]", "terseLabel": "Marketable Securities [Line Items]" } } }, "localname": "MarketableSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in marketable security.", "label": "Marketable Securities [Table]", "terseLabel": "Marketable Securities [Table]" } } }, "localname": "MarketableSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r784" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r105", "r108" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Organization" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r143" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r143" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r78", "r79", "r80" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r68", "r80", "r100", "r116", "r131", "r133", "r137", "r146", "r153", "r157", "r158", "r159", "r160", "r163", "r164", "r173", "r182", "r189", "r193", "r195", "r237", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r407", "r420", "r506", "r563", "r582", "r583", "r610", "r643", "r778" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss)", "negatedLabel": "Net loss", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://vcel.com/role/NetLossPerCommonShareDetails", "http://vcel.com/role/OrganizationDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Net Income (Loss) Attributable to Parent [Abstract]" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r74" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r753" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/OrganizationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r182", "r189", "r193", "r195", "r610" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r789" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r442" ], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 1.0, "parentTag": "vcel_LeaseLiability", "weight": 1.0 }, "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total leased liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails", "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r442" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails": { "order": 3.0, "parentTag": "vcel_LeaseLiabilityNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating", "verboseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r442" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails": { "order": 1.0, "parentTag": "vcel_LeaseLiabilityNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r441" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails": { "order": 1.0, "parentTag": "vcel_RightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating", "verboseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/LeasesNarrativeDetails", "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r745" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "terseLabel": "Non-cash lease costs" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r129", "r632" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r123" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r3", "r7", "r92" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized gain (loss) on investment", "verboseLabel": "Unrealized gain (loss) on investments" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r15", "r632" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r18" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r80" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other (expense) income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r142" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Payments on employee\u2019s behalf for taxes related to vesting of restricted stock unit awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r77" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Purchases of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r77" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Expenditures for property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r76" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments to Acquire Short-Term Investments", "negatedTerseLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r2" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Net proceeds from common stock issuance" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r722", "r743" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": { "auth_ref": [ "r24" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds from Sale, Maturity and Collection of Short-Term Investments", "terseLabel": "Sales and maturities of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r723", "r724", "r773" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r724", "r771" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r721", "r735", "r772" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "totalLabel": "Total property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r85", "r121", "r505" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]", "verboseLabel": "Property and equipment, net:" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsNarrativeDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [ "r566", "r567", "r568" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r57", "r372", "r800" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r734", "r746", "r801", "r804" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/OrganizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r25", "r104", "r144" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r734", "r746" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareDetails", "http://vcel.com/role/StockBasedCompensationNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r60", "r91", "r503", "r523", "r528", "r530", "r544", "r632" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/OrganizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r113", "r150", "r151", "r152", "r154", "r162", "r164", "r241", "r247", "r368", "r369", "r370", "r376", "r377", "r388", "r391", "r392", "r395", "r405", "r519", "r521", "r531", "r809" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r183", "r184", "r188", "r191", "r192", "r196", "r197", "r198", "r320", "r321", "r487" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Product sales, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r109", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r322" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueNotFromContractWithCustomerOther": { "auth_ref": [ "r107" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue that is not accounted for under Topic 606, classified as other.", "label": "Revenue Not from Contract with Customer, Other", "terseLabel": "Other revenue", "verboseLabel": "NexoBrid revenue" } } }, "localname": "RevenueNotFromContractWithCustomerOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r139", "r146", "r183", "r184", "r188", "r191", "r192", "r196", "r197", "r198", "r237", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r420", "r496", "r778" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving credit facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r448", "r631" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Right-of-use asset and lease liability recognized" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]", "terseLabel": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SalesChannelDirectlyToConsumerMember": { "auth_ref": [ "r625" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred directly to consumer.", "label": "Sales Channel, Directly to Consumer [Member]", "terseLabel": "Directly to consumer" } } }, "localname": "SalesChannelDirectlyToConsumerMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesChannelThroughIntermediaryMember": { "auth_ref": [ "r625" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred through intermediary.", "label": "Sales Channel, Through Intermediary [Member]", "terseLabel": "Through Intermediary" } } }, "localname": "SalesChannelThroughIntermediaryMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r752" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two class method" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of non-cash stock-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r32", "r33", "r488" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r32", "r33" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of finite-lived intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r11", "r64", "r65", "r66" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsNarrativeDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r51", "r52", "r566", "r567", "r568" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r333", "r335", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of finite-lived intangible assets, future amortization expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r72" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r4" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Restricted stock units granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted-average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r333", "r335", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant-date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails", "http://vcel.com/role/StockBasedCompensationNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Restricted stock withheld for employee tax remittance (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r98", "r99", "r739" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r592", "r593", "r594", "r601" ], "lang": { "en-us": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-Term Investments [Member]", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r447", "r631" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-Term Lease, Cost", "terseLabel": "Short-term lease costs (less than)" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r9", "r20", "r113", "r135", "r136", "r137", "r150", "r151", "r152", "r154", "r162", "r164", "r181", "r241", "r247", "r311", "r368", "r369", "r370", "r376", "r377", "r388", "r390", "r391", "r392", "r393", "r395", "r405", "r425", "r426", "r427", "r428", "r429", "r430", "r454", "r519", "r520", "r521", "r531", "r584" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r150", "r151", "r152", "r181", "r487", "r529", "r532", "r535", "r536", "r537", "r538", "r539", "r540", "r543", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r556", "r557", "r558", "r559", "r560", "r562", "r564", "r565", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r584", "r638" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r150", "r151", "r152", "r181", "r487", "r529", "r532", "r535", "r536", "r537", "r538", "r539", "r540", "r543", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r556", "r557", "r558", "r559", "r560", "r562", "r564", "r565", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r584", "r638" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockAppreciationRightsSARSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.", "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "localname": "StockAppreciationRightsSARSMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r9", "r58", "r59", "r91" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Shares issued under the Employee Stock Purchase Plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r9", "r58", "r59", "r91" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of stock for restricted stock unit vesting (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r9", "r58", "r59", "r91", "r346" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "verboseLabel": "Stock option exercises (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r9", "r58", "r59", "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Shares issued under the Employee Stock Purchase Plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r9", "r20", "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock option exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r59", "r61", "r62", "r82", "r545", "r561", "r585", "r586", "r632", "r644", "r748", "r770", "r788", "r809" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r733" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Selected Balance Sheet Components" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TimeAndMaterialsContractMember": { "auth_ref": [ "r622" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which amount of consideration is based on time and materials consumed.", "label": "Time-and-Materials Contract [Member]", "terseLabel": "Time-and-materials contract" } } }, "localname": "TimeAndMaterialsContractMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r307", "r310", "r396", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r507", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r766", "r767", "r768", "r769" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails", "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r111", "r112", "r113", "r114", "r115", "r153", "r154", "r155", "r156", "r165", "r202", "r203", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r265", "r368", "r369", "r370", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r418", "r419", "r421", "r422", "r423", "r424", "r431", "r432", "r436", "r437", "r438", "r439", "r450", "r451", "r452", "r453", "r454", "r489", "r490", "r491", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfCostGoodOrServiceExtensibleList": { "auth_ref": [ "r783" ], "lang": { "en-us": { "role": { "documentation": "Indicates type of cost from product sold and service rendered.", "label": "Cost, Product and Service [Extensible Enumeration]", "terseLabel": "Cost, Product and Service [Extensible List]" } } }, "localname": "TypeOfCostGoodOrServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_TypeOfRevenueExtensibleList": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.", "label": "Revenue, Product and Service [Extensible Enumeration]", "terseLabel": "Revenue, Product and Service [Extensible List]" } } }, "localname": "TypeOfRevenueExtensibleList", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r607", "r626", "r802" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government agency bonds" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails", "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentDebtSecuritiesMember": { "auth_ref": [ "r802" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by the United States government.", "label": "US Government Debt Securities [Member]", "terseLabel": "U.S. government securities" } } }, "localname": "USGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails", "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r168", "r176" ], "calculation": { "http://vcel.com/role/NetLossPerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted-average common shares outstanding:", "verboseLabel": "Anti-dilutive shares excluded from diluted net loss per common share:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r167", "r176" ], "calculation": { "http://vcel.com/role/NetLossPerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Basic weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "vcel_A25NetworkDriveBurlingtonMassachusettsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "25 Network Drive, Burlington, Massachusetts Member", "label": "25 Network Drive, Burlington, Massachusetts [Member]", "terseLabel": "25 Network Drive, Burlington, Massachusetts" } } }, "localname": "A25NetworkDriveBurlingtonMassachusettsMember", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "vcel_AccruedExpensesOtherCurrent": { "auth_ref": [], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents other accrued expenses, current.", "label": "Accrued Expenses, Other, Current", "terseLabel": "Other accrued expenses" } } }, "localname": "AccruedExpensesOtherCurrent", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_AnnArborMichiganMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ann Arbor, Michigan", "label": "Ann Arbor, Michigan [Member]", "terseLabel": "Ann Arbor Michigan" } } }, "localname": "AnnArborMichiganMember", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "vcel_AssetsAndLiabilitiesLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets And Liabilities, Leases [Table Text Block]", "label": "Assets And Liabilities, Leases [Table Text Block]", "terseLabel": "Schedule of assets and liabilities" } } }, "localname": "AssetsAndLiabilitiesLeasesTableTextBlock", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "vcel_BiopsyKitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Biopsy Kits [Member]", "label": "Biopsy Kits [Member]", "terseLabel": "Biopsy kits" } } }, "localname": "BiopsyKitsMember", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vcel_ComputerEquipmentAndComputerSoftwareIntangibleAssetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and the collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Equipment And Computer Software Intangible Asset [Member]", "terseLabel": "Computer equipment and software" } } }, "localname": "ComputerEquipmentAndComputerSoftwareIntangibleAssetMember", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "domainItemType" }, "vcel_DebtInstrumentCovenantIncreaseOptionLeverageRatioMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Increase Option, Leverage Ratio, Maximum", "label": "Debt Instrument, Covenant, Increase Option, Leverage Ratio, Maximum", "terseLabel": "Increase option for leverage ratio" } } }, "localname": "DebtInstrumentCovenantIncreaseOptionLeverageRatioMaximum", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "pureItemType" }, "vcel_DebtInstrumentCovenantLeverageRatioMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Leverage Ratio, Maximum", "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum", "terseLabel": "Leverage ratio" } } }, "localname": "DebtInstrumentCovenantLeverageRatioMaximum", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "pureItemType" }, "vcel_DebtSecuritiesAvailableForSaleContractualMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-sale, Contractual Maturity Period", "label": "Debt Securities, Available-for-sale, Contractual Maturity Period", "terseLabel": "Remaining contractual maturity period" } } }, "localname": "DebtSecuritiesAvailableForSaleContractualMaturityPeriod", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "durationItemType" }, "vcel_EmployeeStockAndEmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock And Employee Stock Option [Member]", "label": "Employee Stock And Employee Stock Option [Member]", "terseLabel": "Employee stock purchase plan and service-based stock options" } } }, "localname": "EmployeeStockAndEmployeeStockOptionMember", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "vcel_EpicelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Epicel [Member]", "label": "Epicel [Member]", "terseLabel": "Epicel" } } }, "localname": "EpicelMember", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vcel_EscrowDepositPercentContributed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Escrow Deposit, Percent Contributed", "label": "Escrow Deposit, Percent Contributed", "terseLabel": "Percent contributed to escrow account" } } }, "localname": "EscrowDepositPercentContributed", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "vcel_EscrowDepositRemainingPercentToBeContributed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Escrow Deposit, Remaining Percent To Be Contributed", "label": "Escrow Deposit, Remaining Percent To Be Contributed", "terseLabel": "Remaining percent to be contributed to escrow account" } } }, "localname": "EscrowDepositRemainingPercentToBeContributed", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "vcel_FinanceLeaseLiabilityTenantImprovementAllowance": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 1.0, "parentTag": "vcel_LeaseLiabilityTenantImprovementAllowance", "weight": 1.0 }, "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Liability, Tenant Improvement Allowance", "label": "Finance Lease, Liability, Tenant Improvement Allowance", "negatedLabel": "Less: tenant improvement allowances" } } }, "localname": "FinanceLeaseLiabilityTenantImprovementAllowance", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_FinanceLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Liability, to be Paid, After Year Four", "label": "Finance Lease, Liability, to be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "auth_ref": [], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "vcel_ImplantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Implants [Member]", "label": "Implants [Member]", "terseLabel": "MACI implants and kits" } } }, "localname": "ImplantsMember", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vcel_IncreaseDecreaseInLeaseLiabilities": { "auth_ref": [], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Lease Liabilities", "label": "Increase (Decrease) In Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInLeaseLiabilities", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "vcel_LeaseLiability": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 2.0, "parentTag": "vcel_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability", "label": "Lease Liability", "totalLabel": "Total leased liabilities" } } }, "localname": "LeaseLiability", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LeaseLiabilityLiabilityToBePaidYearOne": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails_1": { "order": 2.0, "parentTag": "vcel_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability, Liability, to be Paid, Year One", "label": "Lease Liability, Liability, to be Paid, Year One", "totalLabel": "2024" } } }, "localname": "LeaseLiabilityLiabilityToBePaidYearOne", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LeaseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability Noncurrent", "label": "Lease Liability Noncurrent", "totalLabel": "Total leased liabilities" } } }, "localname": "LeaseLiabilityNoncurrent", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LeaseLiabilityPaymentsDue": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails_2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability Payments Due", "label": "Lease Liability Payments Due", "totalLabel": "Total lease payments" } } }, "localname": "LeaseLiabilityPaymentsDue", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails_1": { "order": 1.0, "parentTag": "vcel_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability Payments Due After Year Four", "label": "Lease Liability Payments Due After Year Four", "totalLabel": "Thereafter" } } }, "localname": "LeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LeaseLiabilityPaymentsDueRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails_1": { "order": 6.0, "parentTag": "vcel_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability, Payments Due, Remainder Of Fiscal Year", "label": "Lease Liability, Payments Due, Remainder Of Fiscal Year", "totalLabel": "Remainder of 2023" } } }, "localname": "LeaseLiabilityPaymentsDueRemainderOfFiscalYear", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LeaseLiabilityPaymentsDueYearFour": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails_1": { "order": 5.0, "parentTag": "vcel_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability Payments Due Year Four", "label": "Lease Liability Payments Due Year Four", "totalLabel": "2027" } } }, "localname": "LeaseLiabilityPaymentsDueYearFour", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LeaseLiabilityPaymentsDueYearThree": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails_1": { "order": 3.0, "parentTag": "vcel_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability Payments Due Year Three", "label": "Lease Liability Payments Due Year Three", "totalLabel": "2026" } } }, "localname": "LeaseLiabilityPaymentsDueYearThree", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails_1": { "order": 4.0, "parentTag": "vcel_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability Payments Due Year Two", "label": "Lease Liability Payments Due Year Two", "totalLabel": "2025" } } }, "localname": "LeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LeaseLiabilityTenantImprovementAllowance": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 1.0, "parentTag": "vcel_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease, Liability, Tenant Improvement Allowance", "label": "Lease, Liability, Tenant Improvement Allowance", "negatedTotalLabel": "Less: tenant improvement allowances" } } }, "localname": "LeaseLiabilityTenantImprovementAllowance", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 3.0, "parentTag": "vcel_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease, Liability, Undiscounted Excess Amount", "label": "Lease, Liability, Undiscounted Excess Amount", "negatedTotalLabel": "Less: interest" } } }, "localname": "LeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LeaseOptionToExtendTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Option To Extend Term", "label": "Lease Option To Extend Term", "terseLabel": "Lease option to extend term" } } }, "localname": "LeaseOptionToExtendTerm", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "vcel_LesseeLeaseCommencementRentPaymentStartDateTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Lease Commencement, Rent Payment Start Date, Term", "label": "Lessee, Lease Commencement, Rent Payment Start Date, Term", "terseLabel": "Rent start date, term" } } }, "localname": "LesseeLeaseCommencementRentPaymentStartDateTerm", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "vcel_LesseeOperatingLeaseAnnualLeaseIncreaseLimitPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Annual Lease Increase Limit, Percentage", "label": "Lessee, Operating Lease, Annual Lease Increase Limit, Percentage", "terseLabel": "Annual lease base rent square subject to increase percentage" } } }, "localname": "LesseeOperatingLeaseAnnualLeaseIncreaseLimitPercentage", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "vcel_LesseeOperatingLeaseAnnualLeasePerSquareFoot": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Annual Lease Per Square Foot", "label": "Lessee, Operating Lease, Annual Lease Per Square Foot", "terseLabel": "Annual lease per square foot" } } }, "localname": "LesseeOperatingLeaseAnnualLeasePerSquareFoot", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "vcel_LesseeOperatingLeaseLiabilityTenantImprovementAllowance": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 2.0, "parentTag": "vcel_LeaseLiabilityTenantImprovementAllowance", "weight": 1.0 }, "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, Tenant Improvement Allowance", "label": "Lessee, Operating Lease, Liability, Tenant Improvement Allowance", "negatedLabel": "Less: tenant improvement allowances" } } }, "localname": "LesseeOperatingLeaseLiabilityTenantImprovementAllowance", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesMaturitiesofleaseliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LesseeOperatingLeaseMonthlyContractualPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Monthly Contractual Payments", "label": "Lessee, Operating Lease, Monthly Contractual Payments", "terseLabel": "Monthly contractual lease payments" } } }, "localname": "LesseeOperatingLeaseMonthlyContractualPayments", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LesseeOperatingLeaseNumberOfRenewalOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number Of Renewal Options", "label": "Lessee, Operating Lease, Number Of Renewal Options", "terseLabel": "Number of renewal options" } } }, "localname": "LesseeOperatingLeaseNumberOfRenewalOptions", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "vcel_LesseeOperatingLeaseTenantImprovementAllowance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Tenant Improvement Allowance", "label": "Lessee, Operating Lease, Tenant Improvement Allowance", "terseLabel": "Tenant improvement allowance" } } }, "localname": "LesseeOperatingLeaseTenantImprovementAllowance", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LesseeOperatingLeaseTenantImprovementAllowancePerSquareFoot": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Tenant Improvement Allowance, Per Square Foot", "label": "Lessee, Operating Lease, Tenant Improvement Allowance, Per Square Foot", "terseLabel": "Tenant improvement allowance per square foot" } } }, "localname": "LesseeOperatingLeaseTenantImprovementAllowancePerSquareFoot", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "perUnitItemType" }, "vcel_LesseeOperatingLeaseTermOfContractInclusiveOfFreeRent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Term of Contract Inclusive Of Free Rent", "label": "Lessee, Operating Lease, Term of Contract Inclusive Of Free Rent", "terseLabel": "Term of contract" } } }, "localname": "LesseeOperatingLeaseTermOfContractInclusiveOfFreeRent", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "vcel_LetterOfCreditCashDeposit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Letter Of Credit Cash Deposit", "label": "Letter Of Credit Cash Deposit", "terseLabel": "Letter of credit cash deposit" } } }, "localname": "LetterOfCreditCashDeposit", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LetterOfCreditCashDepositLeaseYearFour": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Letter Of Credit Cash Deposit Lease Year Four", "label": "Letter Of Credit Cash Deposit Lease Year Four", "terseLabel": "Letter of credit cash deposit lease year six" } } }, "localname": "LetterOfCreditCashDepositLeaseYearFour", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LetterOfCreditCashDepositLeaseYearThree": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Letter Of Credit Cash Deposit Lease Year Three", "label": "Letter Of Credit Cash Deposit Lease Year Three", "terseLabel": "Letter of credit cash deposit lease year three" } } }, "localname": "LetterOfCreditCashDepositLeaseYearThree", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LicenseAgreementAdditionalFunding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Additional Funding", "label": "License Agreement, Additional Funding", "terseLabel": "Additional funding" } } }, "localname": "LicenseAgreementAdditionalFunding", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails", "http://vcel.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LicenseAgreementConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Consideration", "label": "License Agreement, Consideration", "terseLabel": "Consideration payment for license" } } }, "localname": "LicenseAgreementConsideration", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LicenseAgreementContingentConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Contingent Consideration", "label": "License Agreement, Contingent Consideration", "terseLabel": "Contingent consideration" } } }, "localname": "LicenseAgreementContingentConsideration", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LicenseAgreementContingentConsiderationMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Contingent Consideration, Maximum", "label": "License Agreement, Contingent Consideration, Maximum", "terseLabel": "Maximum contingent consideration" } } }, "localname": "LicenseAgreementContingentConsiderationMaximum", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LicenseAgreementInitialMilestoneSales": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Initial Milestone, Sales", "label": "License Agreement, Initial Milestone, Sales", "terseLabel": "Sales threshold for first milestone" } } }, "localname": "LicenseAgreementInitialMilestoneSales", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LicenseAgreementSupplyAgreementRenewalTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement, Supply Agreement Renewal Term", "label": "License Agreement, Supply Agreement Renewal Term", "terseLabel": "Renewal term of supply agreement" } } }, "localname": "LicenseAgreementSupplyAgreementRenewalTerm", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails" ], "xbrltype": "durationItemType" }, "vcel_LicenseAgreementSupplyAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement, Supply Agreement Term", "label": "License Agreement, Supply Agreement Term", "terseLabel": "Term of supply agreement" } } }, "localname": "LicenseAgreementSupplyAgreementTerm", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails" ], "xbrltype": "durationItemType" }, "vcel_LicenseAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement [Text Block]", "label": "License Agreement [Text Block]", "terseLabel": "NexoBrid License and Supply Agreements" } } }, "localname": "LicenseAgreementTextBlock", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreements" ], "xbrltype": "textBlockItemType" }, "vcel_LongtermInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term Investments [Member]", "label": "Long-term Investments [Member]", "terseLabel": "Long-term investments" } } }, "localname": "LongtermInvestmentsMember", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "vcel_MACIImplantsAndKitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MACI Implants And Kits", "label": "MACI Implants And Kits [Member]", "terseLabel": "M A C I Implants and kits" } } }, "localname": "MACIImplantsAndKitsMember", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vcel_MediWoundLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MediWound Ltd [Member]", "label": "MediWound Ltd [Member]", "terseLabel": "MediWound Ltd" } } }, "localname": "MediWoundLtdMember", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails", "http://vcel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "vcel_NexoBridMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NexoBrid", "label": "NexoBrid [Member]", "verboseLabel": "NexoBrid" } } }, "localname": "NexoBridMember", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vcel_NumberOfContractedSpecialtyPharmacies": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Contracted Specialty Pharmacies", "label": "Number of Contracted Specialty Pharmacies", "terseLabel": "Number of specialty pharmacies" } } }, "localname": "NumberOfContractedSpecialtyPharmacies", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/RevenueNarrativeDetails" ], "xbrltype": "integerItemType" }, "vcel_NumberOfProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Products", "label": "Number Of Products", "terseLabel": "Number of commercial-stage products" } } }, "localname": "NumberOfProducts", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/OrganizationDetails" ], "xbrltype": "integerItemType" }, "vcel_OperatingLeaseLiabilityIncrementalBorrowingRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease Liability, Incremental Borrowing Rate", "label": "Operating Lease Liability, Incremental Borrowing Rate", "terseLabel": "Estimated incremental borrowing rate" } } }, "localname": "OperatingLeaseLiabilityIncrementalBorrowingRate", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "pureItemType" }, "vcel_ProviderorFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Provider or Facility [Member]", "label": "Provider or Facility [Member]", "terseLabel": "Provider or Facility" } } }, "localname": "ProviderorFacilityMember", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vcel_RevenueRevenueRecognizedChangeinUncollectibleAnalysisPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue, Revenue Recognized, Change in Uncollectible Analysis, Percentage", "label": "Revenue, Revenue Recognized, Change in Uncollectible Analysis, Percentage", "terseLabel": "Change in estimate of uncollectible (percent)" } } }, "localname": "RevenueRevenueRecognizedChangeinUncollectibleAnalysisPercentage", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/RevenueNarrativeDetails" ], "xbrltype": "percentItemType" }, "vcel_RevenueRevenueRecognizedEffectOf0.5ChangeInTheEstimatedUncollectiblePercentageAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue, Revenue Recognized, Effect Of 0.5% Change In The Estimated Uncollectible Percentage, Amount", "label": "Revenue, Revenue Recognized, Effect Of 0.5% Change In The Estimated Uncollectible Percentage, Amount", "terseLabel": "Change in revenue recognized due to 0.5% change in uncollectible percentage" } } }, "localname": "RevenueRevenueRecognizedEffectOf0.5ChangeInTheEstimatedUncollectiblePercentageAmount", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vcel_RightOfUseAsset": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Right Of Use Asset", "label": "Right Of Use Asset", "totalLabel": "Total leased assets" } } }, "localname": "RightOfUseAsset", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_SecuredOvernightFinancingRateSOFRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "terseLabel": "SOFR" } } }, "localname": "SecuredOvernightFinancingRateSOFRMember", "nsuri": "http://vcel.com/20230630", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org//942-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org//946-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1)(e))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org//320/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(4)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "50", "Subparagraph": "(a)", "Topic": "405", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479719/606-10-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "6B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "6B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//842-20/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(d)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r645": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r646": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r647": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r648": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r649": { "Name": "Form 20-F", "Paragraph": "a", "Publisher": "SEC", "Section": "16", "Subsection": "J", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r651": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r652": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "A", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r653": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "B", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r654": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "C", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r655": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "D", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r656": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "E", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r657": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "ii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r658": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "iii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r659": { "Name": "Form 20-F", "Paragraph": "2", "Publisher": "SEC", "Section": "6", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "ii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r661": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r662": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r663": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "i", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r664": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "ii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r665": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "iii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r666": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "iv", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r667": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "v", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r668": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r669": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "3", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Form 40-F", "Paragraph": "b", "Publisher": "SEC", "Section": "19", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r671": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r672": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r673": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "i", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r674": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "ii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r675": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "iii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r676": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "iv", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r677": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "v", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r678": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r679": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "3", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Form N-CSR", "Paragraph": "b", "Publisher": "SEC", "Section": "18", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r681": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r682": { "Name": "Regulation S-K", "Number": "229", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r683": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r684": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r685": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r686": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "iv", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r687": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "vi", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r688": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "3", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r689": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "4", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r691": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r692": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r693": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "iv", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r694": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "6", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r695": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "6", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r696": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r697": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r698": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "A", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r699": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "B", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "C", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r701": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "D", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r702": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "E", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r703": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r704": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r705": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r706": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r707": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r708": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "A", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r709": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "C", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "D", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r711": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "E", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r712": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "F", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r713": { "Name": "Regulation S-K", "Number": "229", "Publisher": "SEC", "Section": "408", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r714": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "408", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r715": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "A", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r716": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "B", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r717": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "C", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r718": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "D", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r719": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "408", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r726": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r727": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r728": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r729": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r731": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r732": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r733": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org//210/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r775": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r81": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org//940-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 67 0001628280-23-026596-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-026596-xbrl.zip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

4PG+/B]V>&2^XY M+G*2IN%]X$0A"_T \D!%R'MN $GB<9A$'A8DYHARL[96.K/.CTL-?<]=A&=.S-SWDPP1^UU#9[:9F@9&L[I#7GM+LB$Q@.-D=& M-UNNN?DQ7?&;DC\5"]]%F'L\AB()A7*\^##V1 *#1!#FXIA@;-AEZ_RD\XOF MNCM1>7/%=0L]&4#.7>ZXF I($TRD>4L2*%&.823BR ^BF,F]JI52IX, GZ1\ M15^]3O"'DAM4@AL&/6N K_<9L OIR-\ "VC:JX%Z -#8=5"W$\ZC%NH! -KU M4 _O',;ZG_FW[<=%SK:2/]*ZMO-=MDSI:_W?;?6'1* H#@F%(O!BB(1*\2!4 M$I(7DRAQA=QN$Q-",A5@;O3TA=.J0][6MMI5PHR4C!^''D6-"?+(A"5%/PVN M9+%*)S8RGGY3;AH*SSW2#Q[%>"_HS+Q>"\S@)DQ@F'I.6 M+G$XQ'X<0!RZB@#]R/6-CAC[IYL;I]WL'RE6QJVU,LX*X"3BE%(<0>(G'D1( M&K?8\>5^(B(.QMR5>XE0I\S*" !/4&6E*N%O%4^][X ]E$9F_=YBUO)U_-SS M.MJL4-U!9?SBTVJRN=25[BAN4#*Z>Y=Y,4;5>!J7%>>_XZK^0+JJCH/?R5_J MEF3L&V-N--N1%>P("Y2T^A49>W'K)P:;D(U,"0/1,BK+J /%H.*,O0-/5J)1 M1[UNH4:MZ\W6>9&7]W/\B5HJMD@%$:(2N,+ ML\_O-F5?5] MWY[[;E.P%Y2P,!%)!.. JO1'+X3$=0@,B>]%"8XQ3CR3_9_!W'.CGTI0L,I6 MD#9I[/6>L'(==]+6!^P139Z(W@9G))Q'9J=6:O!S*_LDE*P6NZ@_"LN>2LP]+_*"]5SI^ M^]P(2(D)E)S0W6DFTXALL$\Z 9?&%NERI,;>'?6#!/Y0\EKJO',&C6$;I!-C M3KF+1_4_=<3W@I?*\:WV7WFJNK:I?[A>L=U?=*YKM1B9[0&-[3ZJGHOX+ MWG>?RE9V4%^B'M/>+[MWV-NU6$'6TC[F,EDFW=E8@6U_KV-G4/LMG2E=/ZV7 MJA%@-[=PX3!%PI$/F>NKRO.>!XFTD""-41(31BF*2-O/\-Y.(^?CDF@M\-V. MAO?3A-RWTN[T"K;7Q?G$@[GX"/L2G.=QK&V,O=5NS/WP3=!\^80 2K M&HR8."D!UV.X$6$"+E\*25WR9_B0)IRGAN2R(D%"XE6S-"YB>9& M4INRFFDEINEYVPDT=0_7+L=H]).T5D10R[@M1&KSR*P?!VOG8R>FF?@PK%_9 MPY.O,]>;'W-]+?^\R^EM?E_D[XLR?:ILI4^\?,S8-A%"\\Q+9ZRYK?FFN)K< M/W.)&;C_^@5L90>U\/JG8%IHGC\2LPWDR,2@@Z'EKJ^F* TZ-].:8+)#-!-U MNR=J1O<-/%[+GIZR5?4:U-7KZJIVBR#B-%8]"..02T/"(0ABH;)L?=]#R U] M1'T30^+$/'/CE%I,4"@YKYH"FFWES<$E-4]AK.DMOQRYL?W@-6A?:]#:(IBU MF!9]V_TXV/):GYAE6G]TOZH'GN8SEP_I""T_"*M.Y.'7]?/S\G7SUR]\Q;_A MI>I$N0@2/V1)$*D*+"Y$2>S Q!,,NB+@C'K(QTZHPQ2&\\Z-.1K1@(H'5X=O M124YP*WH)HV/]<'OIY 1(1W;95(+#39B2EZI =W\!K2(*]''0=>DO?0H*$_5 M9MH6VH;]IHTQZ^\[K3_$G*9K8+[0*FM_,<",/(C%0C<->/@/'N\HBNEG:4W9$G MW44>46E_YWCLDH&'[.F*WXJZAF5YU+V61"/]566*U/(# MP7GE>WJNM3!T/ID\&#U:& GNT7>4-=)-5ZL/&Z2WH@,I.]@*;_'XW1PQ6T?O M!C-/>^QN#LG!D?N (/*GU(Y=TN8AR%U"4!Q'$20(29#V/F MA9"Z'B))% F7:"7@GYI@;C35R@A:(:MDX^7UBEVSIW25%J6*WWOA;2=J+R9Q*.(8ADRX$ 6$0,QB%W(4X8@*CX>N M42RPWK3S^_Q74E^!AUKN*J$)[TANV&12#WT]-K&/Z>AV0P/G;QTX=X6VWQ[< M#"5;O2'U)IVV%:01$ >='\WN'MP)I/:ZJ1C-/G5?E2'0'.FP,FB88;RWTSGW]KF.=JPZ#^$@1)&#,,21ZO<1 M. (FH4=@XG%!!<*$<&%BAYV<:7:F5Q6@FU42&A+6:33UJ,D*1B.3T%ZG[5K* M$;HUG<7"$J><=&'=(575!IC MUU2:7G4Y/$:#F#DN@T2H_"?JQ3 )0B$W;9$?>\S'$3/:KQG./S?VJ.0T[O]C MA+@>EXR(X\@,TTH.U"H!/[?" Y'EOS1VST8!L-7 :IN@(=#9ZQED-/O4#82& M0'.DF]"@8Q)DC$@_I MEG'>&7EN--0(IU^7>1>G?HJY2/N1R:.1RZ)!JZYG02] MO= IT@>KGF5@":R1%[*F:^,*7)=EGI)UB57]FC(#=SCO2_X8D@5U#BY[F5 G M9YHZ&^J,B0KZDB1A^O5:BV7J?KQCN=?_[Z6#_Q#EI4++)(DBAT/ M,E6 5&&( D1@EXL+K1@1XYGG]O6OY03+JI2WU 4E:C2@LZ,LJ), MP._GGE$A'9F)3A:3:6"N_J:BV$ M/O@P(LPF"5(CP3U5BI15V WSI 9 UY\I M93+@A+E2 _3K?E:^!(&125=/>:, OV.:#@KLVQEHLH"^ M8^)W _F._KMYC9M[3-9+G'],B_)>F=3&A6U.#C"W]=4("I2D5Z"25;]XS6F8 M^I><-81&7G]=<, ?E9AV>QIK 3&H$LWI42\SR4B4J M5Y_BMUE1+HB#/9_["?1P@E0>D =C#Q.Y3?+D!LGU8I\'1L%U!U/,;9%7$L*J M1$2]':)2R +\O)2&"R@?\<(J'I>E\N@&GFUUR@IZ5HC6PEH,13NI/*V MPMX.)Y@VQ.VD@@?A;*>O'+;,U??^5E3M7[;Q!B0A/(D\92-'%"+DNI!03&$4 M$QYRQ&/BNR8+_=@DK!J7FT[WQT$H&O@V[:(YD4?S8E3-G)CZ&/6Z+C6&F6>9&NK6@H!'QJOT!*&'![16*0#_3T MJ),Y1,\JUO6.GK]X<-\G+"7M[SX@$>8+2B('!R2".! !1 E13?<0@<@1#J4T M]"@V\KUHSSPW@I#O46C@].@NZ'D/9A')LK])E M*)JG(&I"8ROG\-QTTR89:BI_D%6H>]\PJMD6B;@5*A*0KXIJ+_V%5XF,RLM= M5(72WTC.8RW7;<], Q1R)'PN^4<5?4A<#(GK89@PQ+DCJ!,)HR2B"^69&U%5 M.5ZPDA5TU3&CIDL?DAYS30C]Z(=B4LH&]49.<)WGJDA2];/=)BV6\;/$?I=* M,RDY6H)NGSMM#3N,6JN MC/GJ+!:6F.CT/)-RS%EU]]GC_ WC.)X^2_ZY_\:7+_Q3MBH?BT7D!;'K. P& ME*I&E8ZTM@3W88)59RF&A>M$-OU/^P+,S:B2;QBRZX8Z@-R.-^H2(.?CE++B MS[X4LHD\4P?3S\I!=0H<4S_5R7$&NJN6R^R;FO!#EK_+UJ04ZV43L5)\X92G M+RHX\NTZ5^E]BR!6F=PXACY3% MU4@ K!$?X$9^0P^6T7/0=&>-A>[8OJU&1K 5\@KLHMU4-U>)J5>@T<"BLVL( M<+8\7T9S3^L&&P++@4]LT" #8['I(V?KI=Q!2E9-2\FG+YS=K$KYLJ5RDKKF MZEXB@0@"$CJ4P,#EN&UL*9!ZV>0]7 QW495I-XN#HBCF!_G4'!IF_KR"S3>[9. MJWK4K]5S^3 F^!O.4\4L7W#)K[^GQ2)@+A$1#2'&.(#(CQ.81#&21A / XYB MGB1&%+ _P=S6?BL?^%)E92@1#2,0#B#46^^7 #/R0C?"Q'B)GU+5HREMT352U=EHN0HHX"3&%-$D$1-Q'J@)8"(5/ M!8J(&P;8*"WMQ#QS6]3-Z MR#[(--!\$GIL8A_?D2^WA>UF=P,-GF+R7TUCK67/+C&O#+5 MS:I(Y97W.;O+EG*]<]5'FU;Y])Q]6.('W0I59P>:V]IL! ;W.6;J ]6*7;4Q MJVJIL[6<#S0JZ%>Q.@]I_R*VCN;H^PLC(,$?2GY+Q:ZT<1I4].K\Z),5O])6 MM%L$2_^F@9L07#Q>KYCZX_W?U^D+7E8]!XXT5 T$CUQ$$RAW';[J-"U@XC,, M'9[#>("!1%5UX;Y9;8LUO2_*] F7 M_,VKJB!4[="]2% 1HPC&JH5)=2I"8EP5]TFBA(0)#;4JG9M,.C=ZJF4&Z0IT MZEJU8@/R6E6.'>8FT7D$FIQE&=BQZ[Y79AM7$.ZX&59-&5[0\]Q?2'*!C54QT)[HFJJ)JC72EBJJSH$M]X*JT8#3E=K M=8B>.U57!PUP009!G9G0AKE[,8H=STE@Z(L((N91U9C9&\KMY T/RH([ J&<77@;.R/Q>O[Y;\_NLJ9UQ*]ZO1"9?CRI,\:G4]3X9##FWQ=V( M#EK9 5M7^YE&?!6JTE'@"EP_*5>@OA_*!.WS[JB1@!Z9*"QC;.2+&H#8()>4 MR3R3>:8&*-]U4 VY?>1"AZ1;"VSC9'&8XX4TC&&($%-5*V(8HY#!(!!!S&). M,38ZM[M,G+E17%UPCYPNN#?0X77A0].S@*9[%".3X-FRAR-XSNR -W7-P^/" MS+/D82]P@RL>]H\ZP+MWM.;0/9>_+&^>GG-)[Q6/MY4[%MSE6$34AYZ'78B0 MYT$>*N3&<4/.S,=.Z&(?TQGY[E ]Z;Y:^?N3J>]%WA>#&,?=^'R/$I3.*$0"Z\B%./^UYH=#S9'7QN?+21S;3: M20>OT,,AD:P-?2^6])U@#F,J#3L41QY-B!LA%B[*K,3+D?':3#$>7O=J#I!: M0$W/=SD4B[&INQ7K2D5ZV"P 4:55GVQEU;NREZN&D12GMTB7X M)#>TZ[QUA.NG%NW"UK\J!X,Q]L' ,!RTE^=1O?O6I;RALR;EW[;K<7>L21;B M4?';%7C\'P<75]MK9EV%730!%W7TQ<*)0QPS$4&.D9"?RPC!)'$]B'% 2!Q@ M%B*AYQ@WF79^#O'+8Z*TX-;]SEJ"<+)J; ?]ZM/5_T_=N_:XK6/IPG^%P !S M=@/%@2[4;>93):GT"=XD54AJ]V#>_<'@32EUNZQJ6ZZ=ZE]_2$FV95N62)I4 M-!]F.CN1R+4>FH\6%]<%-)"V0K=A55:KLREC9*]4V_B44]=M4P:AIXB;^KMF M#/0.+Z77]OL3Y]7GLO'7M.U-?<000AC#/)91ESB,(49<6@1^DL=QGO-$*\+A M\E1S,Q-:24$M*MC):MA&=@!A-:JQ@YMC@C&%3)M4QM&P1"4#$TU*(.,*G]*& MPAO7-"HK\/+3:E.M:]]6;03["<]\+PB@%_M8G!UP!HF/>S_(*V8!=5[>_^ M=?EQTYO:3RNQRS"5C:@_X KOT@PX2[CTY,$ HQ"BG&4P"R,"X]3SN(^C-(QB MO8O:_HGF1@?MK6-'6""E'W(\\;AU+BM!"',C?O\&W_EJRVOF\LL2(P]BO( !GXL@Z43'Q*,J/A3 MD$813W,>*%&"RF1SHX5C667B02MMVV=)/P+Z,LYJ!H,M]!P3A#EP)D'+HXC8 M"TF^/-74 <>C2O>$$X^_HY\?5M^2U6'(3^52O/*M6FFD@O6_/3<>:&X".V** MGW.U7:^TT[LN@#6\]^W@Y'C'FT*DE9TUC()1(M:%(2?+N1I6J9M>-?*D>4'6 MDV**W[@X:1149A@TQ1:/_Z+SY#XW)XW"/**$0!Z&'"(B# 7L\1AZF1]$,<>8 M9ZENL=:KI9H;BO\9J]LGD*^>8UJ2$-SUE8P\Z@.81&=YW\I?=-YSD M:UD%VV+AV>MEFKPHK348^PK6VAO03GW MAS%,"D4\BF(5!!"FE6<1\+T.)I^?T&9IN;K3<^C(:D4$M\TUC MQVQ 1VQ=%] @XJJ.(%LX3N,.,H;0P"VD@LP5SJ'!X2=V$:FH>NXH4GK+H @M M^_MC^_JIHN2@=.PR.6;78"V-.5R!V6*FCFK CCYH="FO"J$L/=!>R M4WW@W=OAD3;O_/9/O&:?BQ7_5/'GS2(B09)F80PC>0Y$?I+"C# ?9CR/_(PF ML9\HI?G8$VEN'%-3RF70#'C-4MKG%4[[I;88.\@=XB M'%(I\(=4"]1Z63S0V0/9TFG.@D"3'N7L 7AZCK,XLF$ SZ['R;NW_1__;\'7 M8J"GM\_\5> JXT[RF">4#K33LWM8F75=\X6@I9(2,,< MHL#/("(^AB3!$>0TBL+$1QG!2B4@M&>>&S7MQ04OC;RRM"&I/?\[D>7?\%I% M@)M>,AK9TEJK,LQ73K%V[9-J\&OEE@[['>RMZ/*L^HZ#CO2N0-9(6'<%]D3I M[#9!UTMX-P%N,!U>:\#IDN5-]#Q*I3<:P,QB_<8K++O3W.&UG&-S2\6/<%O7 MKOO \X(6U2)!E,648)C+*%-$TAAF)!:?AI2$&?C4\[M<]"1$+!& M1#W+5 %E+\;40YX'.?%SV44]A2FG.0S3$.>Y[P=>JEB>SS+.D^8@3H&TFOUO M]U?J^$.Z$Q;LI 6_=9%L!?Z+/?M?'1U+MK_"A)/:_>H G-K\&F_J7_VTR>;U M.5?QNJ?SRMQXMQ5-,93F5/_Q:QM#U1UOYE8J:V?V"YH:W;MTQYGLKJ5'^.[] M2M\_&P;:E<_/1=54Z%TQ:62)#Z*W^G:;5R97&]MU+[QSA!WS! VP=8/ M:#,!S5;@FM;!@9(0/#3F:3C*O6 M-5$4GC;P[7_FE=A ]_G[-6=%)<-26Y=174OZ?SA>?Q2_F@7UA#F2< J#'!.( M8N+!S,]3F+$\\S'C&>*YLE=?;3W=CASRFJ^:%WR@Y?JE7-<_+%E#D+^7%XOKM_2QB7@QQ3A%$64AA&L>KW&7[8;+_7ILDA-3B, AK% M!$,BSGVR*#R&:>XSB-(,,9*D?I0KQ7;U#S^W'=Y(9^QL/L%.;7.;(^+\K*8* MAO9F[M?9TBX^&7S2[=NOV.F^O?"4J?U_RYA8]TW]X;]?/ZS+UT)VK_,QIC[V M?2B^T^(;'2 .,YK(*,TX22*QG7.JY, 9FVANF[@U5%MA.R;J3F!=._\"OJH& M_O6H36/9&P!F8,\/HW&%(7]AX(DM^&'USDWWD>?U[VAD"LLMK;9XN7Q[P 7[ MVZ:GN(QVJ'-CA.,\L%8-(/4 KYO_ )?J&ZE?_VB"/GXEY YOQUQB"+6# M_&$S"(UNEC2GFNRVR0R"[@V4X0CZ'6]JAP5?O^!U]28ON)KF-S&+2(XCF.(X M@BB.?4B2,($X2Y%'4QZ'<:+:_*9O@OGQU$'&^CY5NP-.+XS#=&,#'.>DHHF+ M5D><(>6O:([3.^QD?7*&E.JVS!E\[IIR]">=B7D'(%9S/=@$SC$% M7.Y.WJ38R8^3[:+UX\!8K5X_,-TO*&,_KGQ_/7N%]PPO(L1YB17+K:R/_9W3 M[;JH"KZY^TF76\;91Z&&-%:V55L"=Q5\4(V !H3'WA56191"Q MA,*4^!SRV*.)1[S4][72Z&T)-C=KI*L7."@&=IH!^=,!'=UDH,P^DT2HU]CY M:O4TW"ZYXC7++UA(USW[" %7WB M;+ODLLAYG?WT($W7QS5>;63OA'*U>?=V]"]U!?Z<\Q21/(.,> @B''LP2ZDX M248\]9+N5'EXQ-?#8_L-J*4WBOO6@%@C]ML-U!/%?]N%7"\.7!^XP5APC>&FBP?7 MU_$H)MS@=6,W;%&)*5XY^R1^=*L?A?AJ-!%CM\_ENBK^5?\0[W[*^SK^E?^L M'O_DRU?^I5Q53YM%PM,,YR2#)!)V,J*!K-SB^9#Y012A.$ECIE0YWHXX<_L> MB-\JTG;97K,F%?@.D G4OCJY6-PV=W:\LQ*O8 M!=2>F_@:8:9V(EL KL?%;&-4HZ1),0N_?^$RR'[UHZ;O>M3E6UU5"]>7Y#MO M]X*@)(DB&L$LP(F,N/,ACB(.&6,\\5#@QZFOD3RI,_?FFBZTD*IM$0YH6 +C8&"M+4IUF<0>:% 40\X9#(L"8:(\3R.,4( M:Z5,_6]JQ-2V#]HT[8,V3?N@LE-1XK=BU?[UY6IS^I#[XF/K!S&!:4!2B!!& M$'M9!H/,QBW>=RO%"B7!7T#?[3_ M:S4)1P,J:]_%WYW#W^]_)I^'V.@%,P8-H#H+C MW;\3;/S;/0J#AG?/'(Z)O'>C/PH]AUR_OH,.MY-7IG.H]%)E]:V678WV];V:BR6/U%_%^K %*+21^0 M4P/*8 1+]\"/?(57U:=GN5_K?J&WRV7YIW3_R>#W?V[QFLL^V0O?B[.4QC$, MB>]#E.R;: $4GS?P.C^P$EU2#F] M?<7%4H[]L5Q_QTO>B>/Y@BOYT-M#?=F_X 'C(4$Y1'Z40)0P G&(&(Q(D"1> MY)$,(66#VU"(N9'7H6]O-R#SN949-&$2&O:H?L"RH=9\_K$O!JM7;AU(R[X+Q MA$2)[\.<1APBXC&8Y7$.Q2?*#^*0)"S+5(O:F0HQMX]27=--&(([*<$?C9P: ME>^,UV/X0S05RJZ=W=H :Y70NQ:A*\KL&4\]62F^:\'IENN[>JRKFC[>_OA1 MW:W7=5'0Y\J@Y^/Q '-CH6Z+0R'INFY=#X2\Y8J7VPTXKFW[+"LG&G6(/(%Q MF("L(>B886R"9]HMLA^<:YM%GHSZ*WI%]BMVH57DA8?-G(/'#LE]POJ"QW$6 M\#B$7N*'$/$LD>7TF+!G0B_C:1S@4*N@TH5YYD81G=*=#"Q;*;4OX"^!JN;L MLP"5:RXXO:;8"VG/B3>"@B6?W:59)G71C:AZZI$;>]Q!5=_&J<1DK\./Q8;B MI'$'?Z%'7BYBH:/ @B%.4$>X78#Z%A08F[L MU68.[$34:DXP *0:15T'CV,*TD1&/X7BHO*V,B?.)Y@V8>*B@F=Y$I>?-&QX M>+#B%RG-/!KX"+(@YK(T> *Q[T40XS2)2!IG"%.=(.3.V%J;>;HF!*9'F"YJ M:AO8$ O'._>S @#Z[0W/5;75V[ S\K2-#<]5.NMJV/.(OKNQI[_0WS8/G*__ MNBZW+]J-RQ2'F]NG]F*?K+_)JNSB/VOQU;V/JJB.^R(= .IXBZMAZ: #F294 M1GY*U3DF\UIJ*MWU8>J^:O:]OWM^699OG'_GZ]>"\GJ^=]*?U_50RT!+VE:R M_\9I^6-5_(NSYM+X?;FI-I\/[43B* ^0[T$EJ&J.,KZZ3 MZ:QDLW0NW:_X(B?4]\.

]/G%=MRY0/Q88NR\U6_+)NR::. UU$.$M( M&#/H>UX"$2($8D8I)&GD!QQE*=4K;J\V[=Q,\59J4(N];RS4$1S\L1-=T]!6 M7 8U^]D^N([9W0JNVD:O'DR6;%G%22^:<5+9]Y6WA'5E2E//>@%T=,,!5/8>I[#'H)8X2%<4PRI4+RVC// MC:PZ@H-:BK/.VWC3ETXSCIS:@^@?RUC%OH][WAOZS'>VH'= MLXWFGC2"VV+8]J^*U1X/T+8:E?T1%^N_X>56[&LL[1)YF/ZXYO_<\A7=Y35Y MN9?X".>R!+LGDY\3B&/&8!0%2*9"TR!22G[6F'-N&[PC*=B+JIE;I@.YFH%@ M&4C'3&"(H7[TI#HJML(E%6:<-CY2'8*S@$B-5PT^_LOEW4].Z];?[\5'X4>Y M+OA&KY+[T!ASXPTA*]@+"P[2:E@"0X@IV 66P')M)5S R7*Q>!4TS*R%H8&G MLQT4U#NR)%2>OSH6\JL0O*GCLG?7Y7F4AL3/H"\KJ: \%1:%%T?0SU&"4AJF M.-.R* 9GFQLG" EA*Z)QI&0/IFHF@S6D7-]K'>2\ 0=)G?@[E3"Q'W;9,]>O M"L2\K/9 :.; 2\:^S/66LW?E:KOAF[;VTX*S($0Q09#E"$&$20ZS)$PARICG M)Q[/LDBIUNG@+'/CB%HZN&X=_K1S7M9V2?9 JNQ^O XHUS9#(Q]H!=Q7?+/J M7KR,@#U78L\<4[L-+ZO9XR(<>%C_1"!8Y-MVR7V/1/[M>GW+RA?QD_^XQ#]4 MSP.71YC;KI9??BDJD+)"OQOA!EJQU0\& \"-'POL8.9X@RO !?Z0,ELZ'8R# M8G0V&!AVLI/!N&K=%E]F' \@2B M,/1AFOB"'H(@\T.Q3*U0_XN7@51L.C^/M"QB;<;C:\78D^#!-9C I!XN4^Q$&:&E$U%O";:(P^F^R MMN1&5E8!9>\/[@:T'L7_L!1!KX#/8-C\T/O3QC:2R&M1Z+RO8M,)J-M2[C*^:368'-=>.G3U@!S'!]S' ]%OCC6)AJQ7> MY8FF;7TWJO!9J[OQ-PQSX_%:MH;8R/9",N5R[Y:(XR@,0\D0(;B M/Y.,!E'*E.WH:/E\W.Y ALI\']J9IY? E:-'VS MY9@==B(V3<>DD$Z94V//6^:5+YL$]DS*^8 M8$$QIR3V?/'*UZ14+FQY,H7.[[<[D;N? M\?OVPRY%O &K$KS@-7B5LOY7\[7? +RMGLJUK"\!_OW?TL /_@LDT8WG>?LG MBLUFVU0Z^?=_\V/OO\I.07R4W,1^7+N#Q1^#*+P1AX[-"Y4&YL^J9EYXS8X_? MO_^U%%MT)<\>QRV8VE!G\5-/ HYR2(CLP.?+]%4>A##!R ]Y(#-8M=)7QR:< MF]WP^W]\_P_P8R\RV.SEU=OSHT"K<8!-^!QSPN_?P4%6<-*PS4%2JBHTENAB M=+I)Z4-5^5,Z47[/J.Y254DG1U/P]SW>/'W@+^6FJ(2)0L.$IAGT">40R<3X M+,HSB,(\\N(4Q2E1NF@>GF9N5-((*HUMVE2;ID)6P!IAM0H$7<)5X<;'"EJ. MF:,%ZCX';5EN*2;X8!$HK>))%@";K%Z2"7"ZQ9%&\!BIAW3I[2E+((UH<%+U M:.QIP[Y,ZQ]X5?RK_D6\+U>;BG5]%+('@NR54.#E=]DVKO82[[V/ M+$N3).8YI%'N0Y1X,4S]5/IV?9HE*.$DUHK2MR+5W(BWJU3=%?:@5GVBZRK6 M-!=I50,'W8S#!.VLLYIU./GJ.?X03+5P^KVK; )MJ].5%9FF[8ME$\:S+EI6 M![?1?.];\>.INL]_W_ Z .[VN5Q7K8!MS, B]5!. YI GDA[V*,(DHP$D$>4 MIF%$,^9=T95O7("Y47>=M"F-F+IC'Z"R*.PUK?H4ED"1:AT"ZYI53YO[U=+# M,H="_B8V\Z9MDUY0\(VS+1V\++FR\Y\Z=DY: BI,_PM[!:J#,]Q$4&,<@^H2 M?^(UV[Q?EAO^6'Y9O10R>OU11C5H=_M0&&IN%-6(#&J90;$"C\5S77WMR]>' M3]V:D3>@UD.C!(4"K,-DY0!1Q]RD"B;XHU8!6&_YH0&76<4*A?&G*URAKNQ1 M_0J-UXS\AH*B^#%_W:Y66[RL__AI1==-)>+GHA*?*2H-N1]\$<5^$J0H@AR% MH3@*B_,P2;P $AIQ+TKCT(N5VOE=(ARSVO?^"*WG/_79R MG KCC#,2>3#@&8&(> 2FC!+H^WF>QH21%"57-[SOGWMNMN-.2NE7;PQ(XU:S M.BN@1@:.<'5,%6I][O? NSCB7@&@RQ[W%V;^]GYQ=< MK*6]_/X)KW_PS0+EX@3L93'T8LH@RL(89C1.(<[S,(S",(ZB5*MH6^\T^V8RT]? M63N^4Q2RK1K-[E??9 3?6IR#ZD2#PX=5L +U**.0LR2$"',.,QX%T(M\2C,4 M^$F,C:K)ZT@Q-^;X3I\XDZ7.!&W(=(%])$'UQ.ORCWCU]G\VH%B]\DW5$(R, M.\CW<0;%:E.MM\V_5$]8'(?6'#RW, #QW[F JG%M8U>-HND*\EPZ\IF6\"T\4B M^D:#F;'Q-\$,ZX)6G,G8P 7R<8@"#\/ 1X'L(HM@BG(*4402S,5_>YD6S1X/ M/S?^/$A7!S/KL=D)X%,(T1@3&GE/ PRFFHY=I0G'=NN[PK-F"'^JPRJTC& M2>9"#7$JV>NA6>9$=374/M8.,';,&D?PUMDS4F;0$=I)/+DF4)8^_JJS3FH5 M:$)Q:B[HOF[H?F5_W[8.@8_E^BO_\U#.X6%=KL0?:1M'_K/8+*(,L]SWL*8Q-8SAS) M1H-^3Y#I),T\R&3(.HZ\D@V+R9)_+C;5(O-9G$3"5*-Q+/W-60S3 M-(]@2&,4IA1QK-F]U(94]S[]V]>Y6V^YE'-.N'#D\W-YYN MZK3_UM;+_HN,EQ?":B8B#@.L1J'V8'/,C0UB74E!(RKXK17V+Q83"I50L94^ M.#S9M,F"2HJ?I0:JO:7'(XP7BSMAD%9O'XLE7[=];=\6.$W2 %,&XYRGLN=L M"E/L8X@903Y)_8@SIO-EL=/&'P_Z^--XD&WI$F=T.'GO,J _D R^_\O+V]4<=V/^^?'ZY M?:XTND#VOC^W?2D+"3S"@261XW^GR"FZ?Y:E:JQMD/WSC M]VM.U.$G70TX+%<9(D M-(0X(\*J9PD7!CU)8$(8C2,G6W=5QT//NVU5*]B9[=/_4_I6])MZM/'8D/Q\G\X7M^MV ]&&$F_@!1BA.8X8#!-$B# <\%QM9U9R^-,G<-F\K)V@$!5)2($0% M4E9UT_HBI./VM0V@'.]I(XRT;.TQ$(P,[HN#3F9UCZG5-;U'G[54[>*1KY_O M\_?EJKZK%J?SY793O/+[_..:\V\R9U: M>:H4ORQ5UT[[^-R(OG9(8-7;EZ[>XSX9 Y4=4_"HMEK>E1/]C)PINS$F\YV< M"-UUE9S^DW%[-/Y-F'%MZ#N/2$Y)BJ"?13)RQ0\A(93"!&./1%&*-#NJ'@\_ MM^WTKBX+IGR2NH"9FD?$' G'NZP&X5L=%&>]+TF_TO:ZGG4'G[KE68]B/?W. M^IXRVZF?#HFXBY#$<8)D9Z*$)S*A.8$I8@2R,$LYBS)*$ZUMVAE[;GOT^U.Y MKD E#;Q.*K+>ANU"I[9;#0%QO%4_*0"@O4=[5+6T0;LC3[H[>U0ZW9I]CQC> M+<@.>G*GL^[%T.UZ+5:N]H>^>SL\\H#?Y%_5543O_KDMJK=/ARSZ.C;A\0FO M[E_D$)N_BB&JS:=54X_ZO[F,CN*LO8RJ_U$Z8/:)OXN4_'J9^'":?PP6_%"K!R MN<3KI@USW6_QC8[C[\A)J0T'M5<'$7!2>N.7U&(=5'.X$,=UM5EK M][?L-WK@G??E*U\),MF5:V[8YS-O>.:;I+,O^&?QO'U>X)AE*,DP#) 70L0R M3]CX/((L\@0A^%'$0Z4F25=),3>VV%".GA-:CSX=#>EU^I_=%EZ]6 6JX>W]O/FPY;+**"/XK>[8#Y- D8R MB-.00!0D.&[?(?%+32R4!^^#6,UZ=0&^A],T;Z@M?_X)6,+_XN"UK6 M12X_%RO^J>+/FP6+\B@,,(=!BG*(?!I <5!&,(HI$<9QQBAC.C0T.-OC(&H"..>@*[+1I1PD32UPS/->D!*.D]BFKJ+UD M1B5?>=W0_F%=OA:,LW=OOV\X^[3:1Z3=TJIXK6=<8(2\),\28=[0!*(HQ#"E M-(91F!#/SW,>)UBGPY'ZU%HD,T'[(R%Y4VKOI95=7EDQF, M8!B!T%;R+V69E*(2!MBKG*@2/RY9(*5I*/5Q6VW7O*?Y\4D3HABA-,$A@YSE M 41>*HRH*":01KD\WB34CV*MW$B+PLW-YNJV4,AK[>!2JB?VZTZ_MB/+#GF-MVOU__P*N6*C7/F.?P*9XEKP+%]9FQ%DX:, ?QQ 9V88E'LI0ZQI#Q/"?<0YCJW;*I3#JW_=^5N6Y'=_UY2@E[-:JPC:AC\NB*>P/V M M>X=D6VQR$Z %EB%:4I)^49'1!.F4?K7<-;_^U:G%?DL63%/A8_Y9]VC9%P M&C&/4P\BG#"(//'_4BJ]1#&//4%-69!&6O?\%Z>:&^_L);T!>2MHO4W*/"\H M!_R?V^+E6;GJ@P+4BO?]5@!T?<._$[)&;">F@VS3<31LW>%?GFC:6_M1A<_N MZ>KH.= MDHI'O>S4WKBRV&9/V?Y]$[4T\Q.$"(<1"2-A0*09)"@B,,KSD"*:AQAKM4A1 MF71N'#+:(&.\VYKY BC>_%B&U?6-SO6(FI?]5(#(=C'0H2E_38E0!1 N%@Y5 M>=>4D@2M/95+\<:F2?I;<(R], L(I%E&((KB&.+$YS#&C.:<9CEEF4Y0S_D4 M::I7UPGHK9S__F]IX"?_51]?*L4;DB%(HRC):>Y!GV$!*4&I@)1R2)+8 M\P)!ZD%.%R]U*J58\W4U!;"GT[F#]QW_4:Q6,CZ'X*4,AKT:SS!/8X3R$/JA M[)T890$D*0U@$B=YRH(0HG0W$WF\+)JQ6P"J?JMNP8:U]=WM4 W MX+:JU@79-L&J50D>L-WLS\L@6/MVG4TP\9?JDH+GWZ6+3YI]A=Z7S\]\77_> ML-A)K:>'I2%+"4XA)4$J6)-SF&8!@YF7)XS(CU&DU5VJ=Y:YF;X'(<&+E%)O MB_<#J;;+KX;'\4;O(%,+Z,!/-@B!I6W>/\>D.WU0S=/-/OSP=7&9]T,A0$UX M"1%[GR>!#WW*,XB"V(-BZV,8QV'DQ8A$$=>ZR5>?>F[,H!Z49]C.0GU1%,T& M)U"[/BC;0]DXI%$=,,L!BPH3_Y)P1'5 +@4;:HQP+:6-%MW97*JZTVPN'\4H M9EX(0Q2E,F>8"<;S8QC*$G899YZ?$3/&NU*R.1-B4QV,#%81VQS*B)'S,F+7 MDN:URZ[+J1,NYH24JU(-;C-8#LXE+5O"W#IK7RO7+R)U2W!>YGQ;$]BK$E'P M32?Y>W_GD$4\R*(HAS$-&40LQ)#X-(,DS3$+$Q0$L59ND?K4_<$:!EV$](S <\> M\VG-/C7]F4#3PX%&PY@1X8Y:'\M;^L]ML>:GOQ MVSCX:HQF!\N).CRULDJ;K97VG,KL\94R-)88:GR^23E)6?U3%E)_T9!WUK*& M3/7V('XVJKLO]TA3N?A0CWOXL-HO0"X(TS#/H$3^&".?"_/+""#+/3U&> M)2A-?1VC2V'.N1E:.Y%O0"UT'4Z_%_L&2+'%V48(KFE9J<"OR#UV077,/I_+ MU8_6?GH\HIPQ%/6)1QT76]2C,..TY*,.P1G]:+QJ> +<5?#_M'K95AM92W49 M[)*>DCA)?9+!- J8,'D2#@G#& :8IH'O>R'3NZ@8F&MNA%/+]N__YL?>?P6: MA[4!0!4/9G9@4E"%PD.(UC8NML-3#3M.>H<97/SDP* MK^C1A.Q_?K>JBNKM[IFO?Q2K'W]=EW]63]+=CE=OBQR%41QY%#(94(P($>!BB659!5*&)DGKG10R,JV,D*&F%!*ZT:88Q!.TP6%@%S3!2&6"E3 MA"(2 WE.8H2&&<0?#H0P-NXD9*"HW(X(5!\WZ-MQW+!Z?^E0EV*OZ_LOWY5K M,9EX0C;^7'AQ'##QVX"$D$C6;$ P#;T<1CAC(4T\$OI*-UXFD\^.+C95\2P] M,Z X2 S(3F2-1KQ&2S',)*X!=DPOA^*@M>C=Z[".]& O?MWPUR'8&NTW'((^ M4=<-N^#K]=DP1&^PO8;NF--UU3#4]JB9AND8II5]<]9>9KXO-]7F*Z\6 MB$4!]?P0,A)SB!*:P0S'(?11$B,<>#E5Z^,T,L_OA)+\B8O]#9/G/VU+-EFD>24^RQ+H,^E4SLC.20^#V" :)QG"144 MH572JW^:N9' 3CCP0TJGW\J]!TBUG7\]/(XW_E[ &[ 'J991MO4M-Y:[OE^& MPF(#^)Y))N\%?UG1OK;P T^;;OZF4=<'WOSOI]5Y:N&WP[U_VV4^ OLKOU]TXB^_]I MFV/KNJB2C#.TG;-//] =\7= @S^D"J#5P:*+VQ ]:X2E-_O$3&8$S3G% MF0VC7Q=,QB6QNY^<;JOBE=_7I?+6FX\K[=)@HP/-C;)J@<%>8K 367S6R[): ME:J^%S44AWG).H".66@<.P=5PI0!,BH4-C[Z9+7"E!7ME@M3?\G I7[LAEG$ M.4T92Q.8$(HA8A&%J8\I9$&4YDGD!W$0J-3EZ1E;BR4F*\BSY'5VU_(0X:[A MEST!3\'';0Z)XWU_XCLU!T'#]VP.QD2N9550])S&_6H/^H1/7IG.Y=LOZY%' M]\(C^G?\']I%;;*&'NIB1Q_%WVT6.0D#C_D$$N2)(QGG(4SC.(=>F/MAAIFL MS*YZPW]QEKE9,3M!=UE4C:B@EE7]=O\RJ,-L90TJU\Y:$Y2T[O5'43"ZU;\\ MZF1W^J.*=6_TQQ\V\\Y\YIL-YQ=NA3K)9E^%L?/X)U^^\B_EJGK:+.(TY3CC M/LP83R'"?@*Q%\EJ;33,.*<[I=^O[)PRVP+1$L>&F,Q)G757 O6J<_FZO%L)\;^ON'Y=OFYR/DB M3A(<((9@CJB@P426KB-Y '',"4VC*/*)4O"CSJ1SH[Q&,B!% [\5*_ FMM_F M+[;R6SM@JQ&>;0@=D]M@)NL-Z( [1>KJ.43.\U4[4\XD2?4"3,8H0@+_D%8'-)B##,>$AK&?N)AI6Q\K5GG M1D#=XD)-\FF='6;F5%*&7L'=Y )0QW34UKT3,H..T#=MK1:=;K]70*OAQ'(! M\43N+7M0ZSG ="$;=(TI#S:=TTQ7OR-WFO;+^C>##Z\O)[]WQ9O LQ?G1L3" M& >O&^D$RLOU&[O)#9B>_VU55L&)9W_=]YU36S1(L3+K>,LX]"0)E, MLVV^#_?Y'5[+S@<;L;!-H;FW_@'J5/( QR'%40+%;R2$B,8<9BF.(?=Y&.4! M2BA-= Z,#F6=&[MT)04'48VR_ETNL=HQ=28+Y]J<-%LS[1/M!&A:.@B[E'32 M\_,$D)\>NZ>8TNT]BG1-?Q2[:T$Q";F/?8CRG$+D<0)Q*%,EI4U]B N0<[TFD#M-?E)RB-_$%R7[Z65Z,G()C>B%R M-H[^6?5QS6[7ZT\K]EA42Z4F'.=OS8UJ:J'4CZ$G$(R?062;JL>"W8%B_!,#!:!]!^#(Q.GR=#37;T[%>A>^Z\\(29!7&\G>]^RE+F M?$'\G(0T(C## 8<(,PYQD&20^=3S>111&BN%7@W.,K<->OA^U>&A@#=BZID' M_7BJV0!7H^1X(Y]]X.]&$-+^C@\B8.ECW3_'I%_D035//[O##QNVE.GM7K!@ M),MIR#V8>:R.KA($$% "4>JC) TBC%.M;=\_S=SV?9V*T_9MH=W&($8$< %: M-0:X'C#'%-#;&Z7[7?\J=@#>/-FGAF%H;/4]Z9]DVB8F@XJ>=209?MJ\:6;9 MI*BU]0.)1V+"O!3R0%[X!WX,2ROD;.PI.A)G,6]JO0=19>>.+Z MMH/?BA]/U7W^^Z8)0'['!5WS6TJWS]NE+#AZ^URNJ^)?S>DWC7(:1P&"E+,, MHMR+8$:#' 9IDJ8Y9Q[./=,FA#J"S&UC-WK4A5BE%K#,X7;#&_^C>8-"K:51 MLS&F -PQBYPT+_RV USHLJ41[ZT4"3I9[WB=_- M-N_]=].N$;>,B>7QSO< !GE MS3VF_I#9+M[MF.SBOPZ;^^*PDVSK,:5V&WKT.3.?PVDT]2$M*_=21)(XAQQE M"419CF#*T@"*O\]]C C)PTC'J7!QIKEM[J^\ I_+39W3!7:W_RF7^OQ&%= MWLE]E@LESNIM/_HXX3'#.9%M:U.(_%2V@O)S\2>$(X\SA&.M5-!&UP<8+ "?5AXGL8HQ!1YBD5.AF88VZT<5I;L4W7 MN:+^Y '.<2^!!9 <4X,!/E=4GCQ#P$+=R<.8OZCJY)E2EVM.GC]J9B=\P>M_ M\$H&(1SB#>KL_462AEG(.851$LMC!(XA">,(IG% PA1G* ^1CHUP<::Y;?2# MH$]V9P:5L#HU!8L@0NSS.I%3"J[JD%,/Z"O53J M1[Y^OL_?EZMJC6FU\,7Y(4EX"'TOB\09PD]A%F:Y8 H_PB2-:>8'UR9/'T\Y M-\J0TLER9[25[_K4Z1.(U>C"+G".>>-B>O0.S/=C8%I)A^['QV$"],F$OSSE MN1\ E23G"V_J7TU\*5;%\_:YS0B(*2$RH1(&>>Q#%'KB;!&%$60T)#EB(4:> M4NKSV%4_+1IL!"#D7(.:],5Q-WJR )# M<%_PJET3WA8H G+?@?I?Q7^L> 66\O)(?.*.%M'UNJF9=B[7PC';[T0'K>R@ M$5Z:>(WXH"/_#?C0+L@?.U4L'B)-4;1D#FI//ZEQ: K.J:EH/(YASCY>\LW[ M)[Q:\>6'8LUIM7Q[+(55NMD^\_4N3Y>+CY2?9C! 7-B4W,LAR6,/LB".LC@. M0B]1\E?K3#JW3]5.3EETBK:2:N;PJT"MQF>V 73,8;6XH)57FO,N6T>?\:()Q5 =!Y5S^G[E8VI;W[N:8/ZX(JE^,Z?FMN+''WDZ]I ML>&@EDX]K>X$BV$6N X&QWN]%@PHXJ"56=>OLE%FW"TJ>&EEUU D:%W'46 M1HUG','MF'JL(FVQH=A%S)SW%3N?>2;MQ2Y"HMYE[/(0ABZ-71S???X>;YX^ M+LL_-WM_(8J\)(W\%$9!2B'B.8=I$E/HT3 -XMRG7"\N9VBRN1'8(>Y4W@_+ M>GJUN"J^0GV@%1T9EN!S[< P1T[?;:$ B2UWQ=!4T[HI%)0^[Q^^:QZ%C MP'#F>9CG(0RPS(L(*(59Z'DPQ^*\R4)$? &8UFV:.603W975\ET%FN+)T1@( MU^?%QCAS08G].MLZ&AX//NV!L%>QLV-@_U.&'M?'YQ]?5B^%[&6GW;3OX@"S MX[#:"_E8/,O(N"]?'SYU>O=I>F5[\5)TT%X+U22^VGZ4+&WL&'#6T62M=;>;@2JR%-L[G-YSR3HO\VW]0+.44AD*:,TDX9[!M,D#V"4X0S3&(6,I7H5V=4FGAM[ M[.0&?PK!P4[R&U#++IT K?2&2<_*ZZ%&*BY0=LPR]@ V* FOAY:U2O&*TTY< M0%X/C/.Z\IKOFQ'8KA' G_[4!A#_A90[R<@TJ_)-OP,YPJDH@:]7+O5G?I(M3:4'E/VSJ M%@[;55$!+&U<3;O*>(G5.-+ILDW6<[UIAR-$!QW9;\!( QU[W'DMBI:XU%B, M2;GU6K!.N?;J\0QS6 \GI4,BBT_3,.<)],,,0^1%3!PJ40HSE 51&L5I1+2J M9/7,,3>3\+/I@;$//S7.NA(5QW34DUL)ICTS3)M1>EG%LQ32@4?- M]O577LE[LX=U^5HPSMZ]_;Z1!\]]]?A;6A6O]832R"M66_%W;0IKN3K\E'.Q MY1'W4Y@&LAI61!E,8Y9!CT1QE'/.::A5A=^.6'-CCT--?KR77S,WRM)ZJ5'/ M]*O@F*UD>D(CZ89#Y,*<1@BC, TB2A,$@XS'W$H(3%BZJLL)+V^2L M11'X>"N,R#&'B\3#+4)3FN=XY MY(8)YUH\'--) M+1FXS\&^\^052+"V6G)SP>H*D:-99H&,,HL.J=YPI'RB)CXO#KV:_'K?F83: MAJ3=$=?@,V9VUS=>86'"L5V7CK;$#0HIPAGV((DY$K0D6"K-Q,$N#Y#'HC@- M CW[JG^:N=E1W?:O'WA>T$*SSNT%--6LI.LQ%8D#*">.I[D$9!"!$1S)&E*(,XR@.>\2S#>BXA9Y+.C8%V MBLJPK56Y@K4WO [:@J0VH&A'3+M73,E".Q7C?@KEDY MUIPJ\4LA;&2IUXUL.[X53S?=!8"38Z7S%;"5^NQ,SFGSIEW#?99T[7Q"@[1& M]O?'\FNY>N#E5U[*Z3^N]%,;AP:9&Y4+8;>;VKL@PW&%U/#A[AY\%?_7!1]\ M+,MJ558Z&8^#4 Z3L%44'9.H)H NDB%5D#)+B!P<>;JD2!4%CQ(CE5XP3X[D M-2$]E^NJ^%=+2=(5)S^)TD?WL.;/Q?9Y\VDEP]MKS]W""Q+F>2B%41X*6]-G M$<0!]X3!28(L)!A[>;C+'GC42Z'4ET9I^QPG$#Q.P44=':1I^=)*7IL?;*>2 MS#%X/O0ZVNR[[.@G7QJLHYKUZ'!9IDO=K!4 OW55^(M:(VDQ_=- B,FS0\V!ZDL>O6*TZ],#5NR[/$_*A 3!/'?_W!;5VR).0Q3& M-(0TY!@BA@6))CR'49(1DL?,CU*L$X,V-N%,+RDZT?)R!];=$5JYVZ0KP&OY MS;,+>N%7XSZ;H#IFN<\G2-X-HW95WL$0% Z2$'JG^V49"4/*#Z4G#+YG:+^] MXF(I+0>9Y(27_ ,GU:%37TMWO#Y2UMFG"YRG+(YB"GT<,8ABPF'JASZ,4)#Q M@)(\"G.MJA>: LSNQ+B3$$@1-8TN7? 5S2V'D#JF("EJIU_G#=CK O-R#:4V MM;=-!7)]X\H0-UMFE>[TTQI4AN"& M+(08^[()&V*01!F%C,0D2 G/DT2K"''O+',CC%HH\%NQ K]__U WEZS])G_1 M,P?Z ?4XBU@>!I"$$1?6%4<"VE1&DS :L(SX218L5KQR#>?>95]- F9OFTY' M$*M97%?_$AVS[CXD30C8,&Y3IXS:,[D&(;!DNH M!?MIV#.)4\:C5'RHF!=#E&(?9B0.8.9YU,<>2Q#A>F7+!^?3^8E/4\6\%A"6 M.=QNN-G!:Q#?W(\BRGT* X(RB$C 81IA"G-/MAEBOD!9*_+7&KJ3G&MWPMI$ M5/%(:PLGUT?;G9R[7,W][]%BZ+X6*+9.NX-S37OJ55'[[/2K])(9)4O/VJ?5 MIEK7N2!U:.*")SG.?!Q!ED08HM@3',P]"N,XY#%):9#26(N:8&SUTHW,_ M[YU?M:/Y(/FFC=W4S/CN@UB-.:X$SC%?G&'V:(29-G4,H&*),/IFF)0F!E0\ M)8>A1TT[>)7T'Y\VFRUG'[9K03M-P.C?\'++]V&G\ID'\4MZ$HST('X6B\#W MB9<$"8Q#S(1UP1)9*P+!*!"3^%'F\52K$)F1%+.CE;IO/"AJ-7^R:P8SCG.5WE\Y6;DL:+?D:(BQEX1)!GW&"41!D,$T M9!S&G*"0T"3SHT2S#\B%J>;&@0=)P4Y4XYZ' P"K49H=V!SSEB%B)G&B(V#8 MBP6]--'4\9XC"O?$=(Z]H7_[V,1D229JLG0$23W7)7<^%'G.UUSH8I!"HS?J MW%BBD1[LQ0<'^<%!@1N#I!I-M,Q9WD71?YV:'4AFP>) M0>_SC\6&XN7_<+Q>Y(A%B/OB*$.H.,IXJ0]3GU-($2;(B].4AUI=RLQ%F1N/ M[(64+E'YFS,I#6JT)FJGGVF0=LQ"NX*B9]=5>TUN9%8QX> !%^P&'"U*HQ&0 M*MFN.'H-K%:+D1H)\@OJE%X#6'\)TZM&-./1IB@S/YZP;1OYO<)5715$SE?7 M;L;+AW)3R*_FW<]*?$ +LA1O;:H%PVD8,)G@G) $HABE$'M^"AE*XB"-*8MR MK809.V+-C5];K7HV?*O:#=@KU^SV5CVPTP_\<= 02!4U'5"6EEN-KJ=?1,?4 M;7G][E;;Y[:Y@T6OF%W4+3&[):$F97F[0)XRON71]0_'CVMVNUY_V#8_0-4C M\?%;]96B\@?FF-L6;<0$K9SBRRG_JUP#*:O:5AT"='C/6H+) MM9O*!"'ES:N P< N%F\WNUC\X;"+A\:<9#LK*+7;URJ/&A21DRV+'Y]_?%F] M%.]7&[9F'Y?XAW+UN-ZWY[9S:RG!8_$LORQ?OCY\DDT'-H4 B#.-&G']2(U_ M;*\'R?6U]P ^X \IK*WB;X-(F%5]ZQ]RNG)O@RH=U7D;?M*@!4)M@M_7%U"/ M96U>R\IGSPL>4C\+LQ 2GGL0!6D*4^)E$/MIPG"0AA%1\FD,33*W/5Z+"Y+9R<^V\E1(V(XIL,&B'!HQV(-'HG6(!JHAX* M)I#I-5,8P6*PJ<*E=Z=KKC B_5&3A;%G30EP[X/HE+P(. \(#5)(\T <3[(H MAC@D2/R_R.=9YG/?4^K_.3B+%@5.W16F4W=-=W/W :I*@%?"- D#[F54J2*B M@9$N UZ)U:04J(69 0,.8#%.@7TO3\R! _*?D^#0PX:9(]N7EV7M+^Y%3VIFD%![7D=9A-N1HL#GO].JC=1;E"US'5=L4^ ;\TA/]/*QWA===+C12G7P7'=#G22?ZP/@?-;L!!-W!0 MSDG"BEV\W?:AUQ5J#CWJ#8%4[%]O.KIAV^DG>7/[:77(X+D3DS_CBC^* 3^4 M,A1L$:38QW%(8!2'P@;UDA@2+\E@Y$-QFL0HI;E: M<<&A2>9&.SLYP4%0T$BJ'L5P$=!A4K$%DV,2,4!(*XIA# *C,(:+@TX6QS"F M5C>08?19\TB&AS5GU?IY913(%M:P4@ MQWOV,C9.(AAZ8;@J@.%XQ,GC%WH5Z@M?Z'_0T&V-E^(H(K[]*[Y\?%J7VQ]/ MGU9RW3@K\/JM;?6=,I8E>< A(4$"49Z&D& OA*E8Y#PC$?&34,M?K3+KW/9^ M*RCH2JKIFU8"6]$I;1M"U]YH*2]H!1;'@!XP'31>UT+)EO]9:-DTF>*R_%;4;Y(,X=.CE%)R\/#OF.(@'I'RZ:06GV(S;"E?#XI@-^I(, ME%$R2#:X@,05.0>G(TZ<>G!!H?,,A$L/FID+GU9T+>_//_#F?_?^@LT#?JNK M>R:$<$H9@AFF 41>R&!*$PJSQ..QS\,@#@,=4V%TQKEM]IUXX*613\]$& =8 MS3RP"IMC,MC)"G[;2?N7COMP QY&@-2V"I3!L601C,\WJ36@K/ZI):#^HN&] M1=T7HJY,V%0/O=U63^5:MCM;Y D)T] C$"4)DY4WB*"4&,ER@CX)&"<\U^I( M-C#7W!CE?=LN0\IZT_3(V "\%[?NH-'\K6;KC"&\%>\F[*#H^DJB ?![ V!; MF/8@J<5;B'$X;%T^#,PT[9W#N,IG5PT*K]AIUGKHFWC<17$1A!G&B",8<%GF MW2,13!.*(?=Y$A.:<"_2*O.N.O'>'$:X20EL5Z+$Q>@3]/MI"X4O^ET<C( MNKXI&F^(ZZX![A@^CAK?7ISVES:\'0-CK-'MZ/NF1]97OA++^O8-__E%4-VZ MP,O-P@N(%_NQ.)S6YF2. T%$>01)FC+*<9A3KO4!Z)UE;FPO9 //.^%TSZ5] M**J>1:_$QOGYLY7O!DB$]B+>R(:7F\M &9P[!X"P=M;LFV/B\^6 FN=GRJ&' M#0N3B:]I;QS[/8,SDY1<*0IABFL.L(5 MD"T>GUNE@/CO@Z4#Q)$,@[U>@&#E>K-N%EJ-S7[9\CEFP<,!X*;M\0WPBH'N M@NZT W4TSF[=Y%-=#>L.E1OPAU02U%K:K%#F GU;A4OI]GF[E ?CV@3X74B!E])!\5=1)U@L] M#E% ,22Q..(&09IPWV/"C-1*;;$BU=P^";6LX" LD-)J$KV=Y3([!#M?A%]_ M0KX!';5 [X+= %+K!H1R[@[45V'MZ+1M)M,O/8I?!>/8.?VZP0W#U)[*=26O MLIM$FKJD<1LN%?@A8T'@09RD@H,1QC!#400YSRF)PA@1JM6=_O)4;!0-6T%FER>:-K)L5.&S<++Q M-PSJT'SCKWRUY?O_H>6/E22A)JVE6/V^HN52%AJ0U6]W#24>N/A]K2K\@R]P MDBK 5T[1S3E0RRA,9192%;8QIZ--C?M^WG]+&4DZ]H ML>1?>?5)3/O,/PO;_+'LRTW?=PXYY*;O:T%@%".*,@PC0I PKGT"<8!CF 5) M3A%B,2.1EH/#@9!S^UQV=)1E,-<[+<&*5V IC];B;^6?J:PVD2_+/S= _CI! MN>_J8UP"Q,F/0-%M\HN7UO'W]V15]PH"63>D41'\)I7\B_SG@4(BA]Y-!WW= MM+AUN""V7"TN1)S6\^(0Y#-'C,NYS#XZWWCM^7G Z^JM3B26S-4M)H0X3C(> M4)A%0091&!"8I;D'@RP3OX8;8+DVR2[@9-&OJXJ&6=V!H8&G*S^@H-Y1%0*5 MY\VL"6&W"$NE>GL0RUS=KIAL]OTBAQ=_[O8\^U;\>*KN*IC?XBMT^E^NJ^%?C?XH3%NCT;QNU*JQE OW[UIJ')G9XW MH-;TI@[8VBM;_]=1 M@<\$EN4 -/8-S M0F)J5I\--:4Q>4.7$A+STE'G1.5D _;-B+/?%]^;T&^R6 M4SLJV/_99F#U*!17E50['G'RDFJ]"O655.M_T*@?DO@N\;W#];C9R",77[+J MT_/+NGRMCTUB(Y1_RH_;(O'D;1J.(0\"&4F,.<0^#B -$\_WTR3U D_M<'*- M&/,\<_PGJ&J)07$0&>"=S'K-EDS6_LG1NN@VB;H*T)$>4F9C3]EBZBKM3SI073>6OHUTOZTV ME3BIB]GDO>$K7[])V^OVN5(]SEP>86['FB-#71P#MZJMY4: &KBP?L.Q/N0_OR'*QR0.2PACE"40Q MC\0>#S!,4!S@T,]XP)1ZBUN6:V[L4*L%:%>O.OI2,Z+2UJJI<4:\S/>\-/0B MP[[GY[-I<>X$_<_%KS@R[N/= Z:2W\T>1,X=;,=]O'?" B$MD.("(:]-^(S; MH5\'XR]JBZX'YS4=TB_#H]$IO6>07]4Q_;(^ YW3!UXRS/$7/YC:XW6?-[1^ MNV(]9'\(+<>89#SR(41F_^N=F[>_&E+=5K M;YD&G.LNC)JIZQ!NQSQN!6G]T@)F>-FJ-Z Y^[1%",R@.:M,8#B,(=W1)\ZV M2WZ?WSV_+,LWSK_S]6LAV[D+:_6=H%K6=X.0?T,^W&2P4WX.ZGU% 6,%PQ\!Z_%%53XN:F=9:#/VJ]='G5R2] D7U_];JZYNAZ2=\Y M7%)] G<)N2V:=R+CM!\#ES"??3*<3F98_;83+[NWUA=1@@,OS%(8,IF(R9"P MEOTPA"R(PIB&"<5AJE7%MF^6N1'[H_1Y@"6O:6!Y*#:I666V%U UGKT:)L<\ M>13YWPDIL5BQ=0@!6Y57>^>8MH+JD)IGE5 ''S;>]D4E1GN5&=^56..ZRDA3 M:;43#-]^]^HCNT"?+[PDBE'L^Y"G#,GKI!RF:>Y#+^5!@%"<$:I+#"9RS(TZ MQ&\LUJ8)HP50)A+7L+JG&J$!K%4 !QUV&492-R GD8^Q!%7B#. M@&$*$Q)E/F+<3V*MXD;]T\R-V*1PL%C!ET8\PS8@QTBJ4=CU^#AFJ$XC$"FB M+,_6"NFN%4@O%K9[@1Q/\FN:@?0J>K$;2/_3^I&OGU:;0CQYR%C_K)$B=/GE M6?UH:R$O5$+X;#M7:!P3HXC.@6$GB^@<5ZT;T:GPM-G7ZE&\)MT#=17!NY^5 M]#V+K^3G8E,MDAQG0"/@^Q "J_IB1V"7.W;9@E(QURAC.'=:OM4*XL>4 60 M+'WYAF::]/.GH/+I-U#E%3UF8;Q8W*VJHGK[QG\4\O9J57T5/Y-%@CF->$@@ MSTDBZ"3',"/8AS1'24AIGJ9(Z0K]T@1SXY!&1G 0$D@IU;CB(HC#!&$#&L>L MH(F*\K8?4WW 4!"O-MM<_.&PNR\..,F6'E-GMX]'G].W8K]4ZZ4LF;^YSQ_7 M3-@:C_QG]4X(]0_5_*W+(\QMC^Z: ():W#HP^-RR5<_H&H!N_ !@!S7'VU<) M,/"'%!W4LELZ"8R#8W02&!AVLI/ N&K=DX#"T^9E+;[PZJEDVOO]PNMSV^Q' M12X:637JSER :'Q?6T#'\:;N <;!%A[!X:K2'Z=C3E[\XX)2?>4_+CUJZFZF MZYIT\?)]^?QB%N(\@R:,$,IPD M-,E13#RMIE;7BS0WYKC+5#+[<5&+M0/G25 :61ULQH5"POE5J M_G&[*JH-^*U8@4T-@&*[&HLKJ^HJGW*]G'LH]\J 1AO0J'.6Y?5AMY2'U1T) MY++JDK>%N37W_=4"3>SJMP7@^;6 M9$G"Z[XLUQ@V38LRRADN8$U1A(SO*"HZ_+J!BJJ0K M*S!9"*8P3M*JK>5=S4:-ND'==^;&1(<*GZ<%/F^T"P<=8:-P #6$Q?6I\R(B M5JL"]6EO=M;L#C3= ;-'_*-39=^_F]D=,BC\/I==EW?=&ZB?QS%-4L@"/X8H MCE*81A3! +$T\E$4I2S1L2G.9IC;+I4"RH/ 2WMEN9&BZAD0YRBJ&0=78>-X MJ^Y@J:5ST,GXHNZ6/M;GXT_Z(;ZHWNE']O*#^G>P']K$^";AXV[%/N"*+\2Q M(/.Q[\'7/SI0&5GG2A-,9K7KJ-NUYK7>TZ>2YL;XEC77%O5W3)$XSM^<&TWL9-/X MNE^ 9'SC7X>&XVW>%Y"A!H[6CKZ,@='^[1ENLMUZ697NWAQX2G\G/G"^_NNZ MW+Y\VFRV8G=\7&E_RP>&F-O>E**"6E;0"GL#/I9EM2IUMNH09N-[UA);& D)*4(L)=G)JU!^\ ./POK<$ MCFM'^ Z7FSTPXSXV980TZC)>C]1$U1A[$+-4>W$8@L&*BQ=>G:[.XK#L1]45 M1QXUNS]HLTB^EM5'(=C[X$.4 MD P2[C/QIX3Y/DNR.-$J J$X[]SHL"E6O6Z$U[MC4$8ZPHC$#$$O2JGXR"0! MS/PH@![R>$ ]1BD3/P@N?@F_$.ON_.[0_LI_EN_6!7,+N-I5CP,0'7^B6HF! M$!E(U@$[H<&?0FJP$_L&U(+;NQC21,K2=9'JK)->(FE"<7JUI/NZ:=+?>RY' M7GY:,?[S_^-O"R]EB(0A@EGL8T%!V(-I+K@_Y'E VOR/X['7'B]+\+"IWG_UUZ M\.J^ P,M$I$?AG'JB=V,PQPBGE%(PIC"(,:I^&ON49+M&HD^&K4AL-H^]'&" MK@2V>XC:;!KZO[!+J+.>H"Z:@/XO[OKY2WI\6FWJ.<,NGE>U[73:IW-G%;8U M8CGK+R';1O,N6)B&-$\HS+DX/2(4RA,[C6'N$6'>Y7E(::!S8E>;=FZ675/@ M=56N(,6;IR;)JRWD3;M7Z[P17^^$J;@2:@=,^_@Z)GK5"MKV3I9Z$%DZ6"I. M.NFY4@^(TV.EYMOZ%Z5?R]6W[9+['HE\F>V^?EY5[.,2_U"])KTXP-SH10@* MI:1 B@K]H_M[F?%?K"3.ZM>EEY$;ORRU IICSE##"_PAQ;9T73H*B]%EZ>51 M)[LJ_7_575F/V[B6?I]?P<=NH A0$K5P'@:HSG)1F"152-+3&/2#P3717)== MU[+3R?WU0\J2=TLD32EJH-&I"$G4P%JA M,T5!,,CX1UR"8_O\SB[^JU)W;<3G2N2=]Y/ZO=JJ_QF-$:9E&D&!144XB*/(8N3!":Y5%$:94@F3LW6.^::FN)J MH/KWRCGETMJP"<'0\#;-8=^<&BA<*JBAMK47J-)/"=QSK4(V1HI17@6<^)DI73--C7E8L"" M&BUXK[7[9M53&,Z#7TO+)11K0]LN>\(.D 9.97$B)91]TCG7N!:*C=AG-HK5 M3;XYI@\+4=>K=THO;6Z:VIJW+]M_+G^_J\5;]($7[H4TTCL3LU=^*X6VI@*5 M[;_*P U)I.U((^>/G@APGCIZ>H'?RUDO5_KER\I$M#6M?>O WKJ9[_XE4I \ MBG+&($UX#C&5^J<8,8ABIM_>68IY9-5LPVG6J2WK>;/;._RNJ? MU?U"_*[%6:UIN3#[D7M6U7D&,XEI4A0\@P0K G$J,:282RNLDG^:#D)F3L7JNK;:BK$*716G3^=K,P%ND,19K,J."0%81I7:*X MUB4(0T8RRA0M8B2%M4>W=[JI*9,]0*"V"%WBWGO)[=8>X2D;6'TT6,$.[!TX M(/#M 2Z9 R$)'*L5(&;"'7,$+#EISLUH'>4$7,";"4Z3@:PONNFQ/UKB:%O MOO/YINX[6U52_R<^T^^S5.!$DEQ A6/CJRYB2%!4P"0CBJ X-9D"'DG\+ABF MIIF?#HL&WX&%= S6\WD,EL;>L.0.;0(VN\S.Q/.=#* 5 F@I@F>B^U 8-BO= M"<'/R%#WH>A*MKK74"$JK+Y:?I+SNIE%X^4)4&GU^IA34V0]A4+-G^GB!VC% M:3UAM]1?[2"\_PA]**X'UFN>-(]2G;6?P$!56CLF^HG56OO%[Z[::G%_@*VQ M48U:"6Y_JDK1-%%_3[^7SYOG68:I3+)801EQ!+$R)>883:"B2"$L,R93^\AG MM[FGIM$:6(#O4)L?][!OV 'V/ 2/_70X:L??7.^Q@R/P=Z"!/QS3-VR\PS'^ M\W;A_LS?MBFWX\YIA]XSY,_;KMO)VKEWMQS";R/_;KGXHM7I\VO)UI_U$/?? MRVJ62H;27$B(3'T6G"<8%JDH(!9Z!GF=IRK%&" MYQIF[91TC(>^0J;=:_9VB@9>K%MVM@AK!]D0'?2Z60CTJKTRR:@OVVY!3U^W M/5=[]LFDU=?[A3#_O/G7IOQ&YR8%H+8,<\$Y42*"Q*1%8$8D9#01,*.9C+,B MR2)B=>32/]74=("!6(?IU#\<@/4RNSLHMM,*88@;^@#8ES/W!IN]=(3JM'E] MHG%;;O8*?-9[L_\.KU*J527EXTN]S5]\J3-".\I-%G5!Y!Q!)J(Q_LC*6Z^*K< MXPYB69XP?I.1Z<_CS[(W[P!=@Q;U-EMW<-OS,DO#FJ$GN5F M/UU45W"M3/S"V^7J,_UN JZ^+NPDL_E>EV7^OFE7("J)N%7-_WF]13MU-U@#V4B-::W\H$_#I^/%A,< MR D>V;S\$KBFTBV\!M*77A!&59^WD'2J36\:R],S7X4N!"Q.-IRUTFU4VA!J!IZ MTWZ!I0'\![U4A/+67YUG7)=]G[AG?OO>&SP.!]]+4?ZQW"S$N[5HVP)'N4H+ M;4JQ+,/&<2]AH;=WL!")*F@4)SBR;PM\/O[4=, .(= 0'8Z:+C!G<7)W&Q]# MNPD/J?"I6WN!$XD8S9$CMW.RZPQTGH5=N&V\\Z[KF(_.M#HN\SRW M6ND1UV\IK]L3O5X^TW(QXTPDB*,(1BA-M.Z*)*0R22&12#(F"4F84\V92Y-, M38%M,8(6)/AS"]/5W7F)3LLSJ!M)&OK(R94?]^.E#@)"G29=FF+YG;;B4T$*U#&S0.C(Z2 MJ=M)6* DWC,NVY_K%1$PZD]Y':SIP?*!#(9+]=!&-,N;86(-(Y(!J/4-%9D.(&$8PF52 H1 MIRA/8J?JG!US34T?[: >1IJZ^J$ZJ+7T1(4A;&A?U(ZK0YA#>*/ZZ0CEC^J8 M:5R/5+_(9SXIBUL\O%)M=Y%/)EKE?B&.?G]\J;/5M]]MB7"$F,JAB"2#.(\9 MI$6<0ID+ICE@*$;W4-$@+M GO>='C?M4/!KSHJ^IW<;75YDVK^.U5 MRUH@ER:-]H_%PA,V"-D#:Y\=SS5(H%&#DX^VP'U\9_;D.KC4!B%Y)$];.++= MG'#.G'7ZYNQ'&\]EYRSAD2?/_6X_:_$/:=K627'_3>\8OL@/&S/FHWI=SC?Z MTVT U>-F7:WIMNHM*1)$L"B@WL:F$&<9A2RJ^W.31&0YDR)Q:@KE./_4W@D- M3O\P3E?^!4HD%W$&F2*F-;K D&2(&B\L%C**D>1TMEZNZ?SG\[]#,3S_?S5B M0+J5 _#E\_.R?29@N9=@O$=EMR,8\ $,_)YND8,&.MAB-_U"F@C; ]QWH)$H MW.;!D[E &PK7V4?=9'A2<[KQ\!W&W8OS5DNZ7,B/DNO]S>K'F^_&J&Z:F)A= M#^7KDF^['_YP]NEX#3ZU-TTC!&BE,)60=W*8-7(;\91_,1W43(H%M]DM3X\.XR2B)$$Y3"F MC$-LD@0*E5"8*IK&BA91%EL%U'5/,S6-5A>F,TA!N8?JDH9^E4^+@Y$@+ U] M#+LCZ "ESZG'=:9<$RO_XHB 8TLX$3Q MA6Q,>B.AP9J6^N(8N:'IC72=-SN]=4 /$_B3Y)N5%(_?Y&IAYM].4"Z^F-#X M3X]O/S9[M8Q*E? ,01XC!;' "I(HD3")8JX(82I)J/4I@>6D4U.8!IF#L69+ MK87].P!A VNV!C'8008[S'7.#/C%P/[5YT#!EE<'*W@ ?D#>PHW9$1['JOGQ5\4?W_OA!EQ9>;Q5H*_:J0577_;'Z;)5DN$>$, M:@TM((ZDA"R+$30U7GF:<(P*U);-LK-]G>:W6BW'I;*&/O35V/Y3&U;Z92$K MQ[ZI;M3;F;#AZ1S)-W5HBM[M;=$[< @>;-&#+?QP=JH7:X%L4[>Y1[5'O6@Y MM4']!O$L[U ;M0^+>UZ/K77E>[G^NA3-[]+4S;JOVJO>5.OR6>N(YN6.,!** M%C&,J(@AQI3!(B$1I"S3%JJ,"A5;V:,AP$S-3MVB-!M(V>"L]"Y^;A0L6"_! MRZK4V\D7J?]Q[:%QTR.STXEC/8B!5>3^&>P% 5M)P$Z4>E]/*["_N)5G@'2' M$,2&*G5Q"Y1Q2V($(.VL=$:(,3U/4;L[7N_C:PAFA-,BAY+'VG0TG?Q(RC&D M<8'R(LF4%$XM1FPGGIHJ;7 [GGS:LFQYT#D =T.?:VXA [.@0 NZKDD+6MB! MPY5\R0IU9FD[[;A'E(YDG)U(NM[OIY5:E]'GY3W_UZ9R;[R]2 MV^;KC8EW-K;$2X.]=N3(%KB;]G)X&G;Z*S##XVBPG3M9&\P-;-#BO@,U\KN: MY3>]+#OK,'?" FDQAXE'U6/NA)QJ,H\1?*H!?9)S:8JP-Y4_[I_7]J5_SN^= MFC%DRIS0Q0_0(MU5H.DYX;$CJEN9A.!HZ"V?)SV.I7FN<^!9A^?"@",6W;DN MSG&%G8[K_*R.W^C<''5]^BKE^IWAO%PNZMY_F4(JQRJ"6.0<8I3'D,51 DG, M5205RE'J5*?BVD136]X-3E #!2U2K\Z*5[FULQA",#;P8O[Z<8ZNB+:B85H3'F*4P$RR F60H)$2;C.*:T0&G"$ZNH MW^-AG1;]&(&]9HYM])?C67!#D]V*=A=^X/5[WRVQ\T(]%C#0LFP&'741'@MR MNN1._NIN(]__15>B>C5?5O+S\OWBI7Q=5OQA(3[H9V5K*W>-,;67JL%D;QAW MLM-O((D!&,CZ#^9(XPYH[.6W4FRTBNHD MTLF$MF')RY3N''@TD]I&O$/3VNIZMX4N9*DM]F]R=<^J^M1PEJJ4$951R'-3 MM9\5.:1,$9BE-"DBI(I<6;EKST:>VGJOP6DSL(%G:3>?$]:]V&^B8?!ML"4# MUHOVJK0=JU3?LUVE^H?]*CT?:91E>56 =AU>O\"GX<_]JX>'9Y-0O*[N%^*_ MRWT7,!3'BF8F?E>O/2QC#HN<(A@AI'].(Z&P5?V<[FFFMB3?@WOP"CR %FQ] M;/O/TBG=]SJGW0LU'%,#KUJ#<<^0J<1E8'IU"+I*E4NCH!"4C=4OZ")UH?H% M]1'1W3;HZMTC=@_JD^"XB5#OU9[!9LOG9[GB)9T_T1>Y^K!A9;C6HH[H.4 K2!-3,6UEMM#A)'=3&JH(#)_(..&D-U, MV%D V>TC>IZ,BO_;-,47/B_OA2C-B]6@*,7#XA5]*==T7A?F8J>-;3^:8(2J M7,NFZ/A3'7WZ<9M::BZH>XO/I,CSB$@*,161-E 1ATQ_!.,TY3*+7C4MPKMZB.OE MOJJS@$W,CRGH#PYD"GBF/1+QH4[+AX8[[CG\2.2?G?"/-:_G*^AYN5J7_VY* MI>VR[,PBJ&8B13E#)(*$8%.?-DDA+4QTH$JB5.2GUT3#8UU7^(U90' M%*:%75E5F]I-S0UD1^W?Q;2EY@[$W]!:]X2Z;?>_EKI7G=2Y*U4+3D(IQ*ZI MQE5F%D*?*2*;>WR*?M5-UN6NQ;J);-;C;G^J2M$T+YH1*3 C$D$1(P8Q2V/( M,DQ@@7$N<()5ANW[3EA..C6ELH>I-<@!3I>2599T6YRC#D#BP)JE00QVD._ M :6O!J;4I0Q8>&K'J@,6@&+',F!N7'77 ;,<:\1"8&[2'5<"<[S7LP@"+5>U M*=F$@M:VZD=3?V%5Y]*U56V50"F"F>04XD+%D.9%!I.4\XCG2LBH<#$%;2:= MFO;>P7.L=&##KYT!&)JU@=6U@0MJO'=@AW* ,U076D(5+K"9+X'[:9C.MBUTRQA.!M8GVSI.D!IG#_P*<*P^(.]UA6/<@'N6Q]DI;!JT7%52/K[4^X3%EZN% MA6=,H311<0SS2!00LQQ!HN(49@DI1"J3B"'BDIMA.['3>ATM>V-;L?>E@>G: M5=B2 26!\("';#[M1%:P7L>6T(S?S20N8<*JC2_Q :N+B%*.JA"XA3Y=_ MY[6^ :.+:KW:<'-@^;!X6BV_Z&_(+I(YHECDIN,GS2G$!"/(A$ P)9F,4A*) M%+E5'^R8;&I+_Q"KR=YZ62U-24C7V,\.=NUT0"C.!M8%IW2U0 <)S>QG)%CP M9<=4(X=7]@M]'D!I<4_(?E+[SCPY4I@4&4QEEIL\. QI4B0P4IE($"M$S.7M MK:2FVD5*?XWR$-V.@K2.^KMUC0K:+RIHJZB_:Y>HT?I#A6D--:6N4'X-H0+U M@MIM\]YLHYJKF2QD2GF20(Q3#G&:F1! 24S)'H95%.6Y=&I,?S;#U#3I]N!G MN3NR:.*[7;TP9T1:.E]NH6=HG\N.DS=]G+@[6J[)'5.N M7A@F'N\@ABG*,THCI6!$:0QQ0KE9U!S&$4F11"A3*KTE"F_2L7=[<.WI;AWQ M/]^*<5O$V,VA=W^C@+M047;!8NO^AA%U8X31W1X\-Y60.?= N6#A<2;Q[R3Y M[Z/4V]W25$]LD@.//SBX87O9;;?[?IA;6^WW:B,TV-WB@E^7H6DRC) M:1QK@RLU.1<1@@PE!:(2Y&)ZC0M_:G;=![D&99O=]8MH!/C5'!QQ M+>I=_?^ZLG,C\;8(\6I'2'V!XUG+M M)>:YGWQX?,>6A7VRX"\M$;_>@1T7^QZC=;>X+1T!CR1_RF,,=<@Y+OAQCTU_ MRH,Y.XC].2B\0KV>Y/*#7#H'>QW>-K4MA@EZ>GKS"#Z\>72*^#JBHEN?W\C" MP,KV@(#P@5^79/8-_3H::\S@KTM"G(1_7;S$XR#@:;7\9HS@Y>HMY?718=OK M+.%>8L>G6-E5FASV]R'H&FEK[T>;V[Z^CX[.+?W5F\?;S??A/]K( M]U[LMXFRZKDLZKMOM2\^64N& %3RG,>&R*.;($%ADA,"^DB$4D ML,PCE_"3[NFFIAD-6JAW/_"YQ6N2DVO ;AO?'I;M-JKAN!M89>YHVT'==V8+ M'XMB1TN@C5K/9*-NK.P$/]T(6=[EITW,GFG]PY1J62[T.^;U\IF6BUF4$B01 M0S!#*H5820$+;4_!@B8$B2+/\DRX*)&+LTQ-=VQ!@AU*\.<6IV-_D\N,VBF, MFWD:6$^X4^2L'#HI"*03+L\QJBKH%/-4 W1?[)DI?ZF;]ZLFSY)E<2ICO:$2 M!9'&LQI#&C$**4HH(H)%<>R4Q=HUV=340(/5,2^^BTV[M1^*HX%50 /S0B+, MJ]"YJS:,A$J![YIJW-1W"Z'/4MYM[O'HQR+^[_/2:)VZ/9=M Y;#FZ:VMO<% M[$S:UF&!NO]T:,1R1$O_$:@G?P/ M?0Q:N20"DC>"E^(:;X';J+MQX^O-Z!M^3 >'I:@G/@_;N_SL=E. \J%.43&: M^UVYD ]K^5S-DH+E*E$$LIC$$'-MO+,B0S#.I2+ZT0]-=+[+O=3 M!W_(\LO7M13WW^2*?I$?-N9,\%'559BKQ\VZ6M.%B7CXC58EGV5Q7"0)+V"& M4U-#/\MAD?$4(BKU/UF2Q[F5M]1K]JFICAH4^*5<@*K&^ZN;OG!COHB8(&F: M:>9%"C&C.:0HIK!@"HD"<4*9F.F1V/*GE,\+QLGPA8 M[L48ZT'9J?O!R!_X)=#B!@UPL$5N*EMOL8,#\'>@AA_NY>#%6J!7AMO+>N_/-8KT_7/HH7TPA[L673VNZWE0SAEF4\^01 M@C$F>4I1CDB1>J7?[^=P6OXC)&H93, \I#8)?[GP3;X_(-). =Q(S\!K?Y^ MOX4'?C$ K^_G_+/PS\4/G8=_,,//R<0_%_%J+OZ%2P-DX^^=*IP@H@3C,)<\ M@ECD#&K;'VOV""I2ED3XAGXXT_59R>_+WU:E &U6M$F[^[1Y>9G_V"=(NW02 MOTYP]^(/1]O Z_\L?=S.1>7"U W)]UZ,_:S$^\#./3M"G%+N1_;9V4G0F6H? MRD?7V9\ZRW,I)&V^&[:)O0@:=O+Y\IFTO;()_V^JDM\B?Z M WRK3(D!M5P]U\&BK\N*SY"]F5BX(7;28)^=QNX@6)R3J7W MBKS9#3):?,TI[,,HFK._^;V'/\BU6:1-(I[X[0/,B+-^!#)% H$8U6<(2>6K&WD[+XS"\R%1KI41" MCF,&<9(S6"BAU7$:%Z3 )*(%<^JD<3;%U!3J#J%CZXQS[NP4XFV,#*S<=N & MBEN\+GRHIAGG$XS;,N.J@&<-,ZY?Z;ZI>:OQ+A?RH^3+;W+UX_5&?EYJ0_A? M&SHO5VNL'[2?3OO89^" /KE<'X=]K"W4*BUW;/:\+1MH:WT'&XC;QI M'(]\R;_H2E2O]!Y?S_-^\5*:';_3D<[U$::FM[9(00W55" U12K,NGG_X>GA MX*3#H5MH!WO]6B@,<0/K&EO.PAX/]5/CEXQY?=CQ,C-[13M*T^R_VK,UJ;:3 M'M6KE13E>I:(-!-QRB!/&(<8D0P6*-([EHQE249HDN961>DO#3XU)7 05@S8 MDB>W4;%EY*!E_<[T_J\;NQ7[U"TP;"%&+ MZ 7!0[7^/!QZ MW/:>%X0Z:^%YZ1K__,E/DF]6]1G&_3=:SHT*T*;")SJ7M3K8!Q.D:5Q(S&.8 MY3B'6 D*:93F4+)"?X*9RJ53OI3+Y%-;[)_X5RDV\_J+K6BY M_H?%/_5NTD MN@.+95VDO"D@[5YPW.GQV*F+H4@?6)W4^9J?#JC=(8=JN8(&>V,H@*"1(+?0 M%C"]TWKJT7,^74FYE CJ/(:;LJM6Z]E'2>=O*G.6<[\0]YQOGC=S_8MX+5]6 MDI?UYN<@/_U1/:U,N.KZ1UW6)%>""D=2E[?0D!YI._[;7 MC=M;GV3?U1KK^^VE3KY;.L-6[UZBM=+.2\J=28<,RC M/"F@5"C5&[@,06IJBXLLC5$FHUP1*\WG-NW4U-PN,^"7W?&UP#!*Q>E#C0%_=X[%&_GQ?%.OT:7K[HVK?MD/-W^J?_^H_V$_T_ M1BOY7__Q_U!+ P04 " #[10)7N^0;I6%X !/C@4 %0 '9C96PM,C R M,S V,S!?<')E+GAM;.R]69-;28XF^CZ_(F_=UXM*WY>V[AF+U-(M&Z6DD513 MT_>%Y@MC[3)10J%&.? @<_A !S+/_^W;Z>S M7[[B/+\']Y;_]U__R7_[Y_P'X7[^] M?_W+\T4Z.\7Y^I=G2PQKS+_\,5U__F7]&7_Y^V+YC^G7\,N[65B7Q?(4X+]N M?NS9XLOWY?33Y_4O@@EY^;'+OUW^DS*,.Z\,I* 8*.$+1!429.^TDL%P:\3_ M]^F?@C+%-8;KO^4 MKE\>_$3]$UQ^#.JW@ N0_*_?5ODO__6__/++.3N6BQF^Q_)+_?UO[U]=O?)K MPME?T^+TU_H7OSY;$!"(Q,V/K+]_P7_YRVIZ^F6&E]_[O,3R+W^I/P15ELQ( M5E_T_Y[_X*\_WO=EB2L"R69]K^D;%S]?W[+]N_';&N<9S]=Q^>39(MWXT*QR M<7'UD[,0<;;Y[B3C=+)YZDE'#G=>?\V(_NRUWVD3X[<0&M M*4CB%8Z#LHS(1A6(;-H?S-*_/!Q$]O6WW:3ZNAQ/ENF7Q3+CDM3$Y>O",MV0 MZ5V 7GSBUR]A20^"]'DZRY<_79:+TQ:R6B\:<.Y<+$3N7WZA51=<+C&_/I?* M@XO;K&Q-RA,WGVPA\?]Q%I;TQ-GW]_AEL5Q/07\_R<#MR)*2&4(@4PHPTHF8DA MEA:@C58L>1.+3DT <>.U6\%!]@^'_7G9"1@^+L-\-:V,OP!TTEDFJ3*8'#6H MXABX%"60680R98Y2YS:GPZTW;P4)U3\D#N+HR*AX,5]/U]]?3F?XYNPTXG)B M0]!",0.6U!FI-QX@,J(=A7:).9:+.DP[W'[C5BC0_:+@( YV(?WW^&E:F3!? MOPFG.+$VLU2\(R= D,TC)8(3R8,.3"L=,O>A-$# S;=NA0+3.PH.X&072'A% MCON25-B&\1^(__AL<39?+[\_6V2<9(?%*V>@2*U D4C!9RQ@%;>8C)>B'&9) M;D'$5CBQO>.D'9^[@,W'\.U5)O9-R_0\(G&A"4D-TC\LDDU$/I-*.H&+28!( M#D.2/BCI'/HE<)!82 @N!D7M= M-,1(UK1EVD?GH[?H&P#DGE=O!0[?.S@.Y6E/P'A&7[Y=?ES\,9]H+WE"E\"G M3$S)@8-#Q@ Y^==HK#3N,(_D@1=O%[IB3P05>S*T)TQLCL:WRW?+Q=?I/-') M6 0&81""X(3M)"P$SLFT4C$D[RTQJ<6!'0<\&S$UI'!4;7> MR1+#AFYTW"E?+!BO-2A=2 ,:P\ 'C5ZG:/V!%Q_7W[8= #H.<>[-NI%%7N]! M9^\^+^:7$9B8ZDU-%,!=MJ \MQ #\X I%QP0N/W&[<3? M<0SS(!:.+/Z/RU!S33Y\/XV+V41%[V66A3JN*E.2,X45S:I* M:[+QK[]U.PQT')(\F)5=N //SI:57>Y5MPF3>:@C9 M69"N<)U=5"'+@R#QV-NW@T;W(<@&K.T"(J_F]#1BQ_0K/@_K<+&L>ENK##>D M]4)PH#*MR(MH("@F"_D[EAV8U/78V[>#2/>!R :L[0(B]1IW^2RL\=-B^9V, MX*QI[363U)+;:V(!YY !EY:L8#0RBA;AIALOW2YMJOL8Y/Z,[ (''T[#;/;; MV6HZQ]5J(IQ(.90 .A0$I90%KU0&+UUF1&)0N@4.;KQT.QQT'VWH("M>(\@?4N@K). M@$N%C*$HR38R6%)N<2/Q& W;@:3CZ&1C-OS3-^^^_X?:*-S#8( M#RQXK '7#*%82>OQ/)C(A59-<'+SM=M!H^/(Y>','/N^ZMQ5>CE=I3#[=PS+ MR]1R(MUEEP7I/4_*STM)'/'D0&E#8)?6^ .#60^]>3M,=!S4;,+23K+U?RSB M)7UG-8E9!,9\!L-=S>1(EI =.019L"J\S-1A&5,/O'@[4'08]YJ^L7/Y]=LWSU^\^?#B.7WQX>WK5\]//KYX_MO)ZY,WSUY\^+<7+SY^ MN$GYEK79/W_J887;.U)]8%7WV0H^A?!ELDF JV)_6UY.YV&>IK3]%^=U7%>8 M,@Q]SJ6 $K:V%H@"@O%T1&23@CTE4SAXXQS8X OSM"ZG'[N4WP<[6Q'6 Y8. L!B:&ET M +'W2)R9IC5NUG5YTZQ9D0PE!RUJTKK4K"8Q2?"J)*=%KIE-C2%U+R'C=+T8 M#D*'<[L#R'SXO%BN/^+R]-7\*ZVG'O7U+M)'I&.;=+6D4]T@@O/:@^91*-H% M1CK6VK2[AXYQ^F(,!YB#>=T!7DY2JN6XJ_>8D+1FG.$;7%]BGU==F0H#)DS- M96 < M,.'-9F0?0]%AX+U.]E^#Q"SSA--(;#3S/>=X"CN@7F])'OM(0))J.U MC73,QN#)@9#52B2F<.V\=*J@=8^EF>V#F^OO'Z?-QG XV9NW'>#B[?HS+F^P M9))MCD8'"[5!"*@4),2L([B@M:F-0U)\K+?"/NBX2\4X33B&P\B!?.X *3>) M#R*'5&NRN!"5^.C "T=_#-)P[F6*Z;'BAH-][G&:;PQXUNS-W?VAL5B'61-H MO%LNON!R_?W=+! [YKEZ>%^JN45?GX>Q\#6&%;ZOG5/?EK^M<+/2W&>3TYKCO=_;OXX2=[D'(NHO>UJ/8@@WHJ-%5>,8-X+ MC:U-G>%7U8.'UB1@U!D .M"6M.KI&E]/OV)^13*=?YJ2^7C.\6HE")[C>P#Y\&ON(R+EJ9 M;E_#=%;]UY>+Y8&3:>B4@:$LK07*&7*25 M:,&2E]Q=V)D!][DZVF(T]E&WY$3L$FR_[R8$=-7U:U8?[]B M#:+5WF( )JRMW6TYG<,A S-Z=H-GD0PBH@XTS[5UW0[N MZ,*,4(+,^N##C#O(B9%L#)$XU>063$)L9X,,DG)@>[O+M)23=@.DC.#]S='<#T M/J"S/*.WWN'1)* ,,7L-M3=:+6/7$ I*H+->8W$,'6L>?W^(F'$/N^$ U(#U M'6#H9BSC\@7!]XH#R*5PA(OGC;%X.;UN/'$@3!S(+,[" @\ MH#RO!;B"1%J.]2!M3;K1M5+*FD)^APHQ.*;$HUUQ&AYB.\84CV$5#>>CM15, MEP?;M;6@,IJ'FI=>FTXKX@MX6218&0*2@F7X:'.V%F?;CN@ZAI4T(+K:B**O M\VYB8F2T=DUJU[#:5RA =+K4 3O69?H[%P:,(W5C%1TE<+03LSLXZ&I;F>EY MGGJME5G,JV[%>:I+T2Y(A;$6Q C2I"4PB)Z3BQ!#\8EDGIL;2(^0TXVE-!R. M6@FC _WS"(<$3Z+R@8Q*K#F+MN8L"@TYHLZV\,#58_-M]JLJ/NC69+!KV*.@ MJI$H.@#5M1Y8Y\5[T1<=6'*07:%-$>A0#K8DD(SXX;@W[-'.'_MJJ.LTC%V\ MW4:V]RBBO1G=A5%]+<5S8]35]GI+_(SSU?0KU@&$I_AZL:KY>6_+Q_!M@EKR M'%""1U;-NV# N<1 Q<2Q[[?'01H0XJI"QR^QW68SC&_",LY M'>:K&ZG'99JFI-NYM(Y) X873B=[IKWE?09K.'@+4QK\9U^@:"SX',[L#; M^YF].3%.FR!B ,V0>*1])"_#$8\BLU)JXIX=,"9^+TWCIL8=.WYPN%B:P>QH M;;G>;23Q&=?3%&8WE]&J1]?-5PSU?1PO(2)6@5"ZFZHL%K;L G MEG0JJ2AL[1P=I7O7;+;XHY9WO5PLGR_.XKJZ6S5_>.PE;0(SH:]@V M@6[DN]EU^]"X-CN8V,K5:G=$R M+%KE>%%$MR._A)/CZZTG0X-A5#9A%,H.C:=S4L;V#(^-I3T$T"..KH\+L$H( MQG4$:R1Y+Z'C_3K[R_> M?/SP]N7;=R_>GWQ\17_;S*I_X/'M+?IMUM'(FC^/:M9'_GVZ_OSL;+6FURU? M?$NSL[H=:O48_9=KJ#>DG#QM*W*C:]>T4G<&68Q@+?F[/FIK!@B+[DSFN/9[ M"^3<#9(.*ZL.#L>+);Y9K!]:Y>8R8I)0&QX5N2),;7K@2P@^9=+0-K":\BIM MZT3U+4D;UZ ?$'9-9=(/U%:3FFN?D'6>+ M33.T%]^^X'R%$RVE,,4+R($34T*.X+.)D(56DNG@<_.V38\2-&[:W3!'4BO^ M=Z!C/N!L5L?3XAR785;[XN73Z7Q:V52'G%^NRGE2CSY;H"=D4-$JVB)2@$C2 M)%>OU%WS5(.M*!OWSG@(> T@D0YP=E7-F,PI8RR><7+;2*V0D_SH6Y#HN

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end

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